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The activation of the innate immune system is the first line of host defence against 
infection. Nucleic acids can potently stimulate this response and trigger a series of 
signalling cascades leading to cytokine production and the establishment of an 
inflammatory state. Mutations in genes encoding nucleases have been identified in 
patients with autoimmune diseases, including Aicardi-Goutières syndrome (AGS). 
This rare childhood inflammatory disorder is characterised by the presence of high 
levels of the antiviral cytokine interferon-α in the cerebrospinal fluid and blood, 
which is thought to be produced as a consequence of the activation of the innate 
immunity by unprocessed self-nucleic acids. This thesis therefore aimed to define the 
role of one of the AGS nucleases, the Ribonuclease H2 (RNase H2) complex, in 
innate immunity, and to establish if nucleic acid sub trates of this enzyme were able 
to induce type I interferon production i  vitro. 
 
The AGS nucleases may function as components of the innate immune response to 
nucleic acids. Consistent with this hypothesis, RNase H2 was constitutively 
expressed in immune cells, however, its expression was not upregulated in response 
to type I interferons. RNase H2-deficient cells responded normally to a range of 
nucleic acid PAMPs, which implied that a role for RNase H2 as a negative regulator 
of the immune response was unlikely, in contrast to the reported cellular functions of 
two other AGS proteins, TREX1 and SAMHD1. Therefore, no clear evidence was 
found for the direct involvement of RNase H2 in theinnate immune response to 
nucleic acids.  
 
An alternative model for the pathogenesis of disease hypothesises that decreased 
RNase H2 activity within the cell results in an accumulation of RNA:DNA hybrids. 
To investigate the immunostimulatory potential of such substrates, RNA:DNA 
hybrids with different physiochemical properties were designed and synthesised. 
Methods to purify the hybrids from other contaminati g nucleic acid species were 
established and their capacity as activators of the innate immune response tested 
6 
 
using a range of in vitro cellular systems. A GU-rich 60 bp RNA:DNA hybrid was 
shown to be an effective activator of a pro-inflammatory cytokine response 
exclusively in Flt3-L bone marrow cultures. This reponse was completely dependent 
on signalling involving MyD88 and/or Trif, however the specific receptor involved 
remains to be determined. Reduced cellular RNase H2 activity did not affect the 
ability of Flt3-L cultures to mount a cytokine response against the RNA:DNA 
hybrid. These in vitro studies suggested that RNA:DNA hybrids may be a novel 
nucleic acid PAMP. Taken together, the data in this t e is suggest that the cellular 
function of RNase H2 is in the suppression of substrate formation rather than as a 
component of the immune response pathways. Future st die  to identify endogenous 
immunostimulatory RNA:DNA hybrids and the signalling pathways activated by 
them should provide a detailed understanding of the molecular mechanisms involved 
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Chapter 1. Introduction 
 
Enzymatic cleavage of most ribonucleic acid (RNA) molecules is necessary for 
producing their mature functional forms or conversely, for their degradation. These 
cleavage reactions are performed by cellular ribonucleases (RNases), essential 
components of all living organisms. Multiple classe of RNases acting upon a diverse 
range of substrates have been characterised extensively in Escherichia coli (E. coli) 
(reviewed by Nicholson, 1999). RNases can be broadly classified as either 
endoribonucleases, cleaving internal phosphodiester bonds in the backbone of the 
RNA molecule, or as exoribonucleases, which remove single ribonucleotides from 
the ends of the molecule. 
 
In eukaryotes, RNase activity is a vital component of many cellular processes. 
Members of the RNase A superfamily exhibit antimicrobial activity (reviewed by 
Dyer and Rosenberg, 2006), whilst RNase L functions as an effector of the innate 
antiviral response (Zhou et al., 1993) (see Section 1.4.3). The RNase III-like family 
of endoribonucleases are essential components of the RNA interference (RNAi) 
pathways (Bernstein et al., 2001; Wu et al., 2000). Defective enzymatic activity can 
be causative of human disease, exemplified by the congenital auto-inflammatory 
disorder Aicardi-Goutières syndrome (AGS) which canbe caused by mutations in 
the genes encoding the subunits of a member of the RNase H class of enzymes 
(Crow et al., 2006b). 
 
1.1. Ribonucleases H 
Ribonucleases H (RNases H) are endoribonucleases which specifically hydrolyse the 
RNA strand of an RNA:DNA hybrid (Hausen and Stein, 1970; Miller et al., 1973). 
They are found in all kingdoms of life. Eukaryotic RNases H can be classified into 
Type 1 and Type 2 RNase H families based on amino acid similarity, size and 
biochemical properties (Ohtani et al., 1999a). The major biochemical difference 
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between the two families is in the choice of diavalent cation required to bind 
substrate and catalyse nucleotidyl transfer: Type 2 enzymes can substitute Mn2+ as a 
cofactor in place of Mg2+ but Type 1 enzymes cannot and may be inhibited by the 
presence of Mn2+ (Eder and Walder, 1991; Nowotny et al., 2005). 
 
1.1.1. RNase H substrates 
Both classes of RNase H enzymes are highly specific for RNA:DNA hybrids and 
hydrolyse the RNA strand in an endonucleolytic manner, however, Type 1 enzymes 
require at least four consecutive ribonucleoside 5ʹ triphosphates (rNTPs) for activity 
(Hogrefe et al., 1990). In contrast, Type 2 RNases H are able to excis  a single rNTP 
embedded in a DNA duplex, always hydrolysing the 5ʹ phosphodiester of the rNTP 
(Eder and Walder, 1991) (Figure 1.1). Additionally, it has been demonstrated that 
RNase H1 and RNase H2 exhibit different cleavage patterns on the same RNA:DNA 





Figure 1.1. Differences in substrate choice for the two types of RNase H enzyme.               
Schematic representation of RNase H substrates. Both Type 1 and Type 2 enzymes are able 
to bind to and cleave RNA:DNA hybrids with a minimum of four consecutive 
ribonucleotides. In addition, Type 2 enzymes are able to recognise and cleave a single 
ribonucleotide incorporated into a DNA duplex. Sites of cleavage of RNase H2 are indicated 




1.1.2. The RNA:DNA hybrid-cleaving activity of other proteins 
The ubiquitous presence of RNase H enzymes in different organisms suggests this 
activity plays an important role in nucleic acid metabolism (Frank et al., 1998a; 
Frank et al., 1998b). RNase H activity is found in retroviruses as a crucial component 
of the reverse transcriptase (RT) that converts the ssRNA retroviral genome into 
dsDNA (Molling et al., 1971; Wohrl and Molling, 1990). Related RNase H-like 
domains have been found in a number of other proteins, including the PIWI fold of 
Argonaute-2 (the protein component of the RNA-induced silencing complex (RISC)) 
(Parker et al., 2004; Song et al., 2004), and in the retroviral integrase and transposase 
enzymes (Rice and Baker, 2001).  
 
1.1.3. Type 1 RNase H enzymes 
Type 1 RNase H enzymes are present in all prokaryotes and eukaryotes, but are 
absent in most archaea (Ohtani et al., 1999b; reviewed by Tadokoro and Kanaya, 
2009). Human RNase H1 is a monomeric protein consisti g of 286 amino acids with 
a molecular weight (MW) of approximately 32 kilodaltons (kDa) (Figure 1.2). All 
eukaryotic RNase H1 proteins contain a highly conserved region termed the hybrid 
binding domain (HBD). This nucleic acid binding domain is capable of binding 
dsRNA but shows a 25-fold preference for binding RNA:DNA hybrids, independent 
of their sequence (Cerritelli and Crouch, 1998; Nowotny et al., 2008). Upon 
substrate binding, murine RNase H1 is induced to form a homodimeric enzyme 
(Gaidamakov et al., 2005). The HBD contributes to the specific activity of RNase H1 
by increasing the affinity of the enzyme for RNA:DNA hybrid substrates and so 
enhances the processivity of the enzyme (Cerritelli and Crouch, 2009; Gaidamakov 
et al., 2005; Nowotny et al., 2008).  
 
The enzymatic C-termini of eukaryotic RNase H1 enzymes consist of approximately 
150 highly conserved amino acids: the RNase H domain. The catalytic core contains 
four absolutely conserved carboxylic acid residues at the active site, which are 
essential for hydrolysis of substrates (Figure 1.2)(Katayanagi et al., 1990; Wu et al., 
2001). This is highly similar to the catalytic site of prokaryotic RNase H1 enzymes 
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(Tadokoro and Kanaya, 2009). RNA:DNA hybrid recognitio  has been shown to be 
dependent on the identification of both the RNA strand (by the presence of the 2ʹ-
hydroxyl group (2́-OH)) and the DNA strand (by the absence of 2ʹ-OH and/or the B-
form conformation of the strand) (as discussed in Chapter 4) (Cerritelli and Crouch, 






Figure 1.2. The human RNASEH1 protein   
Schematic diagram showing human RNase H1. The 286 amino acid polypeptide contains a 
mitochondrial targeting sequence (MTS) at the extreme N-terminus, followed by a 50 
amino acid hybrid binding domain (HBD). A 64 amino acid connection domain separates the 
HBD from the 150 amino acid RNase H domain. The locations of the four residues which 
form the active site are indicated with red lines at positions 145, 186, 210 and 274 amino 
acids (Wu et al., 2001). The first three residues are essential for catalytic activity (Nowotny 




The N- and C-termini are separated by a connection domain, the length and sequence 
of which is variable between species. The primary role of this domain is to convey 
flexibility to the protein, so that the HBD and catalytic domain can be correctly 
positioned on the nucleic acid (Nowotny et al., 2008), but it may also function in the 
interaction of RNase H1 with other proteins (Cerritlli and Crouch, 2009).  
 
In higher eukaryotes, RNase H1 proteins contain a mitochondrial targeting sequence 
(MTS) located upstream of the HBD at the 5ʹ-end which is coded for by an 
alternative start codon. It has been proven that this is capable of localising the 
enzyme to the mitochondria n vitro (Cerritelli et al., 2003; Pileur et al., 2000). 
RNase H1 has been shown to have an essential role during development for the 
generation of mitochondrial DNA (mtDNA) in mice (Cerritelli  et al., 2003) but not 
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in yeast which replicate mtDNA in an RNase H1-independent manner 
(Arudchandran et al., 2000), discussed further in Section 1.1.5. 
 
1.1.4. Type 2 RNase H enzymes 
Type 2 RNase H activity is present in all organisms (Ohtani et al., 1999b). The 
sequence of the catalytic site of the enzyme is highly conserved throughout evolution 
(Frank et al., 1998b; Frank et al., 1998c; Rydberg and Game, 2002). RNase H2 is 
ubiquitously expressed and constitutes the major source of cellular ribonuclease 
activity in eukaryotes (Arudchandran et al., 2000; Eder and Walder, 1991; Frank et 
al., 1998a; Frank et al., 1998c). 
 
1.1.4.1. The eukaryotic RNase H2 enzyme complex 
Bacterial and archaeal RNase HII are active as monoeric proteins encoded for by 
the rnhB genes (Haruki et al., 1998; Itaya, 1990), however eukaryotic RNase H2 
requires additional protein subunits for functional enzymatic activity. The RNase H2 
complex comprises three subunits; RNASEH2A, RNASEH2B and RNASEH2C 
(Crow et al., 2006b; Frank et al., 1998c; Jeong et al., 2004) (Figure 1.3).  
 
The catalytic RNASEH2A subunit has homologues in all eukaryotic species. The 
sequence and main fold of the protein share significant similarity to the prokaryotic 
and archaeal RNase HII proteins and use the same catalytic mechanism of four 
conserved residues coordinating the divalent cations at the active site (Chapados et 
al., 2001; Frank et al., 1998b; Jeong et al., 2004; Lai et al., 2000). The extreme N- 
and C-terminal regions of the eukaryotic RNASEH2A protein are absent in the 
bacterial and archaeal proteins (Jeong et al., 2004), and significantly the C- terminus 
has been shown to interact with the B/C subunits (Shaban et al., 2010) (Martin 
Reijns, MRC HGU, personal communication).  
 
In contrast to RNASEH2A, the accessory proteins RNASEH2B and RNASEH2C 
share little sequence similarity with their orthologues and have no prokaryotic 
equivalents (Crow et al., 2006b; Jeong et al., 2004). However, they are absolutely 
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essential for RNase H2 activity in eukaryotes (Chon et al., 2009; Crow et al., 2006b; 
Jeong et al., 2004). It has been proposed that they form a scaffold on which the A 
subunit can adopt the appropriate conformation for enzymatic activity (Chon et al., 
2009). It is also hypothesised that they may be essntial for promoting the 
progressive action of the eukaryotic RNase H2 enzyme activity, as the monomeric 
prokaryotic RNase H2 is known to cleave RNA:DNA hybrids in a distributive 






Figure 1.3. The human RNASEH2 proteins 
Schematic representation of the three human RNase H2 proteins. The approximate 
locations of the four conserved residues (D34, E35, D141 and D169) which form the active 
site of RNASEH2A are indicated with red lines (based on murine Rnaseh2a (Shaban et al., 
2010)). The B subunit of RNase H2 has 2 isoforms: the full length protein (RNASEH2B) 
containing a PCNA-interacting protein (PIP) box motif at amino acid residues 294 – 301 
(Chon et al., 2009), and a shorter alternative isoform (RNASEH2Balt) which lacks the PIP box 




Both Saccharomyces cerevisiae (S. cerevisiae) and human RNASEH2B/C can form 
complexes independent of the catalytic A subunit (Chon et al., 2009; Rohman et al., 
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2008). The smaller C subunit interacts with the N-terminal region of the B subunit 
(as indicated in Figure 1.3). This heterodimer structurally resembles the subdomains 
of the eukaryotic transcription factor IIF (TFIIF) complex (Shaban et al., 2010). The 
B/C subcomplex may bind proteins other than RNASEH2A, probably via the C-
terminus of RNASEH2B. This could support a function f r these proteins 
supplementary to their role as components of the enzymatically active RNase H2 
complex (Chon et al., 2009; Jeong et al., 2004; Shaban et al., 2010).  
 
RNASEH2B was identified as being acetylated in a high-throughput screen 
(Choudhary et al., 2009); however post-translational modifications of the A and C 
subunits have not been reported. 
 
1.1.4.2. In vivo functions of the RNase H enzymes 
The functions of the RNase H enzymes in vivo have not yet been fully characterised, 
but there is strong evidence to suggest that mitochondrial RNase H1 plays an 
essential role in mammalian embryogenesis (Cerritelli  et al., 2003) (discussed in 
Section 1.1.5). The nuclear isoform of RNase H1 and the predominantly nuclear 
RNase H2 complex may function during transcription (Broccoli et al., 2004) 
(discussed in Section 1.3.2). 
 
The ability of RNase H2 to hydrolyse 5ʹ of single ribonuleotides embedded in 
dsDNA indicates that it may have a role in the recognition and removal of these 
misincorporated bases from genomic DNA (Arudchandra et al., 2000; Eder and 
Walder, 1991; Eder et al., 1993). The misincorporation of ribonuleotides into DNA 
can potentially occur during DNA synthesis (Joyce, 1997), especially when an error-
prone DNA polymerase is utilised (Bergoglio et al., 2003; Nick McElhinny et al., 
2010). The presence of a ribose in DNA prevents it from adopting the normal 
dsDNA conformation and instead results in a distortion of the DNA backbone (Eder 
et al., 1993). The progression of DNA polymerase can be blocked as the active site 
of the enzyme is unable to accommodate the extra oxygen molecule in the 2ʹ position 
in the ribose ring, stalling DNA replication (Nick McElhinny et al., 2010). RNase H2 
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may be required to excise these bases during DNA replication and repair, which 
potentially provides an explanation for the highly conserved nature of the RNase H2 
enzymes and their representation throughout all kingdoms of life. 
 
1.1.4.3. Interaction partners of the RNase H2 subunits 
Yeast two-hybrid experiments have identified only one protein other than the B and 
C subunits which interacts with the A subunit S. cerevisiae RNase H2, the Rap1p-
interacting factor, Rif2p (Jeong et al., 2004). Following its recruitment to telomeres 
by Rap1p, Rif2p forms a complex which regulates telomere length (Wotton and 
Shore, 1997). The B and C subunits of yeast RNase H2 are not reported to interact 
with Rif2p. 
 
The RNASEH2B protein contains a proliferating cell nuclear antigen (PCNA) 
interacting protein box (PIP-box) at the C-terminus (Figure 1.3), highly conserved 
among different species (Chon et al., 2009; Crow et al., 2006b). This ability to 
interact with PCNA indicates a role for RNase H2 in DNA replication and repair 
(Chon et al., 2009). In mouse and human, a protein-coding splice variant of 
RNASEH2B exists. The isoform, RNASEH2Balt, lacks the PIP-box (Figure 1.3.) but 
still forms an enzymatically active complex with the A and C subunits in vitro 
(Martin Reijns, MRC HGU, personal communication). It is not yet clear if this 
alternative complex exists in vivo and if it has a specialised function distinct from 
that of the known RNase H2 complex. 
 
Interaction studies using the B subunit of S. cerevisiae RNase H2 suggest that it is 
also capable of interacting with additional proteins (Jeong et al., 2004), including the 
Cdk-activating kinase Cak1p, which is involved in cell ycle progression through S-
phase and G2/M-phase (Sutton and Freiman, 1997) and the transcriptional regulator 
forkhead protein 1 (Fkh1) which plays a key role in yeast mating-type switching 




Known protein binding domains have not yet been idetifi d in the C subunit of the 
RNase H2 complex. However, high-throughput interaction studies in S. cerevisiae 
suggest that it could interact with members of the MAP kinase Kss1p complex, 
which is activated prior to mating to induce G1-arrest (Cherkasova et al., 1999). 
Additionally, an interaction with Topoisomerase II (Top2p), which functions in 
replication and repair pathways (Holm et al., 1985), and has recently been implicated 
in the suppression of R loop formation (El Hage et al., 2010) has also been suggested 
(Ho et al., 2002). 
 
1.1.5. RNase H-deficient eukaryotic cells 
 
1.1.5.1. Yeast deficient in RNase H activity are viable  
S. cerevisiae cells with a deletion of the entire RNH1 gene are viable and show only a 
slight increase in sensitivity to the DNA-damaging agent ethyl methansuplhonate 
(EMS) (Arudchandran et al., 2000). Total RNase H activity is not reduced in these 
cells, attributable to an increased level of RNase H2 activity which indicates that 
RNase H2 can compensate for a loss of RNase H1 activity in yeast (Arudchandran et 
al., 2000). Cells lacking RNase H1 activity also exhibit normal mtDNA replication 
(Arudchandran et al., 2000). 
 
Deletion of the gene encoding the A subunit of RNase H2 (RNH2A) does not affect 
viability but does result in a 75% decrease in the total RNase H activity in these cells 
compared to wild type (Arudchandran et al., 2000; Frank et al., 1998b). RNase H 
activity was also detected in cells with a double deletion of both RNH1 and RNH2A, 
which although viable, have an increased sensitivity to treatment with either 
hydroxyurea (HU) or EMS (Arudchandran et al., 2000). HU inhibits the enzyme 
ribonucleoside diphosphate reductase, depleting the dNTP pool available during S-
phase of the cell cycle, and causing cells to undergo slow DNA replication. Cells 
lacking RNase H1 respond as wild-type to HU treatment, but the co-deletion of 
RNH2A prolongs the S-phase arrest and eventually results in cell death 
(Arudchandran et al., 2000). This suggests RNase H2 is required during DNA 
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replication in S-phase, and possibly in the repair of HU-mediated DNA damage 
during the G2/M-phase of the cell cycle (Arudchandr et al., 2000). 
1.1.5.2. Rnaseh1-null mice are embryonic lethal 
In contrast to prokaryotes and yeast which are viable when deficient in RNase H1 
activity, RNase H1-null mice die in utero (Cerritelli et al., 2003). Initially, the 
embryos develop normally but they have a greatly reduc d mtDNA content; 
approximately 10% of wild-type at 7.5 days post coium (d.p.c.) (E7.5). This leads to 
developmental arrest at E8.5 and suggests an essential role for RNase H1 in the 
replication of mtDNA during development (Cerritelli et al., 2003). Mouse models 
defective in RNase H2 activity have yet to be fully characterised and published. 
 
1.1.5.3. Mutations in the genes encoding human RNase H2 cause 
Aicardi-Goutières syndrome (AGS) 
Mutations in the human RNASEH1 gene have not been reported, however mutations 
in any of the three genes encoding the human RNase H2 complex subunits can cause 
the childhood inflammatory disorder Aicardi-Goutières syndrome (AGS) (Crow et 
al., 2006b). This is the first example of an RNase H enzyme being implicated in a 
human disease. Understanding the role of the enzyme in disease pathogenesis should 




1.2. Aicardi-Goutières syndrome (AGS) 
AGS is a rare neuroinflammatory disease, first described in 1984 by Jean Aicardi and 
François Goutières (Aicardi and Goutieres, 1984). They reported eight children from 
five families with early-onset progressive famililal encephalopathy, basal ganglia 
calcification and chronic cerebrospinal fluid (CSF) lymphocytosis. These features 
closely mimicked an intrauterine viral infection, but TORCH (toxoplasmosis, 
rubella, cytomegalovirus and herpes simplex virus types 1 and 2) investigations 
proved negative. This, together with the recurrence of the disease in families, 
suggested that there could be a genetic basis for disease (Aicardi and Goutieres, 
1984). Subsequent confirmation of this has led to the description of AGS as a 
Mendelian mimic of congenital viral infection (Crow et al., 2006b; Crow and 
Livingston, 2008). 
 
The clinical phenotype of AGS, in particular the notable overlap with the common 
autoimmune disease systemic lupus erythematosus (SLE), is described in more detail 
in this section.  
 
1.2.1. The clinical phenotype of AGS 
At disease onset, AGS patients develop an acute onset e cephalopathy and often 
display irritability, inconsolable crying, feeding difficulties, dystonic posturing, 
recurrent fevers and a loss of social and motor skills (Crow and Livingston, 2008; 
Lanzi et al., 2002; Rice et al., 2007b). These periods usually last several months, 
before the condition stabilises and there is no further disease progression (Rice et al., 
2007b). The majority of patients are left severely ph sically and mentally impaired, 
with death often occurring during childhood (Goutieres, 2005; Rice t al., 2007b). 
 
The phenotype of AGS has been shown to be variable n s verity, even between 
affected siblings (Ostergaard et al., 1999; Ramantani et al., 2010; Rice et al., 2007b; 
Verrips et al., 1997) and so a range of diagnostic criteria has been established 
(reviewed by Orcesi et al., 2009). The majority of AGS patients do not present with 
the disease at birth and are born following a normal pregnancy (Goutieres et al., 
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1998; Rice et al., 2007b). However, a subgroup of patients are affected at birth, 
exhibiting an abnormal neurology, jitteriness and seizures in addition to 
extraneurological features including enlarged spleens and reduced levels of platelets 
(Crow and Livingston, 2008; Menson and Lyall, 2005; Rice et al., 2007b). This 
presentation considerably overlaps with that of congenital infection (Table 1.1).  
 
The other patients present at variable times beyond the first few days of life, some 
developing disease progressively following several months of normal development 
(Aicardi and Goutieres, 1984; Crow and Livingston, 2008; Rice et al., 2007b). The 
trigger for disease onset is unknown (Crow and Livingston, 2008) but extensive 
testing for the presence of a range of viruses in AGS patients using a variety of 




Table 1.1. A comparison of the overlapping clinical features of AGS, the common adult-




SLE is a multisystem disorder with a wide range of clinical features, only a small subset of 
which overlap with AGS. Similarly, congenital viral infection has pleiotropic manifestations 
that are absent in AGS.  
a
The presence of autoantibodies has been reported in a small 
proportion of AGS patients. 
b
Chilblain-like lesions with IgM deposition. 
c
Reported in a small 
number of AGS patients. 
d
Although splenomegaly can be present. Table reproduced from 





Neuroimaging of AGS patients showed they have microcephaly, regions of 
intracellular calcification and white matter destruc ion (Figure 1.4) (Bale t al., 1985; 
Crow et al., 2006b; Numazaki and Fujikawa, 2003; Rice et al., 2007b). The 
calcifications, which are typically in the basal gan lia, can vary greatly in size and 
number, although this does not correlate with the severity of disease status 
(Goutieres, 2005; Ostergaard et al., 1999) and they tend to remain stable over time 
from the initial diagnosis of AGS (Lanzi et al., 2002; Lanzi et al., 2005). A similar 
neuropathology is seen in congenital viral infection (Bale et al., 1985; Belman et al., 







Figure 1.4. The neuropathology of AGS patients is reminiscent of both congenital viral 
infection and autoimmune disease. 
Axial CT scans of normal (A), AGS (B), congenital HIV (C) and SLE (D) brain showing 
calcification of basal ganglia (central regions of high signal, B-D) and white matter 




1.2.2. Immunological phenotype of AGS 
In addition to lymphocytic infiltration of the CSF, AGS patients display a number of 
other immunological phenotypes (Rice et al., 2007b), some of which are listed in 





The similarity of the AGS pathogenesis to that of intrauterine viral infections 
prompted measurement of the antiviral cytokine interferon alpha (IFN-α) in patients 
(Lebon et al., 1988). Generally, AGS patients have levels of CSF IFN-α greatly 
exceeding the normal range of less than 2 Internatio l Units (IU)/ml (Goutieres et 
al., 1998), however, the levels tend to fall as the patients age as does the white cell 
count of the CSF (Lebon et al., 2002; Rice et al., 2007b). The average levels of IFN-
α are higher in patients with early-onset AGS compared with patients who present 
with the disease after 3 months of age (Lebon et al., 2002). The biological 
significance of elevated levels of IFN-α is discussed further in Section 1.5 of this 
thesis. 
 
Elevated levels of CSF pterins, a biomarker for CNS inflammation (Dale et al., 
2009), are also found in AGS patients (Blau et al., 2003; Rice et al., 2007b; Wassmer 
et al., 2009). Extraneurological inflammatory features include chilblain-like lesions 
at the extremities resulting from an inflammatory vasculopathy, hepatosplenomegaly 
and thrombocytopenia (reviewed by Aicardi, 2002; Crow and Livingston, 2008; 
Goutieres, 2005).  
 
1.2.3. Cytokine production in AGS 
Elevated levels of IFN-α can be detected in the blood of some patients, but levels are 
usually lower than the equivalent found in the CSF, indicative of predominantly 
intrathecal production (Goutieres, 2005; Lebon et al., 1988; Lebon et al., 2002; van 
Heteren et al., 2008). Consistent with this, glial cells, specifically astrocytes, have 
been identified as producing cytokines, most notably IFN-α, in AGS patients (van 
Heteren et al., 2008). Astrocytes are also the source of cytokine production in viral-
induced encephalopathies (van Heteren et al., 2008). The CNS can direct its own 
immune response by transforming resident cells into components of the immune 
response and the role of astrocytes (the most prevalent cell in the CNS) in the 





A study of 30 cytokines and growth factors in the CSF and sera of a cohort of AGS 
patients showed that in addition to IFN-α, levels of the chemokines CXCL10 (IP-10) 
and CCL2 (MCP-1) are significantly elevated in the CSF of AGS patients (van 
Heteren et al., 2008). Similarly, raised levels of these chemokines were detected in 
the CSF of patients with a known viral infection of the brain (van Heteren et al., 
2008). In all cases, astrocytes were responsible for their production. Increased 
amounts of CXCL10 and CCL2 were also detected in the sera of AGS patients, 
although levels were lower than in the CSF (van Heteren et al., 2008).  
 
CXCL10 is likely to be produced as a secondary effect of IFN-α (Campbell et al., 
1999; van Heteren et al., 2008) as it is known to be induced by type I and type II 
IFNs in vitro (Luster et al., 1985; Padovan et al., 2002). The receptor for CXCL10, 
CXCR3 (Loetscher et al., 1998), is expressed on a number of immune cells, 
particularly on activated Th1 cells (reviewed by Lacotte et al., 2009), therefore it is 
possible that CXCL10 in the CSF of AGS patients is responsible for the 
accumulation of lymphocytes there (Klein, 2004; vanHeteren et al., 2008). This is a 
central element of disease pathogenesis in inflammatory disorders of the CNS, 
including viral encephalopathies (Rosler et al., 1998) and the autoimmune disease 
multiple sclerosis (Sorensen t al., 2002). A study of astrocyte-targeted 
overproduction of CXCL10 in mice showed that whilst the mice had leukocyte 
infiltrates into the brain, mainly comprising of neutrophils and T cells, they did not 
exhibit any pathological signs of an inflammatory disease of the CNS (Boztug et al., 
2002). This suggests that upregulated expression of CXCL10 in the CNS can direct 
lymphocytes to the blood-brain barrier (BBB) but additional signals are required to 
allow the crossing of the BBB and subsequent induction of neuronal damage and 
disease pathology (Boztug et al., 2002; Klein, 2004; Trifilo and Lane, 2003). 
Astrocyte-targeted chronic expression of CCL2 result d in neurological impairment 
due to perivascular lymphocytosis and impairment of the BBB (Huang et al., 2005). 
Therefore, it is possible that production of high levels of both of these chemokines is 




Levels of the interleukins IL-6, IL-8 and of vascular endothelial growth factor 
(VEGF) are significantly increased in the CSF of patients with viral infections but 
not in the CSF of AGS patients (van Heteren et al., 2008). This clearly distinguishes 
the AGS cytokine profile from that of viral infection of the brain, suggesting a 
different mechanism of disease onset and pathology. 
 
1.2.4. Phenotypic overlap with systemic lupus erythematosus 
(SLE) 
As mentioned previously in this section, a number of the clinical and immunological 
features displayed in AGS patients can also occur in the common adult autoimmune 
disease SLE (Table 1.1), notably the elevated level of IFN-α in the CSF. The co-
existence of AGS and SLE has been identified in two patients (one with a mutation 
in the TREX1 gene and the other in SAMHD1; these genes are discussed in more 
detail in Section 1.2.5) (Ramantani et al., 2010), suggesting a common mechanism of 
disease pathogenesis is shared by the two disorders. 
 
SLE is a chronic, remitting and relapsing disorder isproportionally affecting 
females. It has a prevalence of approximately 0.1% of the general population, 
although this can vary with different ethnic populations (D'Cruz et al., 2007). SLE 
affects multiple systems of the body and patients exhibit a wide range of clinical 
presentations which can include arthritis, fever, skin rashes, photosensitivity, 
neuroinflammation and kidney dysfunction often leading to renal failure. Intracranial 
calcifications can be seen in small proportion of SLE patients (Figure 1.4) (Raymond 
et al., 1996).  
 
The aetiology of SLE is not yet fully understood; genetic and environmental factors 
are known to be involved in the development of disease (D'Cruz et al., 2007; Vyse 
and Kotzin, 1998). Increased susceptibility to SLE has been associated with 
polymorphisms in a wide range of genes including; TREX1 (discussed further in 
Section 1.2.5); DNase I (DNASE1) (discussed in 1.4.1); interferon regulatory factor 5 
(IRF5) (Graham et al., 2006; Kozyrev et al., 2007); protein tyrosine phosphatise N22 
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(PTPN22I) (Kyogoku et al., 2004); programmed cell death 1 gene (PDCD1) 
(Prokunina et al., 2002); and deficiencies in the early complement components, C1q, 
C1r, C1s, C4 and C2 (Manderson et al., 2004). 
 
1.2.5. The genetics of AGS 
A genome-wide linkage analysis study involving 13 AGS families established 
linkage of the disease to chromosome 3p21 (the AGS1 locus) in approximately 50% 
of these families (Crow et al., 2000). Further genome-wide analysis of 10 families 
incompatible with linkage to chromosome 3p21 identified a second AGS locus 
(AGS2) at chromosome 13q14-21 (Ali et al., 2006), demonstrating that AGS was a 
single gene disorder with locus heterogeneity.  
 
1.2.5.1. Mutations in the RNASEH2 genes causes AGS 
Genetic refinement of the AGS2 locus identified FLJ11712/DLEU8 as mutated in 18 
families in a larger cohort of patients (Crow et al., 2006b). Bioinformatics analysis 
revealed homology with a distant S. cerevisiae orthologue, RNH202, which encodes 
an essential component of the yeast RNase H2 complex, Rnh2Bp (Crow et al., 
2006b; Jeong et al., 2004). 
 
A third AGS locus (AGS3) at chromosome 11q13.2 was identified and refined 
following the discovery of an ancestral haplotype in five families, which contained 
the AYP1 gene (Crow et al., 2006b). AYP1 was known to co-purify with 
RNASEH2A, the human orthologue of yeast Rnh2Ap (Frank et al., 1998c; Jeong et 
al., 2004). Sequence analysis subsequently identified AYP1 as the AGS-causative 
gene at the AGS3 locus (Crow et al., 2006b). It was confirmed to encode the human 
orthologue of S. cerevisiae Rnh2Cp and was consequently renamed RNASEH2C 
(Crow et al., 2006b). 
 
Sequencing of RNASEH2A on chromosome 19p13.13 in an AGS family who did not 
show linkage to the AGS1-3 loci identified mutations in two patients (Crow et al., 
2006b). Subsequent experiments confirmed that the thre  proteins, RNASEH2A, 
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RNASEH2B and RNASEH2C, interact in vitro and form an enzymatically active 
complex with Type 2 RNase H activity (Crow et al., 2006b).  
 
1.2.5.1.1. RNASEH2 mutations 
The majority of AGS causing mutations identified in the RNASEH2 genes are 
hypomorphic missense mutations inherited in an autosomal recessive pattern (Crow 
et al., 2006b; Rice et al., 2007b). Parents are obligate carriers for the mutations 
(Crow et al., 2006b; Rice et al., 2007b). Biallelic null mutations have not been 
reported in any of the RNASEH2 genes, suggesting that the resulting phenotype 
would be lethal in utero (Rice et al., 2007b). 
 
The most comprehensive study of AGS-causing mutations t  date, involving a cohort 
of 127 families, identified biallelic mutations in all RNase H2-AGS patients with the 
exception of three families with a single RNASEH2B mutation and one family with a 
single RNASEH2A mutation (Rice et al., 2007b). Mutations in RNASEH2A are rare 
and consist predominantly of missense mutations, located throughout the gene. The 
RNASEH2B A177T change is a recurrent mutation, seen in almost every AGS patient 
with a RNASEH2B mutation. No mutations were identified in the final three exons of 
the gene (exons 9, 10 and 11), which is the region that can undergo alternative 
splicing to produce RNASEH2Balt. All RNASEH2C mutations identified are 
homozygous missense mutations, found throughout the gen  with a recurring R69W 
mutation present in a large proportion of patients (Crow et al., 2006b; Rice et al., 
2007b). 
 
1.2.5.1.2. The effect of RNASEH2 mutations on protein function 
Recombinant RNase H2 complexes with AGS-causing mutations in the B and C 
subunits displayed normal enzymatic activity in vitro (Perrino et al., 2009). 
Therefore, it was hypothesised that altered RNase H2 activity is not responsible for 
the pathogenesis of AGS, but instead arises as a consequence of alternations in the 
assembly, stability and localisation of the complex (Chon et al., 2009; Perrino et al., 
2009). However, this is not true in vivo, as the RNase H2 activity of lymphoblastoid 
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cell lines (LCLs) derived from AGS patients is significantly reduced (Martin Reijns, 
MRC HGU, personal communication), indicating that AGS is a consequence of 
reduced RNase H2 enzymatic activity. 
 
1.2.5.2. Mutations in TREX1 cause AGS 
The identification of AGS-causing mutations in genes encoding an RNase prompted 
the sequencing of the single exon TREX1 gene; the only gene in the AGS1 locus 
known to encode a nuclease. TREX1 mutations were subsequently identified in 10 
AGS families (Crow et al., 2006a). 
 
1.2.5.2.1. The nuclease activity of TREX1 
TREX1 encodes the 33kDa Three Prime Repair Exonuclease 1 (TREX1) protein, 
formerly known as DNase III, which constitutes the major 3́ → 5́  exonuclease 
activity in mammalian cells (Lindahl et al., 1969; Mazur and Perrino, 1999). TREX1 
and its close homologue TREX2, with which TREX1 shares 44% amino acid 
sequence identity (Mazur and Perrino, 1999), have no orthologues in lower 
eukaryotes, including yeast (Hoss et al., 1999). However TREX1 does shares 
sequence homology with the E.coli proofreading protein DnaQ, a component of the 
DnaQ/MutD DNA polymerase III holoenzyme. Consequently, TREX1 was 
originally hypothesised to have a similar role in editing mismatched bases inserted 
during gap filling in DNA base excision repair by the error-prone DNA polymerase 
Pol β (Hoss et al., 1999). However, as discussed in this section, this does not appear 
to be the case in vivo (Morita et al., 2004). 
 
TREX1 is a 314 amino acid protein comprising three distinct conserved sequence 
motifs (ExoI, ExoII and ExoIII) (Bernad et al., 1989; Blanco et al., 1992) (Figure 
1.5). These Exo domains bind the divalent cation cofact rs (Mg2+ or Mn2+) required 
for enzymatic activity (Lindahl et al., 1969; Mazur and Perrino, 1999). Unique 
amongst related exonucleases, TREX1 contains an 8 amino acid polyproline II helix 
which may provide a flexible region for interactions with other proteins (Brucet  
al., 2007; de Silva et al., 2007), although to date no interaction partners fo  TREX1  
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have been identified. The C terminus of TREX1 is abent from TREX2 and other 
members of the DnaQ family (Hoss et al., 1999; Mazur and Perrino, 1999; Mazur 
and Perrino, 2001a). It contains a leucine-rich transmembrane domain (TMD) which 
is responsible for tethering the protein to the endoplasmic reticulum (ER) (Lee-
Kirsch et al., 2007b; Richards et al., 2007), presumed to be essential for the 






Figure 1.5. The human TREX1 protein. 
Schematic diagram representing human TREX1. TREX1 contains three conserved 
Exonuclease domains (I, II and III) located between residues 8 – 14, 111 – 120 and 185 – 
194. The N terminus of the protein also contains a polyproline II domain between amino 
acid residues 54 – 62, whilst the C terminus contains a transmembrane domain (residues 




Active as a homodimer, TREX1 catalyses the excision of ucleoside 
monophosphates from the 3ʹ terminus of DNA (Figure 1.6), having 3-4 fold great r 
activity on single-stranded DNA (ssDNA) than double-stranded DNA (dsDNA) 
(Lindahl et al., 1969; Mazur and Perrino, 1999; Mazur and Perrino, 2001a). The 
enzyme has no activity on single-stranded RNA (ssRNA) or partial RNA:DNA 
hybrids and completely lacks endonuclease activity (Lindahl et al., 1969; Mazur and 
Perrino, 1999).  
 
The TREX1 transcript is ubiquitously expressed (Mazur and Perrino, 2001b). The 
majority of the protein is located in the cytoplasm, but relocates to the nucleus in 
response to granzyme A activity (Chowdhury et al., 2006) and genotoxic stress 
(Christmann et al., 2010; Yang et al., 2007). Nuclear TREX1 has a higher catalytic 
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activity than ER-associated TREX1, further suggesting hat this localisation is 
connected to the biological function of the enzyme (Christmann et al., 2010; Lindahl 






Figure 1.6. Preferred substrates of the 3ʹ → 5ʹ DNA exonuclease TREX1. 
TREX1 excises single nucleotides from the 3ʹ termini of ssDNA substrates, including 3ʹ ssDNA 
overhangs, but can also cleave dsDNA (Lindahl et al., 1969; Mazur and Perrino, 1999; Mazur 




TREX1 has been shown to be involved in a range of biological processes, 
predominantly by investigations using transgenic mie deficient in Trex1.  
 
1.2.5.2.2. Trex1-deficient mice have an autoinflammatory phenotype 
Trex1-homozygous null mice have significantly reduced 3ʹ → 5́  DNA exonuclease 
activity but are viable (Morita et al., 2004). Similar to AGS patients, they do not 
have an increased incidence of cancer or spontaneous mutation frequency. However, 
they do develop a severe inflammatory myocarditis which leads to circulatory failure 
and a severely reduced lifespan (Morita et l., 2004). Embryo transfer experiments 
confirmed that the lethal heart failure was not dueto an increased susceptibility to 




Post-mortem examination of Trex1-/- hearts showed that the heart muscle 
morphology was severely disturbed as a result of the lymphoid inflammatory 
infiltrate (Morita et al., 2004). Trex1-/- hearts also had significantly increased 
expression levels of the type I interferon gene, Ifnb1 (Stetson et al., 2008). This 
provides further evidence to suggest that the Trex1-/- phenotype is due to 
inflammation in the absence of pathogenic agents, reminiscent of AGS. However, the 
mice lack the autoinflammatory neurological phenotype seen in AGS patients with 
loss-of-function mutations in TREX1. 
 
Further investigations into the mechanism of autoimmunity in the Trex1-/- mice 
revealed that development of the inflammatory phenotype was mediated by innate 
immunity (Stetson et al., 2008). Notably, mice deficient in Trex1 and the DNA 
recombinase RAG2 did not develop the lethal inflammatory cardiomyopathy but still 
had elevated levels of IFN-β expression, suggesting that type I IFN induction is ot 
sufficient to cause autoimmune disease in Trex-/- mice without the involvement of the 
adaptive immune system (Stetson et al., 2008). 
 
1.2.5.2.3. Single-stranded DNA accumulates in TREX1-deficient cells 
Primary fibroblast cells from AGS patients homozygous for TREX1 loss-of-function 
mutations have an accumulation of DNA in their ER, which is eliminated by 
digestion with S1 nuclease (Yang et al., 2007). A spontaneously transformed murine 
embryonic fibroblast (MEF) Trex1-null cell line also exhibited this phenotype (Yang 
et al., 2007). Analysis of nucleic acid purified from the cytoplasm of these MEFs 
indicated that it was an ssDNA species approximately 60 – 65 nucleotides (nt) long 
(Yang et al., 2007). Accumulating ssDNA was also found in the hearts of Trex1-
deficient mice (Stetson et al., 2008). Sequence analysis of this ssDNA revealed that 
much of it is derived from repetitive elements, and therefore Stetson et al. suggested 
that it is derived from endogenous retroviral DNA (Stetson et al., 2008). 
Consequently, reverse transcribed DNA is a putative endogenous substrate for Trex1 




1.2.5.2.4. Trex1 is a negative regulator of the innate immune response 
to DNA 
Trex1 expression is induced in vitro in response to transfection with phosphodiester-
containing dsDNA which lacks contiguous CpG motifs (Stetson et al., 2008). This 
interferon stimulatory DNA (ISD) is known to induce type I IFN production in a 
Toll-like receptor (TLR)-independent mechanism, involving IRF3 activation (Stetson 
and Medzhitov, 2006). Trex1-deficient cells respond normally to ISD, indicating that 
Trex1 is not a cytosolic DNA sensor but instead is likely to function in the 
metabolism of endogenous ligands of the ISD pathway (Stetson et al., 2008). Failure 
to do this results in the accumulation of unprocessed ssDNA and the development of 
lethal autoimmunity in mice deficient in Trex1 activity (Morita et al., 2004; Stetson 
et al., 2008). 
 
1.2.5.2.5. TREX1 is a member of the SET complex 
TREX1 is a component of the SET complex, an ER-associated multi-protein 
complex also containing the endonuclease NM23-H1, its inhibitor (the nucleosome 
assembly protein SET), together with HMBG2 and APE1 (reviewed by Chowdhury 
and Lieberman, 2008). The SET complex relocates to the nucleus in response to 
superoxide generated by mitochondria damaged by granzyme A protease 
(Chowdhury et al., 2006). Granzyme A cleaves SET, which in turn releases NM23-
H1 to introduce single-stranded nicks in the target cell. TREX1 then removes the 
resulting free 3́ ends, causing irreparable damage to the DNA, resulting in caspase-
independent cell death (Chowdhury et al., 2006). A TREX1 mutation which affects 
enzyme activity and impairs this process has been id tified in families with familial 
chilblain lupus, implicating TREX1 in disease pathogenesis (Lee-Kirsch et al., 
2007a; Rice et al., 2007a).  
 
The SET complex has also been implicated in the facilitation of HIV-1 infection by 
preventing the viral genome from autointegration: a suicidal mechanism whereby the 
viral genome accidentally inserts into itself (Yan et al., 2009). During the generation 
of dsDNA from the ssRNA retroviral genome in the cytosol of infected cells, 
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unwanted byproducts such as autointegrated DNA and ssDNA are generated, which 
are bound to and degraded by the SET complex (Douville and Hiscott, 2010; Yan et 
al., 2009). Failure to do this results in the accumulation of these defective nucleic 
acids which are unable to integrate into the host cell. It is hypothesised that 
subsequent detection of these DNA species by cytosolic receptors of the innate 
immune system induces a type I IFN antiviral response (Douville and Hiscott, 2010). 
Therefore, in the absence of the SET complex, autointegration is enhanced and HIV 
chromosomal integration is decreased (Yan et al., 2009). 
 
Similarly, it has also been demonstrated that TREX1 plays a direct role in the 
suppression of interferon production in response to HIV-1 infection by degrading 
viral reverse transcripts that would otherwise accumulate in the cytosol and trigger 
an innate immune response via an unknown cytosolic DNA sensor (Yan et al., 2010). 
Together, these studies suggest that cellular TREX1 acts to promote HIV-1 
replication although it is unclear why a host nucleas  would have this function 
(Geijtenbeek, 2010). 
 
1.2.5.2.6. TREX1 is inducible by certain types of DNA damage 
Both human and murine TREX1 protein expression is iduced in a time- and dose- 
dependent manner in response to treatment with UV and benzo(a)pyrene, which both 
introduce bulky lesions into DNA. This is completely dependent on the transcription 
factor AP-1 and coincides with the translocation of TREX1 to discrete nuclear foci 
(Christmann et al., 2010), which also occurs in response to ionising radiation (Yang 
et al., 2007). Additionally, Trex1-deficient cells are hypersensitive to treatment with 
UV and benzo(a)pyrene and show a delayed recovery from the resultant replication 
inhibition (Christmann et al., 2010). They also show an abnormal response following 
exposure to ionising radiation (Yang et al., 2007). These findings suggest that 
TREX1 may have a role in protecting the cell from certain DNA-damaging agents. 
 
1.2.5.2.7. TREX1 and Aicardi-Goutières syndrome (AGS) 
The majority of TREX1-AGS patients have biallelic null mutations that abrogate the 
enzymatic function of the protein (Crow et al., 2006a; Rice et al., 2007b), contrasting 
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with the predominantly missense mutations identified in the RNASEH2 genes. 
TREX1 mutations are found throughout the gene and the majority are inherited in an 
autosomal recessive manner, with all parents heterozygous for the allele (Rice et al., 
2007b). There are two reported cases of AGS resulting from different de novo 
heterozygous missense mutations, which alter the same amino acid residue in the 
ExoIII domain of TREX1 (Ramantani et al., 2010; Rice et al., 2007a). The 3ʹ → 5́  
DNA exonuclease activity on ssDNA in cells from one of the patients was 
comparable with controls (Rice et al., 2007a). However, analysis of recombinant 
proteins has shown that this mutation reduces the ability of the enzyme to degrade 
nicked dsDNA (Lehtinen et al., 2008). It also inhibits the activity of the wild type 
enzyme, thereby accounting for the dominant phenotype of the mutant allele 
(Lehtinen et al., 2008). TREX1 mutations constitute approximately 35% of AGS 
cases with a known mutation (Figure 1.8). The early-onset neonatal form of AGS is 
particularly prevalent amongst patients with TREX1 mutations (Rice et al., 2007b), 
 
In addition to the TREX1 mutations found in AGS patients, heterozygous mutations 
have been identified in patients with other inflammatory diseases, often sharing 
significant phenotypic overlap with AGS. 
 
1.2.5.2.8. Familial chilblain lupus (FCL) 
Autosomal dominant mutations in TREX1 have been identified in patients with 
familial chilblain lupus, a subtype of lupus erythematosus which manifests in early 
childhood (Lee-Kirsch et al., 2007a; Lee-Kirsch et al., 2006; Rice et al., 2007a). 
Patients develop ulcerating acral skin lesions, similar to the chilblain lesions seen in 
AGS, but do not develop a neurological phenotype (Lee-Kirsch et al., 2006). One 
TREX1 mutation found in patients with familial chilblain lupus has been shown to 
affect the dsDNA degradation activity of the enzyme, similar to the autosomal 
dominant TREX1 mutation (Lehtinen et al., 2008). 
 
1.2.5.2.9. Systemic lupus erythematosus (SLE) 
The study of a large cohort of SLE patients identified monoallelic TREX1 mutations 
in approximately 3% of patients compared to only 0.1% of controls, suggesting that 
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there is a markedly increased relative risk of individuals with these TREX1 variants 
developing SLE (Lee-Kirsch et al., 2007b). Most of the mutations were missense 
mutations, located in the highly conserved C-terminal region (Figure 1.5). 
Additionally, two frameshift mutations, predicted to result in C-terminally truncated 
proteins, were demonstrated to have an altered subcell lar localisation, although their 
enzymatic function was intact (Lee-Kirsch et al., 2007b). 
 
1.2.5.2.10. Retinal vasculopathy with cerebral leukodystrophy (RVCL) 
Heterozygous frameshift mutations in TREX1 which cause C-terminally truncated 
proteins were located in nine families with the autosomal dominant inflammatory 
disorder RCVL (Richards et al., 2007). This adult-onset degenerative disease is 
characterised by visual loss, stroke and dementia, with death occurring 5 – 10 years 
from disease onset (Richards et al., 2007). The mutant proteins retained full 
enzymatic activity but had an altered cellular distribution, predicted to affect their 
interaction with other proteins/substrates and consequently the normal biological 
function of the protein (Richards et al., 2007). 
 
The identification of TREX1 mutations in human diseases other than AGS has shown 
that the nature and location of a mutation within te gene determine the 
consequences in vivo. Mutations completely abrogating the exonuclease activity of 
TREX1 result in severe, early-onset AGS, whilst heterozygous mutations which alter 
the subcellular localisation of the protein (leaving the enzymatic activity intact) result 
in the adult-onset disorders SLE and RCVL. This also il ustrates the importance of 
TREX1 enzymatic activity at the correct location within the cell. 
 
1.2.5.3. Mutations in SAMHD1 cause AGS 
A genotype-phenotype study of AGS patients in 2007 revealed that 17% of patients 
did not have mutations in RNASEH2A, RNASEH2B, RNASEH2C or TREX1 (Rice et 
al., 2007b). Genetic analysis of these patients located  fifth AGS locus (AGS5) on 
chromosome 20q11 (Rice et al., 2009). Mutations in the SAMHD1 gene, encoding 
the SAM domain and HD domain 1 protein (SAMHD1, also known as Dendritic 
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Cell-derived Interferon γ-induced Protein (DCIP)), were identified in 13 AGS 
families. However, the absence of mutations in the five AGS genes in a proportion of 
patients with clinically diagnosed AGS suggested that at least one other AGS locus 
exists (Ramantani et al., 2010; Rice et al., 2009). 
 
1.2.5.3.1. SAMHD1 mutations 
SAMHD1 encodes a 72 kDa nuclear protein (Figure 1.7). As for the TREX1 
mutations reported in AGS patients, both biallelic null mutations and missense 
mutations were found in SAMHD1, affecting both the protein expression levels and 
nuclear distribution of the protein (Rice et al., 2009).  
 
1.2.5.3.2. The cellular function of SAMHD1  
The SAMHD1/DCIP gene was originally identified as an orthologue of the murine 
Mg11 gene (Li et al., 2000). SAMHD1 is the only human protein to contai  sterile 
alpha motif (SAM) domain and a HD domain in tandem (Figure 1.7) (Rice et al., 
2009); however both domains are found separately in a range of proteins with diverse 
biological functions. SAM domains mediate interactions with other proteins, both 
SAM and non-SAM domain containing, and are capable of binding RNA hairpins 
and lipids (reviewed by Qiao and Bowie, 2005). HD domains are found in a 
superfamily of metal dependent phosphohydrolases, with predicted functions in 
nucleic acid metabolism and signal transduction (reviewed by Aravind and Koonin, 
1998). However, SAMHD1 failed to interact with nuclei  acid substrates including 
RNA stem loops, ssRNA, ssDNA and dsDNA, as assessed by surface plasmon 







Figure 1.7. The human SAMHD1 protein. 
Schematic diagram of SAMHD1. The sterile alpha motif (SAM) domain is situated between 
amino acid residues 42 – 110, and the HD domain extends from residues 164 – 319. 




1.2.5.3.3. SAMHD1 and innate immunity 
SAMHD1 is expressed widely, but is absent in normal human br in and thymus 
tissue (Liao et al., 2008). The pro-inflammatory cytokine tumour necrosis factor 
(TNF)-α leads to the upregulation of SAMHD1 expression in human lung fibroblasts 
in an IRF1-dependent manner (Liao et al., 2008). Similarly, murine SAMHD1 
expression is upregulated in a model of acute lung injury and may also contribute to 
Th1-mediated immune responses (Liao et al., 2008). 
 
In macrophages, SAMHD1 expression increases in response to ISD in a type I IFN-
dependent manner (Rice et al., 2009). This response is TLR-independent, and 
suggests that similar to TREX1, SAMHD1 may function n preventing the activation 
of innate immunity by self-nucleic acids within the c ll (Rice et al., 2009). A similar 
role for RNase H2 has not yet been demonstrated, nor is it known if RNase H2 
substrates accumulate in RNase H2-deficient cells and trigger autoimmunity. 
 
1.2.5.4. Spectrum of mutations in AGS patients  
The majority of identified mutations in AGS patients are in the RNASEH2 genes, in 
particular RNASEH2B (Figure 1.8). Onset of disease in AGS patients with
RNASEH2B mutations is significantly later than in patients with mutations in 
RNASEH2A, RNASEH2C or TREX1 (Rice et al., 2007b). RNASEH2B-AGS patients 
often exhibit a milder phenotype than other AGS patients and are significantly more 
likely to survive into early adulthood (Rice et al., 2007b), suggesting that a possible 





Figure 1.8. The proportion of AGS families with mutations in each of the five known AGS 
genes. 
The majority of AGS families have mutations in the genes encoding the RNase H2 complex 
(45% have mutations in RNASEH2B, 15% in RNASEH2C and <5% in RNASEH2A). 35% of 
families have mutations in TREX1, whilst approximately 10% have mutations in the recently 




1.3. Nucleases in autoimmunity and infection 
AGS is not the only human disease caused by defective nuclease activity. The 
DNases I and II also function to prevent accumulation of their nucleic acid 
substrates; failure to do so results in the development of multisystem autoimmune 
disease. However, nucleases can also play a direct rol  in the innate immune 
response, as exemplified by RNase L (as discussed in Section 1.3.3). Therefore, there 
exist a number of different ways by which the AGS nucleases might act to cause 
disease. This section describes in more detail the dev lopment of human disease as a 
consequence of mutations in genes encoding nucleases. 
 
1.3.1. DNase I and SLE 
DNase I is the major nuclease present in serum and uri e (Nadano et al., 1993). It 
acts on ssDNA, dsDNA and chromatin, preferentially cleaving at phosphodiester 
bonds adjacent to a pyrimide base, resulting in products with 5́-phosphate and 3ʹ-
hydroxyl (OH) ends. DNase I activity is reduced in the serum of SLE patients but not 
in patients with the other common autoimmune diseases rheumatoid arthiritis and 
scleroderma (Chitrabamrung et al., 1981). Enzyme levels correlate with disease 
severity; patients with active lupus, in particular active renal involvement, exhibit the 
lowest levels of DNase I activity (Chitrabamrung et al., 1981). 
 
Heterozygous mutations in DNASE1 correlating with reduced enzymatic activity 
have been described in a small number of individuals with SLE (Bodano et al., 2006; 
Shin et al., 2004; Yasutomo et al., 2001). Additionally, autoantibodies against DNase 
I were identified in the sera of a significant number of SLE patients and were shown 
to inhibit enzymatic activity (Yeh et al., 2003). Murine models of SLE confirmed the 
association with DNase I; SLE-prone NZB/NZW mice have decreased serum DNase 
I activity (Macanovic and Lachmann, 1997), and Dnase1-/- mice generated by gene 
targeting exhibit a phenotype very similar to SLE, including the development of anti-




The antibodies characteristic of SLE can mediate organ damage by binding to host 
tissues. Together with autoantigens, they can form im une complexes (ICs) which 
deposit in vascular systems, leading to inflammation, tissue destruction and the 
subsequent release of self-nucleic acids (reviewed by Chan et al., 1999; Singh, 
2005). Autoantibodies forming ICs with DNA derived from dying cells have been 
shown to activate innate immunity in plasmacytoid den ritic cells (pDCs) via 
engagement with Toll-like receptor 9 (TLR9) and FcγRIIa, mediated by High 
Mobility Group Box 1 (HMGB1) and Receptor for Advanced Glycation End-
products (RAGE) (Barrat et al., 2005; Lovgren et al., 2004; Means et al., 2005; 
Ronnblom and Alm, 2003; Tian et al., 2007). Therefore, failure to clear debris from 
apoptotic or necrotic cells can result in the activation of autoimmune recognition by 
the innate immune system. DNase I, in cooperation with the complement factor C1q, 
plays a key role in the degradation of chromatin released from dying cells (Gaipl et 
al., 2004). Consistent with this, deficiencies in chromatin clearance are seen both in 
human SLE patients and mouse models of the disease, which cannot be attributed to 
defects in populations of scavenger cells such as macrophages and immature DCs 
(Licht et al., 2004; Munoz et al., 2009). 
 
Novel mutations in DNASEI have been identified in a small cohort of patients wi h 
autoimmune thyroid disease (AITD). These mutations are predicted to alter the 
stability of the enzyme and consequently, these pati nts have reduced serum DNase I 
activity (Dittmar et al., 2008). This suggests that DNase I may be implicated in the 
pathogenesis of other autoimmune diseases. 
 
1.3.2. DNase II and inflammatory disease  
DNase II (formerly known as acid DNase) non-specifically cleaves both ssDNA and 
dsDNA, resulting in products with a 3ʹ phosphate (Baker et al., 1998; Bernardi, 
1968). It does not require Mg2+ for activity and displays optimal catalytic activiy at 
an acidic pH (Baker et al., 1998; Bernardi, 1968). DNase II localises to the 




A polymorphism in the human DNASEII gene resulting in decreased enzymatic 
activity has been identified (Yasuda et al., 1992). However, having reduced DNase II 
activity in itself is not pathogenic, as people with the lower activity allele were 
healthy (Yasuda et al., 1992). 
 
DNase II has been reported to cleave the G-rich regions within the Ig switch 
recombination sequences (Evans and Aguilera, 2003; Lyon et al., 1996), however 
studies in mice have shown that the primary functio of DNase II is the degradation 
of DNA engulfed by macrophages (Kawane et al., 2001). 
 
The extensive analysis of DNase II null mice, which die late in embryonic 
development, revealed an essential role for DNase II in degrading the DNA of 
apoptotic cells and nuclei expelled from erythroid precursor cells phagocytosed by 
macrophages (Kawane et al., 2001; Kawane et al., 2003). Consequently, embryos 
lacking DNase II activity exhibit defects in erythropoesis in the liver, leading to 
severe anaemia (Kawane et al., 2001; Krieser et al., 2002), in addition to impaired 
thymic development (Kawane et al., 2003). Fragments of self-DNA were shown to 
accumulate in the macrophages of these embryos (Kawane et al., 2003; Krieser et al., 
2002). The presence of elevated levels of the cytokines IFN-β, IFN-γ and TNF-α in 
the thymii of DNase II-/- embryos implied that the innate immune system becom s 
activated in response to the undegraded DNA engulfed by the macrophages (Kawane 
et al., 2003). IFN-β in particular is reported to be cytotoxic to erythoblasts and 
lymphocytes (Yoshida et al., 2005). The IFN production in DNase II-/- mice was 
shown to be TLR9-independent (Okabe et al., 2005; Yoshida et al., 2005), but was 
dependent upon IRF3 and IRF7 activation, although the TNF-α production was not 
(Okabe et al., 2008).  
 
The embryonic lethality of DNase II null mice was rescued by deficiency of the type 
I IFN receptor gene (IFNAR) (Yoshida et al., 2005). DNase II-/-/IFNAR-/- mice were 
viable but developed a chronic polyarthritis, which closely resembled human 
rheumatoid arthritis (Kawane et al., 2006). At the onset of pathogenesis, levels of 
TNF-α were elevated in the bone marrow of these mice, which suggested that the 
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failure of macrophages to degrade apoptotic/erythroid precursor DNA caused them 
to produce TNF-α. This in turn would activate synovial cells to produce other 
cytokines and so drive the development of chronic polyarthritis (Kawane et al., 2006; 
reviewed by Nagata et al., 2010). Therefore, the consequence of loss-of-functio  
mutations in DNase II provides a further example of the accumulation of 
unprocessed nucleic acids leading to disease.  
 
1.3.3. RNase L and the IFN-induced antiviral pathway 
The endoribonuclease RNase L is the key effector of the 2-5A system, an enzymatic 
RNA decay pathway activated by IFNs and dsRNA (Zhou et al., 1993). RNase L is 
expressed in the majority of mammalian cell types but is latent until it is bound by 
small specialised oligonucleodides called 2ʹ, 5́ -oligoadenylates (2-5A), which are 
synthesised from ATP by 2-5A-oligoadenylate synthetas  (OAS) proteins, in 
response to IFN (Rebouillat and Hovanessian, 1999; Zhou et al., 1993). The OAS 
proteins are constitutively expressed at low levels and can act as pattern recognition 
receptors (PRRs) for the detection of viral dsRNA in the cytoplasm (reviewed by 
Sadler and Williams, 2008). Activated RNase L dimerises and cleaves ssRNA at 
UpN sequences, resulting in products with a 3ʹ-phosphate (Floyd-Smith et al., 1981). 
RNase L degrades viral RNA as a method of intrinsic cellular defence but can also 
cleave self RNAs (reviewed by Liet al., 2010). RNA degraded by RNase L can act 
as a ligand for the cytoplasmic RNA helicases RIG-I and MDA5, leading to the 
induction of a type I IFN response (Malathi et al., 2007). In addition to this role in 
the antiviral response, RNase L has been shown to be required for an effective 
antibacterial response (Li et al., 2008). 
 
A number of other cellular functions have been attribu ed to RNase L, including a 
role in myoblast differentiation (Bisbal et al., 2000) and as a tumour suppressor (Al-
Ahmadi et al., 2009; Liu et al., 2007; Zhou et al., 1997). In addition to defects in 
immune signalling in response to pathogens, RNASEL-deficient mice have enlarged 





Germline mutations in RNASEL have been identified in patients with hereditary 
prostate cancer (HPC) (Carpten t al., 2002; Casey et al., 2002). There is a 
particularly strong association of the RNASEL R462Q variant with the disease, with 
homozygotes having a two-fold increased risk of developing prostate cancer (Casey 
et al., 2002). The mutation was shown to result in a three-fold decrease in the 
catalytic activity of the enzyme, due to impaired dimerisation of the protein (Casey t 
al., 2002; Xiang et al., 2003).  
 
It was proposed that inherited defects in RNase L could permit infection with an 
oncogenic virus leading to disease. Subsequently, a novel retrovirus, xenotrophic 
endogenous murine leukaemia retrovirus (XMRV) was identified almost exclusively 
in HPC patients homozygous for reduced activity variants of the RNASEL gene 
(Dong et al., 2007). XMRV cDNA was isolated from human prostate cancer tissue 
and shown to be infectious, via engagement with xenotrophic and polytrophic 
retrovirus receptor 1 (XPR1) (Dong et al., 2007). The virus was sensitive to IFN, 
which strongly implicated RNase L in the IFN antiviral response against XMRV 
(Dong et al., 2007; Fan, 2007). Interestingly, XMRV does not contain any host-
derived oncogenes, nor was it shown to integrate wihin/near any known proto-
oncogenes or tumour suppressor genes, therefore it has been hypothesised that its 
involvement in the pathogenesis of prostate cancer is via a paracrine mechanism 
(Kim et al., 2008a; Summers and Crespi, 2008). Germline RNASEL mutations 
leading to an increased risk of disease have since been described in patients with 
other types of cancer (Madsen t al., 2008), implying that RNase L defects may not 
be limited to prostate cancer. 
 
1.3.4. FEN-1, inflammation and cancer 
Loss-of-function mutations in the gene encoding the FEN-1 nuclease, which is 
involved in DNA replication and repair, have also been linked to human disease. 
This structure-specific nuclease, formerly known as DNase IV, has three separate 
nuclease activities: flap-specific endonuclease (Harrington and Lieber, 1994), 5ʹ-
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exonuclease (Kikuchi et al., 2005) and gap-dependent endonuclease activities (Zheng 
et al., 2005). Heterozygous somatic mutations in FEN1 have been identified in 
human cancers, the majority of which abrogate both the 5́-exonuclease and gap-
dependent endonuclease activities of the enzyme (Zhng et al., 2007). These 
activities are essential for DNA repair and apoptotic DNA fragmentation. 
Consequently, transgenic mice harbouring one of the human FEN1 mutations 
exhibited an increased sensitivity to DNA-damaging agents, an impaired ability to 
undergo apoptosis, and accumulated incompletely digested DNA fragments in 
apoptotic cells (Zheng et al., 2007). The mice subsequently developed anti-nuclear 
antibodies (ANAs) and ICs, which deposited in the kidneys and lungs, and a chronic 
inflammatory response (Zheng et al., 2007), which therefore provides a further 
example of the activation of autoimmunity and inflammation as a consequence of 
failure to clear apoptotic debris.  
 
In addition to the autoimmune phenotype, these mice had a greatly increased risk of 
tumourigenesis, suggesting that FEN-1-deficiency leads to a higher risk of mutations 
in tumour-suppressor genes and oncogenes (Zheng et al., 2007). Additionally, the 
chronic inflammation promoted cancer progression in these mice, via activation of 
the transcription factor NF-κB (Zheng et al., 2007). 
 
In summary, nucleases function across a wide range of c llular processes. Whilst 
OAS-RNase L functions in a PRR pathway, the other nucleases described in this 
section play key roles in the removal of nucleic acid-containing material from dead 
cells. Failure to clear cellular debris induces a destructive inflammatory response. 
Therefore, loss-of-function mutations in genes encoding nucleases lead to 
autoimmune disease via activation of the innate immune system by their unprocessed 




1.4. Cellular sources of RNA:DNA hybrids 
As discussed in Section 1.2, loss-of-function mutations in the three genes encoding 
the subunits of the RNase H2 enzyme complex cause AGS. Loss of RNase H2 
activity would be expected to result in increased leve s of its unprocessed substrates, 
as occurs in DNase I- and DNase II-deficient cells. The accumulation of TREX1 
substrates in cells from AGS patients with loss-of-function mutations in TREX1 has 
been reported (Yang et al., 2007). The inappropriate activation of the innate immune 
system by such self-nucleic acids is hypothesised to be responsible for the 
development of the inflammatory response seen in cells lacking TREX1 activity 
(Stetson et al., 2008). 
 
Endogenous RNA:DNA hybrids, the substrates of RNase H enzymes, are naturally 
formed during several cellular processes. The accumulation of RNase H2 substrates 
in cells from AGS patients has not yet been published. Therefore, understanding the 
nature of endogenous RNA:DNA hybrids will assist in he identification of substrates 
which may be immunostimulatory when unprocessed. 
 
1.4.1. DNA replication and Okazaki fragments 
The successful replication of DNA during S phase of the cell cycle is an essential 
cellular process. The DNA is first unwound by helicases, forming a replication fork 
structure (Figure 1.9). The two strands of the fork, the leading strand and the lagging 
strand, serve as templates for replication. In eukaryotes, the DNA polymerase-α (pol-
α)/primase complex is recruited to these structures where it initiates replication by 
synthesising short (8 - 12 nt long) RNA primers. The primase tightly binds these 
RNA primers to protect them from degradation (Yuzhakov et al., 1999).  
 
On the leading strand, the primase complex is displaced and the nascent DNA 
synthesised in a continuous manner by pol-ε (Lee et al., 1991; Pursell et al., 2007). 
However, as polymerases can only synthesis DNA unidirectionally (5́ → 3́ ), the 
lagging strand is replicated discontinuously, with small stretches of DNA synthesised 
at a time, which requires frequent re-priming (Figure 1.9). 
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The DNA polymerase-α/primase complex switches from primase activity to DNA 
polymerase activity and extends the RNA primers by ynthesising short 
(approximately 20 nt) stretches of initiator DNA (Arezi and Kuchta, 2000; Waga and 
Stillman, 1994). The pol-α complex is then displaced by the higher fidelity DNA 
polymerase pol-δ, facilitated by the loading of PCNA (reviewed by Burgers, 2009; 
Tsurimoto and Stillman, 1991). Pol-δ then further elongates the chimeric RNA-DNA 
primer (Okazaki fragment) in a progressive manner until it encounters the 5ʹ end of 
the previously synthesised Okazaki fragment (reviewed by Waga and Stillman, 
1998). The synthesis and joining of Okazaki fragments is a highly conserved process, 






Figure 1.9. Okazaki fragments formed during lagging strand replication. 
Replication of the lagging strand involves frequent repriming of the strand, resulting in 




Removal of the initiator RNA-DNA primers is required for DNA replication to be 
completed, as DNA ligase 1 will not efficiently ligate RNA-DNA nicks (Stith et al., 
2008). Pol-α lacks proof-reading activity, therefore part of the initiator DNA as well 
as the RNA has to be removed to maintain replication integrity (reviewed by Kao 
55 
 
and Bambara, 2003). Pol-δ is able to proof-read the nascent DNA for errors made by 
pol-α (Pavlov et al., 2006). Upon encountering the downstream Okazaki fr gment, 
the 5́-end of the primer is displaced, creating an RNA-containing single-stranded 
flap. The size of the flap is determined by the extent of elongation of the fragment by 
pol-δ (reviewed by Burgers, 2009; Stith et al., 2008). Short flaps (1-2 nt) are cleaved 
by FEN-1 to generate a nick, which is filled in by DNA ligase 1 (Ayyagari et al., 
2003; Burgers, 2009). The flap can then undergo nick translation until all of the 
initiator RNA is removed (reviewed by Burgers, 2009). The maturation of Okazaki 
fragments in this way results in a complete strand of newly synthesised DNA. FEN-1 
activity is stimulated by interaction with PCNA (Mag  et al., 2001) and by the 
activity of the WRN helicase in human cells (Brosh et al., 2001; Chakraborty and 
Grosse, 2010). Longer flaps or flaps adopting secondary structures are processed by 
an additional multifunctional nuclease, DNA replicat on helicase 2 homologue 
(Dna2) (Bae et al., 2001; Bae and Seo, 2000). 
 
RNase H enzymes were implicated with a role in the removal of the short RNA 
primers, in cooperation with FEN-1 (Bae et al., 2001; Bambara et al., 1997; Turchi et 
al., 1994). However, studies in S.cerevisiae suggest that RNase H2 is functionally 
redundant with Rad27p (the FEN-1 orthologue) (Ii and Brill, 2005) and instead 
indicate that Rad27p and Dna2 act to remove the RNA primers in an RNase H-
independent manner (Bae and Seo, 2000; Rossi and Bambar , 2006).  
 
In Xenopus laevis, it has been shown that new RNA-DNA primers continue to be 
synthesised by pol-α downstream of stalled replication forks, leading to an 
accumulation of these primers which activate Chk1-mediated cell cycle checkpoints 
(Van et al., 2010). It has not yet been established if primer accumulation occurs in 
mammalian cells. 
 
1.4.2. RNA:DNA hybrids and transcription 
An R loop is formed when a newly transcribed RNA strand is base paired with one 
DNA strand of a DNA duplex, leaving the displaced DNA strand single-stranded 
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(Figure 1.10) (Thomas et al., 1976). In vivo, stable R loops are known to exist in both 
prokaryotes and eukaryotes, arising as a consequence of the synthesis of a guanine 
(G)-rich RNA strand by an RNA polymerase transcribing a cytosine (C)-rich 
template (Lee and Clayton, 1996; Yu et al., 2003). RNA:DNA hybrid duplexes 
consisting of a purine-rich RNA strand and a pryimidine-rich DNA strand have a 
greatly increased stability compared to the equivalent DNA duplex (discussed further 
in Chapter 4) and so the R loop structures persist preferentially in these regions 
(Ratmeyer et al., 1994). It has recently been shown that a nick in the nontemplate 
strand can act as a site for R loop initiation, even in the absence of G-rich sequence 






Figure 1.10. An R loop. 
Schematic representation of the formation of an R loop. The G-rich newly-transcribed 




1.4.2.1. R loops at origins of replication 
The presence of relatively short (~140 bp) R loops at bacterial origins of replication 
has been well characterised (Baker and Kornberg, 1988; Itoh and Tomizawa, 1980; 
Masukata and Tomizawa, 1990). The transcript within e R loop is processed to 
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provide the RNA primer for synthesis of the leading strand (Belanger and Kreuzer, 
1998) following unwinding of the R loop by helicase activity (Dudas and Kreuzer, 
2001). The R loop therefore provides a method of regulating replication. 
 
The mitochondrial origin of replication in eukaryote cells utilises a similar persistent 
R loop structure (Lee and Clayton, 1996; Xu and Clayton, 1995; Xu and Clayton, 
1996). In addition to those priming leading strand replication at the origins of 
replication, supplementary R loops within the mitoch ndrial genome are proposed to 
have other roles, including altering the conformation of the mtDNA into a more open 
state (Brown et al., 2008). 
 
1.4.2.2. The impairment of transcription elongation by R loops 
A key stage during the transcription of eukaryotic genomic DNA is the formation of 
a stable elongation complex comprising of RNA polymerase II (RNA pol II) and a 
minimal 8 bp R loop consisting of the template DNA strand hybridised to the newly 
transcribed mRNA strand (Kireeva et al., 2000b). This hybrid has a key role in the 
stability and processivity of RNA pol II (Kireeva et al., 2000a; Kireeva et al., 
2000b). However, under certain conditions, including the disruption of RNA binding 
proteins, much longer R loops can be formed co-transcriptionally behind the RNA 
pol II complex (Huertas and Aguilera, 2003). These R loops impair transcription 
elongation and lead to genetic instability by promoting transcription-associated 
recombination (Huertas and Aguilera, 2003; Linet al., 2010). Interestingly, this 
phenotype can be rescued in S. cerevisiae mutants by the overexpression of RNase 
H1, suggesting that the RNA:DNA hybrid needs to be removed for transcription 
elongation to proceed, presumably because they block the way for the next 
elongation by RNA pol II (Huertas and Aguilera, 2003). This provides evidence for a 
biological function for RNA:DNA hybrids, as a transcriptional intermediate able to 
reduce the efficiency of transcriptional elongation (Huertas and Aguilera, 2003; Tous 
and Aguilera, 2007). 
 
The SR protein alternative splicing factor/splicing factor 2 (ASF/SF2) plays an 
important role in the suppression of R loop formation, by binding the nascent G-rich 
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RNA transcript (facilitated by RNA pol II), and consequently preventing the RNA 
from associating with the template DNA strand (Li and Manley, 2005). Eukaryote 
cells deficient in ASF/SF2 have extensive regions of R loops and subsequently 
develop DNA double-strand breaks (DSBs) which activte the cell cycle checkpoints 
and lead to arrest in G2 (Li and Manley, 2005; Li and Manley, 2006). 
Overexpression of RNase H1 suppresses this genomic instability phenotype (Li and 
Manley, 2005).  
 
1.4.2.3. R loops and class switch recombination 
The most extensively characterised persistent R loops in mammalian cells are formed 
following transcription of the highly repetitive G-rich switch regions, located directly 
upstream of each constant region in the genes encoding Immunoglobulin (Ig) in B 
cells. In response to activation by antigen, transcription is stimulated from specific 
promoters in order to switch the isotype of the consta t region of the gene to a more 
specialised class, consequently switching Ig production from IgM to IgG, IgA or IgE 
(reviewed by Fugmann and Schatz, 2003). This class switch recombination (CSR) 
results in the formation of large (frequently > 1 kb) R loops in the switch regions of 
the gene (Daniels and Lieber, 1995; Reaban and Griffin, 1990; Reaban et al., 1994; 
Yu et al., 2003). Cytosines in the displaced single-stranded DNA are converted to 
uracils by the single-strand specific enzyme, Activation-Induced cytosine Deaminase 
(AID). Uracils are unable to pair with the corresponding guanines on the opposite 
strand, therefore the base excision repair machinery s activated. Subsequently DNA 
DSBs are induced within the switch regions. The twoR l op regions, including the 
constant region between them, are excised and the remaining ends joined by the 
DNA repair complexes (Fugmann and Schatz, 2003; Huang et al., 2006). RNA:DNA 
hybrid formation at these specific regions of the Ig genes is therefore an essential 
process in the function of the adaptive immune system. 
 
1.4.3. RNA-templated DNA repair 
The use of RNA as a template for DNA synthesis can occur in S.cerevisiae during 
the repair of DNA double strand breaks (DBSs) as the replicative DNA polymerases 
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α and δ are able to copy short RNA templates (Nick McElhinny et al., 2010; Storici 
et al., 2007). In vitro experiments showed that pol-α is able to copy four 
ribonucleotides embedded in a 45 nt partially double-stranded DNA molecule, 
(Storici et al., 2007). This RNA-templated DNA repair generates a RNA:DNA 
hybrid as an intermediate, which could potentially b ock further elongation of the 
newly synthesised DNA by pol-δ (Storici et al., 2007). It has been hypothesised that 
such RNA-templated DNA synthesis could occur in regions where RNA exists 
within DNA, such as the mitochondrial genome, or when large amounts of 
endogenous RNA are present, specifically during or immediately after transcription 
(Nick McElhinny et al., 2010; Storici et al., 2007). 
 
1.4.4. RNA:DNA hybrids at telomeres 
Telomeres consist of repetitive G-rich dsDNA bound to a multiprotein complex 
located at the ends of linear eukaryotic chromosomes, and play an important role in 
protecting chromosome ends from degradation (reviewed by de Lange, 2005). In 
eukaryotic cells, telomeric DNA repeats are transcribed into telomeric repeat-
containing RNA (TERRA) (Azzalin et al., 2007; Luke et al., 2008; Schoeftner and 
Blasco, 2008) by RNA pol II (Horard and Gilson, 2008; Luke et al., 2008). These 
non-coding TERRA molecules range in size from ~100 nt to ~9000 nt, and can form 
an RNA:DNA hybrid type G-quadruplex structure with the telomeric DNA 
(reviewed by Phan, 2010; Xu et al., 2009). In yeast, it has been shown that a hybrid 
formed between TERRA and DNA inhibits the activity of telomerase, a specialised 
RNP enzyme complex responsible for telomere elongation (Luke et al., 2008). This 
inhibition can be overcome in vitro by overexpression of RNase H, however 
resolution of these hybrids is thought to occur in an RNase H-independent 
mechanism in vivo (Luke et al., 2008). Therefore, it is hypothesised that the prima y 
function of such RNA transcripts is the maintenance of higher-order telomeric 
chromatin structures via the formation of a stable RNA:DNA hybrid at these regions 
which block telomerase binding, and lead to telomere shortening (Azzalin et al., 




Telomerase, which is essential during development but is switched off in mature 
cells (with the exception of cancer cells (Kim et al., 1994)), is active as a high-
fidelity reverse transcriptase, adding multiple identical repeats of DNA to the 3ʹ-ends 
of telomeres (Shippen-Lentz and Blackburn, 1990). Replication is initiated following 
the pairing of the RNA-templating region, a small nucleolar RNA called telomere 
RNA component (TERC) with the incoming ssDNA primer to be extended (Shippen-
Lentz and Blackburn, 1990). This forms an initial RNA:DNA hybrid region of 4 - 5 
bp (Gilley et al., 1995). Following one round of telomere replication, the hybrid is 
transiently dissociated before it repositions at the other end of the template. The 
binding of the protein component of telomerase, telomere reverse transcriptase 
(TERT), to the RNA:DNA hybrid is structurally very similar to the binding of 
retroviral HIV-1 reverse transcriptase (RT) to its substrate, supporting a common 
mechanism of DNA replication between the two enzyme families (Mitchell et al., 
2010).  
 
1.4.5. Endogenous retroelements 
A large proportion of mammalian genomes are derived from endogenous 
retroelement sequences (Deininger and Batzer, 2002). Retroelements are 
characterised by the ability to mobilise to another g nomic location using an RNA 
intermediate. This RNA is reverse transcribed, forming a transient RNA:DNA 
hybrid, before conversion into dsDNA and integration into the genome (reviewed by 
Malik, 2005). A subcategory of retroelements is endogenous retroviruses (ERVs): 
ancient proviral remnants of retroviral infection of the germ-line. Most have 
undergone extensive deletions, however some have retained the ability to code for 
functional proteins (reviewed by Bannert and Kurth, 2004). Activation of human 
ERVs (HERVs) has been implicated as a causative trigge  of autoimmune disease 




1.4.6. Incorporation of ribonucleotides into DNA 
It is not known to which extent ribonucleotides areincorporated into DNA in the 
place of deoxyribonucleotides during normal replication in vivo, particularly as the 
normal cellular environment contains both but an excess of ribonucleotides (Nick 
McElhinny et al., 2010). In addition to the misincorporation of rNTPs by error-prone 
DNA polymerases described in Section 1.1.4.2., incidences of ribonucleotide 
incorporation into DNA have been described in replication intermediates purified 
from human mitochondria (Pohjoismaki et al., 2010; Yang et al., 2002b; Yasukawa 
et al., 2006).  
 
The active incorporation of ribonucleotides as an epig netic mark has been described 
in fission yeast. The Schizosaccharomyces pombe mat1 imprint which marks the 
cells that are able to undergo mating-type switching, consists of two adjacent 
ribonucleotides in one strand of the genomic DNA (Vengrova and Dalgaard, 2004; 
Vengrova and Dalgaard, 2006). Switching initiates when the leading-strand 
replication complex encounters the RNA imprint in the emplate strand. It is unlikely 
that the imprint is formed from an RNA primer remaining after the processing of 
Okazaki fragments and may instead be created by ribose oxidation (Vengrova and 
Dalgaard, 2004). It has not yet been confirmed if the ribonucleotides are comprised 
of uracil or ribothymine (Vengrova and Dalgaard, 2006), however, the ribonucleotide 
imprint provides an example of a naturally occurring RNase H2-specific substrate. 
 
In summary, endogenous RNase H2 substrates arise as a consequence of various 
biological processes, and can play an essential role in numerous cellular processes. It 
is conceivable that RNase H2 deficiency could result in accumulation of any of these 
RNA:DNA hybrid-containing nucleic acid species, triggering the inflammatory 




1.5. Nucleic acids as activators of the innate immune 
response 
The innate immune response is the first-line host defence against pathogenic 
infection. It is an evolutionarily ancient system, found in both the plant and animal 
kingdoms, in contrast to the adaptive immune system which is found only in jawed 
vertebrates (Agrawal et al., 1998; reviewed by Hoffmann et al., 1999). Through the 
genetic rearrangement of receptor gene segments, the adaptive immune response can 
produce T and B lymphocytes targeted to specific pathogens, providing a highly 
specialised and effective response. The receptors of the innate immune system are 
fixed in the genome and do not require rearrangement, r sulting in an immediate 
primary immune response to pathogenic invasion, and subsequent stimulation of 
adaptive immunity (reviewed by Iwasaki and Medzhitov, 2010). 
 
1.5.1. Innate immune recognition of pathogens 
The innate immune system is activated in response to the detection of pathogen-
associated molecular patterns (PAMPs), present in pathogens but normally absent in 
host cells. The pattern recognition receptors (PRRs) of the mammalian innate 
immune system recognise a wide variety of PAMPs, including microbial structural 
components and nucleic acids early in the infection process. 
 
PRR signalling can also be activated in the absence of infection by the release of 
endogenous danger-associated molecular patterns (DAMPs), usually from damaged 
cells (Matzinger, 1994). DAMPs can include proteins, such as HMGB1 (Klune t al., 
2008), and non-protein molecules, including DNA (Imaeda et al., 2009; reviewed by 
Rubartelli and Lotze, 2007; Zhang et al., 2010). 
 
PRRs can be broadly divided into four classes, based on their cellular location 
(reviewed by Kawai and Akira, 2009). The Toll-like receptor (TLR) and C-type 
lectin-like receptor (CLR) families are transmembrane proteins, located at the plasma 
membrane or the endosomal membrane. The Retinoic acid-Inducible Gene I (RIG-I)-
like receptors (RLRs) and Nucleotide-binding Oligomerisation Domain (NOD)-like 
63 
 
receptors (NLRs) are cytosolic receptor families. All of these receptors are widely 
expressed; however specialist cells of the innate immune system, including dendritic 
cells (DCs) and macrophages express specific subsets. 
 
1.5.2. Innate immune recognition of nucleic acids 
Nucleic acids are potent activators of the innate immune response (Table 1.2). The 
detection of viral and bacterial nucleic acids by intracellular PRRs rapidly triggers a 
series of signalling cascades which induce a powerful inflammatory response 
(reviewed by Yoneyama and Fujita, 2010). Activation of these PRRs is particularly 
characterised by the production of type I IFNs, which have key roles in the antiviral 
response, and proinflammatory molecules which drive the inflammatory response. 
 
Distinguishing pathogenic ‘non-self’ nucleic acids from ‘self’ nucleic acids is crucial 
to prevent the inappropriate activation of innate immunity. As described in Section 
1.3, the triggering of autoimmunity by nucleic acids s strongly linked with the 
pathogenesis of inflammatory disorders, including SLE, rheumatoid arthritis and 
AGS. Consequently, activation of innate immune respon es to nucleic acids is tightly 
regulated. In contrast to many autoimmune diseases which have a complex genetic 
basis, AGS provides a monogenic model for understanding the role of nucleic acids 
in the innate immune response.  
 
1.5.3. Membrane-bound sensors of nucleic acids 
TLRs are single transmembrane proteins consisting of an N-terminal leucine rich-
repeat (LRR) region and a cytosolic Toll/Interleukin-1 (IL-1) receptor (TIR) signal 
transduction domain (Rock et al., 1998). They are functional as dimers, 
predominantly homodimers although heterodimers also occur. Ligand binding to the 
LRR induces a conformational change in the receptor which allow binding of the 
TIR to adapter proteins recruiting additional proteins, leading to a signal transduction 
cascade (reviewed by O'Neill and Bowie, 2007). Despit  these similarities, each TLR 
is highly specialised at recognising specific PAMPs (Table 1.2). 
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Within the human TLR family, there are four receptors for nucleic acids; TLR3, 
TLR7, TLR8 and TLR9. All are predominantly located on intracellular membranes; 
including endosome, lysosomes and the endoplasmic reticulum (Latz et al., 2004; 
Nishiya and DeFranco, 2004; Nishiya et al., 2005). The intracellular localisation of 
TLR3 is dependent on a cytoplasmic linker region betwe n the TIR and 
transmembrane domains (Funami et al., 2004; Nishiya et al., 2005), whilst TLR7 and 
TLR9 localisation is mediated instead through the transmembrane domains (Barton 
et al., 2006; Nishiya et al., 2005). This suggests that their primary function c uld be 
the recognition of extracellular nucleic acids, including those derived from pathogens 
or those released from damaged cells (Kawai and Akira, 2006). Alternatively, 
nucleic acids produced by viral replication within the cytosol of a cell could be 
captured within membranous vesicles and brought to the endosomes (Sen and Sarkar, 
2005). There is conservation between the nucleic acid TLRs of human and mice but 
the expression of the receptors on subtypes of cells differs (Rehli, 2002). 
 
In resting cells, TLR3, TLR7 and TLR9 interact with the membrane protein Unc93b1 
in the endoplasmic reticulum (ER) (Brinkmann et al., 2007). Upon stimulation with 
their ligands, Unc93b1 delivers TLR7 and TLR9 to the endosomes where they 
interact with their ligands in the acidic environment (Kim et al., 2008b). Mutations in 
Unc93b1 abolish signalling through these TLRs (Tabeta et l., 2006). TLR7 and 
TLR9 signalling is also dependent upon trafficking to the endosome by another ER 
protein, the chaperone PRAT4A (Takahashi et al., 2007). The necessary 
relocalisation of TLR7 and TLR9 to an environment where they recognise their 
ligands provides an additional control step in the avoidance of inappropriate 
recognition of self nucleic acid.  
 
Interestingly, in DCs Unc93b1 was found to differentially bind to TLR7 and TLR9, 
biasing the response to nucleic acid from RNA-sensing to DNA-sensing (Fukui et 
al., 2009), which may have important implications for autoimmune disease 






TLR3 detects dsRNA and can also interact with the synthetic analogue of dsRNA, 
polyinosine-polycytidylic acid (poly (I:C)) (Alexopoulou et al., 2001; Okahira et al., 
2005). dsRNA is a predominantly viral product, present in the genome of dsRNA 
viruses and as a replication intermediate of ssRNA, ssDNA and dsDNA viruses, 
therefore TLR3 plays a role in the response to infection by a variety of different viral 
species (Tabeta et al., 2004; Wang et al., 2004; Zhang et al., 2007). TLR3 can also 
recognise short interfering RNA (siRNA) in a sequence-independent manner 
(Kleinman et al., 2008). 
 
TLR3 mRNA is widely expressed across many tissues and most i mune cells 
(Applequist et al., 2002; Rock et al., 1998). The TLR3 protein is expressed 
intracellularly by most cells, including conventional/myeloid DCs (cDCs) 
(Matsumoto et al., 2003) but can be detected on the cell surface of some fibroblast 
cell lines (Matsumoto et al., 2002). Plasmacytoid DCs (pDCs) do not express TLR3 
(Hornung et al., 2002; Kadowaki et al., 2001; Okada et al., 2003). 
 
Signalling through TLR3 requires the adapter protein TIR-domain-containing 
adapter-inducing interferon-β (TRIF) (Oshiumi et al., 2003). TRIF recruits the 
signalling molecules Receptor-Interacting Protein 1 (RIP1) and Tumour Necrosis 
Factor (TNF)-Associated Factor 6 (TRAF6). This leads to the subsequent activation 
of TRAF3 and Transforming Growth Factor β-Activated Kinase (TAK1) and their 
downstream signalling pathways. Subsequently, expression of proinflammatory 
cytokines is induced (by the NF-κB transcription factor complex) and type I IFNs (by 
IRF3 and IRF7) (reviewed by Kawai and Akira, 2009; and Yoneyama and Fujita, 






Figure 1.11. Activation of the innate immune system by nucleic acids. 
Intracellular PRRs, including TLRs, RLRs, NLRs and the cytosolic DNA sensors DAI and RNA 
pol III detect pathogenic and self nucleic acids, triggering downstream signalling cascades 
(simplified in this diagram). IRF3 and IRF7 induce type I IFN production, whilst NFκB 
stimulates the transcription of proinflammatory cytokines. Both DNA and RNA can induce 




1.5.3.2. TLR7 and TLR8 
TLR7 and TLR8 recognise viral ssRNA, and TLR7 is required for a type I IFN 
response against ssRNA viruses (Diebold et al., 2004; Lund et al., 2004). In vitro 
stimulations using synthetic oligoribonucleotides (ORNs) and purified viral RNA 
have further refined the nature of the TLR7 nucleic acid ligand. ssRNA containing a 
short stretch of uridines is necessary and sufficient for TLR7 activation in murine  
pDCs, when targeted to the endosome using liposomal transfection reagents (Diebold 
et al., 2004; Diebold et al., 2006; Heil et al., 2004; Lund et al., 2004). Synthetic 
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ligands for TLR7 include imidazoquinoline derivatives, which are small anti-viral 
compounds (Hemmi et al., 2002; Jurk et al., 2002). 
 
In humans, the function of TLR7 overlaps with the closely related TLR8 protein (Du 
et al., 2000). The imidazoquinoline resiquimod R848 can activ te human TLR7/8 
and murine TLR7 but not murine TLR8 (Hemmi et al., 2002). In contrast the 
function of murine TLR8 (originally thought to be no -functional (Jurk et al., 2002)), 
is unclear, as murine TLR7 responds to ligands that are specific for human TLR8 
(Gorden et al., 2006; Heil et al., 2004). It has been recently suggested that TLR8 is 
required for the activation of murine pDCs in response to AT-rich viral DNA 
(Martinez et al., 2010). 
 
As with other TLRs, TLR7 expression is heterogenous between different immune 
cell types (Hornung et al., 2002; Kadowaki et al., 2001; Reis e Sousa, 2004). It is 
highly expressed by both human and murine pDCs and B cells (Edwards et al., 2003; 
Gururajan et al., 2007; Hornung et al., 2002; Kadowaki et al., 2001).  
 
Signalling through TLR7 is dependent on its association with the adapter protein 
Myeloid Differentiation primary response gene (88) (MyD88) (Hemmi et al., 2002) 
and subsequent recruitment of the signalling molecules Interleukin-1 Receptor-
Associated Kinase 1 (IRAK1), IRAK4 and TRAF6 (Figure 1.11). Downstream 
signalling through IRF3/7 induces cytokine expression. In both mouse and human, 
signalling through TLR7 leads to the production of large amounts of type I IFN by 
pDCs and the production of pro-inflammatory cytokines, including IL-6, IL-12 and 
TNF-α, by cDCs (Heil et al., 2004; Takaoka et al., 2005). In pDCs, the recognition 
of viral ssRNA within the endosome by TLR7 is independent of infection by live 
virus or viral replication (Beignon et al., 2005; Lund et al., 2004). In addition, pDCs 
also utlise TLR7 for the detection of cytosolic viral eplication intermediates that are 





The ligand for TLR9 is ssDNA; it was originally thought to respond exclusively to 
bacterial DNA, which contains non-methylated CpG dinucleotides rarely found in 
vertebrate DNA (Bauer et al., 2001; Hemmi et al., 2000). Studies using DNA 
oligonucleotides (ODNs) with a phosphorothiorate (PS)-modified backbone (to 
improve the nuclease resistance of the ODN) further defined the TLR9 ligand as a 
nonmethylated CpG flanked 5ʹ by two purine bases and 3ʹ by two pyrimidines 
(Krieg, 2002). However, it has subsequently been shown that TLR9 detects 
unmodified ssDNA in the endosome in a CpG-independent manner, due to the 
immunostimulatory ability of the natural phosphodiester (PD) backbone, compared 
to the immunoinhibitory effect of a PS-modified backbone (Haas et al., 2008). pDCs 
can produce large amounts of IFN-α as a consequence of TLR9 stimulation by both 
viral (Krug et al., 2004; Lund et al., 2003) and mammalian DNA (Lande et al., 
2007). In all cases, a TLR9 response is critically dependent on the 
compartmentalisation of the DNA into the endosomes (Guiducci et al., 2006). 
 
The expression of TLR9 closely resembles that of TLR7, with the highest expression 
found in pDCs and B cells (Bourke et al., 2003; Hoene et al., 2006; Hornung et al., 
2002). Also, as with TLR7-mediated signalling, MyD88 is required as the adapter 
protein for TLR9 (Hemmi et al., 2000) (Figure 1.11). 
 
As described in Section 1.5.2.1, TLR9 is located in the ER of resting cells but 
relocates to endosomes to engage with its ligand (Latz et al., 2004; Leifer et al., 
2004). Upon entry into the endosome, the ectodomain is cleaved by cathepsins into a 
shorter processed form (Ewald et al., 2008; Park et al., 2008). Signal transduction 
occurs only through the cleaved form of TLR9, suggesting that the need for cleavage 
of receptor adds another step of regulation of an immune response through this 
receptor. It is not yet clear if similar proteolytic cleavage is required to generate a 




1.5.3.4. Intracellular TLRs and autoinflammatory disorders 
The intracellular TLRs are strongly linked to disea pathogenesis in a number of 
chronic inflammatory diseases, including SLE (reviewed by Drexler and Foxwell, 
2010). The loss of tolerance to self-antigens, particularly nucleic acids, and 
subsequent development of auto-antibodies against them is a key stage in the 
development of a disease state in SLE (Barrat et l., 2005; Ehlers and Ravetch, 
2007). The pre-existing circulating auto-antibodies in the sera of SLE patients bind 
self nucleic acid, forming ICs. As discussed in Section 1.3, a potential source of self-
nucleic acid is cellular material released from dying cells and a failure to clear this 
leads to the development of an autoimmune pathology. 
 
ICs containing self-RNA and self-DNA facilitate detec ion of nucleic acid by B cells 
and pDCs via TLR7 and TLR9 (Lau et al., 2005; Leadbetter et al., 2002; Vollmer et 
al., 2005; Yasuda et al., 2007). Activation of B cells via association with the B cell 
receptor (BCR), leads to the production of class-switched anti-DNA and anti-RNA 
auto-antibodies. The production of autoantibodies in response to autoantigens 
engaging with and activating the TLRs is referred to as the Toll hypothesis (Martin 
and Elkon, 2005). 
 
Activation of pDCs stimulates the production of vast mounts of cytokines and 
chemokines. The presentation of antigen to autoreactiv  T cells by pDCs further 
amplifies the involvement of adaptive immunity in SLE. IFN-α, produced in high 
levels by stimulated pDCs, has an immunoregulatory r le in maintaining a positive 
feedback loop for immune activation. It exerts multiple effects on other immune 
cells, inducing the maturation of immature DC subsets and the activation of natural 
killer (NK) cells, T cells and B cells (Le Bon et al., 2001; Nguyen et al., 2000). This 
in turn drives auto-antibody secretion and IC formation. In maintaining the activation 
of immunity, IFN-α stimulates the inflammatory response which can lead to tissue 
damage. 
 
Expression of TLR7 and TLR9 was found to be increased in peripheral blood 
mononuclear cells from SLE patients, which correlated with increased IFN-α 
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expression (Komatsuda et al., 2008). In addition, expression of both the chaperon  
protein UNC93B1 and the adapter MyD88 have been shown t  be increased in 
patients with active SLE which further implicated TLR7 and TLR9 in the 
pathogenesis of SLE (Nakano et al., 2010). The investigation of murine models of 
SLE also revealed an association between increased lev ls of TLR7 and TLR9 and 
disease (Christensen et al., 2006; Fairhurst et al., 2008). 
 
1.5.4. Cytosolic sensors of nucleic acids 
There are a several well characterised cytosolic sensors of nucleic acids in 
mammalian cells, including members of the RLR and NLR families of receptors.  
 
1.5.4.1. The role of RLRs in the recognition of cytosolic RNA 
The RLR family contains three members; RIG-I, Melanoma Differentiation-
Associated gene 5 (MDA5) and Laboratory of Genetics and Physiology 2 (LGP2) 
(Kang et al., 2002; Rothenfusser et al., 2005; Yoneyama et al., 2004). They all share 
a central DExD/H-box RNA helicase domain and a C-terminal regulatory domain 
(CTD). RIG-I and MDA5 also contain two N-terminal caspase activation and 
recruitment domains (CARD) but LPG2 does not (Rothenfusser et al., 2005). The 
IFN response induced by ligand binding to RIG-I and MDA5 is mediated through the 
adapter Interferon-β Promoter Stimulator 1 (IPS-1), which is a mitochondrial 
membrane protein (Kawai et al., 2005; Meylan et al., 2005; Seth et al., 2005; Xu et 
al., 2005). Downstream signalling promotes NF-κB-induced expression of 
proinflammatory cytokines and IRF3/7-induced expression of type I IFNs (Kumar et 
al., 2006) (Figure 1.11).  
 
RLRs are essential for a robust IFN response following viral infection in some cell 
types, including fibroblasts and cDCs, but are non-essential in pDCs which utilise the 





The most extensively characterised RLR is RIG-I. The specific ligand for RIG-I was 
originally identified as ssRNA with a 5ʹ-triphosphate (5́-ppp) using in vitro 
transcribed (IVT) ssRNA (Hornung et al., 2006; Pichlmair et al., 2006). Subsequent 
studies using synthetic 5ʹ-ppp ssRNA have shown that optimal IFN-production via 
RIG-I requires the recognition of RNA sequences with short (minimum of 5 – 10 
bases) base-paired regions including a blunt 5ʹ-ppp end (Schlee t al., 2009b; 
Schmidt et al., 2009). The major natural ligand for RIG-I was identified as the 
genome of RNA viruses. The regions of RNA secondary structure found ssRNA 
virus genomes is sufficient to activate IFN-signalli g when a 5́-ppp is present, 
independent of viral replication (Rehwinkel et al., 2010; Schlee t al., 2009b). 
Cytosolic RNA is abundant in mammalian cells, however the 5́-ppp is generally 
removed by cleavage or capping before the RNA leaves th  nucleus, which provides 
a method of selectively distinguishing self RNA from viral RNA (reviewed by 
Yoneyama and Fujita, 2010). It is not yet clear if RIG-I exhibits sequence 
preferences towards its ligands (Saito et al., 2008; Schlee t al., 2009a; Schmidt et 
al., 2009), but a 5́-ppp-cytosine has been shown to be the weakest stimulator of IFN 
production (Schlee t al., 2009b). 
 
Anti-viral signalling by RIG-I requires a two step process of ligand detection and 
binding. Initially, the 5́-ppp is verified as a PAMP and is strongly bound by the CTD 
(Cui et al., 2008; Takahasi et al., 2008; Wang et al., 2010a). RIG-I then translocates 
along one strand of the base-paired RNA using its ATPase activity, without 
unwinding the RNA (Myong et al., 2009). In the absence of a 5ʹ-ppp, the translocase 
activity of RIG-I is suppressed by the CARDs (Myong et al., 2009). 
 
It is not clear whether additional substrates stimulate an type I IFN response via RIG-
I, as results using short (< 1 kb) poly (I:C) and short dsRNA lacking a 5ʹ-ppp have 
given variable results (Hausmann et al., 2008; Kato et al., 2008; Saito and Gale, 
2008; Schlee et al., 2009a). However, it appears that RIG-I can sense RNA cleavage 
products, generated from self RNA by activated RNase L, which although often 
containing base-paired regions, have 3ʹ-monophosphate ends (Malathi et al., 2007). 
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Therefore, the detection of sub-optimal ligands by RIG-I may still be sufficient to 
induce an IFN response. 
 
In response to certain RNA viruses, RIG-I can signal independently of IPS-1 to 
produce the pro-inflammatory cytokine IL-1β. It associates with the inflammasome 
adapter Apoptotic Speck-like protein with a Caspase- ctivating recruiting domain 
(ASC), triggering caspase-1-dependent inflammasome f rmation in a manner similar 
to the dsDNA-induced AIM2 inflammasome (Poeck et al., 2010) (Section 1.5.4.3). 
 
1.5.4.1.2. MDA5 
Although structurally very similar, RIG-I and MDA5 respond differentially to 
specific RNA viruses (Gitlin et al., 2006; Kato et al., 2006; reviewed by Rehwinkel 
and Reis e Sousa, 2010). Viral activation of MDA5 in vitro is dependent on the 
presence of high molecular weight viral RNA, which forms a branched structure 
containing both single- and double-stranded regions (Pichlmair et al., 2009). 
Similarly, MDA5 responds to long ( > 1 kb) poly (I:C) but RIG-I does not (Kato et 
al., 2008; Kato et al., 2006). This could be because long poly (I:C) also forms the 
higher-order structure specific for MDA5 recognition (Pichlmair et al., 2009; 
Rehwinkel and Reis e Sousa, 2010).  
 
1.5.4.1.3. LGP2 
LGP2 binds both single- and double-stranded RNA via its CTD (Murali et al., 2008; 
Pippig et al., 2009). It was originally characterised as a negative regulator of the 
RIG-I-dependent anti-viral response (Rothenfusser et al., 2005) but in vivo studies 
have since revealed that LGP2 actually functions as a positive regulator of RIG-I- 
and MDA5-mediated anti-viral immunity, in cDCs and MEFs but not pDCs (Satoh et 
al., 2010). LGP2 was shown to act upstream of RIG-I and MDA5, and is 
hypothesised to facilitate binding of these helicases to viral RNA by unwinding 
complex structures or removing proteins from the viral ribonucleoprotein complexes 
(RNPs) to free the RNA genome (Satoh et al., 2010). Accordingly, LGP2 was not 
required for the response to synthetic RNA including poly (I:C) and IVT 5́-ppp 
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dsRNA and ssRNA (Satoh et al., 2010). However, LGP2 can also interact with IPS-
1, potentially blocking its associations with downstream kinases and subsequent 
stimulation of IFN production (Komuro and Horvath, 2006). Its roles in the RIG-
I/MDA5 pathways have not been fully elucidated. 
 
1.5.4.1.4. Regulation of RLR signalling 
In addition to control by LGP2, RIG-I-mediated anti-viral signalling can also be 
positively regulated by STimulator of IFN Genes (STING), a mitochondrial 
transmembrane protein which potently induces IRF3 (Ishikawa and Barber, 2008; 
Ishikawa et al., 2009; Zhong et al., 2008; Zhong et al., 2009). STING forms a 
complex with IPS-1 and RIG-I, to which it recruits TRAF family member-
Associated NF-κB activator (TANK)-Binding Kinase 1 (TBK1), which activates the 
downstream transcription factors, consequently stimulating type I IFN expression 
(Zeng and Chen, 2008). This appears to be cell type specific, as DCs and 
macrophages from STING-deficient mice responded normally to RNA virus 
infection whereas viral replication in fibroblasts lacking STING was increased 
(Ishikawa and Barber, 2008). The recently identified WD-repeat containing protein 5 
(WDR5) may also play a key role in the assembly of a virally-induced signalling 
complex with IPS-1 and RIG-I at the mitochondrial me brane (Wang et al., 2010b). 
 
1.5.4.2. PKR 
The IFN-regulated, dsRNA-dependent Protein serine/thr onine Kinase R (PKR) has 
also been implicated in the production of IFNs following viral infection (Meurs et 
al., 1990). Inactive PKR binds dsRNA in the cytosol and subsequently becomes 
activated via autophosphorylation events. It then phos horylates the α subunit of 
eukaryotic protein synthesis Initiation Factor 2 (eIF2α), resulting in a global 
inhibition of protein synthesis in virally infected cells (reviewed by Cole, 2007). 
PKR requires a minimum of 33 bp dsRNA for activation (Zheng and Bevilacqua, 
2004), however it has been proposed activation can o cur following the binding of 
PKR to 5́-ppp ssRNA with limited secondary structure (Nallagatla et al., 2007). The 
role of PKR in generating an anti-viral IFN response differs from the RLRs, which 
induce IFN gene expression. Instead, PKR acts post-transcriptionally, influencing 
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protein translation by regulating the stability of the IFN mRNA transcripts (Schulz et 
al., 2010). The involvement of PKR in an antiviral IFN response is both virus 
(Schulz et al., 2010) and cell type specific (Diebold et al., 2003; Hornung et al., 
2004). 
 
1.5.4.3. NLRs and nucleic acids 
The NLR family of cytosolic proteins includes the Nucleotide-binding 
Oligomerization Domain-containing proteins NOD1 and NOD2, which have an 
established role in the response to intracellular bacterial components (reviewed by 
Ting et al., 2010). In murine cells, Nod2 expression is induced in response to 
transfection with 20 nt ssRNA or infection with a ssRNA virus (Sabbah et al., 2009). 
The protein was shown to positively regulate type I IFN production via an interaction 
with IPS-1, although it is not yet clear if Nod2 directly interacts with viral ssRNA or 
if it forms a complex with RIG-I and IPS-1 (Sabbah et al., 2009). Additionally, 
human NOD2 has been shown to interact with one of the OAS proteins (OAS2), 
which positively regulated RNase L activity, implying that it may also play a role in 
enhancing antiviral responses (Dugan et al., 2009). 
 
The pro-inflammatory cytokine response to viral infection is mediated by a member 
of another NLR subfamily. NLRP3 is triggered by a range of pathogen- and host-
derived molecules, including nucleic acids, to form an inflammasome, via the 
adapter protein ASC (Allen et al., 2009; Delaloye et al., 2009; Muruve et al., 2008). 
The NLRP3-inflammasome triggers the release of IL-1β and IL-18 through caspase-
1-mediated cleavage of their precursors. Gain of function mutations in NALP3 are 
present in several autoinflammatory disorders (reviewed by Franchi et al., 2009). 
 
Inflammasome formation in response to cytosolic nucleic acids also occurs via the 
Haematopoietic Interferon-inducible Nuclear protein (HIN)-200 family member 
Absent In Melanoma 2 (AIM2). In response to direct binding of dsDNA, AIM2 
forms an inflammasome with ASC and caspase-1, leading to the production of IL-1β 
(Burckstummer et al., 2009; Fernandes-Alnemri et al., 2009; Hornung et al., 2009; 
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Roberts et al., 2009). However, neither the NLRP3- nor the AIM2-inflammasome 
pathways are essential for IFN production in respone to cytosolic dsDNA (Hornung 
et al., 2009; Muruve et al., 2008). 
 
1.5.4.4. DAI 
Transfection of dsDNA into cells is known to induce a TLR9-independent IFN 
response (Ishii et al., 2006; Stetson and Medzhitov, 2006; Yasuda et al., 2005b). The 
IFN-inducible protein DNA-dependent Activator of IRFs (DAI) was identified as a 
cytosolic sensor for dsDNA, increasing in expression in response to the synthetic B-
form DNA poly(dA:dT) (Takaoka et al., 2007). Poly (dA:dT) is also an activator of 
the AIM2 inflammasome, but only induces an IFN-response via DAI (Takaoka et al., 
2007). DAI responds to the introduction of bacterial, viral and mammalian DNA to 
the cytosol, inducing cytokine expression via activation of both the IRF3 and NF-κB 
pathways (DeFilippis et al., 2010; Kaiser et al., 2008; Stetson and Medzhitov, 2006; 
Takaoka and Taniguchi, 2008; Takaoka et l., 2007). It does not interact with RNA 
in vitro (Takaoka and Taniguchi, 2008). The stimulation of DAI by cytosolic DNA is 
sequence-independent but is dependent on DNA length, with longer (in excess of 500 
bp) dsDNA inducing a greater IFN response than short dsDNA (Takaoka and 
Taniguchi, 2008). The role of DAI as a PRR appears to be cell type specific 
(Lippmann et al., 2008). Additionally, DAI-deficient mice still produce type I IFN in 
response to poly(dA:dT), suggesting the existence of other receptors capable of 
inducing an IFN response to this ligand (Ishii et al., 2008). It is not yet clear how 
DAI distinguishes between pathogenic and host DNA in vivo but it is possible that 
nuclease digestion of self-DNA, which could act as a ligand, is required to prevent 
inappropriate activation of immunity via DAI (Takaoka and Taniguchi, 2008). 
 
1.5.4.5. RNA polymerase III 
RNA polymerase III (RNA pol III) is predominantly located in the nucleus, but also 
localises to the cytosol where it has been shown to ac  as a sensor for pathogenic 
dsDNA (Ablasser et al., 2009; Chiu et al., 2009). RNA pol III detects stretches of 
AT-rich dsDNA in the cytosol and uses it as a template for transcription. This 
generates 5ʹ-ppp AU-rich dsRNA which acts as a ligand for RIG-I and stimulates 
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type I IFN induction (Ablasser et al., 2009; Chiu et al., 2009). The RNA pol III-
dependent IFN induction pathway was demonstrated for synthetic dsDNA in the 
form of poly (dA:dT) but was also shown to be crucial for the innate immune 
response to some bacterial DNA and dsDNA viruses (Ablasser et al., 2009; Chiu et 
al., 2009) which were previously known to stimulate RIG-I (Choi et al., 2009; 
Rasmussen et al., 2009). Therefore the uncovering of RNA pol III as the primary 
sensor for poly (dA:dT) reaffirmed the specificity of the RLRs for sensing RNA. 
 
1.5.4.6. Additional sensors of cytosolic DNA 
Recently, two proteomic screens of DNA binding proteins identified novel sensors of 
cytosolic DNA. IFI16, which contains a pyrin domain d two HIN domains, directly 
binds to transfected dsDNA containing a viral sequence motif, leading to the 
recruitment of STING and IRF3/NF-κB mediated expression of type I IFNs and 
other innate immune response genes (Unterholzner et al., 2010). Similarly, two 
members of the aspartate-glutamate-any amino acid-aspartate/histidine (DExD/H)-
box helicase (DHX) family were identified as cytosolic sensors of CpG ODNs in 
human pDC cell lines (Kim et al., 2010). DHX36 binds to type A CpG ODNs to 
trigger production of type I IFNs and other cytokines via IRF7 signalling, whereas 
the closely related protein DHX9 binds to type B CpG ODNs and initiates innate 
immune signalling via NF-κB-dependent pathways. Notably, both helicases requi 
interactions with MyD88 to elicit downstream signalling, demonstrating a vital role 
for the adaptor protein in both endosomal and cytosolic DNA sensing pathways in 
pDCs (Kim et al., 2010).  
 
1.5.5.The production of type I IFNs in response to stimulation 
of the innate immune response by nucleic acids 
As mentioned throughout this section, the triggering of the innate immune response 
by PRR detection of nucleic acids, both pathogenic a d self, leads to the production 
of large amounts of type I IFN. The IFNs are a group f cytokines with numerous 
functions, and exhibit antiviral and antiproliferative actions, whilst modulating both 
the innate and adaptive immune responses. In humans, there are three major classes 
78 
 
of IFNs; type I IFNs, consisting of multiple IFN-α isoforms and single β, ε, κ and ω 
isoforms; type II IFNs consisting of IFN-γ; and type III IFNs consisting of the three 
isoforms of IFN-λ (reviewed by Bogdan, 2000; reviewed by Bogdan et al., 2004; 
Kotenko et al., 2003; Sheppard et al., 2003). 
 
The two major groups of type I IFN isoforms, IFN-α and IFN-β, signal through a 
common cell surface receptor complex called the typI IFN Receptor (IFNAR). This 
comprises two subunits (IFNAR1 and IFNAR2) that are both required to assemble a 
functional receptor complex (Mogensen t al., 1999). The interaction of IFN with 
IFNAR activates a number of signal transduction pathw ys, the best characterised of 
which is the JAK-STAT pathway (reviewed by Taniguchi and Takaoka, 2002). The 
tyrosine kinases Tyrosine Kinase 2 (Tyk2) and Janus Kinase 1 (Jak1) are associated 
with the cytoplasmic tails of the two IFNAR subunits. Receptor binding by 
exogenous IFN-α/β activates the kinases and subsequently results in the 
phosphorylation of the signal transducer and activator (STAT) proteins. This induces 
assembly of the STATs into transcriptional activator c mplexes; including the IFN-
α-Activated Factor (AAF) and IFN-Stimulated Gene Factor 3 (ISGF3) complexes. 
Upon translocation to the nucleus, they bind with hgh affinity to IFN-Stimulated 
Response Elements (ISREs) and IFN-γ Activated Sites (GASs) in the promoters of 
target genes. This leads to induction of the expression of numerous genes, 
collectively known as IFN-Stimulated Genes (ISGs), including IRFs, cytokines, 
chemokines and apoptosis-related genes (de Veer et al., 2001; Samarajiwa et al., 
2009). Members of the IRF family of transcription factors, in particular IRF3 and 
IRF7, bind to the promoters of the IFN-α/β genes and induce expression, contributing 
to the feed-forward loop. Although IFN-α production is primarily controlled at the 
transcriptional level, there is variation in the affinity of the different IFN-α proteins 
and IFN-β for the type I IFN receptor. This affects the stability of the IFN-IFNAR 
complex and consequently the resultant downstream signalling (Cutrone and Langer, 




1.5.5.1. Type I IFN production by plasmacytoid dendritic cells 
Expression of type I IFNs can be rapidly and transie tly induced by several factors, 
but they are produced most notably in response to pathogenic nucleic acids. Virtually 
all cells can produce type I IFNs in response to pathogens, but cells of the immune 
system, pDCs in particular, are by far the most potent producers of IFN-α (Siegal et 
al., 1999).  
 
pDCs are specialised for rapidly producing significant amounts of IFN-α 
immediately following viral infection, via TLR7 and TLR9 – the only TLRs they 
express. They constitutively express high levels of IRF7 mRNA (Coccia et al., 2004; 
Izaguirre et al., 2003; Kerkmann et al., 2003) and initially produce IFN-α 
independent of the IFNAR-dependent feedback loop (Di Domizio et al., 2009; 
Kerkmann et al., 2003). IFN-α production is subsequently amplified via the feedback 
loop, which results in the sustained production of IFN (Kerkmann et al., 2003). pDCs 
produce large amounts of IFN-α in response to TLR9 ligands (CpG-ODNs) and some 
TLR7 ligands (including the synthetic dsRNA poly (A:U), which is approximately 
80 – 350 bp in size (Sugiyama et al., 2008)). 
 
 Studies using the TLR9 ligands have revealed that pDCs have a unique mechanism 
of ligand transfer compared to cDCs, which further enhances their ability to mount a 
robust IFN response. In cDCs, CpG-ODN is rapidly transferred from the early 
endosome to the late endosome, stimulating the expression of pro-inflammatory 
cytokines and the co-stimulatory molecules CD40, CD80 and CD86 via NF-κB-
dependent transcription. In contrast, CpG-ODN is retain d in the early endosome of 
pDCs for much longer, allowing TLR9-MyD88 complexes to form and activated 
IRF7, resulting in a prolonged IFN response (Honda et al., 2005). This mechanism is 
dependent upon the multimeric nature of Type A CpG-ODNs, which are capable of 
forming tertiary structures (Haas et al., 2009; Honda et al., 2005). In contrast, linear 
Type B CpG-ODNs only weakly stimulate IFN-α production by pDCs (Krieg, 2002). 
The retaining of TLR9 ligands in the endosome has also been shown to occur in vivo. 
In individuals with the autoimmune disorder of the skin psoriasis, self-DNA forms a 
complex with the antimicrobial peptide LL37, which has been shown to facilitate 
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uptake of the DNA by pDCs (Lande et al., 2007; Nestle et al., 2005). The DNA was 
shown to be retained in the early endosomes, where it stimulates a sustained IFN-α 
response via TLR9 (Lande et al., 2007) and so drives the development of disease 
(Nestle et al., 2005). This process may also occur in SLE patients, via engagement of 
the pDC FcγRIIa receptor by nucleic acid-containing ICs (as discussed in Section 
1.3.1). 
 
1.5.5.2. Differential expression of type I IFNs 
The boundaries of the type I IFN gene locus, located on human chromosome 9 and 
murine chromosome 4, are defined by the evolutionarly conserved genes encoding 
IFN-β and IFN-ε (Hardy et al., 2004). The number of genes encoding IFN-α family 
members varies between species: 13 protein-coding ge es have been identified in 
human and 14 in mouse. All human and mouse IFN-α and IFN-β genes are 
intronless. The human IFN-α subtypes share approximately 70% amino acid 
sequence identity, and the IFN-α consensus sequence shares 35% identity with 
human IFN-β (Genin et al., 2009). 
 
The IFN-α subtypes are differentially expressed in response to viral infection, 
although this varies greatly depending on both the infecting virus and cell type 
(reviewed by Honda et al., 2006). Although the sequence identity between subtypes 
is high, there seems to be little redundancy in their function, with evidence of 
subtype-specific intracellular signalling during the anti-viral response (Genin et al., 
2009). In mouse, IFN-α4 is the only IFN-α directly induced in response to infection 
with a ssRNA virus and is rapidly produced (Marie et al., 1998). Similar to IFN-α4, 
IFN-β is also an early response gene (Marie et al., 1998).  
 
1.5.5.3. IFN-α in disease 
IFN-α has been implicated in the pathogenesis of an increasing number of 
autoimmune diseases, including AGS, SLE, psoriasis, Sjögren’s syndrome, systemic 
sclerosis and polymyositis (reviewed by Meyer, 2009). Therapeutic uses of IFN-α in 
the treatment of cancer and hepatitis can cause vascular lesions, similar to the 
81 
 
chilblain-like lesions seen in AGS and SLE (Bachmeyer et al., 1996; Campo-Voegeli 
et al., 1998). Additional SLE-like symptoms are also seen, most notably the 
development of ANA, anti-dsDNA antibodies and in rare cases humans undergoing 
IFN-α therapy develop active SLE (Ioannou and Isenberg, 2000). An incident of 
trisomy of the short arm of human chromosome 9 (the location of the type I IFN 
locus) was shown to result in high levels of type I IFN and the development of an 
SLE-like disease (Zhuang et al., 2006), which further implicates IFN production in 
the development of an autoimmune disease state. 
 
Mice with astrocyte-targeted overexpression of IFN-α in the CNS were shown to 
exhibit a significantly increased resistance to infection by neurotrophic viruses. 
However, they developed a structural and functional neuropathology reminiscent of 
that seen in AGS and congenital viral infections (Akwa et al., 1998; Campbell et al., 
1999). This strongly implies that intracellular calcificatations and atrophy seen in 
AGS patients (Figure 1.4) are a direct onsequence of IFN-α production, and further 




1.6. How do mutations in nucleases cause AGS? 
Five genes have been identified as being mutated in AGS patients, which encode two 
nucleases, RNase H2 and TREX1, and the putative phosphohydrolase SAMHD1 
(Crow et al., 2006a; Crow et al., 2006b; Rice et al., 2009). All identified AGS 
mutations in the RNASEH2 and TREX1 genes result in a loss of enzymatic activity, 
and are therefore likely to lead to an accumulation of their unprocessed endogenous 
nucleic acid substrates in patient cells (Figure 1.12). Self-nucleic acids are known to 
activate the innate immune response, inducing production of the type I IFNs, in 
particular, IFN-α which is known to potentiate autoimmune diseases (Chung and 
Older, 1997; Ioannou and Isenberg, 2000; Kataoka et al., 2002; Ladoyanni and 
Nambi, 2005). Excessively high levels of intrathecal IFN-α is likely to be the direct 
cause of the white matter destruction and calcificat ons in the brains of individuals 
with AGS, and also contributes to the development of systemic features (as discussed 
in Section 1.5.5.3).  
 
Evidence from the study of mice deficient in Trex1 activity suggested that Trex1 
may function in the suppression of retroviral infection by degrading replication 
intermediates (Stetson et al., 2008). Another study proposed that Trex1 acts to 
degrade aberrant nucleic acids accumulating in cells as replication intermediates 
during the cell cycle (Yang et al., 2007). It is conceivable that RNase H2 could also
act to degrade RNA:DNA hybrid substrates arising from both of these sources. 
 
Although the true cellular functions of all of the AGS proteins have not yet been 
fully elucidated, it is clear that loss-of-function mutations in nucleases are highly 
likely to result in an accumulation of unprocessed nucleic acid substrates. TREX1 
substrates, potentially derived from reverse transcribed endogenous retroelements, 
stimulate type I IFN production via recognition by an undetermined cytosolic 
receptor (Stetson et al., 2008). The origin and nature of RNase H2 substrates that are 
expected to accumulate in AGS patients is unknown. Furthermore, the 






Figure 1.12. Model of how loss-of-function mutations in the AGS nucleases may result in a 
neuropathology reminiscent of congenital viral infection. 
Impaired enzymatic activity of either TREX1 or RNase H2 is likely to result in accumulation 
of their unprocessed self-nucleic acid substrates. Potential endogenous substrates species 
are illustrated here (ribonucleotides are shown in red, deoxyribonucleotides in blue). 
Pathogenic nucleic acids entering a cell are detected by intracellular PRRs, triggering 
downstream signalling cascades and the production of IFN-α. Accummulated self-nucleic 
acids could potentially be inappropriately recognised by these PRRs, resulting in the 
development of an autoimmune response. High levels of IFN-α is likely to be a direct cause 
of the cerebral calcifications and atrophy in the brains of individuals with AGS and with 





Alternatively, the AGS proteins may function directly in the innate immune response 
to nucleic acids by functioning as PRRs, although this is not thought to be the case 
for TREX1 (Stetson et al., 2008). Furthermore, they may act as components of PRR 
signalling pathways, required to process immunogenic self nucleic acids before the 
induction of type I IFN production and the subsequent damaging autoinflammatory 
response. Evidence of this from mice deficient in Trex1 activity led to the proposal 
of TREX1 as a negative regulator of cell-intrinsic immunity (Stetson et al., 2008). 
 
1.6.1. Hypothesis 
Mutations which reduce/abrogate RNase H2 or TREX1 activity result in an 
accumulation of their unprocessed self-nucleic acidsubstrates which are 
inappropriately recognised as pathogenic by receptors of the innate immune system, 
and that the ensuing production of IFN-α is a direct cause of the neuropathology seen 
in AGS patients (Figure 1.12). 
 
1.7. Aims of this thesis  
The main aims of this thesis were to define a role f r RNase H2 and its RNA:DNA 
hybrid substrates in innate immunity; specifically, does RNase H2 function in the 
innate immune response to nucleic acids and can its RNA:DNA hybrids stimulate 
immunity in vitro? 
 
Initial experiments were performed to establish if RNase H2 is directly involved in 
the innate response to nucleic acids, which revealed that this was unlikely (Chapter 
3). Therefore, a role for RNA:DNA hybrid substrates of RNase H2 in the activation 
of innate immunity was investigated. Reagents for the study of RNA:DNA hybrids 
were characterised (Chapter 4) before a range of synthetic RNA:DNA hybrids with 
different physiochemical properties were designed, synthesised, purified and 
validated (Chapter 5). The ability of RNA:DNA hybrids to stimulate innate 
immunity in vitro was investigated using cell lines and primary cells of the immune 
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system (Chapter 6). In summary, this thesis aimed to define a role for the RNase H2 
complex and its nucleic acid substrates in the innate immune response and in the 
production of IFN-α in AGS. A greater understanding of this would provide 
important clues as to the cellular function of the mammalian RNase H2 complex, the 
development of disease pathogenesis in AGS patients, a d the ability of a novel 
nucleic acid species to stimulate the innate immune system. 
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Chapter 2. Materials and Methods 
 
2.1. General reagents 
2.1.1. Sources of reagents 
Unless stated otherwise, chemicals used during this thesis were obtained from 
Sigma-Aldrich or BDH. UltraPureTM nuclease-free distilled water was from 
Invitrogen. Cell culture media was purchased from Gibco (Invitrogen) or Sigma-
Aldrich. Oligonucleotides were synthesised by Sigma-Genosys, Eurogentec, 
Invitrogen and IBA. Murine cytokine qPCR primer sets were ordered from Real 
Time Primers Llc. All oligonucleotide sequences are list d in Appendix 1. 
 
2.1.2. Preparing solutions 
Solutions were sterilised by autoclaving at 121oC for 15 min at 1 bar. Solutions 
unable to be autoclaved were filter sterilised through a 0.22 µm filter (Millipore). 
RNase-free solutions were prepared using UltraPure wat r, or alternatively by 
overnight treatment with 0.1% (v/v) diethyl pyrocarbonate (DEPC). DEPC-treated 
solutions were autoclaved to inactivate the DEPC. Commonly used solutions are 





Table 2.1. Composition of commonly used buffers in this thesis 
Buffer Components 
10 X PBS 
1.37 M NaCl, 26.8 mM KCl, 26.5 mM Na2HPO4.7H2O, 17.6 mM 
KH2PO4, pH 7.4 
1 X TE 10 mM Tris-HCl, 1 mM EDTA, pH 8.0 
20 X TBE 1.75 M Tris base, 1.78 M boric acid, 40 mM EDTA, pH 8.0 
10 X TBST 0.5 M Tris-HCl pH 7.5, 1.5 M NaCl, 0.2% (v/v) Tween-20 
10 X Tris-glycine SDS PAGE 
buffer 
250 mM Tris base, 1.92 M glycine, 1% (w/v) SDS 
1 X Western transfer buffer 
25 mM Tris base, 192 mM glycine, 0.1% (w/v) SDS, 20% (v/v) 
methanol 




2.2. Cell culture 
2.2.1. Human cell lines 
The HeLa, HEK293 and K562 cell lines were maintained in DMEM. The CCRF-
CEM cell line was maintained in RPMI-1640 containing 2 mM L-glutamine, 0.2 
IU/ml insulin, 1 mM oxaloacetic acid and 0.45 mM pyruvic acid. Jurkat cells were 
maintained in RPMI-1640 medium containing 2 mM L-glutamine and 12.5 mM 
MOPS. LA155n cells were maintained in a 1:1 (v/v) mixture of EMEM and Ham’s 
F-12 containing 2 mM L-glutamine. THP-1 cells were maintained in RPMI-1640 
medium containing 2 mM L-glutamine, 1 mM sodium pyruvate, 10 mM HEPES (pH 
7.2) and 0.05 mM β-mercaptoethanol. All media were supplemented with 10% (v/v) 
foetal calf serum (FCS) (HyClone, Thermo Fisher Scientific), 100 U/ml penicillin 
and 100 µg/ml streptomycin. Trypsinisation of adherent cells was performed with 
trypsin:versene (1:1, v/v) at room temperature for 5 min (room temperature was 
between 18 – 20oC). B lymphoblastoid cell lines (LCLs) were maintaied at 2 – 5 x 
105 cells/ml in RPMI-1640 supplemented with 15% (v/v) FCS, 100 U/ml penicillin 




2.2.1.1. Differentiation of THP-1 cells into macrophage-like cells 
THP-1 monocytic cells were treated with 5 ng/ml phorbol 12-myristate 13-acetate 
(PMA) for 48 h to induce differentiation into fully adherent macrophage-like cells, as 
described previously (Park et al., 2007). Cells were harvested by incubation with 
EDTA solution (3 mM glucose, 10 mM EDTA in RPMI) for 15 min at 37oC. 
Differentiation into macrophage-like cells was confirmed by the upregulation of 
CD14 mRNA using quantitative real time-PCR (qRT-PCR). 
 
2.2.2. Murine cell lines 
The L929 cell line was maintained in DMEM containing 10% (v/v) FCS, 100 U/ml 
penicillin and 100 µg/ml streptomycin. Trypsinisation was performed with 
trypsin:versene (1:1, v/v) at room temperature for 5 min. The S9.6-secreting 
hybridoma cell line HB-8730 (ATCC-LGC Promochem) was maintained in DMEM 
supplemented with 20% (v/v) FCS, 100 U/ml penicillin, 100 µg/ml streptomycin, 0.1 
mM hypoxanthine and 0.016 mM thymidine and grown at 37oC under 5% CO2. 
High-density cultivation of the HB-8730 cell line was achieved using the miniPERM 
Classic Bioreactor System (Greiner Bio-One), following the manufacturer’s 
instructions. 
 
2.2.2.1. Preparation of L929-conditioned medium 
4.7 x 105 L929 cells were seeded in a 75 cm2 flask in 55 ml DMEM containing 10% 
(v/v) FCS, 100 U/ml penicillin and 100 µg/ml streptomycin. Cells were grown under 
standard culture conditions for 7 days without subculturing, after which the 
supernatant was harvested, filtered through a 0.22 µm-filter and stored in 50 ml 
aliquots at –20oC. 
 
2.2.3. Preparation and culture of primary cells 
Murine primary cells were generated from wild type C57/Bl6 mice, except Rnaseh2b 




2.2.3.1. Mouse embryonic fibroblasts (MEFs) 
Embryos were harvested at 13.5 d.p.c. (E13.5) and held in a tissue culture petri dish 
containing culture medium (DMEM supplemented with 20% (v/v) FCS, 100 U/ml 
penicillin and 100 µg/ml streptomycin). Placental and maternal tissues w re removed 
by blunt dissection and each embryo transferred to a fresh dish of medium. Tail-tips 
were taken for genotyping (described in Section 2.3.2.5) and the heads and 
abdominal cavities were removed and discarded. The embryo bodies were separated 
into individual wells of a 6-well tissue culture plate (Greiner Bio-One) with 2 ml 
culture medium and finely chopped using a sterile scalpel. The tissues were then 
passed several times through a graduated pastette to further disrupt them before 
transfer into a 25 ml tissue culture flask with 5 ml culture medium. Adherent 
fibroblast colonies were visible following culture for 48 h at 37oC under 5% CO2. 
When cultures reached 80% confluence, they were washed with PBS and incubated 
with 1 ml Accutase (Innovative Cell Technologies Inc.) for 5 – 10 min at 37oC to 
detach the cells, which were collected and pelleted by centrifugation at 300 x g for 5 
min. Cells were passaged at a 1:3 ratio. MEFs were discarded after approximately 
four passages (prior to the cultures becoming senesc t). 
 
2.2.3.2.1. Harvesting bone marrow 
Adult mice were sacrificed by cervical dislocation, a d femurs and tibiae were 
dissected. The bones were washed once in 70% (v/v) ethanol and rinsed three times 
in PBS. Bone marrow was collected by flushing the marrow through with culture 
medium (RPMI containing 2 mM L-glutamine, 10% (v/v) FCS, 100 U/ml penicillin 
and 100 µg/ml streptomycin) using a 5 ml syringe with a 25 G needle (BD 
Biosciences). Clumps within the bone marrow suspension were dispersed by passing 
the cells through a 21G needle (BD Biosciences). Cells were centrifuged at 300 x g 




2.2.3.2.2. Bone marrow derived-macrophages  
Bone marrow was harvested as described in Section 2.2.3. .1. Live cells were 
counted using trypan blue exclusion, discounting any red blood cells. They were then 
seeded in sterile 9 cm triple vent petri dishes (non-c ated, Greiner Bio-One) at 2 x 
105 cells/ml, in 20 ml culture medium supplemented with either 20 ng/ml M-CSF 
(R&D Systems) or 10% (v/v) L929 conditioned medium. Cells were cultured at 37oC 
under 5% CO2 for 7 days, replacing 10 ml of medium with fresh culture medium on 
days 4 and 6. On day 7, the medium was removed and the adherent cells washed with 
PBS before incubation in EDTA solution (3 mM EDTA, 10 mM glucose in RPMI) 
for 15 min at 37oC. The suspension was collected from the plates and ce trifuged at 
300 x g for 15 min. The pelleted cells were resuspended in culture medium without 
antibiotics and viable cells counted using trypan blue exclusion. 1 x 106 cells were 
seeded in 2 ml culture medium without antibiotics into 6-well plates and the cells 
allowed to adhere for 4 h at 37oC. Cells were washed once with medium and 0.8 ml 
culture medium without antibiotics was replaced in each well. Cells were stimulated 
with PAMPs and nucleic acid ligands (Section 2.2.4) and harvested by incubation 
with EDTA solution (3 mM glucose, 10 mM EDTA in RPMI) for 15 min at 37oC. 
Analysis of expression of the surface markers CD11b and F4/80 was used to confirm 
the phenotype of the cells (Section 2.2.5.1). 
 
2.2.3.2.3. Granulocyte macrophage-colony stimulating factor 
differentiated dendritic cells (GM-CSF DCs) 
Bone marrow was harvested (Section 2.2.3.2.1) and de ritic cells (DCs) were 
generated as described previously (Lutz et al., 1999). Cells were seeded in sterile 9 
cm triple vent petri dishes (non-coated, Greiner Bio-One) at 2 x 106 cells per plate in 
10 ml RPMI-1640 supplemented with 10% (v/v) FCS, 100 U/ml penicillin, 100 
µg/ml streptomycin, 2 mM L-glutamine and 20 ng/ml recombinant murine 
granulocyte macrophage colony stimulating factor (GM-CSF) (Peprotech), and were 
cultured at 37oC under 5% CO2. On day 3, a further 10 ml culture medium containing 
20 ng/ml GM-CSF was added. On days 6 and 8, 9 ml of culture supernatant was 
removed and replaced with 10 ml fresh culture medium containing 20 ng/ml GM-
CSF. On day 10, the cells were harvested by gentle ri sing of the plates with the 
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culture medium. Viable cells were counted and seeded into non-tissue culture grade 
sterile 12-well plates (Corning Life Sciences) at 2 x 106 cells per well in 0.8 ml 
culture medium (without antibiotics) containing 5 ng/ml GM-CSF. Cells were 
stimulated with PAMPs and nucleic acid ligands (Section 2.2.4) and harvested by 
gently rinsing each well with the culture medium. Analysis of the surface marker 
CD11c was used to confirm the phenotype of the cells (Section 2.2.5.1). 
 
2.2.3.2.4. Fms-like Tyrosine Kinase 3 Ligand differentiated dendritic 
cells (FL-DCs) 
Bone marrow cells were harvested (Section 2.2.3.2.1) and resuspended in 0.168 M 
NH4Cl pH 7.2 for 1 min on ice to lyse red blood cells. Following three washes with 
50 ml RPMI containing 10% (v/v) FCS, cells were resuspended in culture medium 
(RPMI-1640 supplemented with 10% (v/v) FCS, 100 U/ml penicillin, 100 µg/ml 
streptomycin, 2 mM L-glutamine, 50 µM β-mercaptoethanol and 200 ng/ml 
recombinant murine Fms-like tyrosine kinase 3 ligand (Flt3-L) (Peprotech). Viable 
cells were counted and 2 x 106 cells/ml seeded in culture medium in 25 cm3 tissue 
culture flasks. Following culture for 8 days at 37oC under 5% CO2, cells were 
harvested by gently rinsing the flask with the culture medium. Cells were centrifuged 
at 300 x g for 5 min and resuspended in culture medium without antibiotics. Viable 
cells were counted and seeded at 2 x 106 cells per well in non-tissue culture grade 
sterile 24-well plates (Corning Life Sciences) in 0.8 ml culture medium without 
antibiotics containing 200 ng/ml Flt3-L. Cells were stimulated with PAMPs and 
nucleic acid ligands (Section 2.2.4) and harvested by gently rinsing each well with 
the culture medium. Analysis of the surface markers CD11c, B220, CD11b and 
CD24 was used to confirm the phenotypes of cells (Section 2.2.5.1). 
 
2.2.4. Stimulation of cells with PAMPs and nucleic acid 
ligands  
Cells were stimulated with a range of TLR ligands, purchased from Invivogen unless 
stated. The TLR3 ligand polyinosinic:polycytidylic a id (poly (I:C)) was used at 
concentrations between 1 – 25 µg/ml and the TLR4 ligand lipopolysaccharide (LPS) 
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(Sigma-Genosys) at concentrations between 100 – 200 ng/ml. The imidazoquinoline 
compound R848, a TLR7/8 ligand, was used at concentrations between 1 – 2 µg/ml. 
The TLR9 stimulatory CpG oligonucleotide (ODN) CpG-ODN 1585, a type A CpG-
ODN (5́ - GGggtcaacgttgaGGGGGG - 3ʹ, where phosphothiorate (PS) bases are in 
capital letters) was used at concentrations between 1 – 10 µg/ml. 45 bp interferon 
stimulatory DNA (ISD) was prepared by annealing twoPAGE-purified 
complementary phosphodiester DNA oligonucleotides (forward: 5́ - 
TACAGATCTACTAGTGATCTATGACTGATCTGTACATGATCTACA - 3́, 
reverse: 5́ - 
TGTAGATCATGTACAGATCAGTCATAGATCACTAGTAGATCTGTA - 3́ 
(Stetson and Medzhitov, 2006). Double-stranded ISD was purified from unannealed 
ssDNA using size exclusion FPLC (Section 2.3.1.8). An immunostimulatory in vitro 
transcribed (IVT) RNA corresponding to the first 99 nt of the neomycin resistance 
gene (a gift from Delphine Goubau) (Rehwinkel et al., 2010) was used to transfect 
IPS-1-/- FL-DCs at 1 µg/ml. The synthetic RNA:DNA hybrid poly (rA:dT) (Midland 
Certified Reagent Company, Inc.) was used at concentrations between 1 - 25 µg/ml. 
Nucleic acids (RNA:DNA hybrids and single stranded oligonucleotides) were used at 
the concentrations stated in the figure legends. All stimulations were performed in a 
final volume of 1 ml. 
 
Prior to transfection, adherent cells (HeLa, L929, MEFs and macrophages) were 
seeded into 6-well plates in 2 ml culture medium without antibiotics and allowed to 
adhere for approximately 4 h at 37oC. HeLa and L929 cells were seeded at 2 x 105 
cells/ml, MEFs were seeded at 1.5 x 105 cells/ml and macrophages were seeded as 
described in Section 2.2.3.2.2. Cells were approximately 70% confluent before 
transfection. The medium was replaced with 0.8 ml fresh medium before the cells 
were transfected. Suspension cells (GM-CSF DCs and FL-DCs) were resuspended in 
0.8 ml culture medium and seeded immediately before transfection (Sections 
2.2.3.2.3 and 2.2.3.2.4). 
 
For the transfection of nucleic acids into cells, Lipofectamine cationic lipid 
transfection reagent (Invitrogen) was used as initial pilot studies showed a high 
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transfection efficiency could be achieved using this reagent (Figure 6.1). 
Lipofectamine has been successfully used to transfect nucleic acids into a variety of 
cell types (see discussion in Section 6.1), therefore f r continuity the same reagent 
was used for all transfections throughout this thesis.  
 
Transfections were performed following the manufacturer’s instructions. Two 
transfection solutions were used: the first contained the appropriate volume of the 
nucleic acid diluted in Optimem (Gibco) to a final volume of 100 µl. The second 
contained 2 µl Lipofectamine 2000 or Lipofectamine LTX and 98 µl Optimem. The 
transfection mixtures were incubated at room temperature for 5 min before they were 
gently added together and incubated for a further 20 min at room temperature. The 
mixtures were then added to 0.8 ml cells which were gently rocked to disperse the 
solution. Transfection control wells containing medium only, Optimem only and 
Lipofectamine only were included in each experiment. Cells were incubated at 37oC 
for the time indicated in the figure legends. Subsequently, the medium from each 
well was harvested, centrifuged at 1500 x g for 5 min and supernatants stored at -
80oC until the quantity of secreted cytokines was determined by ELISA (Section 
2.5.5). The cells were prepared for RNA extraction (Section 2.3.3.1), protein 
extraction (Section 2.4.1) or the analysis of activation marker expression by flow 
cytometry (Section 2.2.5.1). 
 
2.2.5. Flow cytometry 
2.2.5.1. Detection of phenotype and activation markers 
Cells were harvested as described in Section 2.2, resuspended in FACS buffer (1% 
(v/v) FCS in PBS) and 200 µl of each sample transferred to a 96-well V-bottomed 
microplate (Greiner Bio-One). The plate was centrifuged at 450 x g for 2 min and the 
supernatants discarded. The plate was briefly vortexed to disperse the pellet before 
the cells were resuspended in 50 µl FcR block (anti-CD32/CD16) (final 
concentration 100 ng/ml; produced in-house by Andrew MacDonald’s laboratory at 
The University of Edinburgh) diluted in FACS buffer, to block non-specific binding 
to Fc receptors. Cells were incubated for 10 min at 4oC before 50 µl of the antibody 
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staining cocktail was added. All antibody dilutions used during this thesis are listed 
in Appendix 2. Cells were incubated for 15 min at 4oC, before the plate was 
centrifuged as described above. Cells were washed twice in 200 µl FACS buffer, 
resuspended in 200 µl FACS buffer and transferred to a 5 ml polystyrene tube (BD 
Biosciences). Samples were acquired on a BD Biosciences FACSAriaII 
(macrophages and GM-CSF DCs) or a BD Biosciences FACSCantoII (FL-DCs). 
Data was analysed using FlowJo software (v7.6.1, Tree Star). 
 
2.2.6. Visualisation of RNA:DNA hybrids using fluorescence 
microscopy 
1 x 105 L929 cells were seeded onto a 16 mm circular glass coverslip in a 12-well 
tissue culture plate (Greiner Bio-Science) in 2 ml culture medium without antibiotics 
and left for 4 h at 37oC to adhere. Cells were transfected with fluorescein-labelled 
RNA:DNA hybrids as described (Section 2.2.4) using Lipofectamine or other 
transfection reagents according to the manufacturer’s instructions. The transfection 
solutions were applied to the cells for 4 h at 37oC in the dark, after which the cells 
were washed once with 1.0 ml PBS and fixed using 0.5 ml 4% (w/v) 
paraformaldehyde (PFA) in PBS for 10 min at room tep rature in the dark. 
Residual PFA was washed off the cells with PBS. The cell nuclei were stained with 
0.05 µg of the dsDNA-specific dye 4',6-diamidino-2-phenyli dole (DAPI) diluted in 
0.5 ml PBS for 10 min at room temperature in the dark. The cells were rinsed in 
PBS, and the coverslips mounted onto glass microscope slides (SuperFrost; VWR 
International) using Vectashield (Vector Laboratories) and sealed. Fluorescence was 
visualised using a Zeiss Axioplan II fluorescence microscope using the wavelengths 
360 nm (DAPI) and 488 nm (fluorescein). Image capture and analysis were 
performed using in-house scripts written for IPLab Spectrum (v 3.9.5, Scanalytics 
Corp.). 
 




2.3.1. General methods 
2.3.1.1. Spectrophotometric quantification  
The concentration of nucleic acid samples was determin d by measuring absorbance 
at 260 nm using a NanoDrop 1000 UV-Vis Spectrophotometer (Thermo Fisher 
Scientific). 1.2 µl of each sample was analysed. Samples with concentrations 
exceeding the limits for detection (3700 ng/µl for dsDNA, 3000 ng/µl for ssRNA and 
2400 ng/µl for ssDNA, as recommended by the manufacturer) wee diluted before 
analysis. The purity of the nucleic acid sample wasdetermined by calculating the 
absorption at both 260 and 280 nm. A260/A280 ratios for nucleic acid samples free 
from contaminants should be > 1.8 (DNA) and > 2.0 (RNA).  
 
2.3.1.2. Calculation of the molecular weight of nucleic acids 
The molecular weights (MW) of oligonucleotides were calculated using the 
formulas: 
 
MW ssRNA = (An x 329.2) + (Un x 306.2) + (Cn x 305.2) + (Gn x 345.2) 
MW ssDNA = (An x 313.2) + (Tn x 304.2) + (Cn x 289.2) + (Gn x 329.2) 
 
2.3.1.3. Ethanol precipitation 
Nucleic acids were precipitated from aqueous solutin by adding 2.5 volumes of ice 
cold absolute ethanol (200 proof, Molecular Biology Grade; Sigma) and 300 mM 
nuclease-free sodium acetate (NaOAc) (pH 5.2). If necessary, 20 µg nuclease-free 
glycogen (Molecular Biology Grade; Roche) was included as a carrier molecule. 
After thorough mixing by pipetting, the samples were placed at -20̊C for a minimum 
of 2 h. Precipitates were pelleted by centrifugation (16,000 x g, 30 min, 4˚C) and the 
pellet washed once with 2 volumes of 70% (v/v) nuclease-free ethanol before it was 
air-dried for approximately 5 - 10 min and dissolved in an appropriate volume of 




2.3.1.4. Annealing oligonucleotides 
Oligonucleotides used for making RNA:DNA hybrid duplexes were subjected to 
HPLC or PAGE purification by the manufacturers. The purity of selected 
oligonucleotides was checked by denaturing PAGE analysis (Section 2.3.1.6) prior to 
annealing. 20 µM oligonucleotides were annealed in nuclease-free 60 mM KCl, 50 
mM Tris (pH 8.0) before being denatured at 95oC for 5 min. The nucleic acid 
mixture was then allowed to gradually cool to room te perature to permit annealing 
of the duplex before being aliquoted and stored at –80oC or –20oC. The sequences of 
all oligonucleotides used for making RNA:DNA hybrids are listed in Appendix 3. 
 
2.3.1.5. Agarose gel electrophoresis 
Nucleic acid samples were mixed with 1 X sample loading buffer (30% (v/v) 
glycerol, 0.4% (w/v) Orange G) and loaded onto horizontal 0.8% - 3% (w/v) 
TBE/agarose (Hi-Pure Low EEO Agarose, Biogene) gelscontaining 0.5 µg/ml 
ethidium bromide. Samples were electrophoresed in 1 X TBE at 5 V/cm. DNA 
markers consisting of known fragment sizes (5 bp ladder (Fermentas), 100 bp ladder 
(Promega) or 1 kb ladder (Invitrogen)) were included on each gel to allow estimation 
of fragment size. The nucleic acids were visualised using a UV transilluminator 
(BioDoc-It System, UVP). 
 
2.3.1.6. Native polyacrylamide gel electrophoresis 
Size separation of nucleic acids under native conditions was performed using 1.5 mm 
thick native polyacrylamide gels (Appendix 4). Gels were pre-run for 1 h at 5 W in 
4oC prior to sample loading. Samples were mixed with an equal volume of native 
loading buffer (30% (v/v) glycerol, 80 mM HEPES-KOH p  7.9, 100 mM KCl, 2 
mM Mg acetate, 0.03% (w/v) bromophenol blue (BPB) and 0.03% (w/v)  xylene 
cyanol FF (XC)) and electrophoresed in 0.5 X TBE for the appropriate length of time 
(usually 2 – 6 h dependent on the size and strandedness of nucleic acid) at 5 W in 
4oC in a vertical gel tank (Cambridge Electrophoresis, Model No. EV200). BPB and 




2.3.1.7. Denaturing polyacrylamide gel electrophoresis 
Samples of nucleic acids were mixed with an equal volume of 2 x formamide loading 
dye (96% (v/v) deionised formamide (Sigma), 20 mM EDTA pH 8.0, 0.03% (w/v) 
BPB and 0.03% (w/v) XC), denatured for 5 min at 95oC and immediately placed on 
ice to prevent renaturation. Samples were loaded onto a pre-run (1 h at 24 W) 1.5 
mm thick denaturing polyacrylamide-urea gel (Appendix 4) in a vertical gel tank 
(Model EV200, Cambridge Electrophoresis). 2 µl of RiboRulerTM Low Range RNA 
ladder (Fermentas) was included as a size reference. The gel was run for the 
appropriate length of time (usually 1 - 2 h, dependent on the size of the nucleic acid) 
at 24 W, with a metal plate used to distribute heat evenly. BPB and XC were used as 
a reference (Appendix 4). Nucleic acids in the gels were stained (Section 2.3.1.7) and 
imaged using a UV transilluminator (BioDoc-It System, UVP) and a phosphorimager 
(Model FLA-2000, Fujifilm).  
 
2.3.1.8. Nucleic acid stains 
Nucleic acids electrophoresed on polyacrylamide gels were stained with either 
acridine orange (BDH), ethidium bromide (BDH), Vistra Green (Invitrogen) or Sybr 
Gold (Invitrogen). All stains were diluted in gel running buffer (TBE) and staining 
was performed in a glass container in the dark at room temperature on a see-saw 
rocker (Stuart SSL4, Bibby Scientific) . Acridine orange staining was performed 
using 4.3 µM acridine orange (Lauretti et al., 2003) for 10 min followed by 
destaining in ddH2O for a minimum of 10 min. 0.5 µg/ml ethidium bromide was used 
to stain gels for 15 min, followed by destaining in ddH2O for 15 min. Vistra Green 
and Sybr Gold were used according to the manufacturer’s instructions (1:10,000 
dilution, staining for 30 min) and the gels transferred to ddH2O before imaging. 
Stained gels were imaged immediately using a UV transilluminator (BioDoc-It 




2.3.1.9. Fast performance liquid chromatography (FPLC) of nucleic 
acids 
An ÄKTA  FPLCTM machine (GE Healthcare) with a 24 ml Superdex 10/300 GL 
column (GE Healthcare) was used to perform size exclusion chromatography of 
nucleic acids. All FPLC was performed at 4oC. Solutions were prepared with 
UltraPure water and before use were passed through a 0.22 µm filter and degassed 
using a vacuum filter unit (MF75, Nunc). Solutions were chilled to 4oC before use. 
The equilibriation buffer used for each run was the same as the sample buffer the 
nucleic acid was contained in. Typically nuclease-free TE or oligonucleotide 
annealing buffer (60 mM KCl, 50 mM Tris pH 8.0) were used. Prior to beginning 
chromatography, the pumps of the machine were washed with 20% (v/v) ethanol 
before being thoroughly rinsed first with nuclease-free water and then with 
equilibriation buffer. The column was washed with water before being equilibriated 
with two column volumes (CVs) of equilibriation buffer. 100 µl of sample was 
loaded into into a 1 ml superloop which had been washed with equilibriation buffer 
prior to injection of the sample using a glass 1 ml injection needle syringe 
(Hamilton). The superloop was emptied with 100 µl of equilibriation buffer to inject 
the sample onto the column. The sample was eluted with 2 CV of equilibriation 
buffer at a flow rate of 0.4 ml/min. 100 µl fractions were collected into sterile, 
nuclease-free 96 well 2 ml boxes (MASTERBLOCK®, Greiner Bio-One). 
UNICORN software (GE Healthcare) was used to create run programmes and 
analyse data. The ÄKTA FPLCTM machine used during this thesis did not have a 230 
nm or a 260 nm source fitted, therefore absorbance t 280 nm was recorded. After 
PAGE analysis of individual fractions, the required fractions were quantified and 
concentrated by ethanol precipitation (Section 2.1.3.2)  
 
2.3.2. DNA methods 
2.3.2.1. Oligonucleotide primer design 
Oligonucleotides for PCR were designed using Primer3Plus (Untergasser et al., 
2007). Oligonucleotides for quantitative real-time PCR (qRT-PCR) were designed 
using Primer3Plus and the Universal ProbeLibrary Assay Design Center (Roche 
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Applied Science). Criteria for designing oligonucleotides included a GC content of 
between 40 – 60%, a melting temperature (Tm) of at least 50
oC and the absence of 
internal secondary structure. Oligonucleotides pairs were designed to have similar Tm
values and were not complementary to each other at the 3́-termini, to avoid the 
formation of primer-dimers. Specificity of primers for qRT-PCR was validated using 
BLAST (Altschul et al., 1990). The sequences of all oligonucleotide primes used for 
PCR and qPCR during this thesis are listed in Appendix 1. 
 
2.3.2.2. Amplification of DNA by polymerase chain reaction (PCR) 
Selected regions of DNA were amplified using the polymerase chain reaction (PCR). 
Specifically designed oligonucleotide primers (Section 2.3.2.1) were annealed to 
denatured template DNA and extended by a thermostable DNA polymerase. 
Reactions were performed in 20 µl reactions unless otherwise specified. A typical 
reaction mixture contained 1 X FastStart Taq DNA Polymerase reaction buffer, 2 
mM MgCl2, 0.2 mM dNTP mix (Invitrogen), 0.2 – 0.5 µM of each forward and 
reverse primer, 0.4 U FastStart Taq DNA Polymerase (Roche) and 0.1 – 100 ng 
template DNA. The total volume was made up to 20 µl with nuclease-free H2O. 
Minus template (-DNA) and minus PCR mix (-PCR) contr ls were included with 
each experiment. A standard PCR programme was used to achieve amplification, 
which consisted of an initial denaturing step at 95oC for 6 min, then 30 cycles of 
denaturing at 95oC for 30 s, annealing at XoC for 45 s, extension at 72oC for 1 min 
and a final extension at 72oC for 10 min, where X indicated the optimal annealing 
temperature of for each set of oligonucleotide prime s, as determined by a 
temperature gradient. Thermal cycling was performed using a DNA Engine Tetrad 2 
thermal cycler (MJ Research). PCR products were analysed by agarose gel 
electrophoresis (Section 2.3.1.4). 
 
2.3.2.3. High fidelity PCR 
When high accuracy amplification of the template DNA was required, such as the 
production of dsDNA templates for in vitro transcription (IVT), PCR was performed 
using Phusion Flash High-Fidelity PCR Master Mix (Finnzymes) which contains a 
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modified proof-reading DNA polymerase with a highly processive activity. 
Reactions consisted of 1 X Phusion Flash High-Fidelity PCR Master Mix, 0.5 µM of 
each primer and 1 – 100ng of template DNA. Thermal cyc ing conditions consisted 
of initial denaturation of the template at 98oC for 10 s, then 30 cycles of denaturing at 
98oC for 1 s, annealing at 66oC for 1 s, extension at 72oC for 3 s and a final extension 
at 72oC for 1 min. The annealing temperature and extension time were optimised for 
each set of oligonucleotide primers. Thermal cycling was performed using a DNA 
Engine Tetrad 2 thermal cycler (MJ Research). PCR products were analysed by 
agarose gel electrophoresis (Section 2.3.1.4). 
 
2.3.2.4. Amplification of genomic DNA for genotyping of mice 
Genomic DNA (gDNA) obtained from Trizol extraction f embryonic nucleic acids 
(Section 2.3.3.1.2) was amplified using a Genomiphi kit (GE Healthcare). 1 µl of 
DNA was incubated with 9 µl substrate buffer for 3 min at 95oC before 1 µl of DNA 
polymerase mix and 9 µl of reaction buffer was added on ice. The reaction was 
incubated at 30oC for 16 h before it was heated to 65oC for 10 min to deactivate the 
enzyme. 1 µl of the amplified DNA was used as a template for the genotyping PCR 
(Section 2.3.2.5).  
2.3.2.5. Genotyping of transgenic mice with mutations in 
Rnaseh2b 
PCR was performed using 1 µl of template gDNA or boiled embryonic tail soup in a 
25 µl reaction containing 12.5 µl 2 X ReddyMix PCR master mix (Thermo 
Scientific) and 1 µM of each oligonucleotide (loxp_forw, exon7_rev and neo_rev ). 
PCR conditions were as follows: denaturation at 94oC for 2 min followed by 30 
cycles of 45 s at 94oC, 45 s at 58oC, 45 s at 72oC and a final extension step at 72oC 
for 5 min. PCR products were electrophoresed using a 1% (w/v) agarose gel (Section 
2.3.1.4). Expected product sizes were 220 bp for wildtype, 220 bp and 420 bp for 




2.3.2.6. Restriction digest of PCR products 
15 pmol of PCR product generated with a reverse primer containing an EcoRI 
restriction site was incubated with 3 U EcoRI (Roche Applied Science) for 1 h at 
37oC. As the digested product will migrate at a similar size to undigested product on 
an agarose gel, plasmid DNA containing EcoRI sites wa included as a control for 
digestion by the enzyme. Digested DNA was purified as described in Section 2.3.2.8. 
 
2.3.2.7. Lambda exonuclease digest of PCR products 
188 bp PCR products generated using a 5ʹ-phosphorylated forward primer were 
digested with λ-exonuclease (M0262, New England BioLabs) which degrades the 
phosphorylated strand of a DNA duplex, leaving the non-phosphorylated strand 
intact. The concentration of the DNA and the enzyme as well as the reaction time 
was optimised. The digestion of 100 ng/µl of DNA with 5 U λ-exonuclease in the 
reaction buffer supplied with the enzyme for 20 min at 37oC was found to result in 
the highest yield of ssDNA product. 
 
2.3.2.8. Purification of PCR products 
To removed contaminating oligonucleotides, dNTPs, salts and proteins from PCR 
products and restriction enzyme-digested DNA longer than 100 bp, a QIAquick PCR 
Purification Kit (Qiagen) was used according to the manufacturer’s instructions. 
DNA was eluted into 30-50 µl of nuclease-free water or buffer EB (10 mM Tris-HCl, 
pH 8.5) and stored at -20oC. PCR products and igested DNA less that 100 bp in 
length and those requiring concentration were purified using a ChIP DNA Clean & 
Concentrator Kit (Zymo Research) and eluted in 6-30 µl of nuclease-free water or 
the DNA elution buffer provided by the manufacturer. Alternatively, PCR products 
or digests were separated by size by agarose gel electrophoresis and gel purified 
using a QIAquick Gel Extraction Kit according to the manufacturer’s instructions 





2.3.2.9. Techniques for generating long ssDNA 
A number of techniques to generate 188 nt ssDNA were used during this thesis and 
are presented in Chapter 5. Specific methodology is described in this section. 
 
2.3.2.9.1. Asymmetric PCR 
A 362 bp region of the CMV promoter was amplified using 1 ng of an endotoxin-free 
maxiprep of pEGFP-N1 (Clontech) as described in Section 2.3.2.2, using the 
oligonucleotide primers CMVprom_F and CMVprom362_R. The PCR product was 
purified as described in Section 2.3.2.8 and used a a template for asymmetric PCR. 
PCR amplification was performed in 20 µl volumes using 1X FastStart Taq DNA 
Polymerase reaction buffer, 2 mM MgCl2, 0.2 mM dNTP mix (Invitrogen), 0.5 µM 
forward primer (CMVprom_F), 5 µM reverse primer (CMVprom188_R), 0.4 U 
FastStart Taq DNA Polymerase using 0.1 – 10 ng template DNA. PCR conditions 
were as specified in Section 2.3.2.2, using an anneling temperature of 62oC and 
varying the number of cycles from 10 to 50.  
 
2.3.2.9.2. Reverse primer only PCR 
PCR was performed on a 362 bp template, as described in Section 2.3.2.9.1 with 
some modifications. The amount of template, concentration of oligonucleotide 
primer, annealing temperature and number of cycles were optimised. Reactions using 
60 ng of template per 20 µl reaction with 0.5 µM of reverse primer (the forward 
primer was omitted from the reaction), gave the best yi ld of product (as discussed in 
Chapter 5). 
 
2.3.2.9.3. Biotinylated dsDNA experiments 
A 188 bp region of the CMV promoter was amplified using a biotinylated forward 
oligonucleotide primer (biotin-CMVprom_F) and an unmodified normal reverse 
oligonucleotide primer (CMVprom188_R). PCR conditions were as specified in 
Section 2.3.2.2. The PCR product was gel purified as escribed in Section 2.3.2.8 




2.3.2.9.4. Streptavidin supershift to purify the non-biotinylated strand 
500 ng of biotinylated dsDNA PCR product was incubated in the presence or 
absence of 2 µl of Streptavidin-Horseradish Peroxidase (HRP) conjugate (GE 
Healthcare), in a volume of 50 µl in 1.5ml nuclease free tubes. The tubes were 
rotated at 20 rpm (Stuart SB3 tube rotator, Bibby Scientific) for 30 min at room 
temperature. Non-biotinylated PCR products of the same length were included as 
controls. Half of each sample was heated to 95oC for 5 min before 200 ng of each 
sample was analysed using native PAGE (Section 2.3.1.5). 
 
2.3.2.9.5. Binding to streptavidin beads 
100 µl of resuspended streptavidin magnetic beads (Dynabeads® M-280, Invitrogen) 
were washed three times in the binding and washing buffer (5 mM Tris pH7.5, 0.5 
mM EDTA, 1 M NaCl, nuclease-free) before they were incubated with 2 µg of 
biotinylated 188 bp DNA diluted in binding and washing buffer. The mixture was 
rotated at 10 rpm (Stuart SB3 tube rotator, Bibby Scientific) for 30 min at room 
temperature to allow complexing of the biotinylated DNA with the streptavidin 
beads. The beads were immobilised using a magnetic stand (Dynal, Invitrogen). The 
non-bound fraction (NBF) was removed and the beads washed three times in binding 
and washing buffer. To recover the non-biotinylated strand using heat denaturation, 
the beads were resuspended in 20 µl TE and heated to 90oC for 5 min to denature the 
strands. The ssDNA-containing TE was removed immediat ly, to prevent 
reannealing of the single-strands. To recover the non-biotinylated strand by alkali 
denaturation, samples were incubated with 100 µl 0.1 M NaOH, 0.2 M NaCl for 10 
min at room temperature on at 10 rpm (Stuart SB3 tube rotator, Bibby Scientific). 
The supernatant was recovered and the treatment repeated two further times. The 
three resulting supernatants were pooled. The biotinylated strand was recovered from 
the beads by boiling for 2 min at 90oC in 40 µl 95% (v/v) deionised formamide, 10 
mM EDTA to break the biotin-streptavidin bonds. Allfractions were concentrated by 




2.3.2.9.6. Spin columns to separate single- and double-stranded 
nucleic acids 
The use of spin columns to separate ss- and ds- nucleic a ids based upon their 
differential binding to silica under certain chemical onditions was performed using 
methods previously described by Borodina et l. and Beld et al. (Beld et al., 1996; 
Borodina et al., 2003). All centrifugation steps were performed 16,000 x g for 1 min 
at room temperature. A mixture of λ-exonuclease digested and undigested 188 bp 
DNA (total 10 µg in a volume of 100 µl) was diluted with 5 volumes of dsDNA 
binding buffer (5 M guanidine thiocyanate (GuSCN), 100 mM EDTA, pH 8.0). This 
was loaded onto a spin column with a silica membrane (Column 1) (spin column 
from a QIAquick PCR Purification Kit, Qiagen) and centrifuged. The ssDNA-
containing flow through was mixed with 0.5 volumes of ssDNA binding buffer (5 M 
GuSCN, 100 mM 2-(N-Morpholino)ethanesulfonic acid (MES) pH 5.0 – 6.0, 250 
mM MgCl2, 0.5% (v/v) Triton X-100) and loaded onto a second silica spin column 
(Column 2) which was centrifuged. Column 1 (containing bound dsDNA) was 
washed with 400 µl dsDNA binding buffer before both spin columns were washed 
once with 400 µl wash buffer (10 mM Tris-HCl pH 7.5, 80% (v/v) ethanol). The 
membranes were dried by centrifuging once again without buffer before DNA was 
eluted by incubating each silica membrane in 30 µl of 10 mM Tris pH 8.0 for 1 min 
and collecting the flow through in a nuclease-free 1.5 ml tube. dsDNA would be 
expected to elute from Column 1 and ssDNA from Column 2. 
 
2.3.2.9.7. Hydroxyapatite column chromatography 
The separation of ds- and ss-DNA using hydroxyapatite was performed using a 
method based upon that described by Sambrook and Russell (Sambrook and Russell, 
2000). Chromatography was performed at room temperatur . A 1 M stock solution 
(pH 6.8) of sodium phosphate buffer was prepared from 1 M NaH2PO4 and 1 M 
Na2HPO4. A series of buffers of decreasing concentrations wa then prepared using 
this stock solution. 1 g of Bio-Gel HTP hydroxyapatite powder (130-0420, Bio-Rad 
Laboratories) was rehydrated with 2 ml 50 mM phosphate buffer. The slurry was 
transferred to an empty 20 ml plastic chromatography column (Econo-Pac, Bio-Rad 
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Laboratories) and allowed to settle. The column volume (CV) was adjusted to 1 ml 
using 50 mM phosphate buffer before the resin was whed with 10 CVs of 50 mM 
phosphate buffer. A mixture of λ-exonuclease digested and undigested 188 bp DNA 
(total 50 µg) was diluted with 50 mM phosphate buffer to final vo ume of 1 ml and 
added to the column. The DNA solution was held in the column for 10 min to allow 
binding to the hydroxyapatite before it was allowed to flow through the column at a 
flow rate of 6 ml/h. This non-bound fraction (NBF) was retained for analysis. 
Fractions were collected in 15 ml nuclease-free polypr pylene tubes. The column 
was washed with 4 CV of 50 mM phosphate buffers, the first 1 ml of which was 
collected (wash fraction). 1 CV each of increasing concentrations of phosphate 
buffers (ranging from 75 mM to 400 mM) was added to the column and each fraction 
collected. Fractions were dialysed into ddH2O using dialysis tubing (SnakeSkin, 
Thermo Fisher Scientific), changing the ddH2O once an hour for 3 h, before they 
were concentrated using ethanol precipitation (Section 2.3.1.2) using 20 µg glycogen 
as a carrier molecule. Pellets were resuspended in 10 µl TE and quantified using a 
NanoDrop before analysis by native PAGE (Section 2.3.1.5). 
 
2.3.3. RNA methods 
RNA was extracted from cells, tissues and embryos and was quantified using a 
NanoDrop spectrophotometer (Section 2.3.1.1). RNA quality was assessed by 
electrophoresis on a 1% (w/v) agarose gel containing 0.5 µg/ml ethidium bromide. 
All procedures using RNA were performed using filter pipette tips. RNA was stored 
at -80oC. 
 
2.3.3.1. Extraction of RNA from cells 
RNA was isolated from cells using an RNeasy Mini Kit (Qiagen). Medium from 
monolayer cells was discarded and the cells lysed dir ctly in the culture vessel using 
an appropriate volume of the supplied lysis buffer (RLT). Suspension cells were 
harvested and pelleted by centrifugation at 300 x g for 5 min before they were 
resuspended in an appropriate volume of buffer RLT. Cells were homogenised using 
106 
 
a Qiashredder column (Qiagen) by centrifugation at 16,000 x g for 2 min. The 
homogenate was mixed with an equal volume of 70% (v/v) ethanol and applied to a 
spin column. RNA was purified according to the manuf cturer’s protocol, including 
a treatment with 30 U RNase-free DNase I (Qiagen) on the column for 15 min at 
room temperature to degrade any DNA. All centrifugation steps were performed at 
10,000 x g for 1 min at room temperature. RNA was eluted into 50 µl RNase-free 
water. 
 
2.3.3.2. Extraction of RNA from tissues 
Brains, spleens, thymii and hearts were dissected from adult mice, placed in 2 ml 
RNase-free tubes (Ambion), snap frozen in liquid nitrogen and stored at –80oC until 
RNA was extracted. Larger tissues were roughly chopped using an RNase-free blade 
before freezing to allow better penetration of the TRIzol reagent (Invitrogen). 
Tissues were thawed on ice in 1 ml TRIzol before they were disrupted and 
homogenised using a rotor-stator homogeniser (Polytron PT 3100, Kinematica) using 
a 12 mm dispersing aggregate fitting (PT-DA 3012/2EC, Kinematica) at 25,000 – 
30,000 rpm for 10 s. Between three and six repeats were required to fully 
homogenise the tissues, with samples placed on ice between repeats. 500 µl of 
homogenate was transferred to an RNase-free 1.5 ml tube and mixed with 1 volume 
of TRIzol. Samples were then centrifuged at 12,000 x g for 10 min at 4oC to pellet 
any insoluble material. The RNA-containing supernata t was transferred to a new 1.5 
ml tube. 200 µl chloroform was added to each sample and the tubes shaken 
vigorously by hand for 15 s. Following incubation at room temperature for 2 min, 
samples were centrifuged at 12,000 x g for 15 min at 4oC to separate the phases. The 
RNA-containing aqueous phase was removed and transferred to a new 1.5 ml tube. 
To precipitate the RNA, 500 µl isopropanol was mixed with the sample. Following a 
10 min incubation at room temperature, the sample was centrifuged at 12,000 x g for 
10 min at 4oC. The pellet was washed with 1 ml 70% (v/v) RNase-fre  ethanol 
before being air-dried for 5 – 10 min and dissolved in 100 µl nuclease-free water 




2.3.3.3. Extraction of RNA from embryos 
Embryos were dissected and immediately frozen on dry ice before storage at -80oC 
until RNA was extracted. Embryos were thawed on ice in TRIzol (200 µl for E8.5, 
500 µl for E9.5) and homogenised by passing ten times through a series of sterile 
needles, decreasing in bore size (19G, 23G, 25G) attached to a sterile 1 ml syringe. 
The samples were incubated at room temperature for 5 min to allow complete 
dissociation of nucleoprotein complexes before 0.2 volumes of chloroform was 
added to each sample and the tubes shaken vigorously by hand for 15 s. Following 
incubation for 2 min at room temperature, samples wre centrifuged at 12,000 x g for 
15 min at 4oC. The aqueous phase was removed and transferred to a new 1.5 ml tube. 
To precipitate the RNA, 0.5 volumes of isopropanol and 20 µg glycogen were mixed 
with the sample and incubated for 10 min at room tep rature. After centrifugation 
at 12,000 x g for 10 min at 4oC, the supernatant was discarded and the pellet washed 
with 1 volume of 70% (v/v) RNase-free ethanol. The RNA pellets were air dried for 
5 – 10 min at room temperature before being dissolved in 30 µl nuclease-free water 
with incubation at 55oC for 10 min. To obtain DNA for genotyping, 0.3 volumes of 
100% (v/v) ethanol were added to the organic/interphase solution following removal 
of the aqueous phase. The DNA was precipitated by incubating the mixture at room 
temperature for 3 min, followed by centrifugation at 2000 x g for 5 min at 4oC. The 
supernatant was removed and the pellet resuspended i  5 µl of TE, and either used 
directly as a template for PCR (Section 2.3.2.5) or, if insufficient DNA was obtained, 
as a template for amplification of the DNA (Section 2.3.2.4). 
 
2.3.3.4. Clean up and DNase I treatment of TRIzol-extracted RNA  
The volume of RNA extracted from tissues and embryos using TRIzol was adjusted 
to 100 µl using RNase-free water before mixing with 350 µl buffer RLT from the 
RNeasy Mini Kit. 200 µl absolute ethanol was mixed with the RNA and the wole 
sample applied to a spin column and centrifuged at 10,000 x g for 15 s. All 
centrifugation steps were performed at room temperature. The column was washed 
once with 350 µl wash buffer RW1 before incubation with 30 U RNase-free DNase I 
for 15 min at room temperature. The column was thenwashed once with RW1, twice 
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with buffer RPE and then the membrane dried by centrifugation at 12,000 x g for 1 
min. The RNA was eluted into 50 µl nuclease-free water. 
 
2.3.3.5. Reverse transcription of RNA 
First strand complementary DNA (cDNA) synthesis was performed in an RNase-free 
0.5 ml tube using 1 µg of each RNA sample in a 14 µl reaction containing 40 U 
Protector RNase Inhibitor (Roche), 100 pmol random pri ers (Promega), 5 mM 
RNase-free DTT made up to volume with nuclease-free wat r. The reaction was 
incubated at 70oC for 5 min to melt RNA secondary structures before being cooled 
on ice for 5 min to prevent secondary structures reforming. After a brief 
centrifugation step to collect condensation from the lids of the tubes the reverse 
transcription mix was added (1 µM dNTPs, 20 U AMV Reverse Transcriptase 
(Roche), 1 X AMV-Reverse Transcriptase buffer, made up to 6 µl with nuclease-free 
water). The reaction was incubated at 42oC for 60 min before the enzyme was 
deactivated at 75oC for 8 min. As a control for gDNA contamination of the cDNA, a 
minus reverse transcriptase (–RT) control was prepared for every cDNA sample by 
omitting the AMV reverse transcriptase. cDNA was stored at -20oC.  
 
2.3.3.6. Quantitative real-time PCR (qRT-PCR) 
Gene expression was measured using quantitative real-time PCR (qRT-PCR) using 
Sybr Green which binds dsDNA PCR products, emitting a fluorescent signal upon 
excitation. Sybr Green does not distinguish between specific and non-specific 
products, therefore to help prevent contamination of the signal by primer-dimers, 
each oligonucleotide primer set was optimised to deermine the lowest possible 
concentration that could be used using a titration curve. Where possible, intron-
spanning primers were designed to avoid amplification of gDNA. 
 
Reactions were performed in a 10 µl volume in clear V-bottomed 384 well PCR 
plates (ABgene) with optically clear plate seals (ABgene). A typical reaction 
consisted of 1 µl template cDNA, 1 X Brilliant II Sybr Green qPCR Master Mix 
(Stratagene), 0.3 µM passive reference dye (ROX) and 0.2 µM of each 
oligonucleotide primer in nuclease-free water. Each sample and -RT control were 
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analysed in triplicate and a no template control (NTC) was included for each master 
mix. A housekeeping gene was included as an endogenous control for each sample. 
GAPDH (encoding glyceraldehyde 3-phosphate dehydrogenase) and Actb (encoding 
β-actin) were found to be suitable endogenous controls for the experiments 
performed during this thesis as their expression did not alter following treatment of 
cells with ligands of the innate immune system. 
 
Quantitative real-time PCR was performed using an ABI Prism HT7900 Sequence 
Detection System (Applied Biosciences) with the following protocol: 2 min at 50oC, 
10 min at 95oC followed by 40 cycles of 15 s at 95oC, 1 min at 60oC. The 7900HT 
continuously detected the fluorescence of each well in the plate in real time, 
producing a cycle threshold (CT) value for each well. This is defined as the cycle 
when the fluorescence detected is statistically significant above background. To 
confirm that the fluorescence detected was true amplification and not as a 
consequence of non-specific product formation, dissociation curve analysis was 
performed on the PCR products. Specificity of the oligonucleotide primers was also 
confirmed by electrophoresis of the PCR products on an agarose gel (Section 2.3.1.4) 
to ensure a single PCR product of the correct size was generated. The CT values for 
each sample were used to calculate the expression of each target gene normalised to 
the housekeeping gene using the comparative CT method (Livak and Schmittgen, 
2001). The relative expression of target genes in treated versus untreated samples 
was represented as fold mRNA induction. 
 
2.3.3.7. Microarray analysis of gene expression 
Analysis of gene expression in transgenic mice withmutations in Rnaseh2b was 
performed using whole-genome gene expression arrays. 
 
2.3.3.7.1. Amplification and biotin-labelling of RNA samples 
Total RNA was extracted from cell and tissue samples as described previously in this 
section. The integrity of the RNA was evaluated by agarose gel electrophoresis 
(Section 2.3.1.4) and on RNA 6000 Nano Chips using a 2100 BioAnalyzer (Agilent 
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Technologies). Samples with an RNA Integrity Number (RIN) of less than 7 were 
discarded. The RNA was amplified and biotinylated using an Illumina® TotalPrepTM 
RNA Amplification Kit (Ambion), according to the manufacturer’s instructions, 
using 200 ng (for embryos) or 300 ng (MEFs and brain) of input RNA. The in vitro 
transcription step was performed for 14 h, incubating at 37oC on a DNA thermal 
cycler. The concentration of the purified amplified antisense RNA (cRNA) was 
determined using a NanoDrop (Section 2.3.1.1), and the size distribution analysed 
using a 2100 BioAnalyzer. cRNA bioanalyzer profiles consisted of a distribution of 
sizes from 250 to 5500 nt. 
 
2.3.3.7.2. Whole-genome expression arrays 
Whole-genome gene expression analysis was performed using an Illumina 
Beadstation at the Wellcome Trust Clinical Research Facility, Edinburgh. 1.5 µg of 
each cRNA sample was loaded onto a MouseWG-6 v2.0 Expression BeadChip, 
which contains 45,281 probes corresponding to over 33,000 annotated coding 
transcripts, including retrotransposon sequences. The BeadChips contain inbuilt 
controls for detecting noise and background signal across the chip, and the average 
signal for a set of housekeeping genes and hybridisat on controls. Biological 
triplicates for each sample were included. 
 
2.3.3.7.3. Data analysis 
Microarray data was analysed with the statistical programming language R, using its 
beadarray (Dunning et al., 2007) and Limma (Smyth, 2004) packages by Graeme 
Grimes (MRC HGU, Edinburgh). Raw, non-normalised bead-summary values were 
imported from the Illumina BeadStudio software into R using the beadarray package. 
Quantile normalisation was applied to the data to enable comparison between arrays. 
A linear model was applied to the expression data for each gene. To determine 
statistically differentially expressed genes the results of the linear model were 
summarised and a Bayes moderated t-test applied. To control for multiple testing, a 
Benjamini and Hochberg false discovery rate p-value of < 0.05 was used to identify 




Gene lists were imported into the DAVID (Dennis et al., 2003) and FunNet (Prifti et 
al., 2008) web-accessible programs which group genes according to their biological 
functions as described in genomic databases, including GenBank (Benson et al., 
2008) and Gene Ontology (Ashburner et al., 2000). This allowed the expression 
profiles of each dataset to be represented in terms of the biological roles of each 
transcript, and biological pathways significantly atered in expression to be 
identified.  
 
2.3.3.8. In vitro transcription (IVT) 
Templates for in vitro transcription (IVT) were prepared by amplifying regions of the 
CMV promoter from pEGFP-N1 (Clontech). Each forward oligonucleotide primer 
containing the minimal T7 promoter sequence (5ʹ-TAATACGACTCACTATAGG-
3ʹ) followed by the first 20 nucleotides of the sequence. The 3́ end of the reverse 
oligonucleotide primer contained the sequence for an EcoRI restriction site (5́-
GAATTC-3ʹ). The PCR, restriction enzyme treatment and purification of the 
template were performed as described in Section 2.3.2. IVT was performed using a 
MEGAshortscriptTM High Yield Transcription Kit (Ambion) to obtain maximal 
yields of RNA transcript. Reaction mixtures were assembled at room temperature 
and contained 100-200 ng template DNA, 7.5 mM rNTPs (ATP, CTP, GTP, UTP), 2 
µl 10 X T7 reaction buffer and 2µl T7 enzyme mixture, made up to a reaction 
volume of 20 µl with nuclease-free water. Following cubations at 37oC for 2 h in a 
hybridisation oven, the mixture was treated with 5 µl Turbo DNase (provided by the 
manufacturer) for 1 h at 37oC to remove all traces of the DNA template. The 
enzymatic reaction was terminated by diluting the reaction with 115 µl nuclease-free 
water and adding 15 µl Ammonium Acetate Stop Solutin (5M ammonium acetate, 
100 mM EDTA). The RNA was the precipitated using 2.5 volumes of ice cold 100% 
(v/v) ethanol (Section 2.3.1.2.) The RNA transcript was analysed by electrophoresis 




2.3.3.9. Purification of ssNA and RNA:DNA hybrids from 
denaturing polyacrylamide gels 
Following electrophoresis on a denaturing polyacrylamide-urea gel (ssRNA and 
ssDNA) (Section 2.3.1.6) or a native polyacrylamide gel (RNA:DNA hybrids) 
(Section 2.3.1.5), nucleic acids were visualised by UV shadowing using a hand-held 
UV lamp (UVITech Ltd.) at 254 nm and a fluor-coated TLC plate (Ambion). 
Alternatively, gels were stained with Sybr Gold (see Section 2.3.1.7) and nucleic 
acids visualised using a using a UV Transilluminator (UVItec). The desired bands 
were excised using a sterile RNase-free blade, placed into a centrifuge tube with a 
0.22 µm cellulose acetate filter (Spin-X, Costar) and crushed using an RNase-free 
pipette tip. The nucleic acid was eluted by passive d ffusion with three incubations in 
200 µl RNA elution buffer (10 mM Tris-HCl pH 7.6, 0.1% (w/v) SDS, 1 mM EDTA, 
pH 8.0) each for 2 h at 40 rpm (Stuart SB3 tube rotator, Bibby Scientific) at room 
temperature. The nucleic acid-containing buffer wasrecovered by centrifugation of 
the column at 16,000 x g for 3 min. The three buffer fractions were pooled and 
ethanol precipitated as described in Section 2.3.1.2, but NaOAC was replaced with 
150 mM NaCl, to avoid precipitation of SDS. Ethanol precipitation removes > 97% 
of Sybr Gold from nucleic acids, according to the manufacturer (Invitrogen). Nucleic 
acids were resupended in an appropriate volume of nuclease-free water. 
 
2.3.4. RNA:DNA hybrid methods 
2.3.4.1. Reverse transcription to generate an RNA:DNA hybrid 
A region of the CMV promoter sequence was amplified an  used as a template for 
IVT, as described in Sections 2.3.2.3 and 2.3.3.8. The RNA transcript was gel 
purified (Section 2.3.3.9) and used as a template for reverse transcription. Reactions 
were performed in 0.5 ml RNase-free tubes in 35 µl reactions each containing 2.5 µg
RNA, 100 U Protector RNase Inhibitor, 25 pmol reverse strand specific primer 
(CMVprom188EcoRI_R, which contains extra bases at the 5́-end to accommodate 
the overhang left on the RNA following EcoRI digest) made up to volume with 
nuclease-free water. The reaction was incubated at 70oC for 5 min to melt RNA 
secondary structures before being cooled on ice for 5 min. After a brief 
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centrifugation step to collect condensation from the lids of the tubes, the reverse 
transcription mix was added (1 µM dNTPs, 500 U M-MLV Reverse Transcriptase 
(RNase H point mutant) (Promega), 1 X M-MLV-Reverse Transcriptase buffer, 
made up to a final volume of 15 µl with nuclease-free water). The reaction was 
incubated at 42oC for 60 min before the enzyme was deactivated by heating at 75oC 
for 8 min. A minus enzyme (-RT) control was included. Multiple reactions were 
pooled together and concentrated by ethanol precipitation. RNA:DNA hybrids were 
quantified using a NanoDrop (using the A260 conversion for dsDNA) and were 
verified as described in Chapter 5.  
 
2.3.4.2. Detection of RNA:DNA hybrids using dotblots 
20 pmol of nucleic acids in a volume of 1µl were dotted onto a nitrocellulose 
membrane (Hybond-ECL, GE Healthcare) and UV crosslinked to the membrane 
using a Stratalinker (Stratagene) at 1200 mJ/cm2 for 30 s. The membrane was 
blocked in antibody buffer (2% (w/v) bovine serum albumin (BSA) in PBS) for 1 h 
at room temperature. Following three 5 min washes in PBS, the membrane was 
incubated with concentrated hybridoma supernatant co taining the RNA:DNA 
hybrid-specific antibody S9.6 diluted 1:2000 in antibody buffer overnight at 4oC. To 
detect ssNA, membranes were incubated with a monoclal anti-ssDNA antibody 
(Clone F7-26, Millipore) diluted 1:500 in antibody buffer. The membrane was 
washed three times with PBS containing 0.1% (v/v) Tween-20 and incubated with 
horseradish peroxidise (HRP)-conjugated goat anti-mouse IgG antibody (Dako 
Corporation), diluted 1:5000 in antibody buffer contai ing PBS containing 0.1% 
(v/v) Tween-20 for 1 h at room temperature. The membrane was again washed three 
times with PBS containing 0.1% (v/v) Tween-20 to remove any unbound secondary 
antibody before visualisation of the antigen-antibody complexes using enhanced 
chemiluminescence (ECL) Western blotting reagents (GE Healthcare) with exposure 
to photographic film (BioMax Film, Kodak).  
 
2.3.4.3. Immunodetection of electrophoresed RNA:DNA hybrids 
Nucleic acids were electrophoresed on a 1 mm thick native polyacrylamide gel 
(Section 2.3.1.5). The gel was stained with Sybr Gold (Section 2.3.1.7) and imaged 
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using a UV transilluminator. The gel was rinsed in dH2O for 10 min before nucleic 
acids were transferred to a positively charged nylon membrane (Amersham Hybond-
N+, GE Healthcare) using a Trans-Blot® Semi-Dry Electrophoretic Transfer Cell 
(Bio-Rad Laboratories). The gel and membrane were sandwiched between two sheets 
of thick (0.92 mm) Whatman® blotting paper soaked in 0.5 X TBE and 
electrophoresed for 30 min at constant voltage of 20 V. This ensured that the current 
did not exceed 3 mA/cm2 and so prevented an excessive build up of heat during the 
transfer. Post-transfer, 20 pmol of an 18 bp RNA:DNA hybrid was dotted onto the 
corner of the membrane as a positive control for the antibody and the nucleic acids 
crosslinked to the membrane as described in Section 2.3.4.2. To confirm transfer of 
nucleic acids onto the membrane, it was stained with Sybr Gold (Section 2.3.1.7) and 
nucleic acids visualised using a hand-held UV lamp (UVITech Ltd.) at 254 nm with 
a fluor-coated TLC plate (Ambion). In addition, the g l was imaged using a UV 
transilluminator post-transfer to confirm nucleic acids had transferred to the 
membrane and were no longer present in the gel. 
 
The membrane was rinsed in ddH2O for 10 min before it was blocked in 1% (w/v) 
blocking agent (GE Healthcare) diluted in PBS containing 0.1% (v/v) Tween-20 
overnight at 4oC to prevent any non-specific binding. Following three washes in 
wash buffer (PBS containing 0.1% (v/v) Tween-20), the membrane was incubated 
with 400ng of protein A/G-purified S9.6 which was diluted in 2 ml of 2% (w/v) 
BSA/PBS overnight at 4oC. The membrane was washed three times in wash buffer 
before being incubated with HRP-conjugated goat anti-mouse IgG antibody diluted 
1:5000 in PBS containing 2% (w/v) BSA and 0.1% (v/v) Tween-20 for 1 h at room 
temperature. Unbound secondary antibody was washed away with three washes in 
wash buffer and the antigen-antibody complexes were visualised using enhanced 
chemiluminescence (ECL) Western blotting reagents (GE Healthcare) by exposure to 
photographic film (BioMax Film, Kodak). 
 
2.3.4.4. Multiwell plate assay to detect RNA:DNA hybrids 
18-mer nucleic acids were diluted to 5 ng/µl in nuclease-free 10 mM Tris-HCl pH 
8.0 to a final volume of 44 µl. An equal volume of the DNA coating agent Reacti-
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Bind (Pierce) was added to each nucleic acid. Controls using 10 mM Tris-HCl 
instead of React-Bind were included, as was a Reacti-Bind only control. Each sample 
was transferred to a glass 4 ml shell vial (Thermo Fisher Scientific) and mixed for 10 
min at room temperature using a see-saw rocker (Stuart SSL4, Bibby Scientific) at 
40 rpm. The nucleic acid-Reacti-Bind complexes were added to a flat-bottomed 96-
well plate (MaxiSorp®, Nunc) (final volume 88 µl/well) and the plate was incubated 
on the rocker (10 rpm) at room temperature for 2 h,to allow bonding of the nucleic-
acid to the plate. Each nucleic acid was added to the plate in triplicate. The plate was 
washed five times with PBS to remove any unbound nucleic acid before purified 
S9.6 antibody (200 ng/µl, diluted 1:1000) in 1% (w/v) BSA in PBS was added to 
each well (50 µl/well) and the plate incubated for 2 h at room temp rature. The plate 
was washed five times with wash buffer (PBS containing 0.05% (v/v) Tween-20) 
before being incubated with HRP-conjugated goat anti-mouse IgG antibody diluted 
1:5000 in PBS containing 1% (w/v) BSA and 0.1% (v/v) Tween-20 (50 µl/well) for 1 
h at room temperature. Following five washes in wash buffer to remove any unbound 
secondary antibody, 50 µl of 3,3́-5,5́-Tetramethylbenzidine (TMB) (BM blue, POD 
substrate, Roche Applied Sciences) was added per well and allowed to develop for 
approximately 30 min in the dark. The reaction was stopped by the addition of 50 µl 
0.18 M H2SO4 per well. The absorbance at 450 nm was recorded using a plate reader 
(Multiskan Spectrum, Thermo Fisher Scientific). 
 
2.4. Protein methods 
2.4.1. Extraction of total protein from cells 
Adherent cells were harvested using a disposable cell scraper and washed once in 
PBS. Pellets were resuspended in whole cell extract buffer (50 mM Tris pH 8.0, 280 
mM NaCl, 0.5% (v/v) NP40, 0.2 mM EDTA, 0.2 mM EGTA, 10% (v/v) glycerol, 
0.1 mM sodium vandate; and also 1 mM DTT, 1 mM PMSF added immediately prior 
to use) and incubated on ice for 10 min. An equal volume of cytoplasmic buffer (20 
mM HEPES, 10 mM KCl, 1 mM EDTA, 0.1 mM sodium vandate; and also 1 mM 
DTT, 1 mM PMSF added immediately prior to use) was added and lysates were 
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incubated on ice for a further 10 min.  Following centrifugation at 16,000 x g at 4oC 
for 10 min, the soluble extract was removed and transferred to a fresh 1.5 ml tube. 
Protein was quantified using the Bradford assay (Biorad), measuring the absorbance 
at 595 nm using a spectrophotometer (6505 UV/Vis Spectrophotometer, Jenway). 
The concentration was calculated using a standard curve constructed using known 
amounts of BSA (Roche). Protein extracts were stored at –80oC. 
 
2.4.2. RNase H activity assays 
Fluorometric RNase H activity assays were performed using the method described by 
Crow et al. (Crow et al., 2006b) using the RNase H substrate (RNA:DNA hybrid) 
(forward strand 5́-r(GAU CUG AGC CUG GGA GCU)-fluorescein-3ʹ) and the 
RNase H2-specific substrate, D-R-D:DNA (forward strand 5́-d(GAT CTG AGC 
CTG GG)r(A)d(GCT)-fluorescein-3ʹ)  where ‘d’ indicates a deoxyribonucleotide 
base and ‘r’ indicates a ribonucleotide base. The forward strands were annealed to 
the complementary DNA oligonucleotide 5ʹ-AGC TCC CAG GCT CAG ATC-
3ʹwhich is labelled at the 5ʹ end with 4-[[4-(Dimethylamino)phenyl]azo]benzoic aid 
(DABCYL). When the complementary oligonucleotides are nnealed together, 
DABCYL quenches the fluorescent signal. Enzymatic cleavage of the fluorescein-
labelled strand releases the fluorescein molecule from the quencher molecule, 
generating a detectable fluorescence. To calculate the xact amount of fluorescent 
substrate released in a reaction, a standard curve was prepared by annealing each 
forward strand with a non-labelled DNA oligonucleotide. Dilutions of 50 pmol, 25 
pmol, 12.5 pmol, 3.125 pmol and 0.78 pmol were prepa d in assay buffer (60 mM 
KCl, 50 mM Tris-HCl pH 8.0, 10 mM MgCl2).  
 
The measurement of RNase H/H2 activity in cell lysate  was performed in a 100 µl 
volume of assay buffer containing 250 nM of substrate and 100 ng/µl of cell lysate 
(see Section 2.4.1) in a black polystyrene flat-botomed 96-well plate (non-coated, 
Costar). Measurement of RNA:DNA hybrid-cleaving activity in preparations of 
commercially available nucleases was performed using the indicated amount of 




A set of standards for each substrate was included in very assay. Standards, samples 
and substrate only controls (to measure background fl orescence from each 
substrate) were analysed in triplicate. The plate was incubated at 20oC (for cell 
lysates) or 37oC (for enzymes) and the fluorescent signal read for 100 ms every 5 
min for 90 min using a VICTOR3 1420 multilabel counter (Perkin Elmer) with a 480 
nm excitation filter and a 535 nm emission filter. A standard curve was constructed 
and the average pmol of substrate released was calculated for each sample. 
 
2.4.3. Western blotting 
30 µg of whole cell lysates from human cell lines were denatured in sample loading 
buffer (62.5 mM Tris pH 6.8, 50% (v/v) glycerol, 5% (v/v) β-mercaptoethanol, 
0.03% (w/v) BPB) for 5 min at 95oC. 100 µg of whole cell lysates from synchronised 
HeLa cells were pretreated with 2.5 U Benzonase ® nuclease (Novagen) for 15 min 
on ice, to eliminate any contaminating nucleic acids, before incubation in NuPAGE 
sample loading buffer (Invitrogen) for 20 min at 60oC. Protein was resolved on pre-
cast 4 – 12% NuPAGE® Novex ® Tris-Bis gradient gels (1.5 mm, 10 wells, 
Invitrogen) using NuPAGE MOPS buffer (Invitrogen). 6 µl of SeeBlue® Plus2 Pre-
Stained Standard (Invitrogen) and 4 µl Precision Plus Protein Standard (Bio-Rad 
Laboratories) were included as size markers. Samples were electrophoresed at a 
constant 160 V in an XCell SureLockTM Mini-Cell electrophoresis system 
(Invitrogen). Protein was then transferred to a nitrocellulose membrane at a constant 
100 V for 1 h at 4oC using a Mini-Trans-Blot Cell system (Bio-Rad Laborat ries). 
Following transfer, membranes were blocked in blocking buffer (5% (w/v) non-fat 
milk in TBS containing 0.2% (v/v) Tween-20) for 1 h at room temperature. 
Membranes were probed using a polyclonal sheep antibody raised against 
recombinant human RNase H2, diluted 1:200 (of a 50%(v/v) glycerol stock) in 
blocking buffer overnight at 4oC. Following three 5 min washes in washing buffer, 
the membrane was probed with a HRP-conjugated polyclonal rabbit anti sheep IgG 
Antibody (Dako Corporation), diluted 1:5000 in blocking buffer for 1 h at room 
temperature. Unbound secondary antibody was washed away with three 5 min 
washes in washing buffer and the antigen-antibody cmplexes were visualised using 
ECL Western blotting reagents by exposure to photographic film. The membranes 
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were stripped by incubation in 0.2 M glycine, 1% (w/v) SDS pH 2.5 for 15 min at 
room temperature. Following three 5 min washes in washing buffer, the membrane 
was reblocked before being reprobed with housekeeping genes to act as controls for 
loading. Antibodies used were: polyclonal goat anti- c n (C-11, Santa Cruz 
Biotechnology) at 1:2000 then donkey anti-goat IgG-HRP (Santa Cruz 
Biotechnology) at 1:3000; monoclonal anti-α-tubulin (clone B512, Sigma Aldrich) at 
1:10,000 followed by goat anti-mouse IgG –HRP 1:5000. Anti-phospho-Histone H3 
(Ser-10) (Millipore) diluted 1:5000 detected by HRP-conjugated polyclonal goat 
anti-rabbit IgG (Cell Signalling Technology) diluted 1:5000 was used as a marker for 
mitotic cells. 
 
2.5.5. Enzyme-linked immunosorbent assays (ELISAs) 
Secreted cytokines in cell supernatants were quantified using sandwich ELISAs. All 
ELISAs were performed in flat-bottomed 96-well plates (MaxiSorp®, Nunc). Murine 
IL-6, IL-10, IL-12p40, TNF-α and RANTES were measured using reagents from 
DuoSet ELISA Development Kits (R&D Systems), according to the manufacturer’s 
instructions. 1% (v/v) Reagent Diluent (R&D Systems) in PBS containing 0.05% 
(v/v) Tween-20 was used as the buffer for blocking, and for diluting the antibodies, 
standards and samples.  
 
Murine IFN-α, murine IFN-β and human IFN-α ELISAs were established using the 
reagents listed in Table 2.2. Each new batch of antibodies and recombinant cytokine 
standards were optimised for use as there was found to be variation in between 
different lot numbers. To optimise each new set of reagents, four dilutions each of 
the capture, detection and standard were tested. 
 
ELISA plates were coated with 50 µl per well of capture antibody diluted in the 
appropriate buffer and incubated overnight at room te perature. Following five 
washes in wash buffer (PBS containing 0.05% (v/v) Tween-20), the plates were 
blocked with 200 µl per well of the appropriate blocking buffer and icubated at 
room temperature for 1 h. Plates were washed five tim s in wash buffer and serial 
dilutions of standards were added in triplicate (50 µl per well). Supernatants were 
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diluted if necessary in the appropriate buffer and 50 µl per well added to the plate. 
Each sample was also added in triplicate. Plates were incubated at 4oC overnight to 
permit capture of the cytokines. Following five washe  with wash buffer, 50 µl per 
well of detection antibody diluted in the appropriate buffer was added and plates 
incubated for 2 h at room temperature. Unbound antibody was removed by five 
washes with wash buffer before 50 µl per well of the appropriate HRP-conjugated 
antibody was added and the plate incubated for 20 min or 1 h (murine IFN ELISAs) 
at room temperature (except for the human IFN-α ELISA). The plates were washed 
five times with wash buffer and 50 µl TMB substrate was added to each well, and 
allowed to develop for 10 – 60 min in the dark. The reaction was stopped with 50 µl 





Table 2.2. Reagents used in the ELISAs to detect type I IFNs. 
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Antibody concentrations given are as a guide only as optimisation of each lot of antibodies 
was required. All antibodies and samples were diluted in the blocking buffer, except for the 
Murine IFN-α ELISA, when PBS containing 1% (w/v) BSA was used instead. The top value of 
the standard protein is given, serial dilutions were made from this to generate a seven 







2.5.6. Reverse transcriptase activity assay 
2 x 105 cells of each patient and control LCL were seeded into a 25 cm3 flask in 
normal culture medium (Section 2.2.1). Following normal growth for 3 days, 1 ml 
was taken from the cells and centrifuged at 1500 x g to pellet any cells. The 
supernatant was transferred to a 1.5 ml tube and stored at –80oC until it was used for 
detection of IFN-α by ELISA (Section 2.5.5) or detection of RT activity. 
 
Mg2+-dependent reverse transcriptase activity was measur d using a HS-Mg RT 
activity kit (Cavidi AB), according to the manufacturer’s instructions for screening 
cell supernatants for RT activity. Each well of the96-well plates provided with the 
kit was coated with poly (A) RNA, which would act as  template for reverse 
transcription. Supernatant was incubated with this template in a reaction mixture 
which also contained a DNA poly (T) primer and BrdUTP. If the supernatant 
contained RT activity, a DNA strand was synthesised, incorporating BrdUTP, which 
was detected using an alkaline phosphatase-conjugated antibody against BrdU. 
Addition of a colourmetric alkaline phosphatase substrate allowed quantification of 
alkaline phosphatase activity, which was proportional to RT activity. A standard 
curve was constructed using known concentrations of recombinant HIV-1 RT, 
therefore the RT activity of a sample was calculated in pg/ml. The detection range of 
the assay was 0.5 – 500 pg/ml RT activity. Signal ws detected using by recording 
the absorbance at 405 nm using a MultiSkan plate reder, reading the plates at 30 
min, 90 min, 120 min and 22 h as recommended by the manufacturer. 
 
2.6. Data analysis 
Data was analysed and graphs drawn using Microsoft Office Excel 2007 and Sigma 
Plot 11.0 (Systat Software, Inc.). Statistical analysis was performed using unpaired 




Chapter 3. The examination of a potential role for 
RNase H2 in innate immunity 
 
The cellular functions of the mammalian RNase H2 complex have not been fully 
characterised. Although hypothesised to be involved in the processing of replication 
intermediates, its connection with AGS raises the possibility that RNase H2 could 
function as a component of the innate immune response to nucleic acids, as proposed 
for TREX1 and SAMHD1 (Rice t al., 2009; Stetson et al., 2008). 
 
RNase H2 is reported to be ubiquitously expressed (Arudchandran et al., 2000; Eder 
and Walder, 1991; Frank et al., 1998a; Frank et al., 1998c), as is TREX1 (Hoss et 
al., 1999; Morita et al., 2004). Human SAMHD1 is expressed widely but is abent in 
thymus and brain tissues (Liao et al., 2008). In this chapter, expression profiling of 
the five AGS genes was performed to establish in more detail the cell types with high 
levels of RNASEH2 transcription, which suggested that RNase H2 may have a 
specific function in certain immune cells. Together with the published evidence for 
TREX1 and SAMHD1 as negative regulators of the innate immune response, this led 
to a series of preliminary experiments to determine if RNase H2 has a role in 
immunity. 
 
3.1. Human T cells and monocytes contain high levels of 
active RNase H2 
During my MSc maxiproject (‘Functional Studies of Human Ribonuclease H2’, 
University of Edinburgh, 2006), I established that expression of the RNASEH2 genes 
could be detected in all 22 tissues from a commercially available human tissue panel 
(Figure 3.1 a). This baseline survey of gene expression also reveal d that expression 
of RNASEH2B was particularly high in thymus tissue, which raised the initial 







Figure 3.1. Expression profiling of the AGS genes in human cell lines 
(a) RNASEH2 and TREX1 transcripts can be detected in all tissues in a human tissue panel. 
Expression was determined by qRT-PCR. Values were normalised to the housekeeping gene 
GAPDH, and the normalised units calculated using a standard curve. RNASEH2B expression 
is approximately 27-fold higher than RNASEH2C expression in the thymus. Absolute relative 
expression levels between tissues can only be compared if it is assumed that levels of the 
housekeeping gene do not vary significantly between tissues. Data are the shown as mean 
+ s.d. of triplicate qPCR wells and figure is reproduced from MSc Maxiproject, 2006. (b) The 
five AGS genes are expressed in an epithelial cell line (HEK293), a neuroblastoma cell line 
(LA155n) and an erythroleukaemia cell line (K562), as determined by qRT-PCR. Data are 
shown as the mean expression normalised to GAPDH + s.d. of triplicate PCR wells, 
representative of four (K562), three (HEK293) or one (LA155n) independent experiments. 
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To further characterise the expression patterns of all five AGS genes, endogenous 
transcript levels were measured in a range of human cell lines. Expression of all five 
AGS genes could be detected in cell lines of epithelial, neuronal and haemapoetic 
lineages (Figure 3.1 b), which confirmed that the RNASEH2 genes are widely 
expressed. In these three cell lines, the normalised expression levels of the RNASEH2 
genes were higher than the levels of TREX1 and SAMHD1.  
 
The expression of the AGS genes in human immune cell lin s was also determined. 
Two T lymphoblastoid cell lines (Jurkat and CCRF-CEM) both had relatively high 
levels of RNASEH2B expression (Figure 3.2 a), correlating with the thymus data 
(Figure 3.1 a). In contrast, TREX1 and SAMHD1 expression in these cell lines was 
much lower. This supports previous evidence that SAMHD1 is not expressed in 
thymus tissue (Liao et al., 2008). The expression pattern of the AGS genes in B 
lymphoblastoid cell lines (LCLs) was very different, with relatively high levels of 
TREX1 detected in both LCLs in comparison to much lower expression of the 
RNASEH2 and SAMHD1 genes (Figure 3.2 b). It has previously been shown that 
LCLs have high levels of TREX1 activity (Crow et al., 2006a). Together these data 
demonstrated a difference in the expression of the AGS genes between two different 
types of lymphocyte, which may be important for thein vivo functions of the 
proteins. 
 
The THP-1 monocytic cell line expressed RNASEH2B at a level equivalent to that in 
Jurkat cells (Figure 3.2 c), assuming that expression of the housekeeping gene was 
constant between cell types. SAMHD1 expression was also high in THP-1 cells, 
relative to RNASEH2A, RNASEH2C and TREX1 expression. However, when the cells 
were differentiated into macrophage-like cells using PMA, expression of RNASEH2B 
and SAMHD1 decreased sharply (Figure 3.2 c).  
 
To investigate if the differences in RNASEH2 expression observed between the 
different cell lines examined during this survey of human cell types are reflected in 
the levels of functional protein, total cellular protein extracts were prepared from 





Figure 3.2. Expression of the AGS genes in human lymphocyte and monocyte cell lines. 
qRT-PCR analysis of AGS gene expression in (a) two T lymphoblastoid cell lines, (b) two EBV-
transformed B lymphpblastoid cell lines derived from two healthy individuals and (c) THP-1 
monocyte (- PMA) and macrophage-like (+ PMA) cells. Differentiation of THP-1 cells into 
macrophage-like cells was confirmed by an average 12-fold increase in CD14 expression, as 
determined by qRT-PCR. Data are shown as normalised mean expression + s.d. of PCR wells, 





three subunits of the complex. Extracts from the two T cell lines contained higher 
levels of each of the subunits and of the alternative isoform of RNASEH2B than 
equal quantities of protein extracted from K562 andLCLs (Figure 3.3 a). This 
correlated with a 50% increase in RNase H2 activity n these cells (Figure 3.3 b). 
RNase H2 activity was also increased by 40% in undifferentiated THP-1 cells 
compared to differentiated cells. This confirmed that in these cell lines, increased 
RNASEH2B expression corresponded to increased RNase H2 enzym  activity. 
 
Together, these data demonstrated that RNase H2 activity was present in a range of 
different human cell types. The high levels of RNase H2 activity in the two T cell 
lines and the monocytic cell line may be indicative of a specific function for the 
enzyme in these cell types. 
 
3.2. The Rnaseh2 genes are widely expressed in the 
mouse 
As many downstream experiments during this thesis were likely to use murine cells 
rather than human cells, baseline expression of the Rnaseh2 genes in murine tissues 
and cells was characterised using qRT-PCR. This also provided the opportunity to 
analyse the expression of the genes in primary immune cells, as all human cells used 
in Section 3.1 were immortalised cell lines. 
 
As shown in Figure 3.4 a, expression of the Rnaseh2 and Trex1 genes could be 
detected in adult tissues. Levels of Rnaseh2b were particularly high relative to the 
other genes for each tissue, whereas Trex1 expression was very low. A similar 
pattern was seen in primary cells (Figure 3.4 b). 
 
Taken together, the preliminary expression data present d here suggests that the 






                             
Figure 3.3. Active RNase H2 protein in human cell lines. 
(a) Western blot of total cellular extracts from four cell lines to detect the RNASEH2 
proteins, including the shorter isoform of RNASEH2B (alt B). 30 μg of whole cell extract 
were loaded per lane, α-tubulin is shown as a loading control. Blot is representative of two 
independent experiments. The band observed between A and alt B was due to non-specific 
binding of the antibody. (b) Measurement of RNase H2 activity in total cellular extracts 
from eight cell lines using an RNase H2-specific substrate. 100 ng/μl of protein was 
incubated with the substrate at 25
o
C in a 100 μl volume. The pmol cleaved substrate 
released over time was recorded for 10 min. Background (substrate only) fluorescence was 
substracted and RNase H2 activity in pmol/min calculated. Data shown are the mean + s.d. 









Figure 3.4. Expression of the Rnaseh2 genes and Trex1 in the mouse. 
qRT-PCR analysis of gene expression in (a) adult tissues and (b) primary murine embryonic 
fibroblast (MEF), bone marrow-derived M-CSF macrophage cultures (Mφ) and bone 
marrow-derived Flt3-L dendritic cell (DC) cultures. Samhd1 expression was not examined as 
these experiments were performed prior to this gene being identified as mutated in AGS. 
Data shown are mean expression normalised to β-actin (Actb) gene expression + s.d. of 
triplicate PCR wells. Note that the level of Actb expression varied between tissues therefore 
it is difficult to compare expression levels of the same gene between different tissues but it 






3.3. Levels of RNase H2 are constant throughout the cell 
cycle 
Expression of the RNASEH2 genes was found to be variable between different 
tissues. One explanation for this could be the presence of highly proliferating cells in 
some tissues. In S. cerevisae, the mRNA levels of RNH2A peak during S-phase and 
at the G2/M transition, correlating with subsequent peaks in enzyme activity 
(Arudchandran et al., 2000). To establish if this occurs at the protein l vel with the 
mammalian RNase H2 complex, total cellular protein exacts prepared from 
synchronised HeLa cells were probed with the anti-RNase H2 antibody. Protein 
levels of the three subunits did not alter throughout the cell cycle (Figure 3.5), which 
implied that the difference in Rnaseh2 expression between tissues was unlikely to be 
attributable to the presence of proliferating cells. 
 
 
       
 
Figure 3.5. Levels of the RNASEH2 proteins do not alter throughout the cell cycle. 
HeLa cells were synchronised using a double thymidine block before they were released 
and total cellular protein extracts prepared at the indicated time points by Carol-Anne 
Martin, MRC HGU. 100 μg per lane of extracts were electrophoresed using a 4 – 12% 
gradient SDS-polyacrylamide gel before transfer onto a nitrocellulose membrane, which 
was probed with antibodies against RNase H2, phospho-histone H3 (a marker of mitotic 
cells) and β-actin (known to remain constant throughout the cell cycle; Carol-Anne Martin, 
personal communication) as a loading control. Cell cycle stages of the same cells were 
confirmed using propidium iodide (PI) staining (also performed by Carol-Anne Martin). Cell 
cycle analysis was performed in FlowJo using the Dean-Jett-Fox model. G1 is shown in 
green, S phase in yellow and G2 in blue. 
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3.4. Rnaseh2 gene expression is not type I interferon-
inducible 
Expression of Trex1 and Samhd1 is induced following the transfection of interferon 
stimulatory DNA (ISD), in a type I interferon (IFN)-dependent manner (Rice et al., 
2009; Stetson et al., 2008). Therefore, to examine the expression of the Rnaseh2 
genes in response to stimulation with this nucleic acid species, primary MEFs were 
transfected with ISD. This induced a sustained IFN-β response in the MEFs (Figure 
3.6 a). In agreement with previous experiments performed in macrophages (Rice et 
al., 2009), Trex1 and Samhd1 expression was increased following transfection of 
ISD (Figure 3.6 b). There was a slight increase in expression of Rnaseh2b and 
Rnaseh2c after 24 h, however, further replicate experiments would be needed to 
determine if this increase is statistically significant. 
 
The IFN-β response to ISD in MEFs was established by 4 h (Figure 3.6 a). Trex1 
mRNA was upregulated approximately 4-fold after 4 h, but had increased further by 
24 h (Figure 3.6 b). This suggested that upregulation of gene expression was in 
response to IFN production and subsequent downstream signalling events, rather 
than specifically to the ISD itself. To investigate this further, primary MEFs were 
stimulated with various PRR ligands and expression of the Rnaseh2 genes and Trex1 
measured.  
 
Following a 24 h stimulation, cells transfected with the dsRNA analogue poly (I:C), 
a 20 nt Type-A CpG oligodeoxyribonucleotide (CpG ODN) and a 188 nt in vitro 
transcribed (IVT) single-stranded RNA (ssRNA) contai ing a 5́-triphosphate (5́-
ppp) had greatly upregulated expression of type I IFNs (Figure 3.7 a). Expression of 
Trex1 in these cells was also elevated (Figure 3.7 b)  In contrast, stimulation with 
R848 and LPS, which stimulated expression of pro-inflammatory cytokines such as 
Il1b but not type I IFNs, failed to induce Trex1 expression. Therefore, Trex1 
expression was upregulated in response to type I IFN produced following stimulation 
of nucleic acid-sensing PRRs of the innate immune system. In contrast, expression of 
the Rnaseh2 genes was not induced following stimulation of innate immunity by any 





Figure 3.6. Induction of AGS gene expression in MEFs following transfection with ISD. 
Primary MEFs were transfected with 2 µg/ml of FPLC-purified ISD using Lipofectamine 2000 
for 4 h or 24 h. Gene expression was measured using qRT-PCR. (a) Basal expression levels of 
the five AGS genes in primary MEFs. (b) Induction of Ifnb1 expression following transfection 
of ISD. (c) Fold change in expression of the AGS genes in response to ISD. Data shown are 
represented as normalised (to Actb expression) fold mRNA induction from Lipofectamine 








Figure 3.7. Induction of AGS gene expression in MEFs following stimulation with PRR 
ligands. 
Primary MEFs were transfected with 25 μg/ml poly (I:C), 10 µg/ml CpG ODN, 10 µg/ml IVT 
ssRNA using Lipofectamine 2000. Cells were also stimulated with 2 μg/ml R848 or 200 
ng/ml LPS added to the culture medium. After 24 h, cells were harvested and gene 
expression determined using qRT-PCR. Data shown are fold change relative to medium only 





To directly establish that Trex1 and possibly Samhd1 are upregulated in response to 
type I IFN but the Rnaseh2 genes are not, Universal type I IFN was added to the 
culture medium of primary MEFs and expression of the AGS genes determined over 
a time course. A rapid increase in the level of Trex1 mRNA was seen, beginning at 
only 30 min (Figure 3.8). Induction of Samhd1 mRNA was later but by 4 h, both 
Trex1 and Samhd1 expression was significantly increased from untreated cells 
(Student’s t-test; Trex1 p = 0.0006, Samhd1 p = 0.026). In contrast, even after 24 h, 
expression of the Rnaseh2 genes was not significantly altered from 0 h (Rnaseh2a p 
= 0.157, Rnaseh2b p = 0.408, Rnaseh2c p = 0.819). Overall, this suggests that Trex1 
and Samhd1 expression is induced in direct response to type I IFN, which is 
consistent with published data (Rice et al., 2009). In contrast, the Rnaseh2 genes 









 U/ml of Universal type I IFN (11200-1, PBL Interferon Source) was added to the culture 
medium of primary MEFs and the cells lysed for RNA extraction at the indicated time 
points. Data are shown as the fold mRNA induction from 0 h from two independent 







In this section, I have demonstrated that the genes coding the subunits of the 
RNase H2 complex are not upregulated in response to timulation of the innate 
immune response by synthetic PRR ligands, nor as a consequence of IFN-α treatment 
in primary MEFs. This is in contrast to the other two genes mutated in AGS, Trex1 
and Samhd1, which could imply that RNase H2 does not function similarly as a 
negative regulator of the innate immune response. From the in vitro expression data 
presented in this section, a connection between RNase H2 and the innate immune 
response remains undetermined. 
 
3.5. The characterisation of RNase H2-deficient cells 
The failure of type I IFNs to induce expression of theRnaseh2 genes implies that the 
enzyme complex is unlikely to be a component of an innate immune response 
pathway. Instead, the function of the enzyme could be to suppress the build up of 
endogenous nucleic acids, and prevent triggering of cell-intrinsic initiation of 
autoimmunity by these substrates, which is one role assigned to TREX1 (Stetson et 
al., 2008). Stetson et al. conclude that Trex1-deficiency results in an accumulation of 
unprocessed nucleic acids, which subsequently trigge  an autoimmune response. 
They show that these nucleic acids are derived fromreverse transcribed endogenous 
retroelements (Stetson et al., 2008). This raises the question of whether RNase H2 
functions in the same pathway, potentially in the processing of RNA:DNA hybrid 
intermediate products of retroelement reverse transcription (Bhoj and Chen, 2008). 
Therefore, it could be hypothesised that RNase H2-deficient cells will have increased 
levels of endogenous retroviral replication. 
 
To test this hypothesis, the level of endogenous retroviral replication was 
characterised in both human and mouse cells deficient in RNase H2 activity. 
 
3.5.1. RNase H2-AGS LCLs do not produce high levels of IFN-α  
Several EBV-transformed B lymphoblastoid cell lines (LCLs) from patients with 
AGS have been established in the lab. LCLs from patients with mutations in the 
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RNASEH2 genes have a significant reduction in RNase H2 activity compared to 
control LCLs (Martin Reijns, MRC HGU, personal communication). This could be 
consistent with an accumulation of nucleic acid substrates which may be derived 
from endogenous retroelements.  
 
Nucleic acids are potent activators of innate immune signalling, and stimulate a 
robust type I IFN response (reviewed by Yoneyama and Fujita, 2010). Therefore, the 
levels of IFN-α in the supernatants of unstimulated RNase H2-AGS LCLs were 
measured by ELISA. There was no consistent difference between the amount of IFN-
α produced by patient LCLs and controls (Figure 3.9). This suggested that IFN-α 
production was generally not increased in B cells from AGS patients, although this 
assumed that clonal EBV-transformed B cells are representative of endogenous B 
cells. Furthermore, this clearly does not exclude the possibility that other cell types 
from RNase H2-AGS patients may produce significantly elevated levels of IFN-α, 
particularly cells from the brain (van Heteren et al., 2008). However, due to the very 






      
 
Figure 3.9. Detection of IFN-α in the supernatants of AGS patient LCLs 
IFN-α secretion by LCLs was measured by ELISA. Samples were taken from nine AGS patient 
cell lines with mutations in either the RNASEH2 genes or TREX1. Supernatants from two 
normal LCLs (WT) and two heterozygous carriers for AGS-causing TREX1 mutations (TREX1 
het) were included as controls. Data were generated from at least two independent 




3.5.2. Retroviral replication is not increased in RNase H2-AGS 
LCLs 
To investigate a role for RNase H2 for the suppression of endogenous retroviral 
replication, the levels of Mg2+ dependent RT activity in AGS patient LCL 
supernatants were measured. This generates a measurement of the retroviral reverse 
transcriptase (RT) activity of human endogenous retroviruses (HERVs), including 
the ancestral HERV, HERV-K (Lee and Bieniasz, 2007), and could therefore provide 
an indication of the production of RNA:DNA hybrid intermediates of reverse 
transcription in these cells. 
 
The assay was performed using supernatants from AGS patient LCLs with a range of 
mutations. There was no increase in RT activity in the patient samples (Figure 3.10). 
All levels detected in the LCL supernatants were greatly below the positive control 
provided by the manufacturer. Furthermore, qRT-PCR of HERV envelope genes also 
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suggested there was no notable increase in expression compared to a control LCLs 
(Appendix 5). Taken together, these data suggest levels of activated endogenous 
retroviruses are not generally elevated in RNase H2-AGS LCLs. However, this 
investigation was limited by both the availability of patient material and the types of 




    
Figure 3.10. Reverse transcriptase activity in supernatants from AGS patient LCLs 
Reverse transcriptase (RT) activity was measured in the supernatants of LCL lines as 
described in Chapter 2 for 22 h. Values were read from a standard curve constructed using 
recombinant HIV-1 RT and the RT activity of each sample in pg/ml calculated. Data shown 
are representative of two separate assays using the same supernatants, both performed in 
triplicate, + s.d. Previous studies using this assay report samples positive for HERV-K activity 




3.5.3. Endogenous retroelement expression is not increased 
in RNase H2-deficient mice 
The difficulties associated with obtaining cellular material from AGS patients limited 
the extent to which RNase H2-deficient human cells can be characterised. Transgenic 
mice with mutations in the Rnaseh2b gene have been established in the lab. To 
establish if the expression of murine endogenous retroel ments was increased in 
mice with deficiencies in RNase H2 activity, whole-g nome gene expression arrays 
which included probes for retroelement sequences were p rformed using three of the 
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transgenic lines. In addition to providing evidence of increased expression of 
retroelements in RNase H2-deficient cells, analysis of the transcriptomes of the 
mutant mice was hypothesised to provide further indications as to the in vivo 
function of RNase H2. 
 
3.5.3.1. Rnaseh2bA177T-neo mice 
The most frequently observed patient mutation is the exon seven A177T mutation in 
RNASEH2B (Crow et al., 2006b; Rice et al., 2007b). Knock-in mice containing the 
point mutation and a neo cassette located in between exons six and seven were 
established, named Rnaseh2bA177T-neo (Figure 3.11 a, top). This mutation is 
hypomorphic: homozygous mice have reduced RNase H2 activity (Figure 3.11 b) but 
are viable and do not develop a disease phenotype (Björn Rabe, MRC HGU, personal 
communication). MEFs prepared from embryos homozygous f r the 
Rnaseh2bA177T-neo allele (n/n) had on average an 87% (Student’s t-te t, p = 
0.0027) reduction in cellular RNase H activity compared to wild type littermates 
(Figure 3.11 b). RNase H2-specific enzymatic activity is decreased by 84% (p = 
0.0084). Notably, heterozygous MEFs (n/+) also had a significant reduction in 
RNase H2 activity, with a 58% (p = 0.0050) reduction in RNase H activity and a 
61% (p = 0.015) reduction in RNase H2-specific activity from wild type MEFs 
(Figure 3.11 b). 
 
Expression microarrays were performed using these primary MEFs lines. RNA was 
prepared from 3rd passage homozygous mutant MEF lines (n/n) and wild type 
littermate controls (+/+) from three separate litters. By the 3rd passage, each MEF 
line should be a homogeneous population of cells which are still actively dividing 
(Parrinello et al., 2003). The integrity of all RNA used for microarrys was validated 
using a BioAnalyzer (Figure 3.12 a). All RNA samples had a minimum RNA 





Figure 3.11. Transgenic lines with mutations in Rnaseh2b. 
(a) Schematic diagram to show the locations of the mutations in the Rnaseh2bA177T-neo 
and Rnaseh2bA177T-stop transgenic lines. The A177T mutation is a result of a G→A 
missense mutation and the stop is encoded by UGA located 83 bp downstream of this. The 
neo cassette is flanked by two loxP sites which are denoted by arrowheads. (b) 
Quantification of RNase H activity in MEFs derived from wild type (+/+), heterozygous (n/+) 
or Rnaseh2A177T-neo homozygous (n/n) embryos. Whole cell lysates were prepared from 
littermate embryos of each genotype from three separate litters. Cellular RNase H activity 
was measured using an RNA:DNA hybrid substrate. RNase H2 activity was measured using 
an RNase H2-specific substrate (D-R-D:DNA). Background fluorescence was subtracted from 






Figure 3.12. Microarray analysis of gene expression in the n/n mouse. 
(a) RNA samples were analysed on a RNA 6000 Nano Chip using a BioAnalyzer prior to 
sample labelling. An RNA Integrity Number (RIN) which is determined by the whole 
electrophoretic trace, is calculated by the BioAnalyzer. A low RIN (< 7) is indicative of RNA 
degradation. Data show a representative sample. (b) The correlation between the average 
log2 expression values for the n/n MEFs versus the +/+ MEFs was assessed using Pearson’s 




A comparison of the average expression of genes showed that very few were 
differentially expressed between the three mutant MEF lines and the three wildtype 
controls (Figure 3.12 b). A measure of the correlation of average expression values 
between the two genotypes using Pearson’s correlation gave a value of 0.999, 




Only 52 transcripts were altered by at least 1.5-fold (p < 0.05) in the homozygous 
mutants; expression of 4 was upregulated and of 48 downregulated (listed in full in 
Appendix 6), which indicated that there was little difference between the mutant n/n 
MEFs and wild types at the transcriptional level. The expression of Rnaseh2b was 
significantly reduced in the mutant, providing a positive control for the mutation. 
Both the microarray probe and the qRT-PCR primers span exons six and seven, 
therefore this suggests that the transcript is unstable, and may undergo nonsence 
mediated decay (NMD) to prevent synthesis of a truncated protein. Microarray and 
qRT-PCR analysis suggest that expression of the other AGS genes is not altered in 
n/n MEFs (Appendix 7). 
 
There was no significant difference in the expression of endogenous retroelements in 
the mutants compared to the wild type controls, which reflects the results observed in 
the AGS patient LCLs. The genes downregulated in the homozygous n/n MEFs did 
not cluster within any particular functional classification group, and the proportion of 
genes altered is very small. Therefore, it was difficult to draw any conclusions 
regarding the in vivo consequence of having significantly reduced RNase H2 activity 
from these data. Consequently, whole-genome gene expr ssion analysis was 
performed on MEFs from a second mouse line. 
 
3.5.3.2. Rnaseh2bA177T-neo/Rnaseh2bA177T-stop mice 
The Rnaseh2bA177T-stop line also contains the A177T point mutation in exon seven 
downstream of a neo cassette. However, this line also contains a stop codon in exon 
seven following the A177T transversion (Figure 3.11 a). Homozygous 
Rnaseh2bA177T-stop embryos are not viable (discussed in further detail in Section 
3.5.3.3) but Rnaseh2bA177T-neo/Rnaseh2bA177T-stop (n/s) compound 
heterozygous animals are and do not exhibit a phenotype (Björn Rabe, MRC HGU, 
personal communication). Therefore, MEFs were establi hed from n/s embryos. 
RNase H2 activity in n/s cells is reduced by approximately 90% from that of wild 




Whole-genome gene expression microarray analysis of three n/s MEF lines from 
three separate litters compared to wild type MEFs revealed a large number of genes 
were differentially expressed; 1257 genes were upregulated (fold change >1.5, p < 
0.05) and 1829 were downregulated (fold change > 1.5, p < 0.05). Of these genes, 
173 were upregulated and 784 down regulated by at leas 2 fold in n/s MEFs (top 100 
genes are listed in Appendix 8). Expression of Rnaseh2b was 2.7 fold lower (p = 
0.0000037) in n/s MEFs than in wild type MEFs. The expression of endogenous 
retroelements were not significantly altered nor wee genes involved in innate 
immune signalling pathways. 
 
Due to time constraints during this thesis, it was not possible to validate the 
expression data generated from the n/s MEFs using qRT-PCR. However, initial 
bioinformatic analysis was performed using the web-accessible programs DAVID 
and FunNet to identify biological pathways putatively affected by the changes in 
gene expression in n/s MEFs. A high proportion of up-regulated genes were 
associated with GO terms for apoptosis. Genes associ ted with protein transport and 
cell cycle were down-regulated in n/s MEFs (Figure 3.13), which could be indicative 
of a replication impairment in these cells. However, differential expression of genes 
associated with the regulation of cell proliferation suggests that n/s MEFs undergo 
increased cellular proliferation. Therefore, from this bioinformatic overview it is not 
clear what the consequences of having only 10% of functioning RNase H2 are at the 







Figure 3.13. Identification of biological processes affected by differentially expressed 
genes in n/s compound heterozygous MEFs. 
Lists of genes differentially expressed in n/s MEFs (fold change > 2, p < 0.05) were uploaded 
to the FunNet browser to generate an overview of Gene Ontology (GO) terms for biological 
processes associated with differentially expressed genes. Data shown here use GO term 
level 3, reported to provide the optimal balance between the quality and quantity of GO 




3.5.3.3. Rnaseh2bA177T-stop mice 
Embryos homozygous for the Rnaseh2bA177T-stop allele are not viable. They 
survive gastrulation (which occurs at E6.5) but fail to develop soon afterwards; by 
E7.5 they are smaller than wild type litter mates, and by E9.5 a profound 
developmental delay is evident. Homozygous mutants re reabsorbed by E11.5 
(Björn Rabe, MRC HGU, personal communication). Analysis of RNase H2 protein 
levels in these embryos confirmed that the homozygous embryos are Rnaseh2b-null, 
and that E9.5 homozygous mutants have an average 92% reduction in RNase H 
activity and 96% reduction in RNase H2 activity (Björn Rabe, personal 
communication).  
 
The early embryonic lethality phenotype of this null mutation suggests that RNase 
H2 is essential for mammalian development. This is n agreement with RNase H2-
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AGS patients, who generally have missense hypomorphic mutations in the 
RNASEH2 genes (Crow et al., 2006b; Rice et al., 2007b). In contrast, Trex1-null 
mice are viable (Morita et al., 2004) and TREX1-AGS patients generally have null 
mutations (Crow et al., 2006a; Rice et al., 2007b). Endogenous retroelements are 
expressed early in murine development (Baust et al., 2003; Peaston et al., 2004), 
therefore microarray analysis was performed on homozyg us embryos to investigate 
the expression of these elements compared to wild type embryos. However, it is 
unclear how an increase in retroelement transcription would lead to developmental 
arrest. 
 
Whole genome expression microarrays were performed on E9.5 homozygous mutant 
embryos (s/s) as insufficient amounts of RNA were obtained from earlier stages of 
development. At E9.5, Rnaseh2b-stop homozygous embryos physically resemble 
E8.5 wild type embryos (Björn Rabe, MRC HGU personal communication). 
Therefore, two stages of wild type controls were usd for array analysis: E8.5 and 
E9.5. Three embryos were used for each condition, which were representative of 
embryos from a number of different litters (Appendix 9). 
 
The E9.5 mutant embryo data were compared to both the E8.5 and E9.5 wild type 
data sets and lists of differentially expressed genes constructed (Appendix 10). The 
Rnaseh2b gene was downregulated in the mutant embryos by approximately 3-fold 
compared to both wild-type sets (Figure 3.14). Expression levels of Rnaseh2a and 
Rnaseh2c were not significantly altered in the mutant embryos. There was no 
significant difference in the expression of retroelements between the s/s embryos and 







Figure 3.14. . List of transcripts that are misregulated in the mutant embryos compared to 
both stages of wild type embryo. 
98 genes showed significant (p < 0.05) changes in expression (> 1.5 fold change), 36 of 
which were altered in the mutant embryos when compared to both E8.5 and E9.5 wild type 
embryos. Of the 30 genes significantly upregulated genes, eight are involved in 
apoptosis/induced in response to DNA damage (shown in blue in the table), including the 
four genes with the greatest fold increase in expression (Ccng1, Cdkn1a, Phlda3 and 
Trp53inp1). Expression of six genes was downregulated in the mutant embryo compare to 
both wild type sets, but only Rnaseh2b expression was decreased by more than 50% 





The expression of 35 genes were upregulated in the mutant embryos compared to 
E8.5 wild type embryos (p < 0.05, fold change > 1.5), and 101 genes compared to 
E9.5 wild type embryos (Appendix 10). Thirty of these genes were upregulated in the 
mutant compared to both wild type sets (Figure 3.14). In turn, eight of these 
upregulated genes encoded proteins which are involved in apoptosis, p53 signalling 
and the response to DNA damage, in particular Ccng1, Cdkn1a and Phlda3 which 
were all upregulated in excess of 4 fold in the mutant embryos (Figure 3.15). 
 
Genes which mediate apoptosis and cell cycle arrest a  active in normal 
development, however, the significant upregulation of these genes in the s/s embryos 
compared to both stages of wild type embryos shows that by E9.5 the mutant 
embryos are undergoing significant cell death, before they are reabsorbed. Therefore, 
it is difficult to deduce the in vivo function of RNase H2 in development using E9.5 
embryos. 
 
In summary, the characterisation of the RNase H2-deficient cells described in this 
section has not revealed a definitive function for the complex in vivo, although it is 
clear that RNase H2 activity is essential for viabil ty. A significant decrease in 
RNase H2 activity does not result in elevated expression of endogenous 
retroelements, therefore the data presented here imply that RNase H2 does not 
function in the suppression of RNA:DNA hybrids generat d by the reverse 






Figure 3.15. Upregulation of transcriptional targets of p53 in s/s embryos. 
A number of the genes that were upregulated in the mutant embryos are targets of p53 
(shown in red). The proteins encoded by these genes are involved in a range of cellular 





The autoinflammatory disease AGS can be caused by loss-of-function mutations in 
the genes encoding the RNase H2, TREX1 and SAMHD1 proteins (Crow et al., 
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2006a; Crow et al., 2006b; Rice et al., 2009). In this chapter, I aimed to characterise 
the expression pattern of the RNASEH2 genes in immune cells and establish if the 
enzyme complex has a role in the regulation of innate immunity. 
 
3.6.1. Baseline survey of RNASEH2 gene expression 
Expression analysis confirmed previous observations that the RNASEH2 genes are 
widely expressed across a range of tissues and cell typ s, in both human and murine 
cells. This also revealed differences in the expression between the AGS genes in 
different immune cell types, notably in lymphocytes. The RNASEH2 genes were 
expressed at relatively low levels in two human B cell lines compared to their 
expression in T cell lines (assuming expression of the housekeeping gene is constant 
between the different cell types) (Figure 3.2). Consistent with this, the T cell lines 
exhibited higher levels of active RNase H2 (Figure 3.3). 
 
The formation of RNA:DNA hybrids at specific regions of the immunoglobulin (Ig) 
heavy chain gene in B cells is an essential part of class switch recombination (CSR) 
to switch Ig production (Yu et al., 2003). The low endogenous expression of the 
RNASEH2 genes could suggest that RNase H activity is not be required for 
processing of these R loops, as was originally hypothesised (Yu and Lieber, 2003). 
However, the two cell lines analysed in Section 3.1 had both been EBV-transformed 
and therefore may not accurately represent B cells in vivo (Siemer et al., 2008). 
Consequently, it would be of interest to determine the basal expression of the 
RNASEH2 genes in primary B cells, and in particular to investigate if they can be 
induced in response to antigen stimulation, when CSR will be naturally occurring. 
Defects in CSR have not been studied in AGS patients with loss-of-function 
mutations in the RNASEH2 genes, however this could provide further insight nto the 
importance of RNase H2 activity in CSR in vivo.  
 
It is not immediately apparent what the in vivo requirement for high levels of RNase 
H2 in T cells and thymic tissue could be. During T cell development within the 
thymus, different T cell receptors (TCRs) are generated via rearrangement of the four 
149 
 
TCR genes, using V(D)J recombination, in a process similar to that of gene segment 
rearrangement the Ig genes of B cells (reviewed by Krangel, 2009). However, the 
formation of RNA:DNA hybrids during V(D)J recombination has not been reported. 
It could be hypothesised that an RNA:DNA hybrid is generated during TCR 
rearrangement which requires processing by RNase H2. The detection of high levels 
of RNase H2 activity in the Jurkat cell line is consistent with this, as TCR 
rearrangement is still ongoing in these cells, despit  them being mature T cells (Zou 
et al., 2007). It could also be hypothesised that deficiencies in RNase H2 activity 
lead to abnormalities in thymocyte development. Theexamination of the TCR 
repertoire of AGS patients has not been performed, therefore it would be if interest to 
investigate if any abnormalities are present when RNase H2 activity is reduced. 
Furthermore, the sequence analysis of V(D)J regions would establish if V(D)J 
function was normal in these patients. 
 
In addition to T cell lines, high levels of RNase H2 activity were present in the 
human monocytic cell line THP-1 (Figure 3.2). However, upon differentiation into 
macrophage-like cells, RNase H2 activity decreased. RNASEH2 expression was also 
detected in primary murine bone marrow-derived macrophages and Flt3-L DCs 
(Figure 3.3). The variation in enzyme activity observed between human immune cell 
lines suggests RNase H2 could have a specific function in certain immune cell types. 
Further examination of this may be of interest in defining the in vivo function of the 
enzyme complex. 
 
3.6.2. RNase H2 as a negative regulator of the innate immune 
response to nucleic acids 
TREX1 and SAMHD1 are type I IFN-inducible and are hypothesised to function as 
negative regulators of the innate immune response to ISD (Rice et al., 2009; Stetson 
et al., 2008). Therefore, a series of experiments were peformed to determine if the 
RNase H2 complex performs a similar function. It was established that both TREX1 
and SAMHD1 expression is induced directly in response to typeI IFNs in primary 
MEFs (Figure 3.8). In contrast, expression of the RNASEH2 genes was not 
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upregulated in response to stimulation of innate immunity with a range of PRR 
ligands. This suggests that the RNASEH2 genes are not inducible by type I IFNs in 
MEFs and therefore that they are functionally distinct from the other two genes 
identified as being mutated in AGS. Performing these xperiments in additional cell 
types would establish if this is a general trend. RNase H2 activity may be altered via 
post-transcriptional regulation of protein levels or modifications, therefore analysis 
of protein levels and enzyme activity would be required to ascertain if this occurs. 
Furthermore, analysis of any changes in the subcellular localisation of the complex 
following type I IFN treatment would determine if relocation of the RNase H2 
complex could be of functional significance. 
 
Taken together, the experiments performed in Sections 3.1 to 3.4 of this chapter have 
demonstrated that whilst RNase H2 is widely expressed, including in at high levels in 
certain cells of the immune system, transcription of the genes encoding the complex 
is not induced in response to activation of innate immunity. This is in contrast to 
TREX1 and SAMHD1, and therefore suggests that the genes mutated in AGS may 
not directly act in the same biological pathway; more specifically, they are not all 
acting as negative regulators of the innate immune response.  
 
3.6.3. Expression of endogenous retroelements in RNase H2-
deficient cells 
The characterisation of cells deficient in TREX1 revealed a role for TREX1 
enzymatic activity in the processing of cytosolic DNA. In the absence of TREX1, 
cells accumulate endogenous nucleic acid species in the cytosol (Stetson et al., 2008; 
Yang et al., 2007). It is hypothesised that these unprocessed TREX1 substrates are 
detected by an as yet undetermined cytosolic receptor of the innate immune system, 
which induces the expression of cytokines, notably the type I IFNs (Stetson et al., 
2008). This in turn could drive an adaptive immune response and the subsequent 
development of autoimmune disease in both humans and mice which lack TREX1 




It is possible that RNase H2 acts to suppress the accumulation of its substrates, 
therefore, RNA:DNA hybrids may accumulate in cells with reduced enzymatic 
acitivity. Inappropriate detection of these RNase H2 substrates by sensors of the 
innate immune system could lead the induction of a type I IFN response and the 
establishment of autoimmunity in a manner similar to that in TREX1-deficient 
individuals. The nature and source of RNase H2 substrate  accumulating in the 
absence of enzymatic activity remains to be established. Reverse transcribed DNA 
derived from endogenous retroelements has been proposed as one species of TREX1 
substrate (Stetson et al., 2008). The reverse transcription process would generate 
RNA:DNA hybrids, which could normally be processed by the RNase H2 complex. 
Therefore, it has been hypothesised that cells deficient in RNase H2 activity may 
have an increased expression of endogenous retroelements, in the absence of the 
suppression of their replication (Bhoj and Chen, 2008). 
 
The level of endogenous retroviral replication in LCLs established from AGS 
patients with mutations in the RNASEH2 and TREX1 genes was not significantly 
elevated. Furthermore, whole genome gene expression microarray analysis of mice 
deficient in RNase H2 activity also failed to detect a significant increase in the 
expression of endogenous retroelements. Taken together, this implies that RNase H2-
deficiency does not result in a global increase in ndogenous retroelement 
expression, and that another cellular source of RNase H2 substrates exists, which 
remains to be identified. 
 
In summary, the data presented in this chapter demonstrate that the RNase H2 
complex is unlikely to be involved in the regulation f the innate immune response 
via the same mechanism as TREX1 and SAMHD1. The immunological phenotype 
observed in AGS patients with hypomorphic mutations in the genes encoding the 
RNase H2 complex, most notably the presence of elevated levels of IFN-α in the 
CSF and plasma, suggests that activation of the immune system in the absence of 
infection occurs in these individuals. As nucleic acids are potent stimulators of IFN-α 
production, it is therefore highly likely that this is due to activation of innate 
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immunity by nucleic acids. Therefore, it is hypothesis d that the endogenous nucleic 
acid substrates of RNase H2, RNA:DNA hybrids, are responsible for triggering 
immunity in specific cells. Work is ongoing in the lab to define the nature of nucleic 
acids which accumulate in cells with reduced RNase H2 activity. However, as the 
immunostimulatory capacity of RNA:DNA hybrids has not previously been 
characterised, I aimed to test this in vitro by generating synthetic hybrids. Therefore, 
the next three chapters of this thesis detail the design and characterisation of 
synthetic RNA:DNA hybrids and their ability to stimulate an immune response in 
vitro. The characterisation of RNase H2-specific substrates that can stimulate the 
activation of the innate immune system should provide indications as to the 
endogenous sources of such hybrids, and consequently provide further insight into 




Chapter 4. Reagents for the study of RNA:DNA hybrids 
 
AGS patients have mutations in genes encoding nucleases, the consequence of which 
is reduced enzymatic activity (Crow et al., 2006a; Crow et al., 2006b). This is 
hypothesised to lead to an accumulation of unprocessed endogenous nucleic acid 
substrates in patient cells. The accumulation of DNA in cells from humans and mice 
lacking TREX1 activity has been demonstrated (Stetson et al., 2008; Yang et al., 
2007). However, as described in the previous chapter, th  accumulation of 
RNA:DNA hybrids in cells with defective RNase H2 activity has not yet been 
established and work is ongoing in the lab to identify and purify such nucleic acid 
species.  
 
Many different forms of nucleic acids can activate innate immune signalling via 
PRRs (Table 1.2). Recognition of endogenous TREX1 substrates is thought to occur 
via an unidentified cytosolic receptor of the innate immune system, which triggers 
the induction of type I IFNs in an IRF3-dependent manner (Stetson et al., 2008). 
However, the ability of RNA:DNA hybrids to stimulate immunity has not been 
characterised. In addition to identifying a novel nucleic acid ligand for PRRs of the 
immune system, understanding the mechanism by which RNA:DNA hybrids 
stimulate immunity may provide further insights into the origin of endogenous 
hybrids. Reverse transcription of retroviral genomes provide a source of 
exogenously-derived RNA:DNA hybrids, the immunostimulatory potential of which 
is unknown. The ability of any of the known PRRs to sense RNA:DNA hybrids has 
not been described, although RIG-I is able to translocate on a RNA:DNA hybrid in 
an RNA-dependent manner (Myong et al., 2009).  
 
RNA:DNA hybrids exhibit different physiochemical properties to dsDNA and 
dsRNA, therefore it was necessary to establish and optimise techniques for 
performing experiments with hybrids. In this chapter, he unique characteristics of 
RNA:DNA hybrids are considered. The methodologies for working with hybrids are 
investigated, including the testing of commercial nuclease preparations for hybrid-
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cleaving activity. Finally, applications for an RNA:DNA hybrid-specific antibody are 
characterised. 
 
4.1. Unique structural and physiochemical properties of 
RNA:DNA hybrids 
4.1.1. The structural properties of nucleic acid duplexes 
Studies using various synthetic RNA:DNA hybrids have revealed that their structural 
conformations are distinct from those of both DNA and RNA duplexes (Noy et al., 
2005; Shaw and Arya, 2008). In aqueous solutions, DNA duplexes adopt a B-form 
structure (B-DNA). Dehydration can induce the DNA to undergo a conformational 
change into an A-form structure (A-DNA) (Noy et al., 2007). In contrast, RNA 
duplexes are always A-form, independent of humidity conditions (Figure 4.1). The 
differences in the helices adopted by RNA and DNA duplexes is considered to be 
important for their cellular functions, for example, detection by specific proteins and 
the transfer of biological information (Pan and MacKerell, 2003). 
 
The differences between dsDNA and dsRNA can be attribu ed to the hydroxyl (OH) 
group at the 2́ position on the ribose sugar ring, which cannot be accommodated into 
a B-form conformation because of steric hindrance (Arnott et al., 1986). In addition 
to lining the minor groove of the RNA duplex, where th y are involved in extensive 
hydrogen bonding with water molecules, intramolecular hydrogen bonds between the 
2ʹ-OH also stabilise the RNA duplex (Egli et al., 1996). This contributes to the 
overall greater thermostability of A-form RNA duplexes compared to both A- and B-
form DNA duplexes. The difference in base stacking between A- and B-form helices 
also confers additional stability to RNA duplexes (Cate et al., 1996). 
 
RNA:DNA hybrids, which contain only one strand of ribose sugars with the 2ʹ-OH, 
cannot adopt the canonical A- or B-form helices. They instead assume a unique 
heteromerous (H-form) helix (Arnott e  al., 1986; Fedoroff et al., 1993), with 
physical characteristics intermediate of those for dsRNA and B-form dsDNA (Figure 
4.1) (Arnott et al., 1986; Fedoroff et al., 1993; Horton and Finzel, 1996; Hung et al., 
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1994; Milman et al., 1967; Noy et al., 2005; Wang et al., 1982). This greatly affects 
the thermostability and electrophoretic migration of the hybrid in relation to dsDNA 






Figure 4.1. Differences in the helical conformations of double stranded nucleic acids. 
The helical conformation of 12 bp nucleic acids of the same sequence greatly varies 
depending upon whether the sugars are ribose or deoxyribose. dsDNA adopts a B-form 
helix whilst dsRNA assumes the shorter, broader A-form. The RNA:DNA hybrid helix is 
intermediate between the two (H-form), but the measurement of various physical 
parameters have revealed it is closer to an A-form helix than B-form. (Figure reproduced 




RNA:DNA hybrids bear a closer physical resemblance to an A-form helix rather than 
a B-form, but they generally exhibit a reduced thermostability compared to RNA 
duplexes (Hall and McLaughlin, 1991; Hung et al., 1994). However, this greatly 
depends on both the base sequence composition of the two strands and the length of 
the duplex (Hung et al., 1994; Lesnik and Freier, 1995). Analyses of RNA:DNA 
hybrids consisting of homopurine (Pu) and homopyrimid ne (Py) oligonucleotides 
have concluded that r(Pu):d(Py) hybrids have a greate  thermodynamic stability than 
r(Py):d(Pu) hybrids. Furthermore, the physical structure of the two is very different 
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(Gyi et al., 1996; Gyi et al., 1998; Hall and McLaughlin, 1991; Hung et al., 1994; 
Lesnik and Freier, 1995). 
 
The RNA strand of an RNA:DNA hybrid always assumes an A-type conformation, 
regardless of the sequence (Chou et al., 1989; Priyakumar and Mackerell, 2008; 
Sanghani and Lavery, 1994). However, the structure of the complementary DNA 
strand can vary depending on base composition; retaining a B-like conformation 
when purine-rich but being forced into the adoption of a mixed A-/B-form when 
pyrimidine-rich and hybridised to a complementary purine rich RNA strand (Gyi et 
al., 1996; Hung et al., 1994; Noy et al., 2005; Priyakumar and Mackerell, 2008; 
Salazar et al., 1993). Therefore, r(Pu):d(Py) hybrids are structurally most similar to 
dsRNA and consequently exhibit a greater thermostability (Gyi  et al., 1996; 
Priyakumar and Mackerell, 2008). Analysis of mixed base oligomeric RNA:DNA 
hybrids and of naturally occurring hybrid sequences confirmed that individual 
hybrids form unique helical conformations, which is strongly influenced by the exact 
sequence composition of the individual strands (Fedoroff et al., 1997; Gray and 
Ratliff, 1975; Huang et al., 2009; Milman et al., 1967).  
 
Crystallisation of the 3 bp RNA:DNA hybrid r(AAA):d(TTT) flanked by dsDNA 
revealed that the structure of the central hybrid region is A-form but the DNA duplex 
regions are B-form (Hsu et al., 2000). Furthermore, the introduction of even a single 
ribonucleotide into a DNA duplex is sufficient to distort the helix into A-form 
geometry (Egli et al., 1993). This conformational change is presumably the key to 
RNase H2 identification and cleavage of such substrates by RNase H2 (Noy et al., 
2005). 
 
In summary, the thermostability and structural conformation of RNA:DNA hybrids is 
greatly influenced by the sequence composition of each strand, which must be given 
consideration when designing hybrids as potential PRR ligands. 
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4.1.2. The electrophoretic mobility of RNA:DNA hybrids in 
polyacrylamide gels 
The different physical properties of dsRNA, dsDNA and RNA:DNA hybrids of the 
same sequence influences their electrophoretic mobility relative to each other. The 
shorter, broader and less flexible A-form RNA duplex migrates slower through 
native polyacrylamide gels than the B-form DNA duplex. RNA:DNA hybrid 
migration is intermediate between the two (Figure 4.2) (Lesnik and Freier, 1995). 
Therefore, it is possible to distinguish between different nucleic acid duplexes of the 
same sequence using electrophoresis. Hybrids with a pyrimidine-rich DNA strand 
migrate more similarly to dsRNA, as their structure is most comparable to A-form 
(Lesnik and Freier, 1995). As no size markers for RNA:DNA hybrids exist, all 






Figure 4.2. The electrophoretic mobility of different nucleic acids.  
500 ng of 18 bp duplexes and 18 nt ssNA of the same sequence were electrophoresed on a 
20% native polyacrylamide gel. D-R-D indicates DNA containing a single ribonucleotide at 
position 15. 200 ng of 5 bp ladder was included as a size marker. After staining with acridine 
orange, the gel was imaged using a UV transilluminator. The Py:Pu ratio of the DNA 





A technique for validating the presence of RNA:DNA hybrids in complex nucleic 
acid mixtures by exploiting their differential migration has been described 
(Gunnarsson et al., 2006a; Gunnarsson et al., 2006b). Two-dimensional 
strandedness-dependent electrophoresis (2D-SDE) firstly separates the nucleic acids 
on the basis of strandedness, length and conformation using polyacrylamide gel 
electrophoresis (PAGE). The first dimension is performed using a urea-containing 
gel which reduces the secondary structure of single-stranded nucleic acids (ssNAs) 
without denaturing double-stranded molecules. After el ctrophoresis, double-
stranded nucleic acids (dsNAs) are heat denatured before samples are separated in 
the second dimension, which segregates the samples according to length, as they are 
all now single-stranded. Although this is suitable for identifying RNA:DNA hybrids 
in mixed nucleic acid samples, it cannot be used to quantify, accurately size or purify 
the hybrids, therefore was not used during this theis. 
 
4.1.3. The binding of nucleic acid dyes to RNA:DNA hybrids 
The distinct physiochemical properties of RNA:DNA hybrids also affects their 
binding by chemicals. Studies using the synthetic RNA:DNA hybrids poly (rA:dT) 
have shown that compounds commonly used to bind the minor groove of dsDNA, 
such as the fluorescent stains 4',6-diamidino-2-phenylindole (DAPI) and Hoechst, 
fail to recognise the minor groove of the hybrid (Ren and Chaires, 1999; Wheelhouse 
and Chaires, 2010). This is likely to be due to the uniqueness of the RNA:DNA 
hybrid minor groove, which is lined with 2ʹ-OH groups (Horton and Finzel, 1996). In 
contrast, the intercalator ethidium bromide strongly binds RNA:DNA hybrids 
(Figure 4.3), and is reported to preferentially bind hybrids over other nucleic acids 
(Ren and Chaires, 1999; Wheelhouse and Chaires, 2010). 
 
Other compounds which have a high affinity for RNA:DNA hybrids, including 
ellipticine and propidium, have been described (Ren and Chaires, 1999; Shaw and 
Arya, 2008), however an RNA:DNA hybrid-specific dye has yet to be identified 





Figure 4.3. Ethidium bromide binds to RNA:DNA hybrids. 
A 60 nt oligodeoxyribonucleotide and a 60 nt oligoribonucleotide were annealed to form a 
60 bp RNA:DNA hybrid. 500 ng of each was electrophoresed on an 8% native 
polyacrylamide gel. 200 ng 1kb ladder (M) was included as a size marker. The gel was 




4.1.4. Quantification of RNA:DNA hybrids 
Nucleic acids are typically quantified using two methods. Electrophoresis alongside 
known amounts of a standard such as a DNA ladder allows comparison of the 
amount of nucleic acid present in a specific volume. However, as discussed in the 
previous section, the unique structure of RNA:DNA hybrids can results in the 
differential binding of fluorescent dyes to them compared to other nucleic acids, 
specifically dsDNA. Therefore, it would not be possible to compare RNA:DNA 
hybrids to dsDNA size standards. 
 
UV spectroscopy is used to more accurately quantify ucleic acids. However, the 
quantification of RNA:DNA hybrids by spectrophotometry has not been well 
documented. The extinction coefficient for a hybrid is unknown and cannot be 
calculated simply by adding together the values for the two complementary strands 
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because of the probable occurrence of hyperchromicity, as known to occur with 
DNA (Tataurov et al., 2008). 
 
Known molar concentrations of oligonucleotides were annealed to generate 20 µM 
RNA:DNA hybrids. Electrophoresis on a native polyacrylamde gel confirmed the 
oligonucleotides had annealed, as evidenced by a shift in electrophoretic migration 
(Figure 4.4). The molecular weight of each strand was calculated, as described in 
Chapter 2. This was used to calculate the expected ng/µl of nucleic acid in 1 µl of 20 
µM RNA:DNA hybrid. The hybrids were quantified using a NanoDrop UV 
spectrophotometer and nucleic acid concentrations determined from the absorbance 
at 260 nm based on the conversion for dsDNA (1 A260 unit = 50 µg/ml dsDNA). 
Each of the single-stranded oligonucleotides was also quantified and the 
concentration determined using the appropriate conversions from the A260 values (1 
A260 unit = 40 µg/ml ssRNA and 33 µg/ml ssDNA). The expected concentrations for 
the ssNA were correct to the nearest ng + 4.5% (n = 6). For the RNA:DNA hybrids, 
the recorded concentrations were slightly higher than expected (+ 10% on average), 
however this could be due to the presence of contami ating unannealed ssNA 
(Figure 4.4). Nevertheless, this was determined to be the most accurate method of 
quantifying hybrids, therefore all RNA:DNA hybrids were quantified using the 




     
 
Figure 4.4. Native PAGE analysis of annealed oligonucleotides. 
500 ng each (as determined by expected concentration based on MW) of 18 and 60 nt RNA 
and DNA oligonucleotides and the hybrids formed by annealing the two were 
electrophoresed on a 6% native polyacrylamide gel, which was stained with acridine orange 





4.1.5. Nuclease digestion 
RNase H enzymes are the only enzymes to exclusively cl ave the RNA strand of 
RNA:DNA hybrids. However, the multi-functional E. coli nuclease Exonuclease III 
can exonucleolytically degrade both strands of RNA:DNA hybrids (Keller and 
Crouch, 1972). 
 
Commercial preparations of nucleases are not tested for RNase H activity, and initial 
experiments performed during this thesis suggested that contaminating RNA:DNA 
hybrid-cleaving activity was present in many recombinant nuclease preparations. 
Therefore, the ability of a range of commercially available nucleases to cleave 




4.1.5.1. RNase A will cleave RNA:DNA hybrids at low salt 
concentrations 
The endoribonuclease RNase A cleaves RNA after cytosine and uracil residues to 
generate 3́ phosphates and 3ʹ phospho-oligonucleotides products (reviewed by 
Raines, 1998). It is active under a wide range of conditions; at salt concentrations of 
less than 100 mM it cleaves ssRNA and dsRNA but at salt concentrations exceeding 
300 mM RNase A specifically cleaves ssRNA (Nichols and Yue, 2008; Tanese et al., 
1991). 
 
The activity of RNase A on RNA:DNA hybrids in both high (300 mM) and low (60 
mM) salt buffers was tested. The amount of enzyme used was determined by the 
manufacturer’s recommended working concentrations fr the degradation of RNA. 
RNase H1 from E. coli was included for comparison (Figure 4.5 a). The use of high 
concentrations of enzyme results in cleavage of the RNA:DNA hybrid substrate in 
the low salt buffer but not in the high salt buffer (Figure 4.5 b and c). However, 
ssRNA is still cleaved in the high salt buffer (Figure 4.5 d). The activity of RNase A 
on RNA duplexes in a high salt buffer was found to be highly variable. The ability of 
RNase A to cleave RNA at such a high salt concentration is unusual as most 
nucleases, including RNase H and DNase I, are completely inhibited by salt 
concentrations exceeding 150 mM. 
 
4.1.5.2. RNase If will cleave RNA:DNA hybrids at high 
concentrations 
The endonuclease RNase If cleaves RNA between all dinucleotide pairs generating 
products with 5́-OH and 3́ monophosphate ends. According to the manufacturers, it 
has a strong preference for ssRNA over dsRNA and will not cleave DNA. The ability 
of RNase If to cleave RNA:DNA hybrids was tested using 25 pmol of hybrid 
substrate. When used at the concentrations recommended for the degradation of 12.5 
pmol RNA (12.5 U), RNase If exhibited a high level of activity on the hybrid (Figure 







Figure 4.5. The RNA:DNA hybrid-cleaving activity of nucleases. 
Commercially available recombinant nucleases were tested for hybrid-cleaving activity 
using the RNase H activity assay as described in Chapter 2. Different concentrations of 
nucleases were tested for activity on 25 pmol RNA:DNA hybrid substrate incubated at 37
o
C. 
Reactions were performed in a volume of 100 μl. All enzymes units are defined by the 
manufacturers. (a) E. coli RNase H (M0297L, New England Biolabs). Reactions were 
performed in the buffer supplied with the enzyme (75 mM KCl, 50 mM Tris-HCl, 3 mM 
MgCl2, 10 mM DTT, pH 8.3). (b) and (c) The activity of DNase-free RNase A (11119915001, 
Roche Applied Science) was tested in a low salt buffer (60 mM KCl, 50 mM Tris-HCl pH 8.0, 
10 mM MgCl2) and a high salt buffer (300 mM KCl, 50 mM Tris-HCl pH 8.0, 10 mM MgCl2). 
(d) 2 μg of a 65 nt oligoribonucleotide (93 pmol) was digested with 5 ng/μl RNase A in the 
high salt buffer. Half of this reaction was electrophoresed on a 1% agarose gel containing 
ethidium bromide. (e) RNase If (M0243, New England BioLabs). Reactions were performed 
in the buffer supplied with the enzyme (10 mM Tris-HCl, 100 mM NaCl 1 mM DTT, 0.5 mM 
EDTA, pH 8.0).(f) RNase-free DNase (M6101, Promega). Reactions were performed in the 
buffer supplied with the enzyme (40 mM Tris-HCl pH 8.0, 10 mM MgSO4, 1 mM CaCl2). (g) E. 
coli Exo I (M0293, New England Biolabs). Reactions were performed in the buffer supplied 
with the enzyme (67 mM Glycine-KOH, 6.7 mM MgCl2, 10 mM 2-mercaptoethanol, pH 9.5). 
(h) The degradation of ssDNA by Exo I. 1 μg of a 65 nt oligodeoxyribonucleotide (46.5 pmol) 
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was incubated with the indicated amounts of Exo I. Half of the reaction was 
electrophoresed on a 2% agarose gel which was then stained with ethidium bromide. (i) S1 
nuclease (M5761, Promega). Reactions were performed in the buffer supplied with the 
enzyme (50 mM NaOAc pH 4.5, 280 mM NaCl, 4.5 mM ZnSO4). (j) The degradation of ssDNA 
by S1 nuclease. 200 ng of a 65 nt oligodeoxyribonucleotide (9.3 p mol) was incubated with 
S1 as indicated. Half of each reaction was electrophoresed on a 2% agarose gel containing 





4.1.5.3. The cleavage of RNA:DNA hybrids by DNases 
To assess the ability of recombinant DNases to cleave RNA:DNA hybrids, DNase I 
and Exonuclease I (Exo I) were tested. The endonuclease DNase I (here purified 
from bovine pancreas) cleaves ds- and ssDNA in a sequence-independent manner, 
resulting in products with 5ʹ-phosphate ends. It does not cleave RNA, however it 
exhibits weak activity on the DNA strand of RNA:DNA hybrids (Sutton et al., 
1997). This was confirmed using the RNase H activity assay; when used at a high 
concentration, DNase I cleaved the hybrid substrate (Figure 4.5 f). However, 
according to the manufacturer’s definition of the activity of one unit of DNase I, 0.25 
U should be sufficient to 25 pmol of a DNA substrate. No cleavage of the hybrid was 
detected when 0.25 U was used (Figure 4.5 f), therefore when using DNase I to 
remove DNA from hybrid containing nucleic acid mixtures, the concentration of 
enzyme used is crucial to prevent degradation of the hybrid. 
 
The ssDNA-specific E. coli Exo I enzyme is a 3ʹ → 5́  exonuclease. It lacks 
endonucleolytic activity and cannot act on dsNA. Consequently, even when a great 
excess of enzyme is used, no cleavage of RNA:DNA hybrids was detected (Figure 
4.5 g). In contrast, Exo I degraded ssDNA even when used at comparatively low 
concentrations (Figure 4.5 h).  
 
Finally, the hybrid-cleaving ability S1 nuclease was tested. S1 nuclease, purified 
from Aspergillus orzyae, non-specifically cleaves both ssDNA and ssRNA. It has 
both endo- and exonuclease activities, and releases products with 5́ phosphates. It is 
approximately five times more active on ssDNA than ssRNA (Vogt, 1973). Although 
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described as a single-strand specific nuclease, S1 has been shown to introduce breaks 
into dsDNA, dsRNA and RNA:DNA hybrids when used at high concentrations 
(Vogt, 1973). However, when tested using the RNase H activity assay, cleavage 
levels were close to background even at high concentrations (Figure 4.5 i). In 
contrast, use of a low concentration of S1 was sufficient to completely degrade 
ssDNA (Figure 4.5 j ). 
 
Together, these RNase H activity assays reveal that caution needs to be taken when 
using nucleases to degrade unwanted nucleic acids, for example, single-stranded 
contamination, from preparations of RNA:DNA hybrids. 
 
 
4.2. The purification and applications of an anti-RNA:DNA 
hybrid antibody 
A number of antibodies with reactivity against RNA:DNA hybrids have been 
generated (Boguslawski et al., 1986; Kitagawa and Stollar, 1982; Nakazato, 1980). 
The S9.6 monoclonal antibody is reported to specifically recognise RNA:DNA 
hybrids in a sequence-independent manner (Boguslawski et al., 1986). The 
hybridoma line secreting S9.6 was produced from mice immunised with RNA:DNA 
hybrids generated by the in vitro transcription of ΦΧ174 ssDNA by E. coli RNA 
polymerase (Boguslawski et al., 1986). Initial characterisation of the antibody 
showed it was specific for RNA:DNA hybrids, and failed to detect dsDNA, ssDNA, 
dsRNA or ssRNA (Boguslawski et al., 1986).  
 
The S9.6 antibody has been successfully utilised in a range of applications, the 
majority of which were for the detection of hybrids formed between RNA probes and 
target ssDNA in an ELISA (Coutlee et al., 1992; Coutlee et al., 1989; Coutlee et al., 
1990; Dutrow et al., 2008; Hu et al., 2006; Kinney et al., 1989). However, it has also 
been used to detect cellular RNA:DNA hybrids by immunofluorescence (Szekvolgyi 
et al., 2007), electrophoretic mobility shift assays (EMSAs) (Pohjoismaki et al., 
2010) and chromatin immunoprecipitation (CHIP) experim nts (El Hage et al., 
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2010). Therefore, the S9.6 provides a powerful reagent for the detection of 
RNA:DNA hybrids and could potentially be very useful for the validation of hybrids 
described in this thesis. 
 
The antibody-containing supernatant of the hybridoma cell line HB-8730 (ATCC) 
was concentrated using a miniPerm system, as describ d in Chapter 2. The 
specificity of the antibody was validated by a dotbl t using 18 bp RNA:DNA hybrids 
and controls (Figure 4.6 a). The antibody specifically recognised the RNA:DNA 
hybrid but did not detect the RNase H2-specific substrate (D-R-D:DNA, a DNA 
duplex containing a single ribonucleotide at positin 15 of the forward strand), which 
suggested that there must be a minimal hybrid region required for binding of the 
antibody. When used at low dilutions or with longer exposures, faint activity in the 
supernatant against ssDNA was visible (Figure 4.6 a) and a trace of RNase H activity 
detected (Pohjoismaki et al., 2010). Purification and concentration of the antibody 
using recombinant protein A/G eliminated all traces of sDNA reactivity and RNase 
H activity, which suggested it was due to contaminants in the supernatant rather than 
the antibody.  
 
The use of the purified S9.6 antibody in techniques that could be useful during this 
thesis was investigated. One application considered was in the immunodetection of 
electrophoresed RNA:DNA hybrids. A method for electrophoresing and transferring 
short (< 200 bp) nucleic acids to a positively-charged nylon membrane was 
established, as described in Chapter 2. The S9.6 antibody successfully recognised 
electrophoresed RNA:DNA hybrids (Figure 4.6 b). This provided an alternative 
method to a dotblot for the validation of RNA:DNA hybrid preparations, with the 
advantage that RNA:DNA hybrids could be accurately sized. As shown in Figure 4.6 
b, the preparation of 18 bp RNA:DNA hybrid also contai ed another band migrating 
at approximately 40 bp. Detection by the S9.6 antibody confirmed that this band was 
RNA:DNA hybrid-containing. Electrophoresis and Sybr Gold staining of the single-
stranded oligonucleotides used to generate this hybrid (ssRNA and ssDNA) revealed 
that there was an additional band in the ssDNA, migrating at approximately 20 bp 
(Figure 4.6 b). All oligonucleotides used to generate RNA:DNA hybrids were 
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purified using HPLC or PAGE by the manufacturers. Therefore, this demonstrated 
that the assumption that commercially purified olignucleotides are homogeneous in 
length is not always the case. Consequently, single-stranded oligonucleotides were 
analysed by denaturing PAGE prior to use to confirm they contained a homogeneous 
population of nucleic acid. 
 
An additional use for this antibody in the detection of RNA:DNA hybrids in a 
multiwell plate format was investigated. 18-mer nucleic acids were immobilised 
using the DNA coating agent Reacti-Bind and an indirect ELISA method with the 
S9.6 antibody to detect hybrids was established (Figure 4.6 c.). The successful use of 
Reacti-Bind to immobilise DNA to plates has been repo ted previously (Hirayama et 
al., 1996). Again, the S9.6 antibody specifically detected the RNA:DNA hybrid. This 
method could be applied to the detection of RNA:DNA hybrids in synthetic nucleic 
acid preparations or in the detection and quantifica on of endogenous hybrids in 







Figure 4.6. Applications of the S9.6 RNA:DNA hybrid-specific antibody. 
(a) Characterisation of the specificity of the S9.6 supernatant using 18 nt nucleic acids. 
ssRNA (PS) is a 20 nt ssRNA oligo with a phosphorothiorate-containing backbone. 20 pmol 
of each nucleic acid was crosslinked onto a nitrocellulose membrane. The membrane was 
probed with the concentrated hybridoma supernatant, diluted 1:2000 in PBS containing 2% 
BSA, as described in Chapter 2. A secondary only (-S9.6) control was included. On the 2 min 
exposure, faint detection of ssDNA can be seen. (b) Immunodetection of electrophoresed 
RNA:DNA hybrids. 500 ng of each 18 nt nucleic acid was electrophoresed on a 15% native 
polyacrylamide gel. 500 ng of 5 bp ladder (M) was included as a size marker. The Sybr Gold 
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stained gel is shown on the left. Following transfer and crosslinking of the nucleic acids to a 
nylon membrane as described in Chapter 2, the membrane was probed with purified S9.6 in 
PBS containing 2% BSA. The bands detected by the antibody after a 30 min exposure (right) 
correspond only to those in the RNA:DNA hybrid lane. The blot is representative of three 
independent blots. (c) Detection of immobilised RNA:DNA hybrids in a multiwell plate. 18-
mer nucleic acids at a concentration of 5 ng/μl were immobilised to a 96-well plate in the 
presence and absence of Reacti-Bind, as described in Chapter 2. Purified S9.6 antibody was 
used at a 1:1000 dilution in PBS containing 1% BSA. A secondary only control for each 
nucleic acid was also at background level. Data are representative of triplicate experiments 





In this chapter, the unique physiochemical characteistics of RNA:DNA hybrids have 
been considered and their consequences for the study of hybrids discussed. The aim 
of this chapter was to establish a greater understanding of properties which might 
affect the design, synthesis and analysis of synthetic RNA:DNA hybrids to be tested 
for their immunostimulatory potential in vitro. 
 
4.3.1. Detection of electrophoresed RNA:DNA hybrids 
The physical properties of RNA:DNA hybrids are distinc  from those of both RNA 
and DNA duplexes, most notably in the formation of a unique H-form helical 
structure (Arnott et al., 1986; Fedoroff et al., 1993). As shown in this chapter, the 
specific physical properties of hybrids influenced electrophoretic mobility and the 
binding of fluorescent dyes to the hybrid helix. The differential binding of nucleic 
acid stains such as ethidium bromide to RNA:DNA hybrids has consequences for 
both the quantification of hybrids and the analysis of their purity. As shown in 
Figures 4.4 and 4.6, it is possible that contaminating nucleic acid species may be 
present in hybrid preparations. The staining of electrophoresed samples using a 
nucleic acid stain with a high affinity for hybrids would therefore give a misleading 




Properties distinctive to RNA:DNA hybrids can be exploited. The differential 
migration of hybrids compared to other nucleic acid species of the same base 
sequence permits separation of a mixed population of nucleic acids by 
electrophoresis. Furthermore, the use of the S9.6 antibody to specifically identify 
hybrids within a mixed population of nucleic acids s also of interest, particularly in 
the identification of products of annealed oligonucleotides, as shown for an 18 bp 
hybrid in Figure 4.6. The detection of the extra band t 40 bp by the antibody verifies 
the presence of an additional hybrid species, which therefore cannot be removed 
using nuclease treatment. Furthermore, the successful use of the S9.6 antibody to 
detect electrophoresed nucleic acids also provides a method for detecting RNA:DNA 
hybrids in RNase H2-deficient cells. Preliminary exp riments using a modified 
version of the method described in this chapter to identify RNA:DNA hybrid regions 
within electrophoresed total nucleic acid preparations have suggested this is possible, 
but further refinement of the method would be necessary.  
 
4.3.2. Quantification of RNA:DNA hybrids 
RNA:DNA hybrid-specific properties and reagents provide a way of distinguishing 
them from other nucleic acid species. Equally, the unique characteristics of 
RNA:DNA hybrids can lead to difficulties, most notably with obtaining an accurate 
quantification of a hybrid preparation. The absorbance of light at 260 nm differs both 
between single- and double-stranded nucleic acids an  between DNA and RNA. 
Therefore, the A260 of an RNA:DNA hybrid is distinct from that of dsDNA (1 A260 
unit = 50 µg/ml) and dsRNA (1 A260 unit = 40 – 50 µg/ml, (Misquitta et al., 2008)). 
However, calculating the concentration of a hybrid using the conversion value for 
dsDNA was found to be sufficiently accurate. 
 
An alternative, highly sensitive approach to the quantification of nucleic acids 
involves the use of fluorescent dyes, such as PicoGreen® (Molecular Probes, 
Invitrogen). PicoGreen fluoresces only when bound to sNA; therefore the precise 
concentration of a sample can be determined from a standard curve of known dsDNA 
concentrations (Ahn et al., 1996). Under specific assay conditions, PicoGreen 
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specifically binds dsNA (Singer et al., 1997). It is widely used for the quantification 
of dsDNA but has also been used to quantify RNA:DNA hybrids in the same way 
(EnzChek® Reverse Transcriptase Assay Kit, Invitrogen). However, PicoGreen 
intercalates at the minor groove of dsDNA (Zipper et al., 2004) and the mechanism 
of binding to RNA:DNA hybrids has not been shown. Aother minor groove 
intercalator, ethidium bromide, strongly binds electrophoresed RNA:DNA hybrids 
(Figure 4.3), and is reported to have a higher affinity for binding hybrids over other 
dsNA (Ren and Chaires, 1999; Wheelhouse and Chaires, 2010). Therefore, it is 
possible that increased amounts of PicoGreen would bind to RNA:DNA hybrids than 
would bind to the same concentration of dsDNA. Therefore, the use of a dsDNA 
standard curve would not accurately determine the concentration of hybrids. 
Consequently, the use of PicoGreen to quantify hybrids was not pursued during this 
thesis.  
 
4.3.3. Nuclease digestion of RNA:DNA hybrids 
Nuclease digestion provides one method of removing contaminating nucleic acids 
whilst leaving the RNA:DNA hybrid intact. Commercially available nucleases are 
not tested for RNase H activity. The two single-strand-specific enzymes, Exo I and 
S1 nuclease, did not exhibit any activity on the 18 bp RNA:DNA hybrid substrate, 
even when used at high concentrations, and so could be used in the removal of 
contaminating ssDNA. In contrast, DNase I exhibited RNA:DNA hybrid-cleaving 
activity when used at high concentrations. Therefore, a specific amount of enzyme 
would need to be used to ensure no cleavage of the hybrid, and this would need to be 
optimised for each hybrid. An additional consequence of the cleavage of the DNA 
strand of a hybrid by DNase I is the generation of potentially immunostimmulatory 
ssRNA. Therefore, DNase I is not ideal for use in studies involving RNA:DNA 
hybrids. Other DNases active against dsDNA including DNase II and Shrimp 





Removal of RNA contamination from hybrid-containing samples using RNase A was 
also found to be less than straightforward and requi d optimisation. Low 
concentrations of enzyme and use of a high salt buffer were required to prevent 
activity against the hybrid. However, at a high salt buffer RNase A is reportedly also 
inactive against dsRNA, therefore an additional nuclease would be required if 
dsRNA contamination was suspected. The dsRNA-specific endonuclease RNase III 
would not be suitable, as it does not completely degrade dsRNA but instead 
generates 12 – 15 bp dsRNA cleavage products (Yang et al., 2002a), which again 
may potentially be immunostimulatory.  
 
In addition to hybrid-cleaving activity when used in low salt buffers, a further 
disadvantage of utilising RNase A is the cleavage pattern demonstrated by the 
enzyme on ssRNA. RNase A will cleave only at pyrimidine residues and will not 
completely degrade ssRNA with a mixed pyrimidine/purine sequence. Instead, short 
RNA fragments would be produced. In contrast, RNase If cl aves ssRNA at every 
phosphodiester bond; however the nuclease exhibited activity against RNA:DNA 
hybrids, even when used at low concentrations. It was not possible to determine if 
this was due to non-specific cleavage by the nuclease or residual RNase H activity 
from the methods used for commercial production of the recombinant protein. 
Nevertheless, RNase If is therefore unsuitable for the removal of ssRNA 
contamination from hybrid-containing preparations. 
 
S1 nuclease is reported to be weakly active against ssRNA (Vogt, 1973). It did not 
show any activity against the 18 bp RNA:DNA hybrid substrate, but is reported to 
introduce breaks into hybrids when used at high concentrations (Vogt, 1973). 
Therefore, further experiments would be required to ensure complete degradation of 
ssRNA without cleavage of the hybrid. The use of nucleases to selectively degrade 
specific nucleic acids is frequently used as a rapid way of removing contaminating 
species, however, these enzyme activity assays revealed that the identification of the 
substrates for each nuclease and optimisation of the reaction conditions would be 




4.3.4. The design of immunostimulatory hybrids 
The identification of endogenous RNA:DNA hybrids accumulating in RNase H2-
deficient cells is ongoing. This thesis aimed to design and generate synthetic hybrids, 
therefore an understanding of the unique physical properties of RNA:DNA hybrids 
was necessary. The sequence of the DNA strand of an RNA:DNA hybrid can have a 
significant effect on the conformation of the hybrid, as discussed in this chapter. 
Pyrimidine-rich DNA strands are less resistant to being forced into a mixed A-/B- 
form by their complementary purine-rich RNA strand. Consequently, these hybrids 
would more closely resemble dsRNA, which always assume A-form structures. 
Therefore, by using specific nucleic acid sequences, it would be possible to design 
hybrids which bear a closer resemblance to dsRNA. The recognition of most nucleic 
acid ligands by the PRRs of the innate immune system is generally sequence-
independent. Instead, characteristics such as length, strandedness and the presence of 
either a ribose or deoxyribose sugar are key to the sensing of such molecules, as 
described in Chaper 1, Section 1.5. 
 
The sequences of endogenous RNA:DNA hybrids are larg ly undetermined, 
however, R-loops generally contain cytosine-rich DNA strands base paired with a 
guanosine-rich RNA strand. Therefore, if hybrids accumulating in AGS patients 
were derived from R-loops, they would structurally resemble dsRNA. Alternatively, 
the presence of a DNA strand, even a pyrimidine-rich strand, may sufficiently distort 
the helix to prevent detection by these sensors. In this instance, it would be 
conceivable that recognition of an RNA:DNA hybrid by a specialised PRR of the 
innate immune system is strictly dependent on the det ction of a unique H-form 
helix. 
 
In summary, it can be concluded that consideration of the unique physiochemical 
characteristics of RNA:DNA hybrids is essential when contemplating the use of 
hybrids for application in downstream experiments. In particular, the validation and 
optimisation of reagents including nucleic acid gel stains and nucleases is required. 
The design and synthesis of different RNA:DNA hybrids s therefore described in 
detail in Chapter 5. 
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Chapter 5. The synthesis of RNA:DNA hybrids with 
different physiochemical properties 
 
Many studies characterising innate immune response pathways to nucleic acids 
utilise synthetic RNA and DNA analogues, such as poly (I:C) and poly (dA:dT), or 
chemically synthesised oligonucleotides, for example phosphorothiorate modified 
CpG ODNs (summarised in Table 1.1, Chapter 1). A synthetic RNA:DNA hybrid 
analogue, poly (rA:dT), is commercially available. This hybrid has been used in 
studies of hybrid structure (Zimmerman and Pheiffer, 1981), RNase H activity 
(Nowotny et al., 2005), and is known to be an RNase H2 substrate in vitro (Chon et 
al., 2009).  
 
In addition to using poly (rA:dT), I aimed to design and synthesise RNA:DNA 
hybrids likely to be immunostimulatory based upon the properties of well 
characterised nucleic acid ligands for PRRs. In vitro testing of hybrids required the 
generation of sufficient amount of hybrid for multip e experiments and so this was an 
important consideration when developing methods to synthesise hybrids. In this 
chapter, the development and optimisation of strategies used to generate hybrids are 
described. 
 
5.1. The design of RNA:DNA hybrids 
5.1.2. Sequence 
Innate recognition of viral nucleic acids by PRRs immune system has been 
extensively studied (reviewed by Yoneyama and Fujita, 2010). Viral RNA in 
particular potently stimulates type I IFN via TLRs/LRs in many cell types (as 
described in Chapter 1, Section 1.5). Therefore, synthetic RNA:DNA hybrids with 




Two short hybrids containing sequence from the HIV-1 LTR were generated. The 18 
bp hybrid (R:D18) was already used as the general RN se H substrate in the 
fluorometric RNase H activity assay developed in the lab (Crow et al., 2006b) and 
R:D12 is a shortened version of this. The sequence of the 20 nt TLR7 ligand known 
RNA40 (Heil et al., 2004) is taken from the HIV-1 U5 region. This was used to 
generate a 20 bp hybrid, termed R:D20(PS). Finally, s GU-rich oligonucleotides and 
viral sequences are known to stimulate cytokine production through TLR7 (Forsbach 





Table 5.1. Properties of the RNA strand of RNA:DNA hybrids designed during this thesis. 
 
Name RNA sequence Source Sugar Linkage 
R:D12 AGCCUGGGAGCU HIV-1 LTR 2ʹ-O-Me PD 
R:D18 GAUCUGAGCCUGGGAGCU HIV-1 LTR Ribose PD 
R:D20(PS) GCCCGUCUGUUGUGUGACUC HIV-1 U5 Ribose PS 
R:D20 (GU)10  Ribose PD 
















The nucleic acid-sensing PRRs of the innate immune system are specialised for the 
detection of very different nucleic acid species (Table 1.1, Chapter 1). The 
membrane-bound receptors TLR7 and TLR9 can both detect short oligonucleotides 
(20 nt long) (Bauer et al., 2001; Diebold et al., 2004; Heil et al., 2004). RIG-I 
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signalling can also be stimulated by short RNA olignucleotides, provided there is 
sufficient double-stranded region and the presence of a 5́-ppp (Schlee et al., 2009b; 
Schmidt et al., 2009). In contrast, other cytosolic sensors such as the MDA5 and the 
AIM2 inflammasome, have a high affinity for longer nucleic acid molecules 
(Pichlmair et al., 2009; Roberts et al., 2009). 
 
Endogenous RNA:DNA hybrids vary greatly in length. Hybrid regions present in 
Okazaki fragments are short (8 – 12 nt) (reviewed by Waga and Stillman, 1998). In 
contrast, R loops formed at the switch regions of Ig genes can exceed 1 kb in size 
(Yu et al., 2003). The size of pathogenic RNA:DNA hybrids was also considered. 
Two persistent hybrids which form at the origin of replication of human 
cytomegalovirus (CMV) are 300 bp and 500 bp in length (Prichard et al., 1998). 
Therefore, RNA:DNA hybrids ranging in length from 12 bp to 188 bp were designed 
(Table 5.1). 
 
The most commonly used method of making RNA:DNA hybrids, including for 
structural (Horton and Finzel, 1996) and biochemical assays (Crow et al., 2006b), is 
the annealing of an oligoribonucleotide (ORN) with a complementary 
oligodeoxyribonucleotide (ODN) (Figure 5.1 a). Although individual 
oligonucleotides are often purified by PAGE or high-performance liquid 
chromatography (HPLC), generally the annealed duplexes do not undergo further 
purification before use in downstream applications. 
 
This method of hybrid production has many advantages; it is rapid and 
oligonucleotides can be synthesised with a wide range of backbone and sugar 
modifications. Therefore it is possible to generate RNA:DNA hybrids with different 
chemical properties. However, the length of hybrid is limited by the maximum size 
of ORN that can be efficiently synthesised, which is approximately 80 nt (Sigma-
Genosys and Eurogentec). Therefore, an alternative strategy was devised for 




5.1.3. Nucleic acid chemistry  
In addition to the sequence and length, nucleic acid modifications can affect their 
immunostimulatory ability (Roberts et al., 2005; Sioud, 2006; Tluk et al., 2009; 
Wang et al., 2010a). Studies using synthetic nucleic acids to stimulate TLR7 and 
TLR9 have predominantly used oligonucleotides with a modified chemistry. 
Phosphorothioate (PS) oligonucleotides, in which one f the non-bridging oxygens in 
the phosphate group is substituted with sulphur, have an increased thermostability 
and a greater resistance to nuclease cleavage than oligo ucleotides with natural 
phosphodiester (PD) linkages (Stein t al., 1988).  
 
Single-stranded GU-rich PS-RNA ORNs and PS-containing CpG ODNs are potent 
TLR7 and TLR9 ligands, respectively (Bauer et al., 2001; Heil et al., 2004). The 
RNA strand of the hybrid R:D20(PS) was synthesised with a PS-containing 
backbone, as the stimulation of TLR7 with this sequence was with a PS-modified 
ORN (Heil et al., 2004). However, all other ORNs used for hybrid production were 
synthesised with PD-containing backbones (Table 5.1), as were the complementary 
ODNs. This was chosen because PD-containing hybrids a e more physiologically 
relevant as a PRR ligand than PS-modified hybrids.  
 
ORNs containing modified ribose sugars can also confer a greater stability and 
nuclease resistance than normal ribose sugars. 2ʹ-O-Methyl ribonucleotides have a 2ʹ-
OCH3 group instead of a 2ʹ-OH and are more resistant to nuclease degradation than 
normal ribose. An RNA:DNA hybrid with a 2ʹ-O-Methyl RNA strand and a PD-
DNA strand is not degraded by RNases H (Crow et al., 2006b). Therefore to prevent 
potential degradation of the hybrid by cellular enzymes, the RNA strand of R:D12 
was synthesised using 2ʹ-O-Methyl RNA. 
 
The RNA:DNA hybrids described in Table 5.1 cover a range of different 
physiochemical properties, varying in sequence, size and nuclease resistance and 
therefore provided a starting point for the elucidation of the nature of 




5.2. The generation and purification of hybrids < 60 bp 
The short RNA:DNA hybrids detailed in Table 5.1 were formed by annealing 
equimolar amounts of each strand, heating to 95oC to denature any secondary 
structure and allowing the mixture to cool to room te perature and form duplexes 
(Figure 5.1 a). Successful annealing was verified by native PAGE analysis, loading a 
large quantity of nucleic acid to permit detection of any unannealed ssNA (Figure 5.1 
b).  
 
Three different nucleic acid stains were tested to establish the most appropriate 
method of detecting single-stranded contaminants using R:D60. As discussed in 
Chapter 4, ethidium bromide has a particularly high affinity for RNA:DNA hybrids, 
but as an intercalating dye it does not detect ssNA trongly (Figure 5.1 b).  
 
Acridine orange, which intercalates dsNA, can also form electrostatic interactions 
with ssNA (Traganos et al., 1977). Under UV transillumination at 254 nm, dsNA on 
PAGE gels stained with acridine orange appear green whilst single-stranded 
molecules appear red (McMaster and Carmichael, 1977) (as represented in Figure 5. 
12). When analysed with a phosphorimager, bands for all three nucleic acid species 
and the dsDNA ladder are detected (Figure 5.1 b).  
 
Acridine orange staining detected only one nucleic ac d species in the annealed 
hybrid, which migrated at the expected size of approximately 60 bp. However, the 
use of a stain with increased sensitivity revealed th  presence of multiple nucleic acid 
species. Sybr Gold, a highly sensitive nucleic acid stain which binds to both single- 
and double-stranded DNA and RNA (Tuma et al., 1999), detected two additional 
bands (Figure 5.1 b). One species, indicated by the blue arrow, is unanne led 
ssDNA60. However, the species which migrated at approximately 100 bp (indicated 
by the black arrow) was unlikely to be ssRNA60, which co-migrates with the DNA 
marker at approximately 80 bp. The band at 100 bp was also visible using ethidium 
bromide staining, which suggested that it contained double-stranded, potentially 
hybrid regions. RNase H1 digestion confirmed that it was, at least in part, an 





Figure 5.1. Generating short (< 60bp) RNA:DNA hybrids by annealing of oligonucleotides. 
(a) Schematic of hybridisation process, as shown for R:D20(PS). (b) PAGE analysis of 
annealed R:D60. 500 ng each of the single-stranded oligonucleotides (ssDNA60 and 
ssRNA60) and 500 ng of annealed R:D60 were electrophoresed on 15% native 
polyacrylamide gel. 300 ng of 5 bp dsDNA ladder (M) was included as a size control. Each 
section was stained with a different nucleic acid stain, as described in Chapter 2, and 
imaged using a phosphorimager (excitation at 532 nm, with SHG laser (green)). Blue arrow 
indicates ssDNA contamination, black arrow indicates an additional nucleic acid species. (c) 
500 ng of annealed R:D60 was incubated in the presence or absence of 10 U of E. coli RNase 
H1 in a volume of 20 μl containing 1 X reaction buffer supplied with the enzyme. After a 1 h 
incubation at 37
o
C, 10 μl of each was electrophoresed on a 15% native polyacrylamide gel, 




Therefore, it was possible to generate large quantities of RNA:DNA hybrids less than 
60 bp in length by annealing complementary oligonucleotides. However, PAGE 
analysis of the annealing products using a highly sensitive nucleic acid stain revealed 
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the presence of additional nucleic acid species, including ssNA. Some PRRs of the 
innate immune system are known to detect ssNA (summarised in Table 1.1, Chapter 
1). Therefore, in order to determine if immunity can be activated specifically by 
RNA:DNA hybrids, it was necessary to purify the correct hybrid away from 
contaminants prior to use in cell stimulation experim nts. 
 
5.2.1. Purification of annealed RNA:DNA hybrids 
Initally, RNA:DNA hybrids were PAGE purified. Analysis of gel extracted hybrids 
showed that they were successfully purified from contaminating ssNA; however the 
yields recovered were very low (generally less than 30% of input), making this an 
impractical method for generating large batches of hybrid for subsequent 
experiments. In addition, contaminants from the process, primarily water-soluble 
acrylamide oligomers which can bind to nucleic acid, are difficult to remove from 
gel purified samples (Lukavsky and Puglisi, 2004). Therefore, an alternative to 
PAGE purification was established. 
 
5.2.1.1. Fast performance liquid chromatography (FPLC) 
Liquid chromatography, most often using a high-performance liquid chromatography 
(HPLC) system, is routinely employed to purify newly synthesised full-length 
oligonucleotides from any by-products of synthesis. S ze exclusion chromatography 
using a fast-performance liquid chromatography (FPLC) system to successfully 
purify homogeneous RNA samples has been described (Kim et al., 2007). As HPLC 
and FPLC systems are very similar (differing mainly i  the maximal pressures to be 
used with the columns), and an ÄKTA FPLC system wasavailable in the lab, the use 
of FPLC to separate RNA:DNA hybrids from unannealed single-stranded 
contaminants was investigated.  
 
5.2.1.2. Size exclusion FPLC can fractionate single- and double-
stranded nucleic acids of the same length 
According to the manufacturer’s instructions, the 24 ml Superdex 200 10/300 GL 
column is appropriate for the gel filtration of dsDNA molecules less than 200 bp in 
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length. Nucleic acids behave very differently to prteins under native conditions and 
can often form extensive secondary structures, in particular ssRNA. Therefore, they 
fractionate at very different molecular weights (MWs) to proteins (Kim et al., 2007). 
Superdex 200 10/300 GL columns are routinely used for size exclusion 
chromatography of proteins, therefore it was necessary to establish the suitability of 
these columns for the fractionation of a mixture of single- and double-stranded 
nucleic acids of the same length. 
 
Firstly, the void volume of the column, which is the elution volume of molecules 
which are too large to enter the pores of the gel, was determined to be approximately 
7.5 ml (Figure 5.2). Therefore, in subsequent experiments any nucleic acid eluting in 





                   
Figure 5.2. Determination of the void volume of a Superdex 200 10/300 GL column 
The void volume was determined using 100 μl blue dextran (2000 kDa) from the GE 
Healthcare calibration kit, eluting with water. The void volume begins at 6 ml and peaks at 





A 40 nt ODN containing a single ribonucleotide at position 21 was annealed to a 
complementary ODN. Equimolar amounts of the duplex and the single-stranded 
reverse ODN were mixed together and loaded onto the column. The absorbance at 
280 nm showed elution of nucleic acid at two main peaks, one at 13.5 ml (peak 1) 
and the other at 15.5 ml (peak 2) (Figure 5.3). A sample of fractions corresponding to 
each peak were analysed by native PAGE. The first peak corresponded to the dsDNA 
and the second predominantly to ssDNA, but this peak also contained some dsDNA 
(Figure 5.3). Therefore, FPLC using the Superdex 200 column can separate a 40 bp 
duplex from 40 nt ssDNA. 
 
5.2.1.3. Size exclusion FPLC can be used to separate R:D60 from 
ssRNA60 and ssDNA60 
To establish if the largest hybrid formed by annealing oligonucleotides could be 
successfully fractionated from contaminating nucleic acids, R:D60 was run through 
the Superdex 200 column. Similar to the 40 bp dsDNA/ssDNA mixture, two main 
peaks were observed (Figure 5.4). Peaks 1 and 2 contain R:D60 and the 
contaminating band at approximately 100 bp. Peak 3, eluting between 13.0 – 13.5 ml 
exclusively contains R:D60, whilst peak 4 (15.0 – 15.5 ml) contains a mixture of 
R:D60 and ssDNA60 (Figure 5.4). Multiple repeats using different batches of 
annealed R:D60 consistently gave the two major peaks, always eluting at exactly the 
same volumes. 
 
The fractions for each peak were concentrated by ethanol precipitation and 
resuspended in nuclease-free TE. On average, 55% of the input was recovered as 




           
 
Figure 5.3. Separation of a 40 bp D-R-D:DNA duplex and 40 nt ssDNA. 
100 μl of a mixture of equimolar amounts of nucleic acids (corresponding to 48.5 μg of 
double stranded and 24.3 μg of single-stranded) was injected into the column. Nucleic acid 
was eluted using nuclease-free buffer (60 mM KCl 50 mM Tris pH 8.0) at a flow rate of 0.4 
ml/min. 100 μl fractions were collected and 10 μl of each fraction was electrophoresed on a 
15% native polyacrylamide gel. Fractions loaded were from 13.2 – 14.0 ml (peak 1), 15.1 – 
15.6 ml (peak 2) and 19.7 – 19.9 ml (peak 3). 200 ng each of dsDNA, ssDNA and the input 
was loaded as a control. 200 ng 5 bp ladder (M) was included as a size marker. The gel was 
stained with Sybr Gold and imaged using a UV transilluminator. Representative of duplicate 







Figure 5.4. Gel filtration to separate R:D60 from contaminating nucleic acids. 
72 μg of annealed R:D60 was fractionated by FPLC using the Superdex 200 column, eluting 
with nuclease-free buffer (60 mM KCl 50 mM Tris pH 8.0) at a flow rate of 0.4 ml/min. 100 
μl fractions were collected and 10 μl of each fraction was analysed by native PAGE using a 
15% gel. Fractions loaded were 10.3 – 10.5 ml (peak 1), 12.0 – 12.2 ml (peak 2), 12.9 – 13.7 
ml (peak 3 ) and 15.4 – 16.2 ml (peak 4). 200 ng each of annealed R:D60, ssRNA60 and 
ssDNA60 were also loaded, and 200 ng 5bp ladder (M) was used as a size control. The gel 
was stained with Sybr Gold and imaged using a phosphorimager. Note the lower band in 
the ssDNA input lane is a by-product of incomplete purification of the oligonucleotide by 






5.2.1.4. Fractionation of 12, 18 and 20 bp RNA:DNA hybrids using 
FPLC 
Size exclusion chromatography of the hybrids R:D12, R:D18 and R:D20 was 
performed as described for R:D60. As shown in Figure 5.5, each hybrid could be 
purified away from ssDNA contaminants. However, the purity of the hybrid fraction 
varied.  
 
R:D18 (peak1, Figure 5.5 b) could be completely purified from ssDNA18 (peak 2, 
Figure 5.5 b). In addition, ssRNA18, which co-migrated at approximately 15 bp with 
the dsDNA size marker (see Chapter 4, Figure 4.2) is not visible in the fraction from 
peak 1. In contrast, the main R:D12-containing fraction (peak 1, Figure 5.5 a) also 
contained traces of ssDNA12 (band below 10 bp, Figure 5.5 a).  
 
PAGE analysis of R:D20 before FPLC purification revealed the presence of multiple 
bands which migrated faster than the expected 20 bp RNA:DNA hybrid, visualised 
as a smear below the band at 20 bp (Figure 5.5 c, lane 3 ‘R:D20’). This could suggest 
that annealing of the single-stranded components had resulted in the generation of 
numerous additional shorter nucleic acid species. Alternatively, the repetitive 
sequence of this hybrid implies that these nucleic ac ds could have been RNA:DNA 
hybrid-containing partial duplexes. Such nucleic acid species would be generated if 
the two strands misaligned when they re-annealed, resulting in a duplex with single-
stranded regions at either end. FPLC failed to separate these bands from the 20bp 
hybrid, probably due to their close proximity in size (Figure 5.5, peak 3), 
 
To identify the composition of the nucleic acid species present in FPLC-purified 
R:D20, a sample of the fractions from peak 3 (Figure 5.5) were digested with RNase 
H1 (Figure 5.5 d). The majority of R:D20 was digested, including the smaller bands, 
leaving ssDNA20 which co-migrates with the dsDNA marker at approximately 15 
bp. However, a band migrating at 20 bp remained. Incubation with greater 
concentrations of RNase H also failed to degrade this hybrid, indicating that is not 




Further reactions using RNase If to digest ssRNA and Exo I to digest ssDNA 
confirmed that this band was ssRNA20 (Figure 5.5 e)  As shown in Figure 5.5 c and 
e, ssRNA20 and R:D20 migrated at approximately the same size on a native 
polyacrylamide gel. It can be assumed that this overlap in migration resulted in a 
failure to separate ssRNA20 from R:D20 using size exclusion chromatography. 
Consequently, low levels of contaminating ssRNA20 were present in FPLC-purified 
R:D20. This indicated a limitation of the use of the Superdex 200 column for the 
separation of ssNA and dsNA of the same length. Size exclusion chromatography 
using a Superdex 75 column may be more appropriate for shorter hybrids (Kim et al., 
2007). The combination of the contamination of R:D20 with smaller RNA:DNA 
hybrid-containing nucleic acid species and ssRNA meant that FPLC-purified R:D20 
was insufficiently pure for use in downstream experim nts.  
 
The migration of nucleic acids through the gel matrix of the Superdex 200 column, 
similar to their electrophoretic migration through native polyacrylamide gels, is 
dependent not only on length but also on the degree of s condary structure formed, 
particularly for ssNA. This in turn is influenced by the sequence of the nucleic acid, 
therefore the suitability of this technique has to be assessed for each hybrid, as 
demonstrated in Figure 5.5. The optimal separation of dsNA from ssNA using this 
column was obtained using longer duplexes; the 40 bp D-R-D:DNA duplex and 
R:D60 (Figures 5.3 and 5.4). Therefore, further characterisation of FPLC-purified 






Figure 5.5. FPLC purification of R:D12, R:D18 and R:D20. 
R:D12, R:D18 and R:D20 were FPLC purified using a Superdex 200 column as described for 
R:D60. Nucleic acids were electrophoresed on 20% native polyacrylamide gels, stained with 
Sybr Gold and imaged using a phosphorimager. 200ng 5bp ladder (M) was included as a size 
marker. (a) Fractions loaded were 12.6 – 13.2 ml (peak 1), 13.8 – 14.1 ml (peak 2) and 14.4 
– 14.7 ml (peak 3). (b) Fractions loaded were 15.4 – 16.4 ml (peak 1) and 15.5 – 16.7 ml 
(peak 2). Note faint white lines at approximately 12 bp and 23 bp are the BPB and XC 
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reference dyes present in the sample loading buffer. (c) Fractions loaded were 12.6 – 12.8 
ml (peak 1), 13.3 – 13.5 ml (peak 2) and 15.7 – 16.6 ml (peak 3). 250 ng each of ssRNA20, 
ssDNA20 and R:D20 input were electrophoresed alongside the fractions. (d) 500 ng 
(equivalent to 75 pmol) of FPLC-purified R:D20 was incubated in the presence or absence of 
10 U E. coli RNase H in 20 μl reactions. Half of the reaction was electrophoresed on a 15% 
native polyacrylamide gel and stained with Sybr Gold. (e) 500 ng FPLC-purified R:D20 was 
incubated with 10 U RNase H, 10 U RNase If and 20 U Exo I as indicated. Half of each 
reaction was loaded onto a 15% native polyacrylamide gel, with 250 ng each of ssRNA20 
and ssDNA20 included for reference. Band were visualised by Sybr Gold staining. ssRNA is 
indicated by a red arrow and ssDNA by a blue arrow (note bands are faint due to co-




5.2.2. Validation of FPLC-purified R:D60 
FPLC-purified R:D60 was digested with RNase H1 (Figure 5.6). As expected, the 
RNA strand was hydrolysed, resulting in a band which co-migrated with the dsDNA 
size marker at approximately 40 bp. This corresponded to the size of ssDNA60 
(Figure 5.4). The nucleic acids were transferred to a positively charged nylon 
membrane which was probed with the RNA:DNA hybrid-specific S9.6 antibody. In 
the minus RNase H1 lane, signal corresponding to the RNA:DNA hybrid was 
detected which was absent in the sample treated with RNase H1 (Figure 5.6). This 
confirmed that the FPLC-purified 60 bp product generated by annealing 






                       
 
Figure 5.6. Characterisation of R:D60 using RNase H digestion and the S9.6 antibody. 
Digestion of R:D60 with RNase H resulted in a single band which migrated at the same size 
as ssDNA60. 200 ng FPLC-purified R:D60 was incubated in the presence or absence of 10 U 
E. coli RNase H1 for 1 h at 37
o
C. Half the volume of each reaction was electrophoresed on a 
1 mm thick 12% native polyacrylamide gel, stained with Sybr Gold and imaged on a UV 
transilluminator at 254 nm. 300ng 5 bp dsDNA ladder was included as a size standard. 
Nucleic acids were then transferred to a positively-charged nylon membrane, which was 




5.2.3. Estimation of ssNA contamination of FPLC-purified 
R:D60 
As an additional quality control step, each batch of R:D60 was electrophoresed 
alongside known amounts of ssNA. This allowed an estimation of any ssNA 
contamination. Most batches did not contain any detectable ssNA, however the 
hybrid shown in Figure 5.7 did contain some ssDNA60, most likely as a result of 
collecting fractions outside of the main peak. From the gel, it can be estimated that 
this batch contains approximately 6 ng of ssDNA60 (indicated by the blue arrow) per 





              
Figure 5.7. Quality controls step to quantify contamination of R:D60 by ssNA. 
100 ng R:D60 was electrophoresed on a 15% native polyacrylamide gel with decreasing 
amounts of ssRNA60 and ssDNA60 (100, 50, 25, 12.5, 6.25, 3.1, 1.6, 0.8 ng). 200 ng 5bp 
ladder (M) was included as a size control. The gel was stained with Sybr Gold and imaged 




5.3. The production and validation of a long RNA:DNA 
hybrid 
The production of short (< 60 bp) RNA:DNA hybrids by the annealing of 
complementary oligoribonucleotides, as described in Section 5.2, provided a simple 
method to generate large amounts of RNA:DNA hybrid for subsequent testing in 
cells. However, it is possible that disease-causing endogenous RNA:DNA hybrids 
are much longer than those produced using this method. R loops can be up to a kb in 
size (Yu et al., 2003). Additionally, hybrids formed from viral nucleic acids may be 
longer than 60 bp, for example the hybrids present at the origin of replication of 
human CMV (Prichard et al., 1998). The source of endogenous RNA:DNA hybrids 
likely to accumulate in AGS patients has not been established, therefore it they are 
relatively long, a hybrid-detecting PRR may not be stimulated by the short hybrids 





The length of RNA:DNA hybrids produced by annealing complementary strands is 
limited by the size of oligonucleotides that can be generated. Solid-support synthesis 
of ODNs between 100 nt and 140 nt long by commercial suppliers is possible but is 
severely limited by the coupling efficiency during the synthesis cycle. Additionally, 
the relative proportion of incomplete oligonucleotide by-products increases with the 
length of the oligonucleotide, so even at a very high coupling efficiency (99%), 
synthesis of an oligonucleotide > 100 nt generates  relatively low percentage of full-
length product which requires extremely efficient purification from the unwanted by-
products. The low yield of oligonucleotide recovered made this option impractical 
for this project.  
 
Reverse transcription of the ssRNA viral genome is a key step in the lifecycle of 
retroviruses, generating an RNA:DNA hybrid intermediate. In vitro, ssRNA of a 
range of sizes can be synthesised using in vitro transcription (IVT), which could in 
theory be reverse transcribed to form an RNA:DNA hybrid. Therefore, to investigate 
the practicality of this method for generating hybrids suitable for testing in cells, a 
region of the CMV promoter sequence from the pEGFP-N1 plasmid (Clontech) was 
chosen as a template for IVT. 
 
5.3.1. Strategy to generate an RNA:DNA hybrid using reverse 
transcription 
The generation of long hybrids using reverse transcription involved a three step 
technique (Figure 5.8 a). Firstly, the chosen sequence was amplified using a high-
fidelity DNA polymerase. The forward primer contained a minimal T7 polymerase 
promoter sequence (18 nt) followed by one extra guanosine to enhance transcription 
efficiency. The dsDNA PCR product was used as a template for IVT using T7 RNA 
polymerase. The resulting ssRNA was reverse transcribed with an RNase H-deficient 
reverse transcriptase (RT) using the reverse PCR primer. The nucleic acid products 






          
 
Figure 5.8. The generation of a 188 bp RNA:DNA hybrid by reverse transcription. 
(a) Schematic diagram showing the process of generating R:D188. A region of the CMV 
promoter (blue) encoded within an endotoxin-free maxiprep of pEGFP-N1 was amplified 
using PCR. The forward primer contained a T7 promoter sequence (green) and the reverse 
contained an EcoRI site (grey). The PCR product was gel extracted and used as a template 
for in vitro transcription (IVT) using T7 RNA polymerase. ssRNA was DNase I treated to 
remove all traces of dsDNA template and PAGE purified to remove aberrant transcription 
products. RNA was then used as a template for reverse transcription (RT) using a sequence 
specific reverse primer. The resulting hybrid was 188 bp long and contained a 5ʹ-ppp. (b) 






5.3.2. Optimisation of method to generate ssRNA 
The method described above was refined to reduce potential contamination of the 
hybrid with other nucleic acids, particularly 5ʹ-ppp RNA which is potentially a RIG-
I/TLR7 ligand. 
 
The MegaShortScript T7 polymerase kit (Ambion) was successfully used to produce 
high yields of 188 nt long IVT RNA, using 200 ng of 206 bp (1.47 pmol) dsDNA 
template, an average of 135 µg of 188 nt (2.1 nmol) ssRNA was produced. 
Electrophoresis of the RNA on non-denaturing gels rvealed the presence of more 
than one band (Figure 5.9 a). Mfold analysis (Zuker, 2003) of the RNA sequence 
indicated that it can form extensive secondary structures (Figure 5.9 a). However, 
subsequent analysis of the IVT RNA by denaturing PAGE suggested that the 
additional bands were multiple RNA species rather tan secondary structure.  
 
The generation of large amounts of aberrant RNA products during IVT with T7 RNA 
polymerase has been described previously (Cazenave and Uhlenbeck, 1994; 
Schenborn and Mierendorf, 1985; Schlee et al., 2009b; Schmidt et al., 2009; Triana-
Alonso et al., 1995). The enzyme is able to extend the 3ʹ nd of the newly transcribed 
RNA transcript using RNA as a primer. This can occur d ring foldback of the 
nascent transcript or from the annealing of another RNA molecule. Both result in the 
formation of a complementary double-stranded template region and the production of 
longer RNA transcripts, with varying degrees of extension (Cazenave and 
Uhlenbeck, 1994; Triana-Alonso et al., 1995). Failure to purify IVT RNA from 3ʹ 
extended by-products resulted in confusion over the true ligand for the RNA helicase 
RIG-I (Schlee et al., 2009b; Schmidt et al., 2009). The use of such RNA as a 
template for reverse transcription could generate multiple RNA:DNA hybrid species, 
which may not be fully duplex, as a sequence specific reverse primer is used during 
the reverse transcription step. Therefore, the IVT reaction was modified to limit the 
possibility of this. 
 
The production of these aberrant RNA transcripts can be inhibited by reducing the 
reaction time, reducing the concentration of T7 polymerase used and decreasing the 
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UTP concentration (Triana-Alonso et al., 1995). Additionally, the use of a dsDNA 
template with a 5́ overhang has also been shown to limit the formation of unwanted 
RNA products (Schenborn and Mierendorf, 1985). Therefore, an EcoRI restriction 
enzyme site was incorporated into the reverse DNA primer used for PCR 
amplification of the template (Figure 5.8 a) and digestion performed prior to the IVT 
reaction. IVT RNA was subsequently purified using denaturing PAGE to further 




     
 
Figure 5.9. Analysis of IVT ssRNA188 derived from a CMV promoter sequence. 
(a) IVT ssRNA188 was predicted to contain extensive regions of secondary structure in non-
denaturing conditions. Three different higher order structures predicted by Mfold (Zuker, 
2003) are shown. (b) 250 ng of PAGE purified ssRNA188 was electrophoresed on an 8% 
denaturing polyacrylamide gel, which was stained with Sybr Gold and imaged using a 
phosphorimager. 2 μl of of RiboRuler Low Range RNA ladder was included as a size marker 






5.3.3. Validation of R:D188 
The 188 bp RNA:DNA hybrid generated by reverse transcription was analysed to 
validate its nature and confirm the purity of the hybrid. Digestion with RNase H2 
resulted in a down-shifted band, which appeared red with acridine orange staining 
which confirmed that it was single-stranded (Figure 5.10 a). 
 
R:D188 was detected by the S9.6 antibody but RNase H2-digested hybrid was not 
(Figure 5.10 b). Probing of the same samples with a commercial monocl nal 
antibody against ssDNA, revealed that RNase H2-digested R:D188 contains ssDNA, 
which confirmed that the RNA strand of the hybrid had been hydrolysed (Figure 5.10 
b). However, there was also signal in the undigested R:D188, which suggested the 
presence of ssNA. Notably, the antibody did not detect a control RNA:DNA hybrid 
thereby excluding the possibility of non-specific bnding (negative control, α-ssDNA 
blot, Figure 5.10 b). However, the antibody also detected signal in the minus RT 
control, which does not contain any ssDNA, other than the 25 nt ssDNA primer used 
in the reverse transcription reaction, which would be used up during the generation 
of the complementary DNA strand. It did however contain ssRNA: the template for 
reverse transcription. 
 
Consequently, the specificity of the antibody for ssNA was characterised using 18 
base oligonucleotides. In addition to the ssDNA olig nucleotide, the antibody also 
detected ssDNA containing a single ribonucleotide (ssD-R-D) and a ssRNA 
oligonucleotide (Figure 5.10 c). This suggested that the ssNA detected in R:D188 
could have been IVT ssRNA template or ssDNA primers carried over from the 
reverse transcription reaction. Alternatively, the reverse transcriptase enzyme may 
dissociate from the primer-template, generating incomplete hybrids and ssNA; it has 
been shown that the presence of certain sequences or s condary structures in the 
template causes the dissociation of HIV-1 reverse transcriptase in vitro (Abbotts et 
al., 1993; DeStefano et al., 1992; Klarmann et al., 1993). If the enzyme does not 







Figure 5.10. Validation of R:D188. 
(a) 10 μg R:D188 was incubated in the presence or absence of 770 ng recombinant human 
RNase H2 (from Rachel White, MRC HGU) for 1 h at 37
o
C. 1 μg or equivalent volumes of 
each of unpurified IVT ssRNA, a minus reverse transcriptase (-RT) control, undigested 
R:D188 and RNase H2-digested R:D188 were electrophoresed on an 8% native 
polyacrylamide gel. 500 ng of 1 kb ladder was included as a size control (M). The gel was 
stained with acridine orange and imaged using a phosphorimager. Images were taken at 
two different wavelengths (excitation at 532 nm with SHG laser (green channel) and 
excitation at 473 nm with He-Ne laser (red channel)). The two channels were digitally 
merged using IPLab software. Single-stranded nucleic acids stained red, and double-
stranded green. (b) Validation of R:D188 using the S9.6 antibody. Decreasing amounts of 
R:D188 (16, 1.6, 0.16 and 0.016 pmol) and equivalent volumes of –RT and RNase H2-
digested R:D188 were UV crosslinked to a nitrocellulose membrane which was probed with 
the S9.6 anti-RNA:DNA hybrid antibody. A duplicate membrane was probed with a 
commercial antibody against ssDNA. Controls for the antibodies were 20pmol R:D18 and 
20pmol ssDNA18. (c) The ssDNA antibody detected 18nt oligonucleotides. Blot is 







An additional complication of this hybrid-generating procedure is the DNA-
dependent DNA polymerase activity in RT enzymes (Roth et al., 1985). They are 
able to utilise both dsDNA and RNA:DNA hybrids as templates for transcription; 
therefore transcription of ssDNA from the RNA:DNA hybrid product could also 
have occurred. 
 
The detailed analysis of R:D188 raised potential issue  associated with the use of 
reverse transcription to generate long RNA:DNA hybrids. The stimulation of cells 
with nuclease-treated R:D188 (detailed in Chapter 6) also indicated potential 
contamination of the hybrid, further questioning the purity of hybrids generated 
using this methodology.  
 
5.4. Alternative approaches to generating long RNA:DNA 
hybrids 
The short RNA:DNA hybrids produced in Section 5.2 may fail to stimulate innate 
immunity due to their size, depending on which PRRs, if any, are capable of 
detecting hybrids. Additionally, long hybrids may be more physiologically relevant 
to AGS and consequently more likely to be immunogenic. The concerns over the use 
of reverse transcription to generate suitable RNA:DNA hybrids prompted the 
examination of methods to produce the two complementary strands independently 
and anneal them together, as described for hybrids of < 60 bp. Once established, this 
methodology could be used to generate hybrids ranging in length from less than 100 
bp to in excess of 500 bp, depending on the efficiencies of annealing longer nucleic 
acid. It could also be used to generate long hybrids of the same size with different 
sequences to determine if the detection of RNA:DNA hybrids by sensors of the 
innate immune system is both length- and sequence-dep ndent  
 
As described in Section 5.3.2, large quantities of a homogeneous population of long 
ssRNA can be produced by gel purification of IVT reactions. Commercial production 
of ODNs longer than 100 nt is inefficient. Therefor, techniques to generate large 
amounts of long (188 nt) ssDNA were established and tested for suitability. An 




5.4.1. The use of PCR to synthesise ssDNA 
It is possible to preferentially amplify one strand of template DNA using an excess of 
one primer. This technique, termed asymmetric PCR, was originally described to 
produce an excess of ssDNA for sequencing or use as a hybridisation probe by using 
a 10 to 1000-fold molar excess of one primer over th  other (Gyllensten and Erlich, 
1988). In the early cycles of the PCR, the entire amplified product is dsDNA. After 
the limiting primer has been exhausted, an excess of DNA is produced with every 
cycle. This increases in a linear fashion, as opposed to the exponential production of 
dsDNA by regular PCR, and so a greater number of cycles are required to obtain 
sufficient ssDNA product (Gyllensten and Erlich, 1988). The products consist of 
dsDNA and an excess molar excess of ssDNA (Figure 5.11 c). 
 
Primers were designed to amplify a 362 bp region of the CMV promoter (forward 
primer; CMVprom_F, reverse primer; CMVprom362_R) (Figure 5.11 a and b). The 
PCR product was purified by gel extraction and used as a template for asymmetric 
PCR, with an excess of the reverse primer (CMVprom188_R) (Fig. 5.11 c). A range 
of primer ratios, amount of template and number of amplification cycles were tested. 
As shown in Figure 5.11 d, the band at 188 bp increased with intensity as the number 
of cycles increased, however no additional band was resolved, which suggested that 
either ssDNA was not generated or that it co-migrated with dsDNA188, which would 
make gel purification of specifically the ssDNA difficult. Therefore, the use of 
asymmetric PCR to generate ssDNA proved unsuccessful using a range of 
experimental conditions. 
 
Single-stranded DNA templates for cycle sequencing are frequently prepared by 
linear amplification, using only a single primer (Kaltenboeck et al., 1992). Therefore, 
reactions were performed using the same 362 bp dsDNA template, completely 
omitting the forward primer, so the only product should be ssDNA from linear 






Figure 5.11. Asymmetric PCR to generate reverse strand ssDNA. 
(a) Schematic showing location of primers within the CMV promoter region (blue) of 
pEGFP-N1. (b) A 362 bp region was amplified using the primers CMVprom_F (red) and 
CMVprom363_R (black). The PCR product (dsDNA362) was electrophoresed on a 1.5% 
agarose gel containing ethidium bromide alongside control PCR reactions (minus template 
(-DNA) and template plus water only (-PCR)). 200 ng of 100 bp ladder (M) was included as a 
size control. (c) Schematic of the principle of asymmetric PCR using a ten-fold excess of the 
reverse primer CMVprom188_R (green). (d) Example of the products generated using 
asymmetric PCR. Increasing amounts of dsDNA362 template were used (0.1, 1, 5, 10 ng), as 
indicated above each gel. The numbers of cycles were varied as indicated underneath each 
gel. Controls for PCR were included with each reaction (-DNA, -PCR). Equal volumes of PCR 
products were electrophoresed on a 1.5% agarose gel containing ethidium bromide, with 
200 ng 100 bp ladder included as a size control. 
 
 
a large number of cycles together with a low anneali g temperature were required to 
generate sufficient product (indicated by blue asterisk, Figure 5.12 a). 
 
A band migrating at approximately 150 bp was consistently produced (Figure 5.12 
b). As ssDNA188 would be expected to migrate faster than dsDNA of the same size, 
this band was extracted from an agarose gel. Native PAGE analysis confirmed the 
successful purification of the correct band (Figure 5.12 c). However, heat 
denaturation of this product revealed that it consisted of two species (Figure 5.12 c), 
which suggested the presence of dsDNA. The failure of any products of the PCR to 
be digested by the ssDNA-specific nuclease Exo I confirmed that it was not ssDNA 
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(Figure 5.12 d). Therefore, under the conditions described, both asymmetric PCR 
and linear amplification using one primer were not sui able techniques for the aims 





Figure 5.12. Reverse primer only PCR. 
(a) Temperature gradient PCR. Products were electrophoresed on a 2% agarose gel 
containing ethidium bromide. The suspected ssDNA188 band is indicated by a blue asterisk. 
200ng 100bp ladder (M) was included as a size marker. (b) PCR products generated from 
triplicate (1, 2 and 3) PCR reactions using an annealing temperature of 52
o
C and 50 cycles. 
PCR products were electrophoresed on a 2% agarose gel containing ethidium bromide. (c) 
PAGE analysis of the gel extracted band. Duplicate extracted bands were electrophoresed 
on 8% native PAGE (left) and 8% denaturing PAGE (right) gels. On both gels, 300 ng of 1 kb 
ladder (M) was included as a size marker. Gels were stained with the ssNA and dsNA stain 
Vistra Green and imaged using a phosphorimager. (d) Exo I digest of a PCR products. 200 ng 
each of dsDNA362 (Figure 5.11 b), reverse primer PCR (this figure, (a)) and a 65 nt ssDNA 
oligonucleotide were digested with increasing amounts of Exo I (10, 20, 50 U) for 20 min at 
37
o
C. Products were electrophoresed on a 2% agarose gel containing ethidium bromide. 
The gels shown in (d) is representative of duplicate experiments. 
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5.4.2. Purification of a non-labelled strand of a DNA duplex 
The second approach to the production of long ssDNA involved the biotin labelling 
of the forward strand by PCR (Figure 5.13 a). The 188 bp biotinylated PCR product 
was gel purified and bound to streptavidin. Techniques for separating the two strands 
to allow purification of the non-biotinylated revers  strand were then tested. 
 
Firstly, the dsDNA-streptavidin complex was heated to 95oC to denature the PCR 
product, without destroying the streptavidin-biotin bonds, before being subjected to 
electrophoresis using native PAGE. The additional size of the streptavidin molecule 
should cause the forward strand to supershift, allowing the unlabelled strand to be 
excised from the gel (Figure 5.13 b). The purification of ssDNA using this technique 
has been reported previously (Pagratis, 1996), however in this case it was found to be 
a very inefficient process, resulting in a very poor yield of ssDNA (Figure 5.13 c).  
 
Alternative methods for purifying the non-biotinylated strand utilised immobilisation 
of the biotinylated PCR production onto streptavidin magnetic beads (Dynabeads, 
Invitrogen). Initially, the beads were heated to 95oC and immediately removed from 
solution using a magnet. The reverse strand was then collected from the supernatant 
(Figure 5.14 b). Upon incubation with streptavidin beads, most of the biotinylated 
dsDNA successfully bound to the beads, as a relativly small proportion was 
detected in the non-bound fraction (NBF) (Figure 5.14 c). However, after heat 
denaturation of the duplex, some dsDNA was recovered from the supernatant (Figure 
5.14 c). Additionally, the supernatant contained very low amounts of non-
biotinylated ssDNA (indicated by a blue asterisk, Figure 5.14 c). 
 
As heating to 95oC in a non-deionising buffer should not break the biotin-
streptavidin bond, this is likely to be unbiotinylated PCR product (despite the use of 
a HPLC-purified biotinylated forward primer for the initial PCR, Figure 5.14 a). 
Recovery of nucleic acids from the beads by heating to 95oC in formamide revealed 
the presence of only dsDNA (Figure 5.14 c). Therefore, the production of large 





Figure 5.13. Streptavidin supershift to purify ssDNA. 
Schematic representations of (a) amplification of a 188 bp region of the CMV promoter 
using a biotinylated forward primer and (b) purification of the non-biotinylated strand. Each 
streptavidin molecule has four biotin-binding sites (Chaiet and Wolf, 1964), although 
binding capacity can also be affected by the fragment length and salt concentration. (c) 
Biotinylated 188 bp PCR products and non-biotinylated controls (dsDNA) were incubated in 
the presence or absence of streptavidin-HRP for 30 min at room temperature, and then half 
were heated to 95
o
C for 5 min to denature the DNA before electrophoresis on an 8% native 
polyacrylamide gel. The gel was stained with Vistra Green and imaged using a 







Figure 5.14. Heat denturation of streptavidin-bound dsDNA 
(a) As for Figure 5.13. (b) dsDNA, bound to streptavidin Dynabeads via the biotinylated 
forward strand only, is heat denatured before the beads are immobilised onto a magnet. 
The non-biotinylated reverse strand is no longer attached to the bead and so can be 
collected from the supernatant. (c) 10% of the input dsDNA, and 15% each of the ethanol 
precipitated non-bound fraction (NBF), supernatant collected following heat denaturation 
and remaining DNA recovered from the beads (by heating to 90
o
C for 2 min in 95% 
formamide, 10 mM EDTA) were electrophoresed on a 2% agarose gel containing ethidium 
bromide. The faint band corresponding to the reverse ssDNA in the denatured fraction is 





Immobilised dsDNA was incubated with 100 mM NaOH and 200 mM NaCl (Figure 
5.15 a). The use of NaOH and high NaCl concentrations to separate an 80 nt non-
biotinylated strand from a biotinylated product complexed to streptavidin Dynabeads 
has been reported previously (Sidorov et al., 2004). Nucleic acid was successfully 
recovered, neutralised and ethanol precipitated using this method (Figure 5.15 b). 
However, when electrophoresed, the eluted nucleic acid comprised of one band at the 
assumed size for ssDNA188 (migrating below the 154 bp band of the dsDNA size 
marker) and a number of higher molecular weight bands.  
 
To identify the presence of any biotinylated nucleic acids in the recovered non-
labelled ssDNA, the fractions were incubated with streptavidin to induce an 
electrophoretic shift. As shown in Figure 5.15 b, the presumed ssDNA band did not 
shift (lane 6), confirming it as non-biotinylated ssDNA. The same size product 
recovered from the beads did shift, confirming it was labelled with biotin (lane 8). 
The supernatant fraction (lane 5) also contained a band which migrated at the same 
size as the 188 bp dsDNA input (lane 1). Following incubation with streptavidin, this 
band also shifted to approximately 220 bp (lane 6), and so indicated the presence of 
biotinylated-dsDNA in the supernatant fraction. 
 
This experiment provided further evidence of the prsence of non-biotinylated 
dsDNA188 in the input DNA, as a proportion of it did not bind to the beads and so 
was recovered in the NBF (lane 3). This dsDNA species did not shift upon 
incubation with streptavidin (lane 4), therefore is not biotinylated. 
 
As described, the nucleic acid fraction recovered in the supernatant contained a 
number of higher molecular weight bands (lanes 5 and 6, Figure 5.15 b), which could 
have been due to the formation of extensive secondary structure upon renaturation. 
To further identify these bands, all samples were electrophoresed on a denaturing 
PAGE gel (Figure 5.15 c). The higher molecular weight bands were not present 
under denaturing conditions, suggesting that they wre a result of a different ssDNA 






Figure 5.15. Sodium hydroxide denaturation of streptavidin-bound dsDNA. 
Biotinylated dsDNA was generated and immobilised onto streptavidin as shown in Figure 
5.15. (a) Dynabeads are incubated for 3 x 10 min in 100 mM NaOH/200 mM NaCl to 
denatured the dsDNA and allows recovery of the non-biotinylated strand. (b) The input, 
non-bound fraction (NBF), denatured fraction and biotinylated fraction eluted from the 
beads were incubated in the presence of absence of streptavidin-HRP. 5% of input and 15% 
of the fractions were electrophoresed on a 2% agarose gel containing ethidium bromide. 
200 ng of 1 kb ladder was included (M). (c) The same volume of samples loaded in (b) were 
electrophoresed on a 10% denaturing polyacrylamide gel. 2 μl of the low range RiboRuler 
RNA ladder was included as a size guide (labelled sizes are in nt). The gel was stained with 




containing ssDNA from the beads, there were two bands present in the ssDNA 
recovered from the supernatant (Figure 5.15 c). Therefore, ssDNA recovered from 
supernatant following denaturation with NaOH/NaCl was not a homogeneous 
species, and so would require additional purification before being annealed to a 
complementary RNA strand. 
 
5.4.3. Digestion of the forward strand by λ exonuclease 
Finally, as an alternative approach to the isolation of reverse strand ssDNA, the same  
188 bp region of the CMV promoter was amplified using a 5́-end phosphorylated 
forward primer (Figure 5.16 a). The PCR product was gel extracted and incubated 
with λ exonuclease, which catalyses the removal of 5ʹ mononucleotides from 5ʹ-
phosphorylated dsDNA in a 5ʹ → 3́  direction. Therefore, when incubated with a 
DNA duplex containing a 5ʹ-phosphorylated strand, the enzyme selectively digests 
only this strand, leaving the non-phosphorylated ssDNA strand intact (Kujau and 
Wolfl, 1997).  
 
The concentration of λ exonuclease used in each reaction required optimisation, as 
the enzyme was found to cleave the non-phosphorylated strand when used at high 
concentrations (Figure 5.16 b). However, when used at lower concentrations, a 
greater proportion of dsDNA remained undigested (Figure 5.16 b). The product 
which migrated at approximately 150 bp was completely d graded by Exo I, which 
confirmed it was ssDNA (Figure 5.16 c). Despite extensive optimisation of 
incubation times, and concentrations of both the template and enzyme, a point where 
the entire phosphorylated strand is digested without degradation of the non-





Figure 5.16. The use of λ exonuclease to digest one strand of a DNA duplex. 
(a) Schematic representation of the amplification of a 188 bp region of the CMV promoter 
using a 5ʹ-phosphorylated forward primer. λ exonuclease will digest the phosphorylated 
strand, leaving the reverse strand intact. (b) 1 μg of gel extracted PCR products were 
incubated with increasing amounts of λ exonuclease (0, 1, 2.5, 5, 7.5, 10 U) in 10 μl 
(therefore final DNA concentration was 100 ng/μl). 2 μl of each reaction was 
electrophoresed on a 2% agarose gel containing ethidium bromide. (c) 4 μl of each reaction 
from (b) was digested with 20 U of Exo I and electrophoresed on a 2% agarose gel 
containing ethidium bromide. 200 ng of 1 kb ladder was included as a size marker (M). 







5.4.4. Summary of methods for synthesising 188 nt ssDNA 
The generation of ssDNA by asymmetric and reverse pimer PCR was largely 
unsuccessful, as it was not possible to identify the ssDNA PCR products with 
confidence. The amplification of 188 bp dsDNA using modified forward strand 
primers yielded more encouraging results. However, th  biotin-streptavidin 
electrophoretic shift would not be an entirely practical method, as it would be likely 
that only very low yields of ssDNA would be recovered. Additionally, the 
contamination of reverse strand ssDNA denatured from streptavidin-bound dsDNA 
with both biotinylated and non-biotinylated PCR products is a further disadvantage 
of this technique. The use of low concentrations of λ exonuclease to degrade the 
forward strand of dsDNA was found to be the most appro riate method, and would 
be a practical technique to scale up for the generation of large quantities of product. 
However, the ssDNA required purification to separate it from any undigested 
dsDNA, therefore techniques to purify 188 nt ssDNA from 188 bp dsDNA were 
assessed. 
 
5.5. The purification of long ssDNA 
The purification of DNA from agarose or polyacrylamide gels is commonly used in 
many protocols. Excision and purification of the ssDNA product of λ exonuclease 
digestion from both agarose and native polyacrylamide gels was tested. Whilst pure 
ssDNA could be obtained following elution from polyacrylamide gels, the yields 
were low, therefore the generation of enough ssDNA to make sufficient hybrid for 
cellular experiments would be very labour intensive and has a high risk of batch 
variability, in addition to the potential introduction of acrylamide contamination. 





5.5.1. Fractionation of single- and double-stranded nucleic 
acids using silica spin columns 
Commercially available silica spin-columns generally have a minimum size 
exclusion of approximately 50 bp, therefore theoretically could be appropriate for the 
binding of 188 nt ssDNA. The use of silica spin columns to fractionate large ( > 1 
kb) fragments of ssDNA from mixtures containing dsDNA has been reported 
previously (Beld et al., 1996; Boom et al., 1990; Borodina et al., 2003). These 
methods exploit the differential binding of ss- and dsNA to silica when different 
binding buffers are used. Initially, the NA mixture is combined with a buffer 
containing a high concentration of the chaotrophic agent guanidium thiocyanate 
(GuSCN). When put over a silica column, only dsNA will bind and the ssNA is 
eluted. The ssNA-containing eluate is then mixed with a second binding buffer 
containing GuSCN and magnesium chloride (MgCl2) and applied to a new silica 
column which it will then binds to. The two fractions are then eluted from the 
columns according to standard protocols. This method has also been applied to the 
fractionation of ss- and dsRNA (Beld et al., 1996; Borodina et al., 2003). 
Interestingly, it has been reported that RNA:DNA hybrids behave like dsNA (Beld et 
al., 1996), although the size of the hybrid tested wasnot stated. Therefore, this 
method could be useful both for purification of thessDNA and subsequently of the 
annealed RNA:DNA hybrid. 
 
A mixture of undigested and λ exonuclease-digested dsDNA188 was processed 
according to the methods described by (Beld et al., 1996; Borodina et al., 2003). 
Despite extensive attempts at optimisation, binding of dsDNA to the first column 
was inefficient, but ssDNA completely failed to bind so the fraction was purely 
dsDNA (Figure 5.17). However, the MgCl2-containing buffer did not seem to be 
specific for ssDNA. Consequently, the ssDNA fraction contained a mixture of ss- 
and dsDNA (Figure 5.17). In addition, the binding of the ssDNA to column was 
extremely inefficient and the majority of the ssDNA (estimated at least 90%) was 
lost. Therefore, this technique was not suitable for purifying ssDNA and the 
inefficient binding of the dsDNA meant it was not a pr ctical option for recovering 





Figure 5.17. Separation of ds- and ssDNA using spin columns. 
dsDNA188 was digested with λ exonuclease. An amount equivalent to 13.5 μg of 
undigested dsDNA was applied to a column as described in Chapter 2. The ds- and ssDNA 
fractions were eluted from the columns using TE. 10% of input and 15% of the fractions 
were electrophoresed on a 2% agarose gel containing ethidium bromide. Representative of 




5.5.2. FPLC fractionation of single- and double-stranded DNA  
Size exclusion chromatography using the Superdex 200 column in an FPLC system 
was successfully used to fractionate dsDNA from ssDNA of 40 nt in length (Section 
5.2). The upper limit of this column, as determined by the manufacturers, is 200 bp 
DNA, however there is no defined limit for ssDNA.  
 
To investigate the elution point for both ss- and dsDNA188, λ exonuclease-digested 
dsDNA188 was injected into the column. As shown in Figure 5.18 a, the main peak 
(peak 5) was at 8.7 - 9.0 ml, which is very close to the void volume of this column 
(approximately 7.5 ml, as shown in Figure 5.2). Native PAGE analysis of the 
fractions revealed that some dsDNA188 eluted in the void volume (peak 1, at 1.0 
ml), whilst a mixture of ss- and dsDNA eluted just after the void volume (peak 4 at 
8.4 ml and peak 5). Therefore, size exclusion chromat graphy using the Superdex 
200 column did not successfully fractionate nucleic acids of this size. Ion exchange 
chromatography may be more successful; however a suitable column was not 






                     
                 
Figure 5.18. FPLC using a Superdex 200 column will not fractionate 188 nt nucleic acids. 
3.5 μg of phosphorylated dsDNA188 was digested with λ exonuclease, ethanol precipitated 
and injected into a Superdex 200 column. Nucleic acid was eluted using TE. 20 μl of each 
fraction, together with 200 ng of undigested dsDNA188 and the equivalent volume of λ 
exonuclease digested dsDNA188 were electrophoresed on an 8% native polyacrylamide gel. 
200 ng 1 kb ladder was included as a size marker (M). The gel was stained with Sybr Gold 





5.5.3. Separation of single- and double-stranded DNA using 
hydroxyapatite chromatography 
The use of hydroxyapatite, a form of crystalline calcium phosphate, to fractionate 
nucleic acids is a well established technique (Bernardi, 1965). The positively charged 
calcium ions on the surface of hydroxyapatite can form non-specific interactions with 
the negatively charges phosphate groups in the backbones of nucleic acids. Both ss- 
and dsNA bind to hydroxyapatite when in a 50 mM sodium phosphate (pH 6.8) 
buffer (Sambrook and Russell, 2000). They are differentially eluted using an 
increasing gradient of phosphate buffers. The structu e of ssNA results in fewer 
phosphate groups available to bind the hydroxyapatite nd consequently they are 
eluted at lower buffer concentrations than dsNA. 
 
In addition to the fractionation of ss- and dsDNA and RNA (Andrews-Pfannkoch et 
al., 2010; Olgiati et al., 1976), hydroxyapatite column chromatography has been 
successfully used to separate RNA:DNA hybrids from ssNA (Maxwell et al., 1978; 
Siebke and Ekren, 1970), although short (36 bp) duplexes do not bind to 
hydroxyapatite very efficiently (Maxwell et al., 1978). Therefore, this technique 
could be a useful method for the separation of bothλ exonuclease digested 
ssDNA188 and a long RNA:DNA hybrid from their respective contaminating nucleic 
acids. 
 
A 1.0 ml hydroxyapatite column was prepared as described in Chapter 2, and a 
mixture of digested and undigested dsDNA188 bound to the resin using 50 mM 
sodium phosphate at room temperature. A series of phosphate buffers of increasing 
concentrations from 100 mM to 400 mM were washed applied to the column. All of 
the input bound strongly to the hydroxyapatite, as nucleic acid was not present in 
either the non-bound fraction (NBF) or the 50 mM phosphate wash fraction (Figure 
5.20). According to the manufacturer, ssDNA should elute at 140 – 160 mM and 
dsDNA at 340 – 360 mM from the batch of hydroxyapatite used for these 
experiments. ssDNA was eluted at 120 mM and 140 mM;however the fractions also 
contained some dsDNA (Figure 5.19). Between 200 – 250 mM a mixed population 
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of ss- and dsDNA is eluted, however after 300 mM, predominantly dsDNA is 
recovered. At concentrations below 120 mM and above 360 mM, no nucleic acid was 
recovered. Therefore, hydroxyapatite column chromatgr phy failed to completely 
fractionate ss- and dsDNA. Hydroxyapatite chromatography is frequently performed 
at 60oC, whereas these experiments were performed at roomtemperature 
(approximately 20oC). Although absorption and elution rates are reported to be the 
same regardless of temperature (Sambrook and Russell, 2000), performing the 





                     
 
Figure 5.19. The fractionation of single- and double-stranded DNA using hydroxyapatite 
column chromatography. 
Hydroxyapatite column chromatography was performed as described in Chapter 2. The 
ethanol precipitated fractions quantified using a NanoDrop. 300 ng of each fraction and 2% 
of the input mixture of ss- and dsDNA was electrophoresed on an 8% native polyacrylamide 
gel. 200 ng 1 kb ladder (M) was included as a size marker. The ssDNA band migrated faster 
than the dsDNA band. The gel was stained with Sybr Gold and imaged using a 
phosphorimager. Representative of two independent experiments. 
 
 
5.5.4. Summary of alternative approaches to generating a 
long RNA:DNA hybrid 
The production of a long (188 bp) RNA:DNA hybrid without utilising reverse 
transcription is complicated by the requirement to synthesise sufficient quantities of 
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pure ssDNA. The techniques discussed in this section revealed that λ exonuclease 
digestion of the forward strand of a PCR product was the most successful, and 
required the least manipulation of the nucleic acids. However, it was not possible to 
establish a method to fully purify the ssDNA from undigested dsDNA. Therefore the 
products of digestion would have to be excised from native gels to ensure only the 
correct strand is purified. Post-annealing, it is highly likely that the hybrid would 
need further purification, to remove any unannealed ssNA, as shown for the short 
RNA:DNA hybrids in Section 5.2. The techniques discussed in this section are also 
likely to be unsuitable for the separation of a 188bp RNA:DNA hybrid from ssNA 
contaminants of the same length, therefore the hybrid would also require purification 
from native gels. This process would therefore requir  purification of each strand and 
the hybrid by gel extraction, and so a large quantity of starting material would be 
required to generate even a relatively small amount f product. RNA:DNA hybrids 
generated during this chapter were to be used to stimulate cells, therefore a large 
quantity of purified hybrid would be required to perform sufficient experiments. 
Consequently, R:D188 synthesised using this alternaive method was not tested in 
cells during this thesis. 
 
5.6. Additional RNA:DNA hybrids  
RNA ligands for the cytosolic helicase RIG-I contai  5́-ppp, which is recognised 
and strongly bound by RIG-I (Wang et al., 2010a). RNA without a 5ʹ-ppp does not 
stimulate RIG-I activity (Myong et al., 2009). It is possible the innate immune 
signalling in response to RNA:DNA hybrids also requires the detection of a 5ʹ-ppp 
on the RNA strand by the PRR. 
 
An RNA strand produced by IVT will contain a 5ʹ-ppp, therefore short RNA:DNA 
hybrids containing a 5ʹ-ppp RNA were produced by combining the methods 
described for generating the other hybrids described n this chapter. A smaller region 
of the CMV promoter was amplified and used as a template for IVT. The resulting 
ssRNA was purified from a denaturing PAGE gel and ane led to a fully 
complementary 51 nt ODN. Initial PAGE analysis confirmed that a hybrid had been 
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formed by annealing and also revealed the presence of additional contaminating 
nucleic acids (Figure 5.20). Therefore, this hybrid would require further purification 
before used in cellular experiments. This hybrid is close to R:D60 in length, therefore 
the use of a Superdex 200 column to fractionate the diff rent nucleic acid species 
would be expected to be successful. Although further purification and validation of 
this hybrid was not performed during this thesis, R:D51 illustrates that short hybrids 
containing 5́-ppp can be generated using this method, therefore pr viding an 






Figure 5.20. The annealing of a 51nt IVT RNA with a complementary ODN to generate a 51 
bp RNA:DNA hybrid. 
A region of the CMV promoter was amplified using a forward primer containing an 18 nt T7 
polymerase promoter site and a reverse primer containing an EcoRI restriction site, 
digested with EcoRI, gel extracted and used as a template for IVT. RNA was extracted from 
a denaturing PAGE gel and then annealed to a complementary PAGE-purified DNA 
oligodeoxyribonucleotide as described in Section 5.2. Sham annealings omitting one of the 
strand were also performed: sham RNA (containing the DNA strand only) and sham DNA 
(containing the RNA strand only). 200 ng of annealed hybrid and the equivalent volume of 
each of the sham annealing were electrophoresed on a 15% native polyacrylamide gel, 
alongside 200 ng of 5 bp ladder as a size marker (M). The gel was stained with Sybr Gold 







In this chapter, the design, synthesis, purification and validation of synthetic 
RNA:DNA hybrids has been investigated. I have shown that whilst it is possible to 
generate large amounts of RNA:DNA hybrids, the removal f contaminating nucleic 
acid species is more challenging. However, removal f such contaminating species is 
essential before the hybrids can be tested for theiability to activate the innate 
immune response in vitro. 
 
5.7.1. RNA:DNA hybrids generated by annealing 
complementary oligonucleotides 
The annealing of complementary oligonucleotides is the most frequently used 
method to generate RNA:DNA hybrids. However, purificat on of hybrids post-
annealing is rarely performed. This is most probably because the annealed product is 
considered sufficiently pure for downstream applications, including RNase H activity 
assays (Ohtani et al., 2008) and co-crystallisation experiments (Nowotny et al., 
2008). Whilst annealed RNA:DNA hybrids have not previously been used to 
investigate immune responses in vitro, the use of short immunostimulatory dsDNA 
and dsRNA generated by the annealing of complementary ODN or ORNs has been 
reported in a number of studies, for example (Karayel et al., 2009; Schlee t al., 
2009b; Stetson and Medzhitov, 2006). In all cases, purification of the annealed 
duplexes prior to downstream experiments was not report d. 
 
Native PAGE analysis of RNA:DNA hybrids generated by annealing complementary 
ORN and ODNs revealed the presence of unannealed ssNA in the preparations, when 
stained with the highly sensitive nucleic acid stain Sybr Gold (Figure 5.1 b). 
Furthermore, the annealing of certain complementary oligonucleotides resulted in the 
formation of higher molecular weight RNA:DNA hybrid-containing species (Figure 
5.1 b and c; Chapter 4, Figure 4.6 b), most likely as a consequence of the formation 
of higher ordered structures upon annealing, or the use of insufficiently purified 
oligonucleotides. It is therefore conceivable that t e use of unpurified hybrids 
generated using this method to stimulate an immune response may well cause 
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spurious results. This could arise as a direct consequence of the presence of 
contaminating nucleic acid species, in addition to the problems associated with 
accurately quantifying a hybrid contaminated with ssNA (as discussed in Chapter 4). 
However, the generation of short RNA:DNA hybrids using this method has many 
advantages: it is a simple and rapid method of producing large quantities of hybrids, 
which can be generated using ODNs and ORNs with a number of chemical 
modifications of any sequence. Therefore, purification of the correct hybrids from 
other nucleic acids using FPLC size exclusion chromat graphy was established. 
 
5.7.2. FPLC purification of R:D60 
The use of FPLC provided a rapid method of fractionating large quantities (up to 150 
µg input per run was used during this thesis) of RNA:DNA hybrids from 
contaminants. The use of nuclease-free reagents and thorough washing of the column 
ensured that samples were protected from degradation nd external contaminants. As 
shown in Section 5.2, excellent separation of 40 bp and 60 bp duplexes from ssNA 
was achieved using this method. The process was found to be more efficient than 
PAGE purification and had the additional advantage of being able to fractionate large 
quantities of hybrid at the same time, therefore reducing the possibility batch 
variability, which is preferable for screening the immune response to the same hybrid 
over a series of experiments.  
 
R:D60 fractionated using FPLC was generally recovered completely free from 
contaminants (Figure 5.4). Quality controls experimnts were performed to monitor 
the maximum amount of contamination (Figure 5.7). Unannealed ssDNA was 
present in very few purified preparations, and could be attributed to technical 
problems (collection of the incorrect fractions and failure to sufficiently clean the 
Superdex column). These issues were resolved by re-running the samples over the 
column. Nevertheless, the quality control gel shown in Figure 5.7 allows a maximal 
amount of ssDNA contamination to be estimated, which is approximately 6% for this 
hybrid batch. Using this method, it was possible to stimate that the R:D60 used in 
the downstream experiments investigating stimulation of innate immunity described 
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in this thesis (Chapter 6) contained less than 1.6% ssNA contamination (as 1.6 ng is 
the limit of Sybr Gold detection, Figure 5.7). 
 
A limitation of this technique was revealed when used to fractionate nucleic acids of 
other sizes. Although complete separation of 18 nt ssDNA and the 18 bp hybrid was 
achieved, the purity of the recovered hybrid-containing fractions of R:D12 and 
R:D20 was lower (Figure 5.5). Furthermore, 188 bp dsDNA and 188 nt ssDNA could 
not be resolved (Figure 5.18). Therefore, it can be concluded that successful 
fractionation of ssNA and dsNA using size exclusion chromatography with a 
Superdex 200 column is dependent upon the both length of the nucleic acid and the 
base sequence, which influences the migration and secondary structure of ssNA. It 
may be possible to achieve better fractionation of these other samples using different 
columns which may have more appropriate size selection ranges. 
 
5.7.3. Synthesis of RNA:DNA hybrids containing 5ʹ-ppp RNA 
The overall aim of this thesis was to determine if RNA:DNA hybrids can stimulate 
innate immunity in vitro as a model of what may occur in vivo in AGS patient cells. 
Therefore, the use of physiologically relevant hybrids would be preferential, 
although as discussed previously during this thesis, many studies performing in vitro 
characterisation of innate immune signalling pathways have used synthetic nucleic 
acid analogues and ODNs.  
 
The production of a much longer hybrid containing virally-derived sequence was 
established, using reverse transcription of a 188 nt ssRNA generated by IVT (Figure 
5.8). Although this method produced a hybrid-containing species of the correct size 
which could be hydrolysed by RNase H2, it was not possible to exclude ssNA 
contamination from this hybrid (Figure 5.10). A number of methods to synthesise 
sufficient quantities of pure 188 nt ssDNA were investigated, with the aim of 
generating a 188 bp RNA:DNA hybrid by annealing the two separate strands. It was 
not possible to obtain sufficiently purified ssDNA during this thesis, however the use 
of an alternative method of chromatography, for example, ion exchange 
219 
 
chromatography, may be more successful in fractionating λ exonuclease digested 
DNA.  
 
Finally, a 51 bp RNA:DNA hybrid with a 5ʹ-ppp ssRNA strand was generated 
(Figure 5.20). Assuming the hybrid can be successfully p rified away from 
contaminating nucleic acid species using FPLC, this provides an additional type of 
hybrid to be tested for the ability to activate thePRRs of the innate immune system. 
Transcription of certain endogenous retroelements by RNA pol III generates ssRNA 
with a 5́-ppp (Boeke, 2003). Additionally, the short RNA primers synthesised by the 
primase complex during DNA replication also have a 5ʹ-ppp (Wilson and Sugino, 
1985). Therefore, it possible that endogenous immunostimulatory RNA:DNA 
hybrids will contain a 5́-ppp, which may be vital to the detection of hybrids by 
PRRs. The production of hybrids similar to R:D51 would allow the generation of 
hybrids of various sizes (< 100 bp) to be produced from any sequence that can be 
used as a template for IVT. The inclusion of a cap analogue during transcription, or 
the treatment of the RNA with a phosphatase would allow for the comparison of the 
immunostimulatory potential of the same hybrid with and without a 5́-ppp, similar to 
studies investigating the ligand for RIG-I (Hornung et al., 2006; Pichlmair et al., 
2006; Rehwinkel et al., 2010). 
 
In summary, I have described the design and synthesis of even RNA:DNA hybrids 
with different physiochemical properties. All hybrids required purification to remove 
any contaminating nucleic acid species, most notably ssNA which is likely to be 
immunogenic. A 60 bp hybrid consisting of a repetitive GU-repeating RNA sequence 
generated from unmodified PD-containing oligonucleotides was successfully 
purified. Further characterisation of the hybrid using detection by the S9.6 antibody 
combined with RNase H digestion confirmed that FPLC-fractionated R:D60 is a 
homogeneous RNA:DNA hybrid. Chapter 6 describes details the testing of several 
RNA:DNA hybrids generated during this chapter for ability to stimulate innate 




Chapter 6. The stimulation of innate immunity in vitro 
by RNA:DNA hybrids 
 
Loss-of-function mutations in the RNASEH2 genes are hypothesised to lead to an 
accumulation of RNA:DNA hybrid substrates in cells. The primary aim of this thesis 
was to determine if these substrates are able to stimulate an innate immune response. 
Synthetic RNA:DNA hybrids generated in Chapter 5 were used to investigate this in 
vitro via the stimulation of different cell types. Initially, the 188 bp 5́-ppp-containing 
hybrid, R:D188, was to be the test hybrid as a long hybrid formed by reverse 
transcription was considered to be a more physiologically relevant hybrid. However, 
failure to validate the precise nature of this hybrid, in addition to the problems with 
purification of the hybrid discussed in Chapter 5, led to the examination of the 
immunostimulatory potential of shorter hybrids. 
 
6.1. Characterisation of reagents for the transfection of 
RNA:DNA hybrids into cells 
Studies using synthetic nucleic acids to stimulate activation of an innate immune 
response in vitro frequently utilise cationic lipid-mediated transfection to deliver the 
nucleic acid into a wide variety of cell types (Ablasser et al., 2009; Boczkowski et 
al., 1996; Burckstummer et al., 2009; Chiu et al., 2009; Diebold et al., 2003; 
Fernandes-Alnemri et al., 2009; Heil et al., 2004; Hornung et al., 2009; Hornung et 
al., 2006; Ishii et al., 2006; Roberts et al., 2009; Stetson and Medzhitov, 2006). In 
addition to facilitating cellular uptake, the complexing of nucleic acids to cationic 
lipids is thought to protect from degradation by extracellular nucleases (Heil et al., 
2004). In the absence of transfection, the immunostimulatory potential of most 
synthetic oligonucleotides is negated (see referencs listed above). 
 
To investigate if RNA:DNA hybrids required transfection for entry into cells, an 18 
bp RNA:DNA labelled with fluorescein on the RNA strand hybrid (*R:D18, where * 
denotes a 5ʹ-fluorescein) was added to the culture medium of transformed cell lines 
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(human epithelial HeLa cells and murine L929 fibroblasts) and primary MEFs. After 
a series of time points (10 min – 24 h), the cells were analysed by microscopy and 
flow cytometry. Fluorescent signal was not detected in any of the cell lines over any 
time point, indicating that the hybrids had failed to enter the cell and transfection 
would be required (Figure 6.1 b). 
 
The ability of various cationic lipid transfection reagents to facilitate entry of 18 bp 
RNA:DNA hybrids into cells was assessed using *R:D18. Each reagent successfully 
delivered *R:D18 into the cytosol (Figure 6.1 a). However, the efficiency of 
transfection and distribution of signal throughout the cytosol varied between 
reagents, with the diffuse signal seen in cells transfected with using Lipofectamine 
2000 considered to be the most physiologically relevant. Therefore, Lipofectamine 
2000 was chosen as the transfection reagent for subseq ent experiments. After 4 h, 
*R:D18 complexed with Lipofectamine 2000 in 99% of cells (Figure 6.1. b and c). 
Although this was only shown for using 18 bp RNA:DNA hybrid, the published 
requirement for transfection of other nucleic acids makes it likely that longer 
RNA:DNA hybrids will also require transfection to ent r cells. 
 
Lipofectamine 2000 is frequently used in studies to timulate an immune response to 
nucleic acid ligands in a variety of cells types including transformed cell lines, and 
primary MEFs, macrophages, monocytes and DCs (see ref rences listed above). 
Importantly, non-specific cytokine production by immune cells is not induced by 






Figure 6.1. Characterisation of reagents for the transfection of R:D18 into L929 cells. 
Semi-confluent L929 cells were transfected with 4.4 μg/ml *R:D18 according to the 





medium was removed, and the cells fixed and stained with DAPI. (a) All transfection agents 
delivered *R:D18 to the cytosol. Cells shown are representative of duplicate slides from two 
independent experiments using L929 cells. Scale bars are 10 μm, images taken at a 
magnification of 100 x. Similar results were also seen in HeLa cells and primary MEFs and 
when different concentrations of hybrid were transfected (1 – 4.4 µg/ml). (b) Efficiency of 
*R:D18 transfection was analysed using flow cytometry. Cells were transfected with 1 
µg/ml *R:D18 for the indicated time. After 4 h, 99% of cells contained *R:D18, as shown in 




6.2. R:D188 stimulates IFN production in transformed cell 
lines 
In initial experiments, two transformed cell lines were stimulated with both short and 
long RNA:DNA hybrids. Both HeLa and L929 cells are known to produce type I IFN 
in response to transfection with poly (I:C) (Milhaud et al., 1992) and infection with 
RNA viruses (van Pesch et al., 2004; Wathelet et al., 1992). Unstimulated HeLa cells 
express mRNA for most TLRs, although expression of TLR8 is weak (Kurt-Jones et 
al., 2004; Nishimura and Naito, 2005). In addition, they can utilise the RNA 
helicases RIG-I/MDA5 (Choi et al., 2009), as can L929 cells (Yoneyama et l., 
2004). 
 
Addition of poly (I:C) to culture medium stimulates type I IFN expression via TLR3 
(Oshiumi et al., 2003), whereas transfection of poly (I:C) stimulates IFN induction 
independent of TLR3, via MDA5 (Andrejeva et al., 2004; Gitlin et al., 2006; 
Yoneyama et al., 2004). In the following experiments, poly (I:C) used as a positive 
control for IFN induction was transfected into the cells, since RNA:DNA hybrids 
also required transfection for successful entry into the cell. 
 
Transfection of short hybrids into HeLa cells did not stimulate an IFN response (as 
shown for R:D18 in Figure 6.2 a). In contrast, transfection of R:D188 produced by 
reverse transcription (Chapter 5, Section 5.3) induce  a type I IFN response, as 
shown by an significant increase in the mRNA levels of the genes encoding IFN-β 





Figure 6.2. R:D188 stimulates type I IFN production in transformed cell lines. 
Cells were transfected with 25 μg/ml each of poly (I:C), R:D18 and R:D188 using 
Lipofectamine 2000 for 18 h. (a) HeLa cells upregulated expression of the genes encoding 
IFN-β and IRF7 in response to stimulation with R:D188. Data are shown as fold increase in 
expression from medium only controls, from three independent experiments + s.d. (b) L929 
cells secreted IFN-α in response to R:D188. Data are from three independent experiments + 
s.e.m. (c) Nuclease digestion of R:D188 did not abolish the IFN-β response in HeLa cells. 
Data shown are from one experiment + s.d. of triplicate qRT-PCR wells. (d) Nuclease 
digestion also failed to abolish IFN-α secretion by L929s in response to R:D188. Data shown 




only controls (Figure 6.2 a). Similarly, transfected R:D188 robustly induced IFN-α 
secretion by L929 cells (Figure 6.2 b). However, in the absence of Lipofectamine 
2000, R:D188 failed to induce a type I IFN response (Figure 6.2 c and d).  
 
To establish if nuclease digestion would abolish the response of the cell lines to the 
long hybrid, R:D188 was digested with RNase H and DNase I. Agarose gel 
electrophoresis of the digested products showed that RN se H treatment hydrolysed 
the RNA strand of the hybrid, resulting in a band at approximately 150 bp (Figure 
6.2 c and d). The migration of this strand and its digestion by DNase I suggested that 
this was the ssDNA strand of the hybrid, as confirmed by Figure 5.10. DNase I 
treatment of R:D188 also resulted in some degradation of the hybrid, which 
suggested non-specific activity of the enzyme (as discussed in Chapter 4). 
Alternatively, there could have been ssDNA contamination of R:D188; however this 
wasn’t evident from agarose gel analysis of the hybrid. 
 
The nuclease treated hybrids were transfected into cells. IFNb1 expression was 
increased in the nuclease digested samples, and was induced most strongly when 
R:D188 was digested with both RNase H and DNase I (Figure 6.2 c). This suggested 
that the short polynucleotide products of nuclease dig stion, which are not evident on 
an agarose gel, were highly immunostimulatory in HeLa cells. Similarly, nuclease 
digestion did not abolish IFN-α production by L929s in response to R:D188 (Figure 
6.2 d). RNase A treatment in a high salt buffer, which did not degrade the hybrid as 
seen on the gel, did slightly reduce IFN-α production (p = 0.572), which suggested 
there may have been some contaminating ssRNA in R:D188. Alternatively, there 
may have been regions of ssRNA in the hybrid, for example, if looping of the RNA 
strand occurred during reverse transcription. 
 
Together, these results demonstrated that in the HeLa and L929 cell lines, a long 
RNA:DNA hybrid with a 5́-ppp RNA strand can stimulate a type I IFN response 
when introduced into cells using a transfection reagent. However, nuclease digestion 
data, combined with the analysis of the hybrid described in Chapter 5, meant it was 
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not possible to verify that this response is due to an RNA:DNA hybrid and not 
contaminating nucleic acid species.  
 
Short hybrids did not stimulate type I IFN production in HeLa and L929 cells. The 
methods used to produce these hybrids, including their successful purification from 
unannealed ssNA by FPLC, as detailed in Chapter 5, suggests they are more likely to 
be free from contaminating nucleic acids than R:D188. It is known that transformed 
cell lines lack certain PRR signalling pathways, such as the ISD response pathway 
(the response to cytosolic phosphodiester DNA) (Stetson et al., 2008). Therefore the 
immunostimulatory capacity of short RNA:DNA hybrids was analysed using primary 
cells, including MEFs, and more appropriately, cells of the immune system. 
 
6.3. Short RNA:DNA hybrids do not induce expression of 
type I IFNs in primary MEFs 
The immunostimulatory potential of short RNA:DNA hybrids was initially tested in 
non-immune cells. Primary MEFs express all TLRs (Kurt-Jones et al., 2004) but can 
also sense nucleic acids via cytosolic receptors. After infection with ssRNA viruses, 
MEFs produce type I IFN via a RIG-I-dependent mechanism (Kato et al., 2005), 
whilst the B-form dsDNA poly (dA:dT) induces expression of the gene encoding the 
cytosolic DNA sensor DAI (Takaoka et al., 2007). 
 
Primary MEFs derived from wild type mouse embryos were established and their 
ability to upregulate type I IFN expression in response to stimulation with TLR 
ligands was tested. The control TLR ligands poly (I:C) and CpG ODN (Type A) 
potently stimulated expression of Ifna1 and Ifnb1 (Figure 6.3 a). 
 
To investigate if type I IFN expression was upregulated in response to RNA:DNA 
hybrids, a range of hybrids were transfected into MEF cultures. As in the 
transformed cell lines, the long hybrid R:D188 strongly induced type I IFN 
expression (Figure 6.3 b). However, the short hybrids R:D12, R:D18, R:D20 and 





Figure 6.3. Expression of type I IFNs is not induced in primary MEFs following transfection 
with short RNA:DNA hybrids. 
Semi-confluent early passage (< 3 passages) primary MEFs were transfected with TLR 
ligands and hybrids. None of the hybrids used in these experiments were FPLC-purified. (a) 
Type I IFN gene expression in MEFs stimulated with 200 ng/ml LPS, 5 μg/ml CpG ODN, 25 
μg/ml poly (I:C) and 25 μg/ml R:D60 for the indicated timepoints. Data are represented as 
normalised fold change relative to Lipofectamine alone, representative of 3 independent 
experiments + s.d. of triplicate qRT-PCR wells. (b) MEFs were transfected with 25 μg/ml 
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each of R:D12, R:D60 and R:188 for 18 h before IFN gene expression was analysed by qRT-
PCR. Data are represented as normalised fold mRNA induction from Lipofectamine only 
controls + s.d. of triplicate qRT-PCR wells. (c) Ifna1 and Ifnb1 expression in MEFs transfected 
with 25 μg/ml of poly (I:C) and each RNA:DNA hybrid for 18 h. Data are represented as 
normalised fold mRNA induction from a medium only control, representative of duplicate 
experiments + s.d. of triplicate qRT-PCR wells. (d) IL-6 and TNF-α production by MEFs 
transfected with 25 μg/ml of poly (I:C) and R:D60 in the presence and absence of 




expression of Ifna1 and Ifnb1 (Figure 6.3 a, b and c) or production of the pro-
inflammatory cytokines IL-6 and TNF-α. Furthermore, pretreating MEFs with IFN-α 
before transfection of the hybrids also failed to induce type I IFN expression. 
Therefore, it can be concluded that these short RNA:D  hybrids could not trigger 
an IFN response in primary MEFs. 
 
6.4. Short RNA:DNA hybrids do not stimulate an immune 
response in primary macrophages 
To investigate whether short RNA:DNA hybrids can stimulate cytokine production 
in antigen-presenting cells of the immune system, primary bone-marrow derived 
macrophages were generated. In response to stimulaton with DNA, including CpG 
ODN and poly (dA:dT), macrophages produce pro-inflammatory cytokines and type 
I IFNs (reviewed by Vilaysane and Muruve, 2009). Similarly to MEFs, macrophages 
respond to RNA viral infection via cytosolic RLR pathways, leading to the 
production of type I IFN and pro-inflammatory cytokines (Kumar et al., 2006). 
 
Bone-marrow macrophage cultures produced IFN-α in response to transfection with 
poly (I:C) (Figure 6.4 a). R:D188 also induced the production of small amounts of 
IFN-α, however R:D60 did not (Figure 6.4 a). The expression of I nb1 was 
upregulated in response to transfection with nucleic ac d PRR ligands (Figure 6.4 b). 
However, no increase in expression was detected following transfection with either 
R:D12, R:D18, R:D20 or R:D60 (Figure 6.4 b). The single-stranded oligonucleotides 
used to produce R:D60 also failed to induce Ifnb1 expression (Figure 6.4 b). This 
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suggested that short RNA:DNA hybrids and ssNA cannot trigger a type I IFN 






Figure 6.4. Short RNA:DNA hybrids do not induce a type I IFN response in macrophages. 
(a) Macrophages were transfected with 25 μg/ml poly (I:C), 10 μg/ml CpG ODN (Type A) 
and 25 μg/ml of each hybrid for 18 h before IFN-α secretion was determined by ELISA. Data 
is from one experiment performed in triplicate + s.d. (b) Macrophages were stimulated with 
100 ng/ml LPS or transfected with 1 μg/ml each of poly (dA:dT), poly (I:C) or CpG ODN. 
R:D60 was added to to the medium or transfected at 1 μg/ml. The hybrids R:D12, R:D18 
and R:D20 were transfected at 1 μg/ml and the ssNA controls for R:D60 were transfected at 
500 ng/ml (the equivalent amount of each that would be present in 1 μg of R:D60). After 18 
h, cytokine expression was determined by qRT-PCR. No Ifna1 mRNA was detected in any of 





Macrophages also produce pro-inflammatory cytokines  response to nucleic acid 
ligands. Levels of IL-6 production following treatment with different concentrations 
of R:D60 and its single-stranded components ssDNA60 and ssRNA60 was measured 
by ELISA. Transfected R:D60 failed to stimulate IL-6 production as did ssRNA60, 
however a high concentration of ssDNA60 induced a large amount of IL-6 






Figure 6.5. Transfected R:D60 does not induce pro-inflammatory cytokine production by 
macrophages. 
Bone-marrow macrophage cultures were stimulated with 100 ng/ml LPS, or transfected 
with 1 μg/ml each of poly (dA:dT), poly (I:C) or CpG ODN. R:D60 was added to the medium 
or transfected at decreasing concentration (25, 10, 1 μg/ml). ssDNA60 and ssRNA60 were 
transfected at decreasing concentrations (25, 10, 1, 0.5 μg/ml). After 18 h, supernantants 
were harvested and IL-6 production determined by ELISA. Data shown are from two 




The expression of activation markers by macrophages tran fected with R:D60 was 
analysed using flow cytometry. There was no significant upregulation of CD86 
(Figure 6.6) or MHC Class II in cells treated with R:D60, either in the presence or 
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absence of Lipofectamine. Together, these data show t at bone marrow-derived 
macrophages do not produce type I IFNs in response to hort RNA:DNA hybrids, 
although the addition of high concentrations of R:D60 to culture medium can 
stimulate the production of low levels of pro-inflammatory cytokines in the absence 






Figure 6.6. CD86 expression is not upregulated by macrophages transfected with R:D60. 
Bone-marrow macrophages were transfected with 1 μg/ml each of poly (dA:dT), poly (I:C) 
or CpG ODN. 25 μg/ml R:D60 was added to the medium or transfected. 25 μg/ml ssDNA60 
and ssRNA60 were also transfected into cells. After 18 h, cell surface expression of CD86 
was analysed by flow cytometry. Medium only controls are shown in grey, sample is in red. 
Data shown are representative of two independent experiments. These cells also failed to 






6.5. Short RNA:DNA hybrids do not stimulate an immune 
response in GM-CSF DCs 
DCs can be generated from bone marrow precursors in vitro using granulocyte 
macrophage colony-stimulating factor (GM-CSF) (Lutz et al., 1999). GM-CSF DCs 
contain both mature and immature cells, as determined by surface marker expression 
(Lutz et al., 1999) and are classed as conventional DCs (cDCs, also known as 
myeloid DCs (mDCs)). GM-CSF cultures do not contain plasmacytoid DCs (pDCs) 
(Brawand et al., 2002). 
 
GM-CSF DCs have been shown to produce type I IFNs and pro-inflammatory 
cytokines in response to stimulation with DNA, particularly the TLR9 ligand CpG 
ODN (Gray et al., 2007; Yoshinaga et al., 2007). They produce IFN-α in response to 
transfection with poly (I:C) and viral dsRNA via activation of cytosolic RLR-
mediated pathways (Diebold et al., 2003; Kato et al., 2005; Kato et al., 2006), but 
can also produce type I IFN in response to poly (I:C) when it is added to the culture 
medium, via TLR3.  
 
GM-CSF DCs were stimulated with the TLR ligands CpG ODN, R848 and poly 
(I:C). R:D60 was included in the presence and absence of Lipofectamine. As 
expected, GM-DCs produced IFN-α in response to poly (I:C) and IL-6/IL-12p40 in 
response to R848 (Figure 6.7). R:D60 failed to stimulate a cytokine response in these 
cells, in the presence or absence of Lipofectamine. Th re was no phenotypic 
activation of GM-CSF DCs in response to the hybrid, evident by the absence of an 
increase of CD40, CD80, CD86 and MHC Class II expression on the cell surface 
(Figure 6.8). Therefore, R:D60 was unable to stimulate an innate immune response in 
GM-CSF DCs. 
 
A second DC subset, plasmacytoid DCs (pDCs), are known to produce vast amounts 
of type I IFN in response to nucleic acids, particularly during viral infection 
(Asselin-Paturel et al., 2001; Cella et al., 1999). Therefore, the ability of R:D60 to 





Figure 6.7. R:D60 does not stimulate cytokine production in GM-CSF DCs. 
GM-CSF DCs were stimulated with 500 ng/ml CpG ODN, 1 μg/ml R848 and 1 μg/ml poly 
(I:C). R:D60 was added to the medium or transfected at a concentration of 1 μg/ml. After 18 
h, supernatants were harvested and the levels of IFN-α, IL-6 and IL-12p40 determined by 







Figure 6.8. R:D60 does not stimulate the phenotypic activation of GM-CSF DCs. 
GM-CSF DCs were stimulated as described for Figure 6.6. Expression of co-stimulatory 
molecules was determined by flow cytometry. The median fluorescence intensity (MFI) was 
calculated using FlowJo. Data shown are the mean from triplicate samples + s.d. Statistical 
analysis using Student’s t-test showed that there was no significant increase in expression 
of any of the molecules from medium only controls following stimulation with R:D60 (CD40: 
R:D60 p = 0.566, R:D60 + Lipofectamine p = 0.137; CD80: R:D60 p = 0.312, R:D60 + 
Lipofectamine p = 0.884; CD86: R:D60 p = 0.643, R:D60 + Lipofectamine p = 0.469; MHC 





6.6. Stimulation of Flt-3L-DCs with R:D60 
 
6.6.1. FL-DC bone marrow cultures 
As discussed in Chapter 1, pDCs can produce large amounts of type I IFNs in 
response to both pathogenic and host nucleic acids (reviewed by Lande and Gilliet, 
2010). In vivo, pDCs are a rare cell population, constituting less than 1% of 
peripheral blood cells. The number of both pDCs and cDCs in the blood can be 
greatly increased by the injection of Fms-like tyrosine kinase 3-ligand (Flt3-L) 
(Maraskovsky et al., 1996; Pulendran et al., 2000). 
 
In vitro, murine pDCs can be generated from bone marrow cultures containing Flt3-L 
(FL-DC cultures) (Brawand et al., 2002; Gilliet et al., 2002). FL-DCs are a 
heterogeneous population of CD11c+ cDCs and pDCs which can be segregated into 
distinct populations by their expression of surface markers (Figure 6.9). These are 
equivalent to steady-state splenic pDC and cDC populations, although the relative 
proportions of each population are slightly altered (Naik et al., 2005). pDCs express 
B220 (CD45RA) but cDCs do not (Figure 6.9 a) (Brawand et al., 2002; Gilliet et al., 
2002). The cDC population can further be subdivided into CD24hi and CD11bhi/Sirp-
α
hi populations, which correspond to CD8+ and CD8- splenic cDC populations, 
respectively(Naik et al., 2005) (Figure 6.9 b). The three different DC subsets present 
in FL-DC cultures exhibit distinct patterns of TLR expression and produce specific 
cytokines in response to stimulation with TLR ligands (Brawand et al., 2002; Gilliet 
et al., 2002; Naik et al., 2005) (summarised in Table 6.1).  
 
To investigate if R:D60 could stimulate a cytokine response in pDCs, FL-DC 
cultures were transfected in a repeat of the experiments with macrophages and GM-
CSF cDCs. All R:D60 used in the following experiments had been FPLC-purified 
and verified by native PAGE analysis. As in the previous experiments in this chapter, 
the TLR9 ligand CpG ODN (A type), which is known to induce high production of 






Figure 6.9. Segregation of FL-DCs into DC subsets using surface marker expression. 
(a) CD11c
+





 (cDCs). During the experiments is this thesis, typically in the range of 20 – 
50% of cells from each Flt3-L culture were B220
+





 populations. Data shown are representative of multiple experiments. 
The relative proportions of the populations did not alter upon stimulation with nucleic 







Table 6.1. Comparison of the characteristics of the DC subpopulations present in Flt3-L 
bone marrow cultures. 
 




6.6.2. Transfected R:D60 stimulates cytokine production by 
FL-DCs 
FL-DC cultures containing 20 – 50% CD11c+ B220+ pDCs were stimulated with the 
RNA:DNA hybrid R:D60, in the presence or absence of Lipofectamine. In contrast 
to macrophages and GM-CSF DCs, FL-DCs secreted cytokines in response to 
transfected R:D60 (Figure 6.10). In particular, high levels of IFN-α were detected in 
the supernatants of transfected cells. IFN-β was also produced in response to 
transfected R:D60, as were IL-6, RANTES and TNF-α. Low levels of the anti-
inflammatory cytokine IL-10 were detected, but were not significantly increased 




      
Figure 6.10. Transfected R:D60 stimulates cytokine production by FL-DCs. 
FL-DC cultures were stimulated with 1 μg/ml CpG ODN, 1 μg/ml R:D60 or were transfected 
with 1 μg/ml R:D60 using Lipofectamine. After 18 h, supernatants were collected and 
secreted cytokines detected by ELISA. Transfected R:D60 stimulates the production of type I 
IFN (a), IL-6 and RANTES (b) by FL-DCs. Some TNF-α and IL-10 are also produced (c). Data 
shown are the mean of five (IFN-α and IL-6), four (IFN-β and TNF-α), three (RANTES) or two 
(IL-10) independent experiments + s.e.m. 
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6.6.3. FL-DCs become phenotypically activated following 
transfection with R:D60 
Unstimulated cells exhibited an immature phenotype, with low expression of CD40, 
CD80, CD86 and MHC Class II; however, expression of all four was upregulated by 
cDCs and of all except CD80 by pDCs in response to transfected R:D60 (Figure 
6.11). These cells also upregulated expression of CD8, as previously reported for FL-
DC cultures activated with TLR ligands (Brasel et al., 2000; Brawand et al., 2002). 
 
In the absence of Lipofectamine, R:D60 failed to induce cytokine production by FL-
DC cultures (Figure 6.10) or expression of activation markers by pDCs, although a 
low level of phenotypic activation was observed in cDCs (Figure 6.11). Thererfore, 
internalisation of R:D60 is required for cytokine production by FL-DCs. 
 
6.6.4. Type I IFN genes are upregulated in FL-DCs transfected 
with R:D60 
A preliminary analysis of cytokine gene expression in FL-DCs by qRT-PCR showed 
that transfected R:D60 strongly induces type I IFN gene expression (Figure 6.12), the 
profile of which differed from that induced by CpG ODN. The fold induction of 
Ifna1 mRNA had fallen by 18 h in response to the hybrid, however it was sustained 
following CpG ODN stimulation. Similarly, expression f Ifnb1 increased over time 
following stimulation with CpG ODN but did not in response to the hybrid. Fold 
induction of pro-inflammatory cytokine gene expression was much lower, as shown 
for Tnfa. No increase in Il1b expression was detected in response to R:D60 (Figure 
6.12). Together with the ELISA data (Figure 6.10), this suggested that the cytokine 








Figure 6.11. R:D60 stimulation activates FL-DCs. 
FL-DC cultures were stimulated with 1 μg/ml CpG ODN, 1 μg/ml R:D60 added to the medium or were transfected with 1 μg/ml R:D60 using 
Lipofectamine 2000. After 18 h, cell phenotype was assessed by flow cytometry. Transfected R:D60 induced an upregulation of the costimulatory 
molecules CD40 and CD86 in both pDCs and cDCs, as did stimulation with CpG ODN. Cell surface expression of CD8 was also upregulated by CpG 




Figure 6.12. Transfection of R:D60 into FL-DCs strongly induces expression of type I IFN 
genes. 
FL-DCs were stimulated with 1 μg/ml CpG ODN or transfected with 1 μg/ml poly (I:C) or 1 
μg/ml R:D60 using Lipofectamine 2000 for the indicated times before qRT-PCR analysis was 
performed. Data are from one experiment, represented as fold mRNA increase from the 





6.6.5. Optimisation of FL-DC transfection experiments 
R:D60 stimulated type I IFN production in FL-DC cultures when introduced into 
cells using cationic-lipid mediated transfection. It was important to establish that the 
response is due to the hybrid rather than any contami ation introduced into the cells 
 
6.6.5.1. Lipofectamine 2000 can activate FL-DCs 
It has previously been reported that Lipofectamine 2000 does not induce non-specific 
cytokine production when used to transfect nucleic ac ds into immune cells, 
specifically DCs (Diebold et al., 2003). Initial experiments using Lipofectamine 
2000 were found to agree with this, however over th course of multiple repeats of 
these transfection experiments, it was observed that by itself Lipofectamine 2000 
could sometimes cause low levels of cytokine production (Figure 6.13 a) and induce 
phenotypic activation of the cells (Figure 6.13 b and c). The extent of non-specific 
activation of FL-DCs was found to be variable dependent on the batch of 
Lipofectamine 2000. The stimulation of type I IFN production by transfection 
reagents has been reported previously (Li et al., 1998). However, the use of a variant 
of Lipofectamine (Lipofectamine LTX), which the manufacturers recommend for the 
transfection of sensitive cell lines, minimised this non-specific activation, and 
confirmed that transfected R:D60 did specifically induce a response in these cells 
(Figure 6.13). Therefore, Lipofectmine LTX provided the better option for the 
transfection of FL-DCs. 
 
6.6.5.2. Dose response test  
A dose response experiment showed that the levels of cytokines produced and 
surface marker expression are similar when 0.5 – 5 µg/ml of R:D60 is transfected 
into FL-DC cultures (Figure 6.14), although the highest dose did stimulate more 
IFN-α production in this experiment. Therefore, to reduce the level of any residual 
contamination of ssNA in the hybrid preparation being introduced into the cell, 




                
 
Figure 6.13. Comparison of non-specific activation of FL-DCs by Lipofectamine 2000 and 
Lipofectamine LTX. 
FL-DCs were transfected with 1 µg/ml R:D60 using Lipofectamine 2000 and Lipofectamine 
LTX. Lipofectamine only controls were also included. After 18 h, levels of cytokine 
production were determined by ELISA and expression of activation markers by flow 
cytometry. Lipofectamine 2000 alone treatment, but not Lipofectamine LTX, stimulated the 
production of cytokine, as shown for IL-6 (a). Expression of activation markers in both pDCs 
and cDCs were also increased in these cells, as shown for CD86 (b) and (c). Data shown are 





Figure 6.14. The response of FL-DCs to different concentrations of R:D60. 
FL-DCs were transfected with increasing concentrations of R:D60 (0.5, 1, 2 and 5 μg/ml) 
using Lipofectamine 2000. After 18 h, supernatants were collected and the cells stained for 
flow cytometry. (a) Levels of cytokines produced by FL-DCs are the same as for 0.5 – 2 
μg/ml, but more IFN-α is produced in response to 5 μg/ml R:D60. Data shown is the mean 
of triplicate samples + s.d. (b) The upregulation of co-stimulatory molecule expression is 
equivalent for all concentrations of R:D60 used, as shown for CD40 and CD86. Isotype 








(cDCs) in blue. 




The data in Figure 6.14, although preliminary, suggests that there is no clear effect 
on levels of cytokine production and phenotypic activ tion with increasing doses of 
the hybrid. An explanation for this could be the establishment of type I IFN feedback 
loops, where early detection of the hybrid in indivi ual cells triggers IFN production, 
which then stimulates further type I IFN production via engagement of the type I IFN 
receptor (IFNAR). This would amplify the IFN-induced stimulation of other 
cytokines in cells which are directly responding to the hybrid and, in addition, trigger 
type I IFN production by other cells. Therefore, this autocrine-paracrine loop would 
generate large amount of cytokines, even by cells that have not been transfected. 
Therefore, the transfection of increased concentrations of R:D60 may not stimulate a 
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noticeable difference in cytokine production and phenotypic activation from cells 
transfected with low amounts. However, the use of 5 µg/ml R:D60 did stimulate 
more IFN-α production (Figure 6.14 a). 
 
6.6.6. Validation of the response of R:D60 
The stimulation of FL-DCs by transfected R:D60 represented the first time an 
RNA:DNA hybrid has been shown to activate immunity, therefore it is not known 
which receptor pathway would be involved. The production of type I IFNs is 
characteristic of an innate immune response to nucleic acids, particularly by pDCs. 
As detailed in Chapter 5, the production of R:D60 involves the annealing of ssDNA 
and ssRNA oligonucleotides. Purification of the hybrid using FPLC and subsequent 
analysis by native PAGE should reduce/prevent contami tion of the R:D60 
preparations by unannealed ssNA. If not removed, it is conceivable that the ssDNA 
and ssRNA oligonucleotides may stimulate type I IFNproduction in pDCs, possibly 
via TLR7 and TLR9. To test the immunostimulatory potential of the ss 
oligonucleotides, FL-DCs were transfected with different amounts of 
oligonucleotides and IFN-α measured by ELISA (Figure 6.15). 
 
When transfected at a concentration of 500 ng/ml, ssRNA60 strongly stimulated 
IFN-α production by FL-DCs (Figure 6.15 a), potentially via TLR7 since it is GU-
rich ssRNA. In contrast, ssDNA60 failed to induce high levels of IFN-α when used at 
this concentration. 1 µg of R:D60 would theoretically contain a maximum of 500 ng 
ssDNA60. Therefore IFN-α production in response to 1 µg R:D60 is unlikely to be 
induced by ssDNA60 contamination. When used at 1 µg/ml, both ssRNA60 and 
ssDNA60 stimulated IFN-α production in FL-DCs at levels at least equivalent to 




                     
 
Figure 6.15. Stimulation of IFN-α production by FL-DCs with different concentrations of 
single-stranded nucleic acids. 
FL-DC cultures were transfected with 1 μg/ml R:D60 and different concentrations of 
ssRNA60 and ssDNA60. (a) and (b) are each from independent experiments performed in 
duplicate, error bars are + s.d.  
 
 
A preliminary experiment suggested that the cytokine response to R:D60 is not 
abolished when the hybrid is digested with E. coli RNase H1 (Figure 6.16.). RNase 
H1 hydrolyses the RNA strand of RNA:DNA hybrids in a distributive manner, 
periodically cleaving the RNA to leave small fragments. Digestion of 1 µg of R:D60 
by RNase H1 therefore resulted in polyribonucleotide fragments, in addition to the 
500 ng of undigested DNA strand. As shown in Figure 6.15, ssRNA60 was highly 
immunostimulatory, even at 500 ng/ml. Therefore, it could be that the short RNA 
products of RNase H digestion are responsible for the s imulation of IFN-α 







Figure 6.16. Digestion of R:D60 with RNase H does not abrogate the cytokine response by 
FL-DCs. 
R:D60 was digested with RNase H as previously (see Figure 5.7). R:D60 minus RNase H and 
RNase H alone were included as controls. Digests were ethanol precipitated and 
resuspended to equivalent concentrations. FL-DCs were stimulated with 1 μg/ml CpG ODN 
or 1 μg/ml R:D60 by addition to the culture medium. 1 μg/ml undigested R:D60 and an 
equal volume of R:D60 + RNase H and the enzyme only control were transfected into cells 
using Lipofectamine 2000. After 18 h, supernatants were assayed by ELISA. Data shown are 




Finally, the possibility that immunostimulatory contaminants were introduced during 
the FPLC process was examined. Oligonucleotide anneali gs containing either both 
oligos (R:D60), only the DNA oligo (sham RNA) or only the RNA oligo (sham 
DNA) were prepared. Native PAGE analysis confirmed that the sham annealings 
contained only one strand (Figure 6.17 a). Each annealing mix was fractionated 
using FPLC (Figure 6.17 b). The sham mixes, which contained only ssNA, eluted  
later than R:D60 (Figure 6.17 b and Figure 5.5). The fractions where the hybrid 
would elute were collected (‘R:D fractions’) as well as the peaks. Following ethanol 
precipitation, all fractions were resuspended in the same volume of nuclease-free 





Figure 6.17. FPLC controls for FL-DC transfections. 
(a) Native PAGE analysis of R:D60 and sham annealings. 500 ng each of ssDNA60, ssRNA60, 
R:D60 and the equivalent volume of sham RNA (DNA oligonucleotide only) and sham DNA 
(RNA oligonucleotide only) were electrophoresed on a 12% polyacrylamide gel, which was 
then stained with acridine orange. The arrowheads indicate the migration of ssRNA60 (red), 
ssDNA60 (blue) and R:D60 (black). Note faint white line co-migrating with ssDNA60 is the 
reference dye front. (b) FPLC analysis of the sham annealings. Black arrows indicate the 
point where the hybrid elutes (R:D fractions) (see Figure 5.4). (c) Native PAGE analysis of 
sham annealing FPLC fractions. 200 ng of FPLC purified R:D60, 200 ng of sham RNA or sham 
DNA input and equivalent volumes of ethanol precipitated fractions were electrophoresed 
on a 15% native polyacrylamide gel. Nucleic acids were visualised by Sybr Gold staining.  
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nucleic acid was detected in the R:D fraction by PAGE analysis (Figure 6.17 c)
which was verified by quantification using nucleic a id absorbance at 260 nm. 
 
FL-DCs were transfected with 1 µg/ml R:D60 and equivalent volumes of the R:D 
fractions from both of the sham annealings. The R:Dfractions from the sham 
annealings failed to stimulate cytokine production in FL-DCs (Figure 6.18 a and b). 
In addition, they failed to induce upregulation of c -stimulatory molecule expression 
above Lipofectamine only controls in both pDCs and cDCs, as shown for CD86 in 
Figure 6.18 a and b (it should be noted that in these experiments Lipofectamine 2000 
alone did stimulate upregulation, which complicates the interpretation of data). 
Therefore, the cytokine response of FL-DCs to transfected R:D60 is unlikely to be 








Figure 6.18. The FPLC R:D fractions from sham annealings do not stimulate FL-DCs. 
FL-DCs were transfected with 1 μg/ml R:D60 and the equivalent volume of R:D fractions 
from FPLC of sham annealings, using Lipofectamine 2000. (a) Sham annealing R:D fractions 
did not stimulate IL-6 production above background (Lipofectamine only controls) in FL-DC 
cultures (Student’s t-test; R:D60 p = 0.054, sham RNA p = 0.481, sham DNA p = 0.489). Data 
shown are the mean of three independent experiments + s.e.m. (b) Sham annealing R:D 
fractions did not induce expression of Ifna1 in FL-DCs. Data are from one experiment + s.d. 
of qRT-PCR triplicates. (c) and (d) Sham annealing R:D fractions did not increase expression 
of CD86 from Lipofectamine 2000 only controls. MFIs were calculated using FlowJo. Data 




6.6.7. The stimulation of innate immunity in response to 
other RNA:DNA hybrids 
To investigate if the response of FL-DCs to R:D60 can be replicated using other 





6.6.7.1. Poly (rA:dT) does not activate FL-DCs 
The commercially available RNA:DNA hybrid poly (rA:dT) is frequently used in 
RNA:DNA hybrid structural studies and is a known sub trate for RNase H enzymes 
in vitro (Shaw and Arya, 2008). Poly (rA:dT) is generated by annealing equimolar 
amounts of each polymer. The individual polymers are synthesised using enzymes, 
so are polydisperse. Consequently, there is extensiv  variability in size between 
different commercially available batches of poly (rA:dT) but typically all contain 
hybrids of at least a few hundred bp in length (Richard V Case, Midland Certified 
Reagent Company, Inc., personal communication). 
 
Lyophilised poly (rA:dT) was reconstituted in nucleas -free water and used to 
stimulate FL-DCs in the presence and absence of Lipfectamine. Transfected poly 
(rA:dT) failed to activate FL-DCs above background levels (Lipofectamine only 
controls) (Figure 6.19 a), and did not induce a cytokine response (Figure 6.19b). 
 
6.6.7.2. R:D20 stimulates cytokine production in FL-DCs 
To determine if shortening the length of R:D60 affected its ability to stimulate a 
cytokine response in FL-DCs, a preliminary experiment using an FPLC-purified 20 
bp hybrid (R:D20) consisting of the same sequence ad nucleic acid chemistry as 
R:D60 was performed. This hybrid stimulated type I IFN production at least as well 
as R:D60 (Figure 6.20). However, although R:D20 definit ly contains RNA:DNA 
hybrid, PAGE analysis performed in Chapter 5 suggest that it could contain more 
than one nucleic acid species (Figure 5.6). Nevertheless, these data potentially 
suggest that recognition of r(GU)n:d(CA)n duplexes could be dependent on the 







Figure 6.19. FL-DCs do not respond to poly (rA:dT). 
FL-DCs were stimulated with 1 μg/ml R:D60 and 1 μg/ml poly (rA:dT) + Lipofectamine 2000 
for 18 h. (a) Expression of CD40, CD80 and CD86 was measured by flow cytometry and the 
MFI calculated for each sample. Note high background levels of expression induced by 
Lipofectamine 2000 alone. (b) IFN-α and IL-6 production were measured by ELISA. Data 








Figure 6.20. Cytokine production is stimulated by a 20bp RNA:DNA hybrid. 
FL-DCs were stimulated with 1 μg/ml CpG ODN or transfected with 1 μg/ml each of R:D60 
and R:D20 using Lipofectamine LTX. After the indicated time points, RNA was extracted 
from the cells and supernatants harvested (o/n indicates an 18 h stimulation). Ifna1 
expression was determined by qRT-PCR and is represented as normalised fold increase in 
expression from medium only controls. IL-6 and TNF-α production were determined by 





Taken together, the experiments using poly (rA:dT) and R:D20 imply that the FL-DC 
response to RNA:DNA hybrids could be sequence-dependent. However, the helical 
conformation of poly (rA:dT) is polymorphic; it is able to undergo A-form to B-form 
changes depending on the relative humidity of the environment (Shaw and Arya, 
2008). As it is only an assumption that R:D20/R:D60 adopt an A-form conformation, 
the lack of response to poly (rA:dT) does not exclude the possibility that nucleic acid 
structure is important in innate immune recognition of RNA:DNA hybrids. The 
identification of the receptor responsible for intracellular detection of R:D60 and 





6.6.8. Determination of the innate immune signalling 
pathways activated by R:D60 in FL-DCs 
The two subtypes of DC present in FL-DC cultures are known to utilise different 
receptors in response to RNA viruses; pDCs use TLR7 and TLR9 signalling through 
MyD88, whereas cDCs rely on the RNA helicase-IPS-1 pathway (Kato et al., 2005). 
Analysis of surface molecule expression by flow cytometry suggested that both 
subtypes are activated in response to transfected R:D60. However since FL-DCs are 
a heterogeneous population, it was not clear from the experiments performed 
whether both pDCs and cDCs can sense RNA:DNA hybrids or if one population 
becomes activated as a secondary effect. 
 
Stimulation of a cytokine response by FL-DCs required transfection of R:D60 into 
the cell (Figure 6.10). As demonstrated in Figure 6.1, introduction of an 18 bp 
RNA:DNA hybrid into L929 cells using Lipofectamine localised the hybrid to the 
cytosol, although the precise localisation has yet to be determined. The TLR9 ligand 
CpG ODN does not require transfection to stimulate a cytokine response in pDCs; it 
is endocytosed and retained in the early endosomal compartments, where it is 
recognised by TLR9 (as discussed in Section 1.5.5.1). The failure of exogenous 
R:D60 to stimulate cytokine production suggested that e hybrid is unlikely to be 
endocytosed in a similar manner. However, pDCs can also respond to cytosolic 
nucleic acids, in a TLR-dependent manner. For instance, the transportation of viral 
replication intermediates from the cytosol to TLR7 in endosomes via autophagy 
provides a mechanism for pDCs to detect cytosolic RNA without utilising cytosolic 
receptors (Lee t al., 2007). Therefore, to establish if the cytosolic RLRs were 
involved in the detection of R:D60 by FL-DCs, cultures from mice deficient in the 
mitochondrial membrane bound adaptor protein IPS-1 were stimulated with R:D60. 
 
6.6.8.1. The response to R:D60 is independent of IPS-1 
FL-DC cultures from IPS-1-/- mice and wild type controls on the same genetic 
background were stimulated with R:D60. The cytokine response of cells from the 
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IPS-1-/- mice was comparable with that of wild type controls (Figure 6.21), as was 
the extent of phenotypic activation (Figure 6.22). There was no detectable difference 
in the response of IPS-1-/- FL-DCs to the known RIG-I ligand IVT RNA, which 
presumably can be detected by TLR7 in pDCs. However, th e was a reduction in the 
phenotypic activation of these cells in response to transfected poly (I:C), a Mda5 
ligand (Appendix 11). 
 
These data show that type I IFN production by FL-DCs in response to R:D60 is 






          
 
Figure 6.21. IPS-1 is not required for the cytokine response to transfected R:D60. 
FL-DCs from IPS-1
-/-
 mice and age/sex-matched wild type mice were stimulated with 1 
μg/ml CpG ODN or 1 µg/ml R:D60, or were transfected with 1 μg/ml each of IVT RNA, 
R:D60, ssDNA60 or ssRNA60 using Lipofectamine 2000. Several nucleic acid ligands were 
included as controls, however IPS-1
-/-
 FL-DCs produced equivalent levels of cytokines to wild 
type. There was no significant difference in the amount of IFN-α produced by wild type 
(WT) and IPS-1
-/-
 cells in response to transfected R:D60 (Student’s t-test, p = 0.938) or IL-6 






Figure 6.22. IPS-1 is not required for the phenotypic activation of FL-DCs by R:D60. 
FL-DCs were stimulated as described for Figure 6.18. MFI values for CD40, CD80 and CD86 
were calculated. Data shown are from two independent experiments + s.d. Several nucleic 
acid ligands were included as controls, however there was no difference in expression 
between IPS-1
-/-
 and WT cells stimulated with CpG ODN and IVT. There was a slight 





6.6.8.2. Trif and/or MyD88 is required for the response of FL-DCs 
to R:D60 
The intact immune response to R:D60 in cells lacking IPS-1 implicated a role for 
alternative pathways in the recognition and response of FL-DCs to R:D60, most 
notably TLR-dependent pathways. The nucleic acid-sensing TLRs require the 
adaptor molecules Trif (TLR3) or MyD88 (TLR7 and TLR9). pDCs do not express 
TLR3, however CD24hi cDCs do (Table 6.1). In addition, cytokine induction by the 
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two DEAH/RHA helicases DHX9 and DHX36 also requires MyD88 (Kim et al., 
2010). Therefore, to establish if the nucleic acid TLRs and/or these cytosolic DNA 
receptors were required for the response to R:D60, FL-DC cultures from mice 
lacking both Trif and MyD88 (MyD88-/-/Trif-/-) were transfected with R:D60. As 
shown in Figure 6.23 a, MyD88-/-/Trif-/- FL-DCs failed to produce cytokines in 
response to R:D60. The cytokine response to ssDNA60 was also abolished. 
 
Phenotypic activation in response to R:D60 was impared, as shown for CD40 and 
CD86 (Figure 6.23 b). However, there appeared to be a difference between the two 
DC subtypes; in pDCs, expression was comparable to background levels 
(Lipofectamine alone); in cDCs, expression was reduc  but not abolished. This may 
suggest that detection of R:D60 by cDCs could also occur in a MyD88-/Trif-
independent manner, which fails to stimulate cytokine production. Further replicate 






Figure 6.23. Trif and/or MyD88 is required for the response of FL-DCs to transfected 
R:D60. 





 and age/sex matched WT controls were stimulated with 1 μg/ml CpG 
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ODN or were transfected with 1 μg/ml each of poly (I:C), R:D60 and ssDNA60 using 
Lipofectamine LTX. Supernatants and cells were analysed after 18 h. Data are from one 





 FL-DCs. Isotype controls are shown in grey, pDCs in red and cDCs in blue. 




6.6.8.3. Reducing RNase H2 activity does not affect the cytokine 
response to R:D60 
Finally, preliminary experiments to determine if RNase H2 plays a role in the 
response of FL-DCs to R:D60 were performed. The induction of type I IFN 
production by DNA via RIG-I-mediated signalling is indirect; the DNA is first 
recognised by RNA pol III in the cytosol and transcribed into immunostimulatory 
RNA (Ablasser et al., 2009; Chiu et al., 2009). Similarly, it is possible that R:D60 
does not directly stimulate innate immunity in FL-DCs but instead requires initial 
detection and processing by RNase H2. Cleavage of R:D60, which was shown to be 
a substrate for RNase H enzymes in Chapter 5, leaves ssDNA and short 
polyribonucleotide products of digestion, which areimmunostimulatory in FL-DCs 
(Figure 6.15). Consequently, FL-DCs with reduced levels of RNase H/H2 activity 
might be unable to mount a cytokine response to transfected R:D60. 
 
An alternative hypothesis may be that RNase H2, in combination with other 
nucleases such as the ssDNA exonuclease Trex1, is required to degrade most of the 
R:D60, and so limit the extent of an immune response i duced directly by the 
RNA:DNA hybrid. Expression of the Rnaseh2 genes and Trex1 mRNA can be 
detected in FL-DCs (Chapter 3, Figure 3.4). Preliminary analysis of type I IFN 
mRNA expression in FL-DCs transfected with R:D60 suggests that levels fall over 
time (from 6 h to 18 h) (Figure 6.12 and Figure 6.20), which could be due to 
processing of the hybrid. If this hypothesis was true, cells with reduced RNase H/H2 




To investigate this further, FL-DCs cultures from a ouse carrying the hypomorphic 
mutation Rnaseh2bA177T-neo/Rnaseh2A177T-stop (n/s) a d a Rnaseh2bA177t-neo 
heterozygous littermate (n/+) were transfected with R:D60 and cytokine production 
measured by ELISA. Although RNase H2 activity levels in FL-DCs have not yet 
been quantified, activity is reduced by approximately 90% from wild type activity in 
MEFs established from n/s embryos. (see Chapter 3, Section 3.5.3). The relative 
proportions of pDCs and cDCs as determined by flow cytometry were the same for 
each mouse. FL-DCs generated from both mice produced approximately the same 
amount of IFN-α and IL-6 (Figure 6.24). This suggests that RNase H2 activity does 
not affect the response to R:D60, although further experiments are required to 
quantify this against wild type FL-DCs, as n/+ MEFs have approximately a 60% 
reduction in RNase H2 activity (see Chapter 3, Figure 3.11). 
 
Finally, to establish if other immune cells from RNase H2-deficient mice can 
respond to RNA:DNA hybrids, bone marrow derived macrophages from the same 
mouse strains were were transfected with R:D60. However, as with wild type 
macrophages (see Section 6.4), R:D60 did not induce a cytokine response in these 
cells (Figure 6.25).  
 
Together, this preliminary data suggested that RNase H2 is unlikely to be required as 
a sensor for RNA:DNA hybrids, as the cytokine response to R:D60 in FL-DCs from 
mice with a 90% reduction in RNase H2 activity is intact (Figure 6.24). Furthermore, 
in RNase H2-deficient cells, transfected R:D60 did not induce a cytokine production 







Figure 6.24. FL-DCs with reduced RNase H2 activity produce cytokines in response to 
transfected R:D60 
FL-DC cultures from a Rnaseh2bA177T-neo/Rnaseh2bA177T-stop (n/s) mouse and a 
Rnaseh2A177Tneo heterozygous litter mate (n/+) were stimulated with 1 μg/ml CpG ODN 
or transfected with 1 μg/ml R:D60. After 18 h secreted cytokines were detected by ELISA. 








Figure 6.25. Macrophages deficient in RNase H2 activity do not produce cytokines in 
response to transfected R:D60. 
Bone-marrow derived macrophage cultures were stimulated with PRR ligands for 18 h. 
Secreted cytokines were measured by ELISA. Rnaseh2bA177T-neo/Rnaseh2bA177T-stop 
compound heterozygote (n/s) and littermate Rnaseh2bA177T-neo heterozygotes (n/+) 
macrophages were stimulated with 100 ng/ml LPS or transfected with 1 μg/ml each of CpG 
ODN, poly (dA:dT), poly (I:C), 45 bp ISD and R:D60. Representative of two independent 






In this chapter, the immunostimulatory potential of RNA:DNA hybrids were tested 
in vitro. A 188 bp hybrid containing a 5ʹ-ppp RNA strand induced type I IFN 
production in a number of cell types. In contrast,  60 bp RNA:DNA hybrid without 
a 5́-ppp elicited a robust type I IFN response exclusively in pDC-containing FL-DC 
cultures. 
 
6.7.1. Internalisation of RNA:DNA hybrids 
Both hybrids required transfection into cells using the cationic-lipid transfection 
reagent Lipofectamine in order to stimulate a cytokine response (Figures 6.2 and 
6.9). Studies using a fluorescently-labelled 18 bp hybrid revealed that this hybrid did 
not enter cells in the absence of transfection reagents (Figure 6.1). Therefore, it is 
likely that the absence of an immune response to exogenous R:D188 and R:D60 is a 
consequence of their failure to enter the cell. Although RNase H activity appears to 
be exclusively intracellular (Appendix 12), secreted nucleases, which include 
members of the RNase A superfamily (Sorrentino, 1998) and DNase I (Nadano et al., 
1993), may act to degrade free RNA:DNA hybrid befor it enters the cell. The 
complexing of RNA:DNA hybrids to Lipofectamine via electrostatic interactions 
may protect from nuclease digestion. All of the hybrids used for the in vitro studies 
described in this chapter consist of fully PD-containing nucleic acids, therefore it 
would be informative to investigate the ability of nuclease resistant hybrids to enter a 
cell in the presence and absence of Lipofectamine, a d ultimately to stimulate an 
immune response, for example, R:D20(PS) or R:D12 (Table 5.1). 
 
Alternatively, it is possible that cells are unable to internalise extracellular 
RNA:DNA hybrids. The TLR9 ligand CpG ODN used as a positive control in the 
experiments throughout this chapter is partially PS-protected. It did not require 
transfection to stimulate a cytokine response in FL-DC cultures (Figure 6.9). Such 
CpG ODNs enter cells via endocytosis, mediated through non-specific interactions 
with cell surface proteins (Hacker t al., 1998). This delivers them directly into the 
endosomal pathway, where they engage with TLR9 and stimulate cytokine 
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expression (Latz et al., 2004). Cellular uptake of CpG ODNs is thought to be 
enhanced by the presence of PS-linkages (Sester et al., 2000), which in addition to 
conferring increased nuclease resistance, lead to the formation of multimeric 
aggregates which are more readily endocytosed (Blasius nd Beutler, 2010). 
However, many other nucleic acid ligands for PRRs of the innate immune system 
require complexing with transfection reagents or prtein components to enter cells 
and engage with their receptors. Internalisation of un-complexed mammalian DNA is 
inefficient and consequently, innate immunity is not stimulated (Yasuda et al., 
2005b). However, intracellular targeting using transfection reagents, host proteins or 
autoantibodies localises self-DNA to cellular compartments where it can stimulate 
immunity via TLR9-dependent and independent pathways (Lande et al., 2007; 
Leadbetter et al., 2002; Yasuda et al., 2005b). Similarly, intracellular targeting of 
both synthetic and self-RNA is necessary for stimulation of innate immunity both via 
TLR- and RLR-mediated pathways (Diebold et al., 2004; Ganguly et al., 2009; Heil 
et al., 2004; Hornung et al., 2006; Lau et al., 2005; Pichlmair et al., 2006; Vollmer et 
al., 2005; Yasuda et al., 2007). Therefore, it is likely that RNA:DNA hybrids require 
similar targeting to intracellular compartments to s imulate their receptors. The 
hybrids hypothesised to accumulate in RNase H2-deficient cells are endogenous 
hybrids, therefore would be translocated to the correct cellular location internally. 
This inability of RNA:DNA hybrids to stimulate cytokine production in the absence 
of transfection reagents reinforces the hypothesis that autoimmunity in AGS is likely 
to be driven through cell-intrinsic detection of nucleic acids (Stetson et al., 2008). 
 
6.7.2. The stimulation of type I IFN production by R:D188 
Transfection of R:D188 into HeLa cells, L929 cells and primary MEFs stimulated a 
type I IFN response (Figures 6.2 and 6.3). In contrast, short hybrids failed to 
stimulate a response in the same cells. As described in Chapter 5, R:D188 differed 
from the other hybrids used in these experiments not o ly by length, but by sequence 
and the presence of a 5ʹ-ppp on the RNA strand. In addition to the sensing of certain 
viral RNAs, RIG-I can detect transfected synthetic 5ʹ-ppp dsRNA, in a largely 
sequence-independent manner (Schlee et al., 2009b). Signalling by RIG-I is a two 
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step process, requiring detection of a 5ʹ-ppp and RNA-dependent translocation of the 
protein (Myong et al., 2009) (also discussed in Chapter 1). The structural similarities 
of RNA:DNA hybrid helices to those of dsRNA suggest that this mechanism could 
also occur for RNA:DNA hybrids. This hypothesis is strengthened by the evidence 
that RIG-I can translocate along short ( < 50 bp) RNA:DNA duplexes (Myong et al., 
2009). In addition, R:D188 was generated from a virl sequence. Therefore, it could 
be envisaged that RIG-I is a candidate receptor for R:D188, although this does not 
exclude the stimulation of immunity via other sensors f dsRNA, including MDA5 
and TLR3. 
 
However, as described in Chapter 5, the purity of R:D188 is questionable. The use of 
reverse transcription to synthesise the DNA strand could potentially generate single-
stranded contamination by separation of the template from the newly synthesised 
complementary ssDNA, or by incomplete transcription, thereby leaving ssRNA (Ma 
and Crouch, 1996). It was not possible to generate sufficient hybrid using the 
alternative annealing method described in Chapter 5 o perform in vitro testing, 
therefore reverse transcribed R:D188 was used. In an attempt to determine if the 
response to R:D188 was hybrid-specific, nuclease dig sted R:D188 was transfected 
into cells (Figure 6.2). However, RNase H digestion of the hybrid did not abrogate 
the type I IFN response. To determine if this could be attributed to the presence of 
contaminating nucleic acids in the preparation of R:D188, DNase I digestion of 
R:D188 was performed but even though it was used at low concentrations, DNase I 
did result in some cleavage of the hybrid (Figure 6.2 c). The induction of type I IFN 
production in both HeLa and L929 cells was increased when stimulated with DNase 
I-digested R:D188 (Figure 6.2 d). This implies that short ODN degradation products 
of DNase I, whether derived from contaminating DNA or the reverse strand of the 
hybrid, could be immunostimulatory in these cells. In addition, cleavage of the DNA 
strand of an RNA:DNA hybrid could release 188 nt 5ʹ-ppp ssRNA, which itself is 
potentially immunostimulatory when transfected into cells. Therefore, the possibility 





Dot blot analysis of R:D188 using an antibody for ssNA suggested the presence of 
ssNA within this hybrid (Chapter 5, Figure 5.11). Digestion of R:D188 with RNase 
A in a buffer containing high salt levels should prevent cleavage of the hybrid whilst 
removing any ssRNA contaminants. RNase A treatment did not degrade the hybrid 
as determined by agarose gel electrophoresis (Figure 6.2 d). However, when 
transfected into cells, the amount of IFN-α produced by L929 cells decreased 
slightly, although this was not statistically significant (Student’s t-test, p = 0.572). 
Digestion of R:D188 with RNase A combined with RNase H also failed to abolish 
the type I IFN response, indicating that 188 nt ssDNA or the products of RNaseA/H 
digestion are also immunostimulatory. Therefore, it was not possible to verify that 
the type I IFN response induced by transfected R:D188 is due to hybrid rather than 
the presence of contaminating ssDNA or degradation pr ducts. For this reason, 
R:D188 was not used in the subsequent experiments stimulating primary immune 
cells. 
 
6.7.3. The immunostimulatory ability of short (< 60 bp) 
hybrids 
The fractionation of a 60 bp r(GU)30:d(CA)30 duplex using FPLC successfully 
separated the double-stranded hybrid from ssNA (Chapter 5, Figure 5.4). Although 
potentially less physiologically relevant than a long hybrid produced by IVT and 
reverse transcription of a viral sequence, the greate  confidence in the purity of 
R:D60 compared to R:D188 prompted further studies using this hybrid. Short 
hybrids did not stimulate a cytokine production in HeLa or L929 cells (Figure 6.2), 
however it is interesting to note that certain transformed cell lines are deficient in the 
use of certain PRR signalling pathways, specifically the cytosolic response to ISD 
(Stetson et al., 2008; Stetson and Medzhitov, 2006). Therefore, R:D60 was 
transfected into primary cells which are known to pr duce type I IFNs in response to 
transfected nucleic acids, but again it failed to induce expression of type I IFN genes 
in primary MEFs (Figure 6.3). Although MEFs can utilise TLRs and RLRs following 
intracellular stimulation with nucleic acids, the failure to respond to transfected 
R:D60 could indicate that a specialist PRR or signalling pathway is required for 
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recognition of this hybrid, which is absent in this cell type. Therefore, the response of 
antigen presenting cells of the immune system to R:D60 was investigated. 
 
Transfected R:D60 failed to stimulate a type I IFN response in bone marrow-derived 
macrophages (Figure 6.4). This was in contrast to the response to the PRR ligands 
CpG ODN, poly (I:C) and poly (dA:dT) which all stimulated induction of type I IFN 
expression. Transfected R:D60 also failed to stimulate pro-inflammatory cytokine 
production and phenotypic activation of macrophages, even when used at 25 µg/ml 
(Figure 6.5 and Figure 6.6).  
 
6.7.4. R:D60 stimulates innate immune activation in FL-DCs 
R:D60 also failed to elicit an immune response in GM-CSF cDCs (Figures 6.7 and 
6.8), however when transfected into FL-DCs, it potently stimulated a cytokine 
response (Figure 6.10). As illustrated in Figure 6.9, FL-DCs are a heterogeneous 
population which can be segregated based on B220 staining into B220+ pDCs and 
B220- cDCs. Flow cytometry analysis revealed that both subgroups were 
phenotypically activated in response to transfected R:D60 (Figure 6.11). 
Furthermore, transfected R:D60 stimulated a robust type I IFN response in FL-DC 
culture (Figure 6.10). 
 
6.7.5. The response to R:D60 is unlikely to be due to 
contaminating nucleic acids 
During this thesis, I aimed to generate RNA:DNA hybrids that were free from 
contamination with other nucleic acid species, with the rationale that ssNA 
contaminants would themselves be immunostimulatory. To test this in FL-DCs, cells 
were transfected with 500 ng/ml or 1 µg/ml of ssRNA60 and ssDNA60. Both 
stimulated IFN-α production, and especially the ssRNA (Figure 6.15). This 
confirmed that the purification of R:D60 from contaminating nucleic acids was 
required, to prevent the introduction of immunostimulatory ssNA into cells. 
However, it was also necessary to show that the process of purifying R:D60 away 
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from ssNA did not introduce any contaminants which might induce an immune 
response in FL-DCs. Sham annealings, where one of the strands is omitted from the 
hybridisation mixture, were fractionated using FPLC. As shown in Figure 6.17, the 
ssNA-containing peaks eluted from the column at different fractions compared to the 
equivalent elution of the hybrid (Figure 5.4). PAGE analysis of the fraction 
confirmed that neither ssRNA nor ssDNA eluted from the column at the same point 
as the hybrid (Figure 6.17). To verify that the chromatography process did not 
introduce other contaminants, the equivalent R:D60 containing fractions were 
transfected into FL-DCs. These fractions failed to induce either cytokine production, 
expression of Ifna1 or phenotypic activation above background levels (Figure 6.18). 
Therefore, it can be concluded that FPLC fractionati  of RNA:DNA hybrids did not 
introduce immunostimulatory contaminants into the hybrid preparation and that the 
purification of R:D60 using this method resulted in hybrid free from ssNA 
contaminants. 
 
6.7.6. The nature of immunostimulatory RNA:DNA hybrids 
Two other hybrids were tested for their ability to activate innate immunity in FL-
DCs; the commercially available poly (rA:dT) and the 20 bp hybrid generated in 
Chapter 5 (R:D20). Whilst poly (rA:dT) failed to stimulate a response, a preliminary 
experiment using the 20 bp hybrid was at least as effective as R:D60 at inducing 
cytokine production (Figure 6.20). These experiments raised questions regarding the 
nature of immunostimulatory RNA:DNA hybrids, specifically, are only certain types 
of hybrid able to stimulate a type I IFN response in FL-DCs? Parameters such as the 
length and structural conformation may all be crucial in determining the ability of an 
RNA:DNA hybrid to induce a response. In particular, the specific sequence content 
of the hybrid could be a major factor, as both immunostimulatory hybrids used 
during this thesis had a GU-rich RNA strand. Further work varying these parameters 




6.7.7. pDCs as the IFN-α producing cells in FL-DCs transfected 
with R:D60? 
FL-DCs are heterogeneous populations of DCs consisti g of cDCs and pDCs (Figure 
6.9). Each subpopulation has a distinct pattern of TLR expression (Table 6.1). pDCs, 
which express only TLR7 and TLR9, are specialised for the production of large 
amounts of IFN-α in response to the binding of nucleic acid ligands to these 
receptors (as discussed in Chapter 1, Section 1.5.5. ). They are therefore likely to be 
the source of the majority of IFN-α produced by FL-DC cultures in response to 
stimulation with CpG ODN (Figure 6.10), although the cDCs present in FL-DC 
cultures also express TLR9. IFN-α production by pDCs is also known to be 
stimulated via TLR7 by transfected 20 nt ssRNA (Heil et al., 2004). Combined with 
the data presented in this chapter, pDCs appear to be a good candidate for the 
production of IFN-α in response to transfected R:D60. Furthermore, R:D60 failed to 
induce cytokine production or phenotypic activation in GM-CSF DC cultures, which 
do not contain pDCs (Figures 6.7 and 6.8). Analysis of activation markers in FL-DC 
cultures showed that both pDCs and cDCs had upregulated expression of CD40, 
CD86 and CD8 following transfection of R:D60 (Figure 6.11). Such phenotypic 
activation of cDCs could be the consequence of initial cytokine production by pDCs, 
which subsequently activates cDCs via a paracrine effect.  
 
Intracellular cytokine staining could be used to identify the IFN-α-producing cell 
type in the FL-DC population. To investigate the hybrid activation of these cells in a 
more refined way, FL-DC cultures could be sorted using FACS or magnetic beads to 
allow the stimulation of pDCs and cDCs separately. Furthermore, analysis of ex vivo 
pDCs and cDCs could be used to investigate if the response to R:D60 is exclusive to 




6.7.8. A Trif and/or MyD88-dependent cytokine response to 
transfected R:D60  
As discussed, the requirement of intracellular targetin  of R:D60 inside the cell to 
stimulate an immune response suggests that FL-DCs are un ble to endocytose 
R:D60, in contrast to CpG ODN. A previous study investigating the mechanism by 
which nucleic acid-cationic lipid complexes are inter alised by a human epidermoid 
carcinoma cell line revealed that uptake is dependent upon the endocytic pathway, 
following fusion of the complex with the cell membrane (Almofti et al., 2003). This 
is in agreement with an earlier observation that cellular trafficking of DNA that has 
been introduced into human fibroblasts via either endocytosis, transfection or 
electroporation occurs via endosomes (Coonrod et al., 1997). Therefore, it is 
conceivable that upon uptake into the cell, R:D60 passes through endosomes and 
lysosomes, where it could engage with one of the intracellular TLRs. However, 
transfection using Lipofectamine is also used to inroduce RLR ligands into cells 
(Hornung et al., 2006; Schlee t al., 2009b) which are presumed to be delivered to a 
cytosolic location. 
 
The use of FL-DCs generated from mice deficient in the adaptors for these nucleic 
acid receptors showed that IPS-1 was not required for cytokine production or 
phenotypic activation in response to transfected hybrid (Figures 6.21 and 6.22). In 
contrast, the cytokine response to transfected R:D60 was abolished in FL-DCs 
derived from mice lacking both the TLR3 adaptor Trif and the 
TLR7/TLR9/DHX9/DHX36 adaptor MyD88 (Figure 6.23). This further suggests that 
RLRs are unlikely to be involved in innate recognition of R:D60, however replicate 
experiments are required to confirm this. 
 
Therefore, these experiments indicate that TLR-signalling is potentially required for 
the cytokine response to R:D60 in FL-DC cultures. Further experiments utilising 
cells from mice deficient in the intracellular TLRs will be required to establish 
precisely which receptor the response to R:D60 is dependent on. The unaltered 
response of IPS-1-/- FL-DCs further strengthens the case for the role of pDCs in the 
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detection of R:D60, as pDCs generally rely on the TLR system for the sensing on 
nucleic acids (Kato et al., 2005). Therefore, it is possible that the receptor could be 
either TLR7 or TLR9, or possibly both in the form of a TLR7/9 heterodimer. These 
receptors are both widely expressed by other cell types; including cDCs and 
macrophages, therefore determining why the response is likely to be pDC-specific 
will also require further investigation. However, the recent characterisation of 
MyD88-dependent cytosolic sensors of DNA in human pDC cell lines (DHX9 and 
DHX36, Kim et al., 2010) raises the possibility that non-TLR receptors may play a 
role in the detection of intracellular R:D60.  
 
In summary, in this chapter I have shown that a 60 bp highly-purified RNA:DNA 
hybrid stimulates a type I IFN response when intracellularly targeted into FL-DCs by 
complexing to a cationic-lipid transfection reagent. The cytokine response was 
shown to be MyD88 and/or Trif-dependent. The specialised type I IFN-producing 




Chapter 7. Final discussion 
 
It has been hypothesised that deficiencies in nuclease activity lead to accumulation of 
nucleic acids which then activate an innate immune response. In the autoimmune 
disorder AGS, loss-of-function mutations in the RNase H2 complex could result in 
an accumulation of RNA:DNA hybrids. This thesis aimed to establish roles for the 
RNase H2 complex and its nucleic acid substrates in the development of 
autoimmunity. 
 
7.1. Summary of the main findings of this thesis 
In Chapter 3, expression profiling confirmed that the genes encoding the RNase H2 
complex are widely expressed, and in particular are expressed at high levels in 
certain cells of the immune system. This could suggest that RNase H2 activity is 
required to perform specific functions in these cell types; however, this was not 
pursued further during this thesis.  
In contrast to TREX1 and SAMHD1, expression of the RNASEH2 genes was not 
induced in response to type I IFN production in primary MEFs. This implies that the 
RNase H2 complex is unlikely to act as a regulator of the cytosolic innate immune 
response to self-nucleic acids, previously proposed as a cellular function of both 
TREX1 and SAMHD1 (Rice et al., 2009; Stetson et al., 2008). Consequently, it 
appears most likely that an accumulation of RNase H2 substrates is the cause of 
RNase H2-AGS. Therefore, I sought to investigate the ability of RNA:DNA hybrids 
to activate innate immunity in vitro. 
 
The nature of endogenous RNase H2 substrates likelyto accumulate in the absence 
of enzymatic activity has not been established. Therefore, the unique physiochemical 
properties of RNA:DNA hybrids were determined, relevant to the design and 
analysis of synthetic hybrid duplexes. In Chapter 5, I demonstrated that whilst it was 
possible to generate large quantities of synthetic RNA:DNA hybrids, the production 
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of highly purified hybrids was more challenging, as preparations frequently 
contained contaminating nucleic acids that may alsohave immunostimulatory 
potential. Therefore, I established techniques to generate sufficient quantities of a 60 
bp RNA:DNA hybrid (R:D60) and verified that contaminating nucleic acids had 
been removed. 
 
Finally, in Chapter 6 I investigated the immunostimulatory potential of RNA:DNA 
hybrids, including the highly purified R:D60, via the stimulation of cell lines and 
primary cells. I showed that R:D60 induced innate immune activation when 
transfected into FL-DC cultures, and therefore propose pDCs as a cell type able to 
detect particular intracellular RNA:DNA hybrids. The cytokine response to R:D60 
was MyD88/Trif-dependent, indicating that RNA:DNA hybrids are likely to be 
detected by intracellular TLRs or by recently characterised MyD88-dependent 
cytosolic DNA sensors (Kim et al., 2010). In summary, I have shown that an 
RNA:DNA hybrid can induce innate immune signalling, resulting the production of 
IFN-α. 
 
7.2. RNA:DNA hybrids: a novel PRR ligand? 
7.2.1. Detection of R:D60 by pDCs? 
The immune response to the 60 bp RNA:DNA hybrid generated during this thesis 
exclusively occurred in pDC-containing cultures. As di cussed in Chapter 6, pDCs 
are therefore likely to be the cell type responsible for the production of IFN-α in 
response to transfected R:D60, via a MyD88- or Trif-dependent pathway. For this 
reason, it could be conceived that detection of R:D60 is via TLR7 and/or TLR9 in 
intracellular compartments, as pDCs express high levels of both receptors and the 
downstream transcription factor IRF7 (Coccia et l., 2004; Izaguirre et al., 2003; 
Kerkmann et al., 2003). Notably, both TLR7 and TLR9 have been implcated in the 
detection of self-nucleic acids and development of disease pathogenesis in patients 





It has previously been shown that the cellular respon e by TLR9 to nucleic acids is 
dependent upon the correct intracellular compartmenalisation of the ligands 
(Guiducci et al., 2006). R:D60 failed to elicit a response without transfection, 
therefore hybrids appear to require intracellular tr fficking via endocytic pathways to 
encounter their endosomal, or cytosolic, sensor. The treatment of R:D60 transfected 
cells with compound such as chloroquine could be used to determine if innate 
recognition of R:D60 occurs via membrane-bound receptors in acidified endosomal 
compartments. However, detection of ligands by TLR9 in the non-acidified early 
endosomes has been reported, notably in pDCs (Guiducci et al., 2006), and so this 
would not be excluded by chloroquine treatment. 
 
The recent characterisation of two novel MyD88-dependent cytosolic DNA sensors 
in human pDC cell lines (Kim et al., 2010) raises the possibility that R:D60 may be 
detected in a TLR-independent manner. Although nucleic acid sensing pathways 
utilising these receptors have not yet been characterised in murine pDCs, it would be 
of interest to determine the requirement for these helicases in the cytokine response 
to R:D60. This may be achieved by using siRNA to knckdown expression of each 
of these proteins in FL-DCs. 
 
7.2.2. Are intact RNA:DNA hybrids detected by PRRs? 
The immune response to R:D60 may not be dependent on the direct detection of an 
RNA:DNA hybrid by PRRs. It is possible its single-stranded components, ssRNA60 
and ssDNA60, are detected instead. For instance, R:D60 could be unwound by 
cellular helicases upon entry to the cell, such as Pif1 (Boule and Zakian, 2007), or 
replicative helicases (Shin and Kelman, 2006), although such proteins are 
predominantly localised in the nucleus. It is instead more likely that the hybrid may 
be degraded by intracellular nuclease activity. Thesubsequent release of either single 
strand would stimulate innate immune signalling in FL-DCs (Figure 6.15). 
Transfected RNase H-treated R:D60, which contains ssDNA60, stimulates innate 
immunity (Figure 6.16). Furthermore, ssDNA60 and R:D60 both fail to stimulate a 
response in the absence of transfection (Figure 6.10 and Appendix 13). Therefore, it 
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is entirely conceivable that the response is due to ssNA rather than direct recognition 
of the hybrid.  
 
To address this, the intracellular stability of thehybrid will need to be investigated. A 
fluorescent oligonucleotide annealed to a complementary oligonucleotide which is 
coupled to a quencher molecule (for example, the RNase H2 substrate for the RNase 
H activity assay) could be transfected into cells. If this substrate is unwound or 
degraded, the fluorescein molecule will be released from the quencher and a 
fluorescent signal generated, which could be detectd using flow cytometry or 
fluorescence microscopy. Alternatively, a time course could be performed whereby 
total nucleic acid extracts are prepared from cells transfected with R:D60 to detect 
the presence of such nucleic acid intermediates, similar to the techniques used to 
define the mechanism of RIG-I mediated immune activtion by poly (dA:dT) 
(Ablasser et al., 2009; Chiu et al., 2009). Detection of RNA:DNA hybrids using the 
S9.6 antibody could be used to establish if the hybrid is stable after entering the cells 
using the techniques discussed in Chapter 4, Section 4.2. 
 
ssDNA60 induced IL-6 production when transfected at high concentrations into 
macrophages but transfected R:D60 did not (25 and 10 µg/ml, Figure 6.5). DNA 
complexed to Lipofectamine is known to stimulate pro-inflammatory cytokine 
production via both TLR9-dependent and -independent pathways in macrophages 
(Yasuda et al., 2005a). The lack of cytokine response to R:D60 implies that the 
hybrid is unable to stimulate cytokine production via the same pathway as ssDNA60. 
Furthermore, preliminary data obtained using FL-DCs generated from mice with 
significantly reduced RNase H2 activity argues against the intracellular processing of 
RNA:DNA hybrids into ssDNA by nuclease activity (Figure 6.24). If this was the 
case, it would be expected that the the cytokine response to hybrids would be 
substantially diminished in these cells. Nevertheless, although it is important to 
define if RNA:DNA hybrids are themselves a PRR ligand, the finding that innate 
immune activation can be stimulated by hybrids, even indirectly, is highly relevant to 




7.3. RNA:DNA hybrids and human disease 
The data presented in this thesis suggest that unprocessed RNA:DNA hybrids are 
capable of triggering an innate immune response. Threfore, one in vivo requirement 
for RNase H2 activity is likely to be the suppression of endogenous RNA:DNA 
hybrid accumulation. Failure to do this may result in activation of innate immunity 
by self-nucleic acids and the development of autoimmunity. This supports the notion 
that RNA:DNA hybrids are a trigger of innate immune activation in AGS patients. 
 
7.3.1. Cell intrinsic mechanism for immune activation 
The requirement for transfection of R:D60 to stimulate immunity suggests that innate 
recognition of RNA:DNA hybrids is cell intrinsic. This is consistent with the 
hypothesis that hybrids likely to accumulate in RNase H2-deficient cells are of 
endogenous origin. Such hybrids could potentially be generated during a number of 
cellular processes including DNA replication, endogenous retroelement replication or 
transcription (Figure 7.1 a). Two independent studies have reported the accumulation 
of endogenous DNA in the cytosol of Trex1-deficient cells, although different 
conclusions were drawn regarding the source of this DNA (Stetson et al., 2008; Yang 
et al., 2007). Therefore, the identification of accumulating RNase H2 substrates in 
cells with reduced enzymatic activity would further strengthen this argument and 
define the source of intracellular nucleic acids in AGS. 
 
The major site of IFN-α production in AGS is intrathecal (Lebon et al., 1988). 
Therefore, if RNase H2 and TREX1 deficiencies lead to the activation of cell 
intrinsic autoimmunity, it can be hypothesised that t eir substrates must accumulate 
in cells of the brain. Immunostaining of post-mortem AGS patient brains suggested 
that astrocytes were likely to be the predominant cell type responsible for cytokine 
production in the CNS (van Heteren t al., 2008). Consequently, to fully elucidate 
disease pathogenesis, it would be of particular interest to investigate if R:D60 could 




7.3.2. Cell extrinsic mechanism for immune activation 
In AGS, IFN-α production can also be systemic; the cytokine is often present at 
elevated levels in the sera, in addition to the CSF (Lebon et al., 2002). However, the 
cell type responsible for IFN-α production outside of the CNS is unknown. 
 
In addition to the hypothesised cell intrinsic detection of hybrids described in Section 
7.3.1, it is also conceivable that detection of cell extrinsic self-RNA:DNA hybrids 
could occur in AGS. The autoimmune disorder SLE, which shares substantial 
phenotypic overlap with AGS, is characterised by the occurrence of large numbers of 
autoantibodies, particularly against self-nucleic acids. The formation of immune 
complexes (ICs) with self-DNA and self-RNA are known to stimulate IFN-α 
production via TLR7 and TLR9 in pDCs from SLE patien s (Vollmer et al., 2005; 
Yasuda et al., 2007). Furthermore, the occurrence of autoantibodies against poly 
(rA:dT) has been reported in a small proportion of SLE patients (16/118) (Talal and 
Gallo, 1972). Preliminary testing of SLE patient plasma using methods described in 
Chapter 4 has revealed the presence of autoantibodies capable of detecting R:D18 in 
the plasma of one patient (Appendix 14). However, there was also a strong presence 
of autoantibodies detecting dsRNA; therefore it is unclear if the autoantibodies are 
simply detecting the A-form-like helical conformation shared by hybrids and 
dsRNA.  
 
If circulating anti-RNA:DNA hybrid autoantibodies in AGS patients are highly 
prevelant, this could suggest an alternative mechanism whereby RNA:DNA hybrids 
are released from cells, for example during apoptosis r necrosis, and form ICs 
which can activate IFN-α production by pDCs (Figure 7.1 b). This could provide an 
explanation for the presence of significantly elevat d levels of IFN-α in the plasma 
of AGS patients, and may be responsible for the development of systemic features of 
AGS, for example, the chilblain-like lesions present o  the skin. SLE patients have a 
decreased number of circulating pDCs, as a consequence of recruitment to affected 
tissues; however pDC counts in the blood of AGS patients have been demonstrated 
to be normal (Van Heteren et al., 2007) which indicates that the mechanism of 





Figure 7.1. Intracellular detection of RNA:DNA hybrids. 
Schematic representation of how RNA:DNA hybrids may be recognised by intracellular 
PRRs. (a) Cell intrinsic detection of hybrids. Nuclear RNase H2 and TREX1 may act to 
suppress accumulation of their nucleic acid substrates. RNA:DNA hybrid containing species 
could arise a consequence of R loop formation during transcription, activation of 
endogenous retroelements or during the generation of Okazaki fragments, amongst other 
processes. In the absence of RNase H2 and TREX1 activity, increased levels of these 
substrates are hypothesised to accumulate. Upon leaving the nucleus by an undefined 
mechanism, RNA:DNA hybrid-containing species could be detected in the cytosol, for 
example, by the RLRs RIG-I or MDA5 which utilise the adaptor protein IPS-1 to stimulate 
type I IFN production. It could be hypothesised that RNA:DNA hybrids with a 5ʹ-ppp are 
potential ligands for RIG-I. In addition, it is possible that MyD88-dependent cytosolic DNA 
sensors (members of the DEAH/RHA helicase family) may play a role in the induction of 
type I IFNs as a consequence of cytosolic RNA:DNA hybrids. Alternatively, RNA:DNA hybrids 
may transported into the endosomal pathway, for instance by autophagy, and encounter 
receptive membrane-bound sensors. These sensors could include TLR7, TLR9 or a TLR7/9 
heterodimer, which upon ligand binding stimulate downstream signalling and cytokine 
production. This does not exclude TLR3, however, pDCs do not express TLR3 therefore if 
they are the hybrid-sensing cells it is unlikely that TLR3 is required. (b) Cell extrinsic 
detection of hybrids. Circulating autoantibodies could form ICs with RNA:DNA hybrids 
released from cells, for example following apoptosis, and engage with Fc receptors on the 
surface of immune cells leading to antigen presentation to TLR7 and/or 9. This would 
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activate innate immune signalling via MyD88, and the subsequent production of type I IFN. 
Again, this does not exclude that TLR3 is involved; furthermore this mechanism could be 
independent of TLR-signalling. It is also conceivable that exogenous RNA:DNA hybrids could 




pDCs in AGS, intracellular cytokine staining for IFN-α in pDCs purified from the 
blood of AGS patients could help to establish if they are the cell type responsible for 
the systemic IFN-α production in this disease. A murine model of RNase H2 AGS 
would be particularly useful in establishing if stimulation of innate immunity by 
RNA:DNA hybrids is via a cell intrinsic or extrinsic mechanism.  
 
Studies using the Trex1-null mouse have shown that the induction of IFN production 
alone is not responsible for the development of a full inflammatory response, as the 
genetic ablation of RAG2 rescued the lethal autoinflammatory phenotype of these 
mice (Stetson et al., 2008). This indicated a role for adaptive immunity in the 
development of disease. Therefore, obtaining a complete understanding of the 
pathogenesis of AGS will require investigation into how the initial innate immune 
response consequently activates and directs an adaptive response. 
 
7.5. Summary 
In summary, during this thesis I showed that a substrate of the RNase H2 enzyme 
complex was able to activate innate immune signalling in FL-DCs in vitro, in a 
MyD88 and/or Trif-dependent manner. This identifies RNA:DNA hybrids as a novel 
nucleic acid species able to stimulate IFN-α production, in contrast to a previous 
report which dismissed the capacity of hybrids to stimulate IFN production (Colby et 
al., 1971). Activation of innate immunity by RNA:DNA hybrids appeared to be 
dependent on the sequence, length, and/or conformati n of the hybrid and there 




7.6. Further work 
Further experiments are required to fully elucidate the immune signalling pathways 
activated in FL-DCs by the 60 bp RNA:DNA hybrid. Once the subtype of cell in 
which innate recognition of the hybrid occurs is identified, appropriate experiments 
utilising cells derived from mice deficient in PRRs can be performed, with TLR7 
and/or TLR9 strong candidates for the receptors involved, although the involvement 
of the DEAH/RHA helicases DHX9 and DHX36 should also be investigated. Given 
some interspecies differences in PRR utilisation (Heil et al., 2004), it will be 
important to establish if human DCs, specifically pDCs, can also produce IFN-α in 
response to R:D60. 
 
The refinement of the exact nature of immunostimulatory hybrids is also of 
importance. Firstly, the generation and purification of 60 bp hybrids with different 
sequences to R:D60 will aid in determining if the response if sequence-dependent. 
Optimisation of the use of FPLC to purify hybrids of different lengths will permit 
investigation into whether there are any size constraints in the stimulation of 
immunity by hybrids, as well as clarifying whether purified long hybrids generated 
by reverse transcription, such as R:D188, are able to stimulate PRR pathways. 
 
The RNA:DNA hybrids designed during this thesis represent only one type of 
nucleic acid species which could result from RNase H2-deficiency. As depicted in 
Figure 1.12, single-stranded nucleic acid flaps derived from Okazaki fragments 
consisting of a chimeric RNA-DNA strand, which may or may not be annealed to 
complementary DNA strand. Such 5ʹ-ppp containing Okazaki fragment-like hybrids 
could be generated using RNA-primed PCR (Shibata et al., 1995). Additionally, 
DNA duplexes containing single embedded ribonucleotid s, such as those 
misincorporated by error-prone DNA polymerases, mayalso occur, also though the 
separation of a response to this type of substrate compared to full dsDNA would be 




AGS provides an example of an autoimmune disease which is mediated by 
inappropriate activation of the innate immune system. Nucleic acids are likely to be 
central to the mechanism of disease pathogenesis. The accurate characterisation of 
such nucleic acid ligands is essential for understanding how they activate immunity: 
failure to do so has previously caused confusion over the exact nature of specific 
PRR ligands (for example, synthetic ligands for RIG-I, as discussed by Schlee and 
Hartmann, 2010). The specific innate recognition pathw ys involved are not always 
immediately obvious (Ablasser t al., 2009; Chiu et al., 2009). Through the 
hypothesis that nucleic acids accumulate in AGS cells, I have been able to identify a 
novel nucleic acid species capable of activating the innate immune system. This is 
relevant to the understanding of nucleic acid-mediat  utoinflammatory diseases, as 




Appendix 1. Oligonucleotides 
 
(a) qRT-PCR: human 
  




















(b) qRT-PCR: mouse 
 
  

























(c) Genotyping of transgenic mice with mutations in 
Rnaseh2b 
 
NAME  SEQUENCE (5' → 3') 
LOXP_FORW  GATAGCTGACAAAGATAACTC 
EXON7_REV  CCTGGAAACCTGACCACC 
NEO_REV  CTGTCCATCTGCACGAGACT 
 
 
(d) Oligonucleotide primers to generate RNA:DNA hybrids  
188 bp hybrid 










51 bp hybrid 





(e) Oligonucleotide primers to generate long ssDNA 
  














      
Antibody Label Clone Source Isotype Host Dilution 
CD11b APC M1/70 eBioscience IgG2b Rat  1:8 
CD11c FITC N418 eBioscience IgG Armenian 
hamster 
 1:20 
CD40 APC 1C10 eBioscience IgG2a Rat  1:8 
CD80 PE 16-10A1 eBioscience IgG Armenian 
hamster 
 1:30 
CD86 APC GL1 eBioscience IgG2a Rat  1:30 
F4/80 FITC BM8 eBioscience IgG2a Rat  1:10 
MHC Class II PE M5/114.
15.2 
eBioscience IgG2b Rat  1:100 
 
 
      
FACSCantoII 
 
      
Antibody Label Clone Source Isotype Host Dilution 
B220/ 
CD45R 
Alexa-450 RA3-6B2 eBioscience IgG2a Rat  1:100 
CD8 PE-Cy7 53-6.7 eBioscience IgG2a Rat  1:200 
CD11b  PE M1/470 eBioscience IgG2b Rat  1:400 
CD11c eFluor-780 N418 eBioscience IgG1 Armenian 
hamster 
 1:100 
CD11c APC N418 eBioscience IgG1 Armenian 
hamster 
 1:200 
CD24 FITC M1/69 eBioscience IgG2a Rat  1:200 
CD40 PE 3/23 BD 
Pharmingen 
IgG2a Rat  1:200 
CD80 APC 16-10A1 eBioscience IgG2 Armenian 
hamster 
 1:200 
CD80 Alexa-488 16-10A1 eBioscience IgG2 Armenian 
hamster 
 1:200 
CD86 Alexa-488  GL-1 Biolegend IgG2a Rat  1:200 
CD86  Alexa-700 GL-1 Biolegend IgG2a Rat  1:200 





Appendix 3. Oligonucleotides annealed to produce 
RNA:DNA hybrids 
 

















Appendix 4. Polyacrylamide gel recipes 
 
1. Native PAGE 
 
8% 12% 15% 20% 
40% acrylamide/bis (19:1) (ml) 10 15 18.75 25 
20 X TBE (ml) 1.25 1.25 1.25 1.25 
10% APS (ml) 0.5 0.5 0.5 0.5 
TEMED (ml) 0.05 0.05 0.05 0.05 
ddH2O (ml) 38.2 33.2 29.45 23.2 
Total (ml) 50 50 50 50 
 
Migration of reference dyes 
    XC (bp) 160 70 60 45 
BPB (bp) 45 20 15 12 
 
 
2. Denaturing PAGE 
 
6% 8% 12% 15% 20% 
Urea (g) 25.2 25.2 25.2 25.2 25.2 
40% acrylamide/bis (19:1) (ml) 9 12 18 22.5 30 
20 X TBE (ml) 3 3 3 3 3 
APS (ml) 0.4 0.4 0.4 0.4 0.4 
TEMED (ml) 0.04 0.04 0.04 0.04 0.04 
ddH2O (ml) 26 23 17 12.5 5 
Total (ml) 60 60 60 60 60 
 
Migration of reference dyes 
     
XC (nt) 106 76  35 28 





Appendix 5. HERV expression in AGS patient LCLs 
 
RNA was extracted from four AGS patient LCLs and a normal control (WT LCL). 
cDNA was generated and qRT-PCR was performed using pr mers from de Parseval 
et al. 2003 to quantify the expression of HERV envelope genes. cDNA prepared 
from human testes RNA (from a FirstChoice® Human Total RNA Survey Panel, 
Ambion) was used to provide a positive control (a), as env genes are expressed at 
high levels in the testes (de Parseval et al., 2003). Normalised fold change in 
expression from WT LCL was calculated (b). Data are from the mean fold change 







Appendix 6. Whole genome gene expression 
microarray analysis of homozygous Rnaseh2bA177T-
neo MEFs versus wild type primary MEFs 
 
Microarray data was validated by qRT-PCR, using the same RNA as the microarray 
samples and is represented as average fold change detected in three n/n versus three 
+/+ MEF lines. Expression levels of the four upregulated transcripts did not correlate 
with the array data. This suggested that the 13-fold increase in LOC383308 
expression is likely to be a false positive, whilst the other genes show no change. The 
expression of a selection of transcripts downregulated in the mutant was verified by 
qRT-PCR (ND, not determined). 
 
 
Up-regulated transcripts (total = 4) (p < 0.05, fold change > 1.5) 
Illumina ID Gene symbol Name Fold increase 
(array) 
p-value Fold change 
(qRT-PCR) 
ILMN_200537 LOC383308 Similar to ribosomal 
protein L29 
12.98 2.09E-05 1.1 increase 
ILMN_221019 RPL29 Ribosomal protein L29 2.11 7.27E-05 ND 
ILMN_212510 4930455C21RIK Hypothetical protein 
LOC76916 
2.08 1.39E-02 0.0 
ILMN_329373 WDR82 WD repeat domain 82 1.73 2.18E-04 1.1 decrease 
 
 
Down-regulated transcripts (total = 48) (p < 0.05, fold change > 1.5) 
Illumina ID Gene 
symbol 





ILMN_258184 ALOX5AP arachidonate 5-lipoxygenase-
activating protein 
2.90 2.82E-02 3.8 
ILMN_203628 E130112E0
8RIK 
E130112E08RIK 2.57 2.92E-02 ND 
ILMN_251042 CFP complement factor properdin 2.33 3.45E-02 1.9 
ILMN_210803 MRC1 mannose receptor, C type 1 2.31 3.76E-02 ND 
ILMN_219967 C1QC complement component 1, q 
subcomponent, C chain 
2.30 4.27E-02 ND 
ILMN_225389 CD68 CD68 molecule 2.22 2.18E-02 ND 
ILMN_211748 C1QB complement component 1, q 
subcomponent, beta polypeptide 
2.20 3.46E-02 ND 
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ILMN_208807 MS4A6D membrane-spanning 4-domains, 
subfamily A, member 6D 
2.19 1.23E-02 ND 
ILMN_239930 IFI27 interferon, alpha-inducible protein 
27 
2.19 4.66E-02 3.4 
ILMN_213846 EMR1 EGF-like module containing, mucin-
like, hormone receptor-like 
sequence 1 
2.15 1.14E-02 ND 
ILMN_223680 LMO2 LIM domain only 2 2.15 1.86E-02 ND 
ILMN_220368 ARL11 ADP-ribosylation factor-like 11 2.11 7.21E-04 5.2 
ILMN_212522 LAPTM5 lysosomal-associated protein 
transmembrane 5 [ 
2.03 3.31E-02 ND 
ILMN_212075 MS4A7 membrane-spanning 4-domains, 
subfamily A, member 7 
1.93 6.88E-03 ND 
ILMN_217604 CCR5 chemokine (C-C motif) receptor 5 1.93 7.10E-03 3.4 
ILMN_258659 CYTH4 cytohesin 4 1.90 4.01E-02 ND 
ILMN_211039 CASP1 caspase 1 1.88 2.85E-03 2.0 
ILMN_219201 CLEC4D C-type lectin domain family 4, 
member d 
1.88 4.53E-02 ND 
ILMN_194028 P2RY6 pyrimidinergic receptor P2Y, G-
protein coupled, 6 
1.87 2.84E-02 ND 
ILMN_192704 TREM2 triggering receptor expressed on 
myeloid cells 2 
1.84 6.77E-03 ND 
ILMN_2622209 2610207P0
8RIK 
RNASEH2B 1.79 1.51E-03 8.5 
ILMN_200650 MPEG1 macrophage expressed gene 1 1.76 3.35E-02 ND 
ILMN_220410 NCKAP1L NCK associated protein 1 like 1.76 3.49E-02 ND 
ILMN_220005 LPXN leupaxin 1.74 2.65E-02 ND 
ILMN_189960 ENTPD4 ectonucleoside triphosphate 
diphosphohydrolase 4 
1.71 2.22E-04 1.9 
ILMN_212052 RNASEH2B ribonuclease H2, subunit B 1.70 2.25E-03 ND 
ILMN_186230 TYROBP TYRO protein tyrosine kinase 
binding protein 
1.70 8.46E-03 ND 
ILMN_219342 CD93 CD93 molecule 1.68 1.70E-02 ND 
ILMN_212868 FCGR4 Fc receptor, IgG, low affinity IV 1.68 1.99E-02 ND 
ILMN_22116 MYO1F myosin IF 1.66 2.03E-02 ND 
ILMN_221982 NCF4 neutrophil cytosolic factor 4 1.65 4.35E-02 ND 
ILMN_260026 DAB2 disabled homolog 2 (Drosophila) 1.65 4.48E-02 ND 
ILMN_222602 BTK Bruton agammaglobulinemia 
tyrosine kinase 
1.64 3.73E-03 ND 
ILMN_202115 IDB2 inhibitor of DNA binding 2 1.63 1.32E-02 ND 
291 
 
ILMN_194894 CTLA2B cytotoxic T lymphocyte-associated 
protein 2 beta 
1.63 2.14E-02 ND 
ILMN_219885 CORO1A coronin, actin binding protein 1A 1.61 2.74E-02 ND 
ILMN_214875 CTSC cathepsin C 1.61 3.80E-02 ND 
ILMN_209055 LAT2 linker for activation of T cells 
family, member 2 
1.60 1.33E-02 ND 
ILMN_196998 LOC665032 similar to ribosomal protein L29 1.58 5.31E-04 2.1 
ILMN_217284 DOK3 docking protein 3 1.57 3.94E-02 ND 
ILMN_188421 PIK3CG phosphoinositide-3-kinase, 
catalytic, gamma polypeptide 
1.57 7.70E-03 ND 
ILMN_193247 SLC11A1 solute carrier family 11 (proton-
coupled divalent metal ion 
transporters), member 1 
1.55 3.16E-02 ND 
ILMN_193902 WAS Wiskott-Aldrich syndrome homolog 
(human) 
1.55 2.93E-02 ND 
ILMN_218837 ARRB2 beta-arrestin 2 1.53 2.73E-02 ND 
ILMN_220172 EVI2A ecotropic viral integration site 2A 1.53 2.72E-02 ND 
ILMN_192975 ZRANB3 zinc finger, RAN-binding domain 
containing 3 
1.52 1.57E-02 ND 
ILMN_187769 VAV1 vav 1 oncogene 1.50 1.63E-02 ND 
ILMN_229771 TM6SF1 transmembrane 6 superfamily 
member 1 





Appendix 7. Expression of AGS genes in homozygous 
Rnaseh2bA177T-neo primary MEFs 
 
MEFs were established from wild type (+/+), Rnaseh2bA177T-neo heterozygous 
(n/+) and Rnaseh2bA177T-neo/Rnaseh2bA177T-neo homozygous littermate mate 
embryos. RNA was extracted from 3rd passage cells and qRT-PCR analysis of 
expression levels of the Rnaseh2a, Rnaseh2b, Rnaseh2c and Trex1 genes determined. 
The primers for Rnaseh2b span exons 6 and 7. Expression data are the mean 







Appendix 8. Whole genome gene expression 
microarray analysis of homozygous Rnaseh2bA177T-
neo/Rnaseh2b-A177T-stop primary MEFs versus wild 
type primary MEFs 
 
Up-regulated transcripts (total = 173) (p < 0.05, fold change > 2.0) 
First 100 transcripts: 
Illumina ID Gene symbol Name Fold 
increase 
p-value 
ILMN_2950286 Ankrd1 ankyrin repeat domain 1 (cardiac muscle) 6.93 5.82E-03 
ILMN_2937596 Ngf nerve growth factor 5.12 8.91E-04 
ILMN_2660233 Ngf nerve growth factor 4.16 2.13E-03 
ILMN_2531737 Dusp5 dual specificity phosphatase 5 3.70 1.13E-04 
ILMN_2849449 Itga5 integrin alpha 5 (fibronectin receptor alpha) 3.45 5.69E-03 
ILMN_2754985 Phlda1 pleckstrin homology-like domain, family A, member 1 3.36 1.09E-02 
ILMN_2711461 Tgfb1 transforming growth factor, beta 1 3.32 3.00E-06 
ILMN_1251114 Gltpd1 glycolipid transfer protein domain containing 1 3.32 3.90E-03 
ILMN_2998658 Erdr1 erythroid differentiation regulator 1 3.21 4.88E-02 
ILMN_1253304 Stmn2 stathmin-like 2 3.19 1.55E-04 
ILMN_2759669 Scaf1 SR-related CTD-associated factor 1 3.19 1.82E-06 
ILMN_2670172 Itga5 integrin alpha 5 (fibronectin receptor alpha) 3.15 9.75E-04 
ILMN_2851288 Ngfr nerve growth factor receptor (TNFR superfamily, 
member 16) 
3.08 1.07E-04 
ILMN_1216042 Apoe apolipoprotein E 3.07 2.71E-02 
ILMN_2692615 Tgm2 transglutaminase 2, C polypeptide 3.07 4.27E-03 





9130213B05Rik 3.00 8.00E-03 
ILMN_2620406 Nptx2 neuronal pentraxin 2 2.92 8.70E-05 
ILMN_1252295 Klra20 killer cell lectin-like receptor subfamily A, member 20 2.88 2.14E-03 
ILMN_1225261 Uchl1 ubiquitin carboxy-terminal hydrolase L1 2.88 3.29E-04 
ILMN_1230443 Tpm1 tropomyosin 1, alpha 2.87 1.13E-04 
ILMN_2868220 Inhba inhibin beta-A 2.86 1.82E-02 
ILMN_2652187 Cux1 cut-like homeobox 1 2.86 2.30E-04 
ILMN_2857957 Mgll monoglyceride lipase 2.81 8.28E-04 
ILMN_1236889 Selp selectin, platelet 2.81 4.53E-04 
ILMN_2624451 4933407C03R
ik 
4933407C03Rik 2.79 1.17E-06 
ILMN_2760619 Tinagl tubulointerstitial nephritis antigen-like 1 2.78 4.05E-05 
ILMN_2715802 Hmga1 high mobility group AT-hook 1 [ 2.74 2.33E-03 
ILMN_2600744 Rgs16 regulator of G-protein signaling 16 2.73 4.25E-02 





ILMN_1228232 Cpe carboxypeptidase E; similar to carboxypeptidase E 2.69 2.06E-03 
ILMN_2522127 Myo1e myosin IE 2.68 5.50E-07 
ILMN_2901944 Col7a1 collagen, type VII, alpha 1 2.65 2.58E-02 
ILMN_3153010 Slitrk5 SLIT and NTRK-like family, member 5 2.61 2.36E-03 
ILMN_2730293 Pde1b phosphodiesterase 1B, Ca2+-calmodulin dependent 2.60 1.09E-02 
ILMN_2822579 Col4a2 collagen, type IV, alpha 2 2.60 1.80E-03 
ILMN_2940713 Garnl4 GTPase activating RANGAP domain-like 4 2.60 1.01E-03 
ILMN_1237606 Foxp4 forkhead box P4 2.59 1.21E-04 
ILMN_1224034 Pde1b phosphodiesterase 1B, Ca2+-calmodulin dependent 2.57 1.53E-02 
ILMN_1226200 Sprr2k small proline-rich protein 2K 2.57 4.54E-02 
ILMN_2698449 Hbegf heparin-binding EGF-like growth factor 2.56 2.55E-02 
ILMN_2626389 Nomo1 nodal modulator 1 2.55 4.84E-05 
ILMN_2955973 Smtn smoothelin 2.55 2.83E-05 
ILMN_2628757 Ehd1 EH-domain containing 1 2.53 6.42E-07 
ILMN_2736514 Galntl4 UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-
acetylgalactosaminyltransferase-like 4 
2.52 2.25E-06 
ILMN_2604521 Cotl1 adaptor protein complex AP-2, alpha 1 subunit 2.52 1.05E-03 
ILMN_2944601 Pisd-ps3 phosphatidylserine decarboxylase, pseudogene 1 2.50 3.59E-03 
ILMN_3143246 Ap2a1 adaptor protein complex AP-2, alpha 1 subunit 2.48 4.89E-05 
ILMN_2436890 Dhrsx  dehydrogenase/reductase (SDR family) X chromosome 2.47 1.21E-06 
ILMN_2854943 Gprc5a G protein-coupled receptor, family C, group 5, member 
A 
2.47 5.40E-05 
ILMN_2855397 Hgs HGF-regulated tyrosine kinase substrate 2.46 3.23E-06 
ILMN_1236368 Orai1 ORAI calcium release-activated calcium modulator 1 2.46 1.64E-05 
ILMN_1233243 Ivl involucrin 2.45 1.56E-02 
ILMN_1255422 Ccrn4l similar to carbon catabolite repression 4 protein 
homolog 
2.44 4.59E-02 
ILMN_2713285 Fhl1 four and a half LIM domains 1 2.43 1.92E-02 
ILMN_2675232 Klk8 kallikrein related-peptidase 8 2.43 1.39E-02 
ILMN_1213989 Pmepa1 prostate transmembrane protein, androgen induced 1; 
similar to Nedd4 WW binding protein 4 
2.42 2.42E-04 
ILMN_3117381 Fhl1 four and a half LIM domains 1 2.40 2.79E-02 
ILMN_2543630 Pisd-ps3 phosphatidylserine decarboxylase, pseudogene 3 2.39 1.87E-04 
ILMN_3031402 Klra4 predicted gene 14378; similar to transforming growth 
factor, beta receptor III (betaglycan, 300kDa); mitogen-
activated protein kinase kinase 7 
2.39 3.16E-03 
ILMN_2424299 Tnfrsf12a tumor necrosis factor receptor superfamily, member 
12a 
2.38 5.92E-03 
ILMN_2598877 Slc7a8 solute carrier family 7 (cationic amino acid transporter, 
y+ system), member 8 
2.36 2.28E-02 
ILMN_2695181 Smtn smoothelin 2.35 1.63E-04 
ILMN_2675261 Taldo1 transaldolase 1 2.34 2.33E-05 
ILMN_2729718 Psme3 proteaseome (prosome, macropain) 28 subunit, 3 2.33 7.31E-05 
ILMN_2521893 Hmga2-ps1 high mobility group AT-hook 2, pseudogene 1 2.33 3.78E-03 
ILMN_2767615 Atp1b1 ATPase, Na+/K+ transporting, beta 1 polypeptide 2.32 6.07E-04 
ILMN_2836710 Cd151 CD151 antigen 2.31 1.14E-03 
ILMN_2630605 Fscn1 fascin homolog 1, actin bundling protein 
(Strongylocentrotus purpuratus) 
2.31 4.51E-04 
ILMN_3105417 Bdnf brain derived neurotrophic factor 2.31 1.80E-03 





ILMN_2656677 Fkbp8 FK506 binding protein 8 2.30 4.67E-06 
ILMN_3116560 St3gal5 ST3 beta-galactoside alpha-2,3-sialyltransferase 5 2.30 5.65E-06 
ILMN_2795078 Unc93b1 unc-93 homolog B1 2.29 3.49E-02 
ILMN_1228501 Tob2 transducer of ERBB2, 2 2.28 3.15E-06 
ILMN_1255175 Unc45a unc-45 homolog A (C. elegans) 2.27 8.55E-07 
ILMN_2511249 Akap2 A kinase (PRKA) anchor protein 2; paralemmin 2 2.27 2.69E-04 
ILMN_1252995 Hist1h2be histone cluster 1, H2be 2.26 1.88E-04 
ILMN_1243862 Il11 interleukin 11 2.25 3.20E-02 
ILMN_1253503 1190028F09  2.25 5.35E-03 
ILMN_3148543 Src Rous sarcoma oncogene 2.24 1.02E-05 
ILMN_1254562 Atp13a2 ATPase type 13A2 2.24 2.33E-04 
ILMN_1234072 Pdlim1 PDZ and LIM domain 1 (elfin) 2.24 2.10E-02 
ILMN_2933394 Ppp1r10 protein phosphatase 1, regulatory subunit 10 2.24 2.89E-06 
ILMN_2976129 Tinagl tubulointerstitial nephritis antigen-like 1 2.23 4.13E-04 
ILMN_2536389 LOC383897 LOC383897 2.23 1.09E-04 
ILMN_3028575 Syngr1 synaptogyrin 1 2.23 1.53E-02 
ILMN_1248181 Zbtb7a zinc finger and BTB domain containing 7a 2.22 1.01E-02 
ILMN_3110425 Myo1c similar to nuclear myosin I beta; myosin IC 2.21 2.83E-05 
ILMN_2808355 Coq5 coenzyme Q5 homolog, methyltransferase 2.21 8.35E-05 
ILMN_2769567 F2rl1 coagulation factor II (thrombin) receptor-like 1 2.20 2.11E-02 
ILMN_2592810 Map3k3 mitogen-activated protein kinase kinase kinase 3 2.20 5.52E-06 
ILMN_2955919 Mcam melanoma cell adhesion molecule 2.19 4.28E-02 
ILMN_3026557 Rbpms RNA binding protein gene with multiple splicing 2.19 7.29E-05 
ILMN_2908056 Tmbim1 transmembrane BAX inhibitor motif containing 1 2.19 5.87E-08 
ILMN_2648661 Cap1 CAP, adenylate cyclase-associated protein 1 (yeast) 2.19 3.97E-03 
ILMN_2700689 Ibrdc3 ring finger protein 19B 2.19 9.35E-04 
ILMN_2895000 Slc35c2 solute carrier family 35, member C2 2.18 1.78E-06 
ILMN_2742455 Gtf2f1 general transcription factor IIF, polypeptide 1 2.18 4.99E-05 
ILMN_2418811 2200002D01R
ik 
2200002D01Rik 2.16 1.96E-04 
 
 
Down-regulated transcripts (total = 794) (p < 0.05, fold change > 2.0) 
First 100 transcripts: 
Illumina ID Gene symbol Name Fold 
decrease 
P-value 
ILMN_1258629 Col3a1 collagen, type III, alpha 1 10.89 8.12E-08 
ILMN_2750515 Fos FBJ osteosarcoma oncogene 8.97 1.92E-03 
ILMN_2596346 Dcn decorin 8.16 1.68E-03 
ILMN_2662802 Ptx3 pentraxin related gene 8.15 1.48E-04 
ILMN_2755660 LOC100044779 similar to prothymosin alpha 7.91 1.02E-07 
ILMN_2494251 Tuba1a tubulin, alpha 1A 7.42 6.10E-09 
ILMN_1221290 LOC636952 LOC636952 6.95 6.88E-08 
ILMN_2634317 Slc1a3 solute carrier family 1 (glial high  
affinity glutamate transporter), member 3 6.69 2.05E-03 
ILMN_1217235 Fam114a1 family with sequence similarity 114, member A1 6.56 1.09E-09 
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ILMN_1253681 LOC433546 LOC433546 6.48 1.09E-09 
ILMN_2906728 H19 H19 fetal liver mRNA 6.47 7.27E-04 
ILMN_2773259 Lum lumican 6.37 5.65E-03 
ILMN_2955671 Slc38a2 solute carrier family 38, member 2 6.35 1.27E-07 
ILMN_2504686 mt-Atp6 mt-Atp6 6.27 1.26E-08 
ILMN_2638114 Ptn pleiotrophin 6.27 5.05E-03 
ILMN_2662803 Ptx3 pentraxin related gene 6.18 5.89E-04 
ILMN_1247853 Zfp36l1 zinc finger protein 36, C3H type-like 1 6.14 8.09E-07 
ILMN_2595612 Idh2 isocitrate dehydrogenase 2 (NADP+), 
 mitochondrial 6.04 2.11E-06 
ILMN_2683958 Col3a1 collagen, type III, alpha 1 5.98 2.51E-06 
ILMN_2700233 Ccng2 cyclin G2 5.90 9.27E-10 
ILMN_2419660 mtDNA_ND4L mtDNA_ND4L 5.89 9.45E-07 
ILMN_1235932 Pdgfra platelet derived growth factor receptor, alpha  
polypeptide 5.88 2.88E-05 
ILMN_3001540 Lum lumican 5.81 2.23E-02 
ILMN_1219335 Igfbp3 insulin-like growth factor binding protein 3 5.76 6.31E-03 
ILMN_1232951 EG434404 ribosomal protein S6 pseudogene 5.68 5.74E-08 
ILMN_2835423 Cfd complement factor D (adipsin) 5.66 3.54E-04 
ILMN_2497616 LOC100048480 LOC100048480 5.65 6.10E-09 
ILMN_2643423 LOC100042773 LOC100042773 5.53 5.14E-08 
ILMN_2668319 Hsp90aa1 heat shock protein 90, alpha (cytosolic),  
class A member 1 5.37 8.36E-08 
ILMN_2768053 Supt16h suppressor of Ty 16 homolog  5.30 1.63E-02 
ILMN_1214602 Sfrp2 secreted frizzled-related protein 2 5.28 1.73E-02 
ILMN_1249235 LOC668387 LOC668387 5.21 3.59E-08 
ILMN_1216880 Emr1 EGF-like module containing, mucin-like, 
 hormone receptor-like sequence 1 5.16 2.25E-05 
ILMN_2426691 mt-Co2 mt-Co2 5.14 1.75E-08 
ILMN_2835117 Ccl7 chemokine (C-C motif) ligand 7 5.08 1.13E-04 
ILMN_1231689 Sfrp1 secreted frizzled-related protein 1 5.05 7.94E-04 
ILMN_2846904 Mest mesoderm specific transcript 5.02 8.68E-03 
ILMN_2763245 Cxcl1 chemokine (C-X-C motif) ligand 1 5.01 2.02E-03 
ILMN_2739760 Prelp proline arginine-rich end leucine-rich repeat 5.00 3.22E-03 
ILMN_2727503 Igfbp3 insulin-like growth factor binding protein 3 5.00 9.82E-03 
ILMN_2530916 LOC225058 LOC225058 4.95 1.80E-08 
ILMN_2832979 Gpc3 glypican 3 4.90 2.80E-03 
ILMN_2669627 Vcan versican 4.89 5.67E-08 
ILMN_1230411 Kpnb1 karyopherin (importin) beta 1 4.77 8.31E-09 
ILMN_2649502 Adam9 a disintegrin and metallopeptidase domain 
9 (meltrin gamma) 4.75 9.27E-10 
ILMN_2434853 mtDNA_ND2 mtDNA_ND2 4.74 1.84E-06 
ILMN_2633229 Atp5a1 ATP synthase, H+ transporting, mitochondrial 
 F1 complex, alpha subunit, isoform 1 4.72 4.93E-09 
ILMN_2485148 Vapa vesicle-associated membrane protein, associated 
protein A 4.66 1.40E-09 
ILMN_1249767 Thbd thrombomodulin 4.63 1.74E-06 
ILMN_2771815 Psmd14 proteasome (prosome, macropain) 26S subunit,  
non-ATPase, 14 4.62 1.09E-09 
ILMN_2677056 LOC100048622 LOC100048622 4.62 4.08E-09 
ILMN_2903440 Hnrpdl heterogeneous nuclear ribonucleoprotein D-like 4.59 5.46E-08 
ILMN_2637639 Rps3 ribosomal protein S3 4.59 4.65E-07 
ILMN_2662926 Egr1 early growth response 1 4.56 3.26E-05 
ILMN_1230157 Rnd3 Rho family GTPase 3 4.53 2.88E-02 
ILMN_1251119 Bmpr1a bone morphogenetic protein receptor, type 1A 4.49 8.63E-09 
ILMN_1256343 H19 H19 fetal liver mRNA 4.48 2.27E-03 
ILMN_2527341 LOC381365 LOC381365 4.47 3.59E-08 
ILMN_2513570 Rassf8 Ras association (RalGDS/AF-6) domain family  
(N-terminal) member 8 4.45 2.46E-09 
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ILMN_1258515 Paip2 polyadenylate-binding protein-interacting protein 2 4.44 1.09E-09 
ILMN_2673936 Rpl18a ribosomal protein L18A 4.41 1.16E-06 
ILMN_1216231 Scoc short coiled-coil protein 4.41 1.24E-04 
ILMN_2607377 Itm2a integral membrane protein 2A 4.40 8.63E-04 
ILMN_2650008 Lgr5 leucine rich repeat containing G protein coupled  
receptor 5 4.38 4.49E-03 
ILMN_1252832 Zc3h15 zinc finger CCCH-type containing 15 4.36 4.74E-08 
ILMN_2674720 Ptges3 prostaglandin E synthase 3 (cytosolic) 4.31 2.58E-09 
ILMN_2747959 Dcn decorin 4.31 4.44E-02 
ILMN_1243256 LOC675985 ribosomal protein S6 pseudogene 4.31 6.14E-09 
ILMN_2725835 Ptp4a2 protein tyrosine phosphatase 4a2 4.24 7.65E-07 
ILMN_2671601 Selk selenoprotein K 4.23 4.31E-09 
ILMN_2719973 Gpc3 glypican 3 4.23 1.18E-02 
ILMN_2710166 Ddx3x DEAD/H (Asp-Glu-Ala-Asp/His) box polypeptide 3,  
X-linked 4.21 3.83E-09 
ILMN_2702444 Csgalnact1 chondroitin sulfate N-
acetylgalactosaminyltransferase 1 4.21 8.63E-09 
ILMN_2757966 Pf4 platelet factor 4 4.20 5.61E-05 
ILMN_2623216 Pgrmc1 progesterone receptor membrane component 1 4.16 1.95E-06 
ILMN_2597332 1700123O20Rik 1700123O20Rik 4.16 3.29E-03 
ILMN_1241536 LOC381649 LOC381649 4.13 4.08E-09 
ILMN_2674966 Igsf10 immunoglobulin superfamily, member 10  4.12 3.88E-05 
ILMN_2692723 Lpl lipoprotein lipase 4.07 1.11E-02 
ILMN_2604282 Sfrp1 secreted frizzled-related protein 1 4.06 1.56E-02 
ILMN_3163159 LOC100041703 LOC100041703 4.06 1.97E-07 
ILMN_2634338 1110002B05Rik 1110002B05Rik 4.02 2.32E-07 
ILMN_2647628 Ppp1cb protein phosphatase 1, catalytic subunit, beta 
isoform 3.94 1.01E-06 
ILMN_2609998 Fxyd6 FXYD domain-containing ion transport regulator 6 3.94 1.46E-02 
ILMN_1232081 Cald1 caldesmon 1 3.93 5.13E-07 
ILMN_2495644 Vps29 vacuolar protein sorting 29  3.91 2.41E-08 
ILMN_1253625 CNOT6 CCR4-NOT transcription complex, subunit 6 3.90 7.41E-08 
ILMN_2621544 2700060E02Rik 2700060E02Rik 3.90 1.68E-04 
ILMN_1259482 Pabpc1 poly(A) binding protein, cytoplasmic 1 3.88 2.20E-05 
ILMN_1223428 Eif3s8 eukaryotic translation initiation factor 3, subunit C 3.87 1.02E-08 
ILMN_1243212 Sparc secreted acidic cysteine rich glycoprotein 3.87 4.18E-02 
ILMN_1231873 Tmed2 transmembrane emp24 domain trafficking protein 2 3.87 4.31E-09 
ILMN_1230620 Ywhaq tyrosine 3-monooxygenase/tryptophan 5- 
monooxygenase activation protein, theta 
polypeptide  3.86 1.60E-07 
ILMN_1229547 Spon2 spondin 2, extracellular matrix protein 3.84 4.91E-03 
ILMN_2680329 Isca1 iron-sulfur cluster assembly 1 homolog (S. cerevisiae) 3.84 5.93E-09 
ILMN_1235619 Wasf2 WAS protein family, member 2 3.82 1.16E-07 
ILMN_1230454 Hadhb hydroxyacyl-Coenzyme A dehydrogenase/3-ketoacyl- 
Coenzyme A thiolase/enoyl-Coenzyme A hydratase  
trifunctional protein), beta subunit  3.81 8.43E-08 
ILMN_2605465 Snx1 sorting nexin 1 3.76 7.96E-10 





Appendix 9. Phenotypes of homozygous 
Rnaseh2bA177T-stop embryos used for microarray 
analysis 
 
Embryos were dissected and phenotype analysis performed by Kirstie Lawson, MRC 
HGU, prior to RNA extraction. The RNA yield listed was the quantity recovered 







Appendix 10. Whole genome gene expression 
microarray analysis of E9.5 homozygous 
Rnaseh2bA177T-stop embryos  
 
E9.5 mutant versus E9.5 wild type 
Up-regulated transcripts (total = 117) (p < 0.05, fold change > 1.5) 





ILMN_2500276 Ccng1 Cyclin G1 6.54 1.37E-05 
ILMN_2634083 Cdkn1a Cyclin-dependent kinase inhibitor 1A (p21) 6.13 4.52E-07 
ILMN_2710229 Ccng1 Cyclin G1 5.15 1.89E-04 
ILMN_2846775 Cdkn1a Cyclin-dependent kinase inhibitor 1A (p21) 4.14 4.52E-07 
ILMN_2923607 Phlda3 Plekstrin homology-like domain, family A, member 3 4.12 1.45E-05 
ILMN_2702233 Ccng1 Cyclin G1 4.12 3.35E-04 
ILMN_2628567 Phlda3 Plekstrin homology-like domain, family A, member 3 3.97 5.98E-03 
ILMN_2506012 Trp53inp1 Transformation related protein 53 inducible nuclear 
protein 1 
3.46 2.30E-04 
ILMN_2868280 Dcxr Dicarbonyl/L-xylulose reductase 3.13 3.34E-02 
ILMN_2846776 Cdkn1a Cyclin-dependent kinase inhibitor 1A (p21) 3.05 1.27E-04 
ILMN_2765454 Svop SV2 related protein 2.95 6.15E-03 
ILMN_2759108 Dcxr Dicarbonyl/L-xylulose reductase 2.73 2.66E-02 
ILMN_1250531 Slc19a2 Solute carrier family 19 (thiamine transporter), member 2 2.72 1.89E-04 
ILMN_2764551 Cox6b2 Cytochrome c oxidase subunit VIb polypeptide 2 2.64 3.35E-04 
ILMN_2418426 Zmat3 Wild-type p53-induced gene 1  2.54 2.17E-04 
ILMN_2617256 Ms4a10 Membrane-spanning 4-domains, subfamily A, member 10 
( 
2.45 1.09E-02 
ILMN_2717678 Muc13 Mucin 13, epithelial transmembrane 2.38 1.33E-02 
ILMN_2695819 Ddit4l DNA-damage-inducible transcript 4-like 2.37 1.89E-04 
ILMN_1232336 1700007K1
3Rik 
Hypothetical protein LOC69327 2.24 2.84E-02 
ILMN_2879681 B4galnt2 Beta-1,4-N-acetyl-galactosaminyl transferase 2 2.24 6.15E-03 
ILMN_1217442  Zfp365 Zinc finger protein 365 2.22 8.72E-03 
ILMN_1228469 Apoc1 Apolipoprotein C-I  2.21 1.09E-02 
ILMN_2518406 Vil1 Villin 1 2.20 3.65E-02 
ILMN_2699466 Pla2g12b Phospholipase A2, group XIIB 2.18 6.15E-03 
ILMN_2615096 Dpp4 Dipeptidylpeptidase 4 2.15 4.11E-02 
ILMN_3163053 Commd3 COMM domain containing 3 2.12 1.30E-04 
ILMN_2599794 Apoc1 Apolipoprotein C-I  2.04 4.38E-02 
ILMN_2483304 Lyve1 Lymphatic vessel endothelial hyaluronan receptor 1 2.04 2.59E-02 
ILMN_2838317 Pqlc3  PQ loop repeat containing 1.98 1.41E-02 
ILMN_2477136 2010003K1
5Rik 
Hothetical protein LOC75606 1.96 1.85E-04 
ILMN_2948945 Sesn2 Sestrin 2 1.94 1.96E-02 
ILMN_1245909 4933402E1
3Rik 
Hypothetical protein LOC74437 1.91 6.66E-03 
ILMN_2497999 Vkorc1 Vitamin K epoxide reductase complex, subunit 1 1.91 3.61E-02 
ILMN_1246289 Got1l1 Glutamic-oxaloacetic transaminase 1-like 1 1.90 5.98E-04 
ILMN_2419185 Tuft1 Tuftelin 1 1.90 9.05E-03 
ILMN_2647313 Klhl26 Kelch-like 26 1.89 8.52E-03 
ILMN_2908065 Gtse1 G two S phase expressed protein 1 1.89 6.67E-03 
ILMN_2850753 Mdm2 Transformed mouse 3T3 cell double minute 2  1.89 3.93E-02 
ILMN_1219298 Art4  ADP-ribosyltransferase 4 1.89 6.15E-03 
ILMN_2661650 Reep6 Polyposis locus protein 1-like 1 1.86 6.15E-03 
ILMN_1238634 4933402E1
3Rik 
Hypothetical protein LOC74437  1.85 8.44E-03 
ILMN_2630428 Fmr1nb Fragile X mental retardation 1 neighbor 1.85 1.33E-02 
ILMN_3136561 Sparc Secreted acidic cysteine rich glycoprotein 1.84 1.75E-02 
ILMN_1223880 Tmprss2 Transmembrane protease, serine 2 1.84 8.72E-03 
300 
 
ILMN_2593134 Rnasek Ribonuclease kappa 1.84 3.05E-02 
ILMN_2728473 Serpina3m Serine (or cysteine) proteinase inhibitor, clade A, member 
3M 
1.84 1.86E-02 
ILMN_3162879 Stx3 Syntaxin 3 1.84 8.72E-03 
ILMN_2920736 Bbc3  BCL2 binding component 3 1.82 2.58E-03 
ILMN_2667805 Ak1 Adenylate kinase 1 1.81 1.02E-02 
ILMN_2777427 Nostrin Nitric oxide synthase trafficker 1.77 3.85E-02 
ILMN_2698046 Stat3 Signal transducer and activator of transcription 3 1.77 6.15E-03 
ILMN_3160626 Cideb Cell death-inducing DNA fragmentation factor, alpha 
subunit-like effector B  
1.77 2.76E-02 
ILMN_1240445 Stard4 StAR-related lipid transfer (START) domain containing 4 1.77 3.05E-02 
ILMN_2707541 Folr1 Folate receptor 1 (adult) 1.74 3.51E-02 
ILMN_2641371 Lgals2 Lectin, galactose-binding, soluble 2 1.73 1.49E-03 
ILMN_3002745 Vkorc1 Vitamin K epoxide reductase complex, subunit 1 1.73 3.93E-02 
ILMN_1255479 Cldn2 Claudin 2 1.72 1.49E-03 
ILMN_1235688 Cd151 CD151 antigen 1.72 2.96E-02 
ILMN_2747857 Slc27a3 Solute carrier family 27 member 3 1.72 3.48E-03 
ILMN_2980323 Cldn2 Claudin 2  1.71 3.05E-02 
ILMN_2861123 Tmem150 Transmembrane protein 150A 1.71 2.71E-02 
ILMN_2767825 2210011C2
4Rik 
Hypothetical protein LOC70134 1.71 4.11E-02 
ILMN_2908070 Gtse1 Two S phase expressed protein 1  1.71 1.49E-03 
ILMN_2628594 Mttp Microsomal triglyceride transfer protein 1.70 3.45E-02 
ILMN_2759762 Stard10 START domain containing 10 1.70 4.29E-02 
ILMN_1255438 Cpped1 Calcineurin-like phosphoesterase domain containing 1 1.70 4.38E-02 
ILMN_1240630 Polk DNA-directed DNA polymerase kappa 1.70 3.05E-02 
ILMN_2492403 Cd151 CD151 antigen 1.70 1.86E-02 
ILMN_2690575 Pcbd1 Pterin 4 alpha carbinolamine dehydratase/dimerization 
cofactor of hepatocyte nuclear factor 1 alpha 
1.69 3.61E-02 
ILMN_2595842 Def6 Differentially expressed in FDCP 6  1.68 6.58E-03 
ILMN_2915833 BC025446 BC025446 1.68 8.52E-03 
ILMN_2644936 Habp2 Hyaluronic acid binding protein 2 1.68 3.11E-02 
ILMN_1239293 Sulf2 Sulfatase 2  1.66 4.60E-02 
ILMN_2907655 Bax Bcl2-associated X protein 1.66 8.72E-03 
ILMN_2522693 Vkorc1 Vitamin K epoxide reductase complex, subunit 1 1.65 4.68E-02 
ILMN_2476139 Tuba6 Tubulin alpha 6 1.65 2.36E-02 
ILMN_2770429 Plod2 Procollagen-lysine, 2-oxoglutarate 5-dioxygenase 2 1.65 8.72E-03 
ILMN_2774349 LOC100046
401 
Similar to SDR2  1.64 9.08E-03 
ILMN_2915835 BC025446 BC025446 1.64 4.60E-02 
ILMN_2604310 1810022C2
3Rik 
Hypothetical protein LOC69123 1.64 1.27E-02 
ILMN_1227282 Soat2 Acyl-CoA:cholesterol acyltransferase 2  1.64 2.01E-02 
ILMN_2730651 Slc7a9  Solute carrier family 7, member 9 1.63 4.11E-02 
ILMN_1226293 Slc39a4 Solute carrier family 39, member 4 1.63 4.38E-02 
ILMN_1217102 Tpcn1 Two pore channel 1 1.62 1.52E-02 
ILMN_2953677 Ei24 Etoposide induced 2.4 1.62 8.72E-03 
ILMN_2655260 Ptp4a3 Protein tyrosine phosphatase 4a3  1.62 4.91E-02 
ILMN_2775512 Ei24 Etoposide induced 2.4 1.62 4.38E-02 
ILMN_1235811 Fam198b Expressed in nerve and epithelium during development 1.61 6.68E-03 
ILMN_2979190 Habp2 Hyaluronic acid binding protein 2  1.60 3.27E-03 
ILMN_2992009 Lrdd Leucine-rich and death domain containing 1.60 2.66E-02 
ILMN_2621708 Abcc4 ATP-binding cassette, sub-family C (CFTR/MRP), member 
4  
1.60 1.47E-02 
ILMN_2874554 Aldh4a1 Aldehyde dehydrogenase 4A1 1.59 4.12E-02 
ILMN_1247811 Ass1 Argininosuccinate synthetase 1 1.59 1.09E-02 
ILMN_1236522 Cbr1 Carbonyl reductase 1 1.58 2.87E-02 
ILMN_2702102 D630023F1
8Rik 
Hypothetical protein LOC98303 1.58 1.49E-03 
ILMN_2806996 Creb3l3  cAMP responsive element binding protein 3-like 3  1.58 6.67E-03 
ILMN_2671165 Krt23 Keratin 23  1.58 1.68E-02 
ILMN_2665715 Gstt3 Glutathione S-transferase, theta 3 1.57 2.66E-02 
ILMN_2715546 Gpx3 Glutathione peroxidase 3  1.57 2.40E-02 
ILMN_2535430 LOC383576 LOC383576 1.56 3.37E-02 
ILMN_3143577 Apaf1 Apoptotic protease activating factor 1  1.56 2.52E-02 
ILMN_1248039 mtDNA_CO
XII 
mtDNA_COXII 1.56 6.58E-03 





Hypothetical protein LOC100044177 1.56 3.81E-02 
ILMN_2775360 Mapkapk3 Mitogen-activated protein kinase-activated protein 
kinase 3 
1.56 4.89E-02 
ILMN_1220609 Ltb4r1 Leukotriene B4 receptor 1 1.55 4.67E-02 
ILMN_1235474 Pdzk1 PDZ domain containing 1 1.55 2.84E-02 
ILMN_1246764 Fam122b Family with sequence similarity 122, member B 1.55 1.80E-02 
ILMN_1247490 Arhgap23 Rho GTPase activating protein 23  1.54 2.66E-02 
ILMN_2546272 Gng12 Guanine nucleotide binding protein (G protein), gamma 
12, 
1.54 2.33E-02 
ILMN_1243433 Gm10080 Predicted gene 10080 1.54 2.84E-02 
ILMN_2596611 Clic1 Chloride intracellular channel 1 1.54 2.15E-02 
ILMN_2946760 Ankrd56 Ankyrin repeat domain 56  1.52 6.67E-03 
ILMN_2631093 Cd81 CD81 antigen 1.52 6.15E-03 
ILMN_2773485 Thnsl2 Threonine synthase-like 2 1.52 4.60E-02 
ILMN_1219136 Vamp8 Vesicle-associated membrane protein 8  1.51 2.84E-02 
ILMN_2606921 Klb Klotho beta  1.51 4.60E-02 
 
E9.5 mutant versus E9.5 wild type 
Down-regulated transcripts (total = 29) (p < 0.05, fold change > 1.5) 
 
Illumina ID Gene symbol Name Fold decrease P value 
ILMN_2622209 Rnaseh2b Ribonuclease H2, subunit B 3.06 8.65E-07 
ILMN_2622208 Rnaseh2b Ribonuclease H2, subunit B 2.87 3.27E-07 
ILMN_1233402 LOC10004598
1 
Similar to synaptotagmin XI 2.40 2.48E-04 
ILMN_1231030 Tcf15 Transcription factor 15 1.96 1.22E-05 
ILMN_2738123 LOC10004651
8 
Similar to Gprin1 protein 1.87 1.78E-04 
ILMN_2828112 Igfbpl1 Insulin-like growth factor binding protein-like 1 1.84 8.29E-05 
ILMN_1256680 Jakmip2 Janus kinase and microtubule interacting protein 2 1.78 2.86E-04 
ILMN_1233535 6330407J23Ri
k 
Hypothetical protein LOC67412 1.73 1.81E-06 
ILMN_2976821 Fzd10 Frizzled 10 1.72 6.51E-06 
ILMN_2584527 Mbd2 Methyl-CpG binding domain protein 2 1.65 1.03E-05 
ILMN_1226157 Pik3r3 Phosphatidylinositol 3 kinase, regulatory subunit, 
polypeptide 3 (p55) 
1.64 6.25E-05 
ILMN_2565262 Lrig3 Leucine-rich repeats and immunoglobulin-like 
domains 3 
1.62 8.34E-05 
ILMN_2776554 Igfbpl1 Insulin-like growth factor binding protein-like 1 1.62 5.56E-05 
ILMN_1247530 Llgl1 lethal giant larvae homolog 1 1.61 2.08E-04 
ILMN_2657409 Rps18 Ribosomal protein S18 1.60 4.98E-05 
ILMN_1220516 Wnt3a wingless-related MMTV integration site 3A 1.59 3.74E-05 
ILMN_1260073 D16Ertd472e D16Ertd472e 1.59 1.01E-04 
ILMN_2776909 Irx3 Iroquois related homeobox 3 1.59 2.41E-07 
ILMN_2758070 Rtn1 Reticulon 1 1.57 6.48E-07 




ILMN_2807665 Gatc Glutamyl-tRNA(Gln) amidotransferase, subunit C 
homolog 
1.57 1.38E-04 
ILMN_1242617 Lpar4 Lysophosphatidic acid receptor 4 1.57 1.81E-04 
ILMN_1244123 Slc38a2 Solute carrier family 38, member 2 1.57 9.30E-06 
ILMN_2661588 Spnb3 spectrin beta 3 1.56 2.06E-04 
ILMN_2552490 6720463L11Ri
k 
Splicing factor, arginine/serine-rich 7 homolog 1.54 2.23E-05 
ILMN_1226660 LOC10004740
2 
Hypothetical protein LOC100047402 1.53 1.31E-04 
ILMN_3115490 Rtn1 Reticulon 1 1.53 6.67E-06 
ILMN_1226103 5730455P16R
ik 
Hypothetical protein LOC70591 1.53 1.72E-04 
 
E9.5 mutant versus E8.5 wild type 
Up-regulated transcripts (total = 41) (p < 0.05, fold change > 1.5) 
 
Illumina ID Gene symbol Name Fold 
increase 
P-value 
ILMN_2500276 Ccng1 Cyclin G1 7.48 3.30E-05 
ILMN_2634083 Cdkn1a Cyclin dependent kinase inhibitor 1 6.87 3.21E-06 
ILMN_2710229 Ccng1 Cyclin G1 5.74 6.01E-04 
ILMN_2923607 Phlda3 Pleckstrin homology-like domain, family A, member 3 4.81 3.30E-05 
ILMN_2702233 Ccng1 Cyclin G1 4.35 1.31E-03 
ILMN_2846775 Cdkn1a Cyclin dependent kinase inhibitor 1 4.00 3.43E-06 
ILMN_2506012 Trp53inp1 transformation related protein 53 inducible nuclear 
protein 1 
3.95 6.01E-04 
ILMN_2628567 Phlda3 Pleckstrin homology-like domain, family A, member 3 3.71 3.41E-02 
ILMN_2617256 Ms4a10 Membrane-spanning 4-domains, subfamily A, member 
10 
3.55 7.47E-03 
ILMN_2846776 Cdkn1a Cyclin dependent kinase inhibitor 1 3.25 3.18E-04 
ILMN_2765454 Svop Synaptic vesicle 2 related protein 3.22 1.90E-02 
ILMN_2764551 Cox6b2 Cytochrome c oxidase subunit VIb polypeptide 2 3.01 6.89E-04 
ILMN_2695819 Ddit4l DNA-damage-inducible transcript 4-like 2.95 2.37E-04 





ILMN_1217442 LOC674611 Similar to zinc finger protein 365 2.33 3.41E-02 
ILMN_3163053 Commd3 COMM domain containing 3 2.30 2.82E-04 
ILMN_2644936 Habp2 Hyaluronic acid binding protein 2 2.22 1.90E-02 
ILMN_2690575 Pcbd1 Pterin 4 alpha carbinolamine dehydratase/dimerization 
cofactor of hepatocyte nuclear factor 1 alpha (TCF1) 1 
2.14 3.39E-02 
ILMN_2647313 Klhl26 Kelch-like 26 (Drosophila) 2.12 1.98E-02 
ILMN_2418426 Zmat3 Zinc finger matrin type 3 2.11 6.44E-03 
ILMN_1247811 Ass1 Argininosuccinate synthetase 1 2.10 3.11E-03 
ILMN_1226293 Slc39a4 Solute carrier family 39 (zinc transporter), member 4 2.06 3.41E-02 
ILMN_2920736 Bbc3 BCL2 binding component 3 2.05 3.11E-03 
ILMN_2979190 Habp2 Hyaluronic acid binding protein 2 2.04 6.93E-04 
ILMN_2477136 2010003K15R
ik 
Hypothetical protein LOC75606 1.92 8.80E-04 
ILMN_1245909 4933402E13R
ik 
Hypothetical protein LOC74437 1.83 4.78E-02 
ILMN_2715546 Gpx3 Glutathione peroxidase 3 1.82 2.95E-02 
ILMN_1246289 Got1l1 Glutamic-oxaloacetic transaminase 1-like 1 1.80 6.44E-03 
ILMN_2619107 Lgals1 Lectin, galactose binding, soluble 1 1.76 3.88E-02 
ILMN_2907655 Bax BCL2-associated X protein 1.74 3.39E-02 
ILMN_2908070 Gtse1 G two S phase expressed protein 1 1.73 6.53E-03 
ILMN_2702102 D630023F18R
ik 
Hypothetical protein LOC98303 1.70 2.39E-03 
ILMN_2604310 1810022C23R
ik 
Hypothetical protein LOC69123 1.69 4.91E-02 
ILMN_2915833 BC025446 BC025446 1.67 4.78E-02 
ILMN_2984462 Ercc5 Excision repair cross-complementing rodent repair 
deficiency, complementation group 5 
1.64 1.68E-02 
ILMN_2595842 Def6 Differentially expressed in FDCP 6 1.62 4.90E-02 
ILMN_2604179 Lrrc3 Leucine rich repeat containing 3 1.61 4.09E-02 
ILMN_2641371 Lgals2 Lectin, galactose-binding, soluble 2 1.61 2.25E-02 
ILMN_1253618 Ccs Copper chaperone for superoxide dismutase 1.60 2.21E-02 
ILMN_2631093 Cd81 CD81 antigen 1.56 2.28E-02 
ILMN_1255479 Cldn2 Claudin 2 1.53 3.44E-02 
 
 
E9.5 mutant versus E8.5 wild type
Down-regulated transcripts
 













FL-DCs in response to transfected poly (I:C)
 
As demonstrated in Figures 6.21 and 6.22, a range of PRR ligands were utilised in 
FL-DCs from IPS-1-/-
equivalent to wild type. The only difference 
was decreased in the IPS




 (total = 9) (p < 0.05, fold change > 1.5) 
 Name 
 Ribonuclease H2, subunit B 
 Ribonuclease H2, subunit B 
fibroblast growth factor 1 
wingless-related MMTV integration site 3A  
Methyl-CpG binding domain protein 2 
Hypothetical protein LOC67412 
karyopherin (importin) beta 3 
leucine-rich repeats and immunoglobulin-like domains 
1 
Iroquois related homeobox 3 
Decreased expression of CD86 by IPS
 mice but the cytokine response and phenotypic activtion was 
was observed in CD86 expression which 






















Appendix 12. RNase H2 activity is likely to be 
intracellular 
 
The supernatants from EBV-transformed LCL lines were assayed for secreted RNase 
H2 activity using the RNase H activity assay. 5 µg of supernatant (as determined by 
protein concentration) were incubated with 25 pmol RNase H2-specific substrate and 
the fluorescence units released determined after 30 min incubation at 37oC. 5 µg 
recombinant human RNase H2 was included as a control. Background fluorescence 
values were subtracted from each value. All supernatants were negative for RNase 
H2 activity. Data are from one experiment + s.d. of triplicate wells. No activity was 
detected when 100 µg of supernatant was tested either, however these data only show 
that transformed LCLs do not secrete RNase H2 activity, and therefore cannot 








Appendix 13. ssDNA60 requires transfection to 
stimulate cytokine production by FL-DCs 
 
FL-DCs were stimulated with 1 µg/ml ssDNA60 in the presence or absence of 
Lipofectamine 2000 for 18 h. Cytokine production was measured by ELISA. Data 














Appendix 14. The detection of autoantibodies capable 
of recognising RNA:DNA hybrids in an SLE patient 
 
The sera of three patients with SLE were tested for the presence of anti-nucleic acid  
autoantibodies using the dot blot and plate assay methods established in Chapter 4. 
High levels of autoantibodies against all nucleic-acid species was detected in the sera 
from one patient, used here at a dilution of 1:10,00 . In particular, high levels of 
autoantibodies detected the dsRNA and RNA:DNA hybrid species. Data shown are 
representative of two independent experiments performed using sera from this 
patient. Plate assay data are presented as mean OD450 reading + s.d. of triplicate 
wells. 
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